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Abstract
The body initiates an immune response to danger signals. The Danger model of the 
immune system postulates that danger signals are produced by exogenous 
molecules from foreign invaders, such as bacteria, and endogenous molecules 
released from damaged or injured cells. The response involves antigen recognition 
leading to up-regulation of cytokines and cell surface markers, followed by the 
recruitment of antigen presenting cells and T-helper cells which determine how the 
immune system responds. Endogenous danger signals include Hsp72 and HMGB-1.
This thesis describes the development of specific antibodies and ELISAs for use in 
the quantification and detection of intra-cellular Hsp72 from cell extracts, and 
released Hsp72 from cell cultures which enabled the confirmation of physiological 
levels of Hsp72 from model systems.
The ability of endogenous Hsp72 to stimulate an immune response was 
demonstrated and this response was not solely due to LPS contamination of 
recombinant protein preparations. Hsp72 was able to augment the response to LPS. 
In the presence of another endogenous danger signal, HMGB-1, relative amounts of 
Hsp72 were shown to augment a pro-inflammatory response whilst being able to 
maintain an anti-inflammatory response demonstrating Hsp72 has the ability to 
modulate the immune response.
Hsp72 was also shown to be able to stimulate an immune response by binding to cell 
surface receptors, which could be blocked by specific peptides corresponding to 
known receptors. These include some receptors not utilised by LPS.
The proportion of these different danger signals has consequences for the 
progression and outcome of an immune response and this may well be modulated by 
imposition of a supplemental or future stress at different points. In the most severe 
case, this can lead to death through sepsis following trauma.
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Chapter 1
Introduction
1.1 Rationale for Study
The immune system mounts a response to exogenous molecules, such as bacterial 
products, and it has been shown that auto-antibodies can be generated, which are 
implicated in autoimmune diseases, such as diabetes (Brudzynski, 1993; 
Brudzynski, Martinez & Gupta, 1992). This demonstrates that it also responds to 
endogenous molecules which have recently been identified as danger signals that 
are released by damaged cells and able to activate the antigen-presenting cells 
(APCs) (Gallucci & Matzinger, 2001; Matzinger, 1994; Matzinger, 1998; Matzinger,
2002).
Heat shock proteins (Hsps), particularly Hsp72, have been reported as being 
danger signals to the innate immune system when found in the extra-cellular milieu 
(Bianchi, 2007; Campisi & Fleshner, 2003; Campisi, Leem & Fleshner, 2003; 
Matzinger, 2002; Williams & Ireland, 2008). The presence and levels of extra­
cellular Hsp72 in particular has been studied extensively in many stressful 
situations such as in vitro and in vivo heat stress (Ai't-Ai'ssa et al., 2003; Currie, 
Moyes & Tufts, 2000; Guzhova et al., 2001), infection (Njemini et al., 2007; Njemini 
et al., 2003b), exercise (Fehrenbach et al., 2000; Madden et al., 2008; Walsh et al., 
2001) and fever (Oehler et al., 2001).
Another protein which has been recently termed a danger signal is high mobility 
group box-1 (HMGB-1) which is normally found bound to chromatin within the 
nucleus but can be released under stressful conditions such as sepsis (Wang et al., 
2001a; Yang et al., 2007), arthritis (Kokkola et al., 2002; Taniguchi et al., 2003) and 
lung inflammation (Abraham et al., 2000; Li et al., 2003), and functions extra- 
cellularly as a late mediator of the pro-inflammatory response (Andersson et al., 
2000; Chen et al., 2004; Harris & Raucci, 2006; O'Connor et al., 2003; Qin et al., 
2006; Williams & Ireland, 2008).
In relation to the innate immune response, Hsp72 is thought to bind to certain 
receptors on cells which can then trigger an inflammatory response resulting in the 
release of cytokines, and that Hsp72 itself can act as a chemokine (Gouwy et al., 
2005; Lehner et al., 2004; Panjwani, Popova & Srivastava, 2000; Wang et al., 
2001b). The stimulatory immune function of extra-cellular Hsp72 has been 
questioned recently as being due to LPS contamination of recombinant proteins
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during in vitro experiments (Bausinger et al., 2002; Gao & Tsan, 2003a; Gao & 
Tsan, 2004; Tsan & Gao, 2004a; Tsan & Gao, 2004b).
HMGB-1 also stimulates the production of pro-inflammatory cytokines and under 
normal stress conditions such as tissue injury or trauma, functions in a regulatory 
protective manner by stimulating the immune system to repair the damage. 
However, when the immune system is stimulated by HMGB-1 and 
lipopolysaccharide (LPS), increased amounts of HMGB-1 are released in an 
autocrine manner in response to up-regulated TNF-a secretion which stimulates a 
solely pro-inflammatory response. If this response is not controlled it can lead to 
sepsis, and eventually death (Chen et a/., 2004; Gaini et al., 2007a; Gaini et al., 
2007b; Qin et al., 2006; Wang et al., 2001a).
The measurement of extra-cellular Hsp72 by enzyme linked immuno-sorbent assay 
(ELISA) has been reported in various matrices such as serum, plasma and tissue 
culture supernatant, but the levels reported vary widely (Njemini, Demanet & Mets, 
2003a; Njemini et al., 2003b; Pockley, Shepherd & Corton, 1998; Wright et al., 
2000), although all rely upon the same components. Part of this thesis therefore 
was to develop a method to accurately quantify Hsp72 in various sample types.
The work in this thesis demonstrates that extra-cellular Hsp72 is able to stimulate 
the innate immune system independently of LPS contamination and that Hsp72 is 
able to modulate the immune response by binding to various cell surface receptors 
involved in cytokine signalling. Also, it is postulated that Hsp72 may help to regulate 
the pro-inflammatory actions of HMGB-1.
1.2 The Danger model
The immune system has recently been suggested to be able to be activated by 
endogenous molecules, now described as danger signals which has lead to a new 
theory regarding how the immune system responds (Matzinger, 1994).
Originally, in 1959, Burnet suggested a response known as the ‘self- non-self 
(SNS) model describing that lymphocytes were able to recognise a foreign body 
which stimulates the cell to generate cell surface receptors and proposed that the 
immune system acted to distinguish between 'self and non-self. However, it was 
later discovered that B cells were able to generate an autoimmune response in 
conjunction with T cells in the presence of a ‘signal’. This ‘signal’ was found to be 
antigen which was presented by APCs. This potentially meant that the immune 
system could be directed against the ‘self, resulting in auto-immunity and therefore
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questioning the SNS model. In 1989, Janeway described APCs as being dormant 
until activated through pattern recognition receptors (PRRs) which recognise 
pathogen-associated molecular patterns (PAMPs) from bacteria, and then up- 
regulate co-stimulatory signals and then present the bacterial antigen to T cells. 
Therefore, it was the PRRs that allowed the immune system to discriminate 
between ‘infectious-nonself, and, ‘non-infectious-self (Janeway, 1989; Janeway Jr 
et a/., 2005b). The SNS model could still not explain certain aspects of the immune 
response such as responses to viruses, auto-immunity or transplant rejection.
In 1994, Matzinger proposed a new model of how the immune responses are 
activated. It was suggested that APCs are activated by danger signals from 
damaged cells. These signals appear in the extra-cellular environment by necrosis 
following a stressful event. This event would up-regulate the intra-cellular 
production of certain endogenous molecules that when presented in the extra­
cellular environment are recognised by PRRs as being a result of an abnormal cell 
death. These signals would not be present when cells are healthy or die via 
apoptosis (Adams, 2003; Kaczorowski et al., 2008; Matzinger, 1994; Matzinger, 
1998; Matzinger, 2002; Williams & Ireland, 2008) (Figure 1.1).
The Danger model provides an explanation regarding a number of issues about 
how the immune system responds. For example, transplants and foetuses are ‘non­
self but are not associated with bacterial products so should not stimulate an 
immune response. However, transplants often stimulate a response and are 
rejected whereas foetuses are generally not. As they are not 'self, using the SNS 
model, both should stimulate a response, but using the Danger model it can be 
explained in terms that a foetus does not send ‘danger signals’ but transplants often 
do. With regards to auto-immunity, in which the immune system responds to the 
‘self, the Danger model simply suggests that this occurs in some cases, due to a 
genetic mutation, resulting in an inadequate clearance of apoptotic cells, such as 
Lupus (Kaplan et al., 2002), or by incorrectly recognising ‘self as being ‘non-self 
following cellular damage caused by a pathogen, such as type 1 diabetes (Abulafia- 
Lapid et al., 1999; Reines, 2001). In both cases, the immune system is simply 
responding to ‘danger signals’ which would ordinarily be cleared. Necrosis and 
inadequate clearance of apoptotic cells can lead to the accumulation of 
endogenous danger signals. These endogenous molecules mediate the innate 
immune response by stimulating APCs to secrete cytokines and other inflammatory 
signals, leading to the recruitment of immune cells to the site of infection and the 
activation of the adaptive immune response (Dybdahl et al., 2005; Gastpar et al., 
2004; Wang et al., 2006a; Yang et al., 2006).
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1.2.1 The innate immune response
The innate immune system provides an immediate defence against pathogens and 
other endogenous molecules and involves the recruitment of cells such as 
macrophages, natural killer (NK) cells, dendritic cells (DCs) and several other 
lymphocyte populations (Janeway Jr et al., 2005b; Janeway Jr et a!., 2005c). Both 
exogenous and endogenous mediators are readily recognised by the innate 
immune system by conserved small motifs known as PAMPs for pathogens, or 
damage-associated molecular patterns (DAMPs) (Bianchi, 2007; Prohaszka & Fust, 
2004). These PAMPs include lipopolysaccharide (LPS), flagellin, lipoteichoic acid, 
and DAMPs include Hsp60, Hsp72 and HMGB-1 (Gutsmann et al., 2001; Nilsen et 
al., 2008; Smith et al., 2003; Sugawara et al., 1999; Ye & Gan, 2007; Asea et al., 
2000b; Dybdahl et al., 2005; Fiuza et al., 2003; Habich et al., 2002; Kol et al., 2000; 
Rouhiainen et al., 2004). These molecules are recognised by PRRs, which include 
cell membrane receptors, for example toll-like receptors (TLRs) and cluster of 
differentiation (CD) markers, which are able to recognise microbial products and 
other endogenous molecules (Asea et al., 2002; Binder, Han & Srivastava, 2000; 
Bosco et al., 1997; O'Connell et al., 2004; Takeda, Kaisho & Akira, 2003; 
Triantafilou & Triantafilou, 2002; Wang et al., 2006b). Interaction between PAMPs 
and PRRs/TLRs leads to the activation of an inflammatory response, including the 
production of feedback signals, such as cytokines, and/or release of mediators, 
such as Hsp72 or HMGB-1, leading to the recruitment of immune cells to the site of 
inflammation and the activation of the adaptive immune response (Ding et al., 2001; 





Figure 1.1: The Danger model of immune stimulation.
APCs are activated by DAMPs from distressed cells and either through 
internalisation and re-presentation, or by co-stimulation, stimulate the adaptive 
immune response.
(Adapted from Matzinger, 2002; Bianchi, 2007).
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1.2.2 The adaptive immune response
The adaptive immune response is initiated when antigens are bound by APCs, 
such as macrophages and DCs, and are presented to T cells (Janeway Jr et al., 
2005b). Adaptive immunity was originally characterised by four fundamental 
elements:
• being antigen specific and allowing the immune system to be able to 
differentiate between two highly conserved proteins;
• being highly diverse in the ability to recognise a multitude of different 
proteins and molecules;
• being able to generate memory B and T cells which are able to mount a 
stronger and quicker immune response when the same antigen is 
encountered;
• ability to differentiate between ‘self and ‘non-self molecules and responding 
only to the non-self molecules.
(Janeway Jr et al., 2005b).
Being able to differentiate between 'self and ‘non-self molecules is obviously now 
debatable with the Danger model proposal that the activation of the adaptive 
immune system by APCs can also be activated by DAMPs which are released by 
cells undergoing stress and damage (Matzinger, 1998), such as infection leading to 
necrosis (Basu et al., 2000; El Mezayen et al., 2007; Mambula & Calderwood, 
2006a; Saito, Dai & Ohtsuka, 2005; Scaffidi, Misteli & Bianchi, 2002).
Two of these proposed DAMPs, or endogenous molecules will be discussed 
further: Hsp72 and HMGB-1.
1.3 Heat shock proteins
The term heat shock response was first used by Ritossa et al. (1962) to describe an 
increase in the expression of certain genes when Drosophila melanogaster larval 
salivary gland cells were exposed to a 30°C heat stimulus. These genes were 
subsequently found to lead to an increase in the expression of proteins with 
molecular weights of 27 and 70 kDa (Tissieres, Mitchell & Tracy, 1974), and these 
proteins were named heat shock proteins (Hsps). Many studies following this 
discovery found that Hsps were expressed by the majority of prokaryotes and 
eukaryotes, and were found to be highly conserved (Boorstein, Ziegelhoffer & 
Craig, 1994; Hartl, 1996).
6
In most plant and animal systems, Hsps are synthesised following a variety of 
stresses such as heavy metal exposure, oxidative stress and in vitro serum 
deprivation (Ireland et al., 2004; Lang et al., 2000; Ménoret et al., 2002). Within the 
ceil, Hsps act as molecular chaperones by assisting the correct folding of nascent 
proteins, prevention of inappropriate protein aggregation, and mediating transport 
of proteins across intra-cellular membranes (Bukau & Horwich, 1998; Mayer & 
Bukau, 1998). Hsps are able to bind to hydrophobic surfaces of unfolded 
polypeptides which expose hydrophobic amino acid side chains that can result in 
aggregation. This binding results in the stabilisation and correct folding of 
polypeptides (Hartl, 1996; Tavaria et ai, 1996).
Hsps are named based on their molecular weight in kDa and gene sequence 
homology. The main Hsp families are small Hsps ( 1 0 - 4 0  kDa), Hsp60, Hsp70, 
Hsp90 and Hsp100 (Table 1.1).
Table 1.1: Classification of Hsps, their localisation and function.
Name Molecular weight (kDa) Localisation Function
Small Hsps 15-40 Cytosol, Nucleus Cytoskeletal stabilisation







Protection against stress 
Downregulation of HSF1 
activity
Hsp90 82-90 Cytosol, Endoplasmic reticulum
Prevention of aggregation 
Maintenance of HSF1
Hsp100 97-120 Cytosol, Nucleus, Mitochondria
Thermotolerance 
Protein refolding
Adapted from (Pockley, 2003) and (Srivastava, 2002)
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1.3.1 Regulation of the heat shock response
The heat shock response is regulated by the activation and translocation from the 
cytosol to the nucleus of heat shock transcription factor 1 (HSF1), which upon heat 
shock, trimerises and binds to heat shock elements (HSEs) that are located within 
promoter regions of Hsp genes (Morimoto, 1993; Sarge, Murphy & Morimoto, 1993) 
which result in the transcriptional activation and synthesis of Hsps (Cotto, Kline & 
Morimoto, 1996). As Hsp synthesis increases, Hsp72 and other Hsps (such as 
Hsp90) re-localise to the nucleus where they bind to the HSF1 trans-activation 
domain and repress transcription of Hsp genes (Shi, Mosser & Morimoto, 1998; 
Wu, 1995). Under unstressed conditions, HSF1 is present within the cytosol as a 
monomer which is bound to Hsps and other chaperones, and is deficient in 
translational activity (Shi eta!., 1998).
1.4 The Hsp70 family
The Hsp70 family of proteins is among the most widely studied of the heat shock 
proteins and are the major chaperones involved in assisting the correct and 
biologically active folding of nascent polypeptides. This process is ATP-dependent 
in eukaryotic cells (Gebauer, Zeiner & Gehring, 1997; Mayer & Bukau, 1998). In 
mammalian systems, the most well known members of the family include the 
constitutive cytosolic Hsc70 (Hsp73), the stress-induced cytosolic form (Hsp72), 
Grp78 (BiP), which is found within the endoplasmic reticulum (ER), and the 
mitochondrial Grp75 (Gebauer et a!., 1997; Liu et al., 2005). The main form of 
Hsp72 in E. coli is DnaK (Krska, Elthon & Blum, 1993).
Proteins from this family contain two domains: the N-terminal domain, and the C- 
terminal domain (Mallouk etal., 1999; Sriram et al., 1997; Tavaria et al., 1996). The 
N-terminal domain is highly conserved and is also known as the ATPase domain. It 
is able to hydrolyse ATP to ADP which leads to conformational changes in the other 
domain. The C-terminal domain contains a variable region known as the substrate 
binding domain. The substrate binding domain contains a groove to which 
hydrophobic peptides bind. The C-terminal domain also contains a hinge region 
which allows it to form a lid for the substrate binding domain (Gething & Sambrook, 
1992; Hartl, 1996; Hartl & Hayer-Hartl, 2002; Ruchalski et al., 2006; Rudiger, 
Buchberger & Bukau, 1997) (Figure 1.2).
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EEVD binding motif (638-641)
Figure 1.2: The structure of Hsp72 protein.
(Adapted from Gething & Sambrook, 1992; Rüdiger et al., 1997; Mallouk, et al., 
1999; Ruchalski, et al., 2006).
1.5 Intra-cellular functions of Hsp72
Within the cell, Hsp72 has a clearly defined role. Under normal conditions, its main 
role is to facilitate folding and assembly of nascent proteins. It does this by binding 
nascent proteins in an ATP-dependent manner (Figure 1.3). When the N-terminal is 
ATP bound, the lid is open and unfolded protein is bound and released rapidly. 
Following recognition and binding of the unfolded protein (by extended hydrophobic 
regions), hydrolysis of ATP occurs leading to Hsp72 being ADP bound. In this 
substrate bound state, the lid is closed, and the protein is tightly bound within the 
groove of the substrate binding domain. In order for Hsp72 to release the protein, 
the co-chaperones Hsp40 and Hsp90 bind to the N-terminal of Hsp72 resulting in a 
conformational change leading to the release of ADP. This then allows ATP to be 
bound which leads to the release of the substrate protein, which is then either 
completly folded into the correct conformation either by being rebound by Hsp72, or 
being transferred to another co-chaperone, such as Hsp60 (Bukau & Horwich, 
1998; Mallouk etal., 1999).
Hsp72 is also involved with translocation of proteins across membranes via ATP 
hydrolysis, to within the mitochondria (Neupert & Brunner, 2002) and the ER (De 
los Rios et al., 2006; Rapaport et al., 1998). Elevated levels of intra-cellular Hsp72 
have also been shown to inhibit apoptosis, or programmed cell death (Garrido et 
al., 2001). When cells are undergoing a stressful event, NF-k(3 signalling pathway is 
up-regulated, and this in turn up-regulates HSF1 and Hsp72, which in turn acts to 
suppress NF-k(3 signalling. This suggests that a negative feedback loop associated 
with Hsp72 could provide an anti-inflammatory response (Hamilton et al., 2004). 
This response is thought to involve inhibition of IkB kinase resulting in the 
protection of IkK (Ran et al., 2004), or prevention of IkB degradation which would 
interfere with the release and translocation of NF-kP to the nuclear compartment, 
thus preventing the up-regulation of pro-inflammatory cytokines (Weiss et al., 2007; 
Yoo et al., 2000). It has been demonstrated that Hsp72 can bind to tumour necrosis
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factor receptor-associated factor 6 (TRAF6) preventing NF-k(3 activation which may 
be useful in helping cells survive tissue injury (Chen et al., 2006).
In relation to HMGB-1, elevated levels of intra-cellular Hsp72 attenuate HMGB-1 
secretion by transfected RAW264.7 cells, by interfering with the CRM1 
translocation export pathway. Following stimulation by LPS, or TNF-a (24 h), levels 
of HMGB-1 secretion into the cell culture media was reduced in transfected cells. 
HMGB-1 remained within cell extracts in transfected cells (Tang et al., 2007a). 
Hsp72 is also found in the extra-cellular milieu. The mechanisms of release and its 
actions outside the cell are still being debated and are discussed further here.
1.6 Mechanisms of Hsp72 release from cells
Release of Hsp72 was first reported in a study on cultured rat embryo cells 
following heat treatment (Hightower & Guidon Jr, 1989). Following this a number of 
studies have reported the release of Hsp72 from a variety of cells (Baretto et al., 
2003; Broquet et al., 2003; Evdonin et al., 2006b; Guzhova et al., 2001; Hunter- 
Lavin et al., 2004).
The mechanisms by which Hsp72 is released are unclear. It has been shown that 
necrosis leads to Hsp72 release in a passive manner (Basu et al., 2000; Mambula 
& Calderwood, 2006a; Saito et al., 2005), which may be the case for the majority of 
disease states. However, active secretion is now thought to be a possible 
mechanism, but how Hsp72 is secreted from the cell still remains unclear. The 
classical pathway of secretion (ER/Golgi-dependent secretory pathway) allows for 
soluble proteins containing an N-terminal signal (leader sequence) to be 
transported to the translocation apparatus of the ER. From here they are 
transported to the Golgi, undergoing post-translational modifications such as N- 
glycosylation, and are enclosed within secretory vesicles which are able to fuse 
with the cell membrane, leading to the release of proteins (Nickel, 2003). However, 
Hsp72 lacks the N-terminal signal required for this form of transport, and the use of 
inhibitors of the classical secretion pathway, such as brefeldin A and monensin, 
have been found to have no effect on the release of Hsp72 (Broquet et al., 2003; 
Hightower & Guidon Jr, 1989; Hunter-Lavin et al., 2004) (Boyce & Yuan, 2006). 
Mambula et al. (2007) have postulated that there are likely three possible 
mechanisms of Hsp72 release. Firstly, Hsp72 is passively released from necrotic 
cells following a severe heat shock (Mambula & Calderwood, 2006a) and correlates 
highly with other markers of myocardial necrosis (Dybdahl et al., 2005). Secondly, it 
can be released within vesicles in a similar way to IL-1 a (Arai & Kuwajima, 2000), 
or IL-1 (3, which are subsequently lysed in the extra-cellular environment
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(MacKenzie et al., 2001). Thirdly, a mechanism has been described which involves 
secretion through endolysosomes that fuse with the cell membrane and release 
Hsp72, as it has been found to be expressed with cathepsin D, a lysosome marker. 
The heat shock which resulted in the release of Hsp72 also correlated with an 
increased expression in cell surface LAMP-1, a lysosomal-associated membrane 
protein (Mambula & Calderwood, 2006b).
Other studies have also demonstrated that Hsp72 may be released by exosomes 
which are lipid-bound (Lancaster & Febbraio, 2005; Tytell, 2005), or may be 
released through specialised membrane domains known as lipid rafts. Lipid rafts 
are specialised sphingolipid and cholesterol rich areas within the cell membrane 
which allow for transport of proteins, both intra- and extra- cellular (Pike, 2004). 
Transport of proteins across lipid rafts can be disrupted by methyl-P-cyclodextrin, 
and Hsp72 release has been found to be disrupted in the cell line, Caco-2 (Broquet 
et al., 2003), PBMCs (Hunter-Lavin et al., 2004), and Hsp72 has been shown to 
integrate within an artificial lipid bi-layer (Arispe, Doh & De Maio, 2002; Vega et al., 
2008).
It is therefore likely that there are at least four mechanisms by which Hsp72 is 
released from cells (Figure 1.4).
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1.7 Extra-cellular functions of Hsp72
The presence of Hsp72 in the extra-cellular milieu has been discovered fairly 
recently and has been found to have a variety of potential roles. It has been found 
on the cell surface of human tumour cells and has been shown to stimulate the 
immune system by causing NK cells to attack tumour cells which have part of the 
Hsp72 C-terminal domain expressed on the extra-cellular surface (Botzler et a/., 
1998).
Hsp72 has also been found to be present in the peripheral circulation of healthy 
individuals (Njemini et at., 2003b; Pockley et at., 1998; Wright et at., 2000), and can 
be found at increased levels in those with certain diseases (Njemini et at., 2007; 
Wright et at., 2000), and also following exercise (Walsh et at., 2001). Hsp72 
appears to be especially prevalent in the circulation of patients with peripheral and 
renal vascular disease (Wright et at., 2000). Levels of Hsp72 are also found to be 
elevated during infection and fever (Njemini et at., 2003b; Stewart & Young, 2004), 
and could be due to cells actively releasing Hsp72, necrosis or apoptosis. Hsp72 
has also been demonstrated to stimulate the production of inflammatory cytokines 
through activation of the NF-kP signalling pathway (Asea et at., 2000b; Hall, 1994). 
This function of extra-cellular Hsp72 appears to contrast with its intra-cellular 
function of suppressing NF-kP (Chen et at., 2006; Weiss et at., 2007). This may 
indicate that extra-cellular Hsp72 acts as a danger signal to nearby viable cells by 
stimulating NF-xp, leading to up-regulation of intra-cellular Hsp72 and anti­
inflammatory signals, and an improved chance of survival of the viable cells during 
a stressful insult.
Conversely, one study has shown that LPS-free Hsp72 from Mycobacterium 
tuberculosis (M. tb) inhibits the maturation of murine DCs and induces pro- 
inflammatory IL-10 secretion, whereas Hsp72 contaminated with LPS does induce 
maturation and the secretion of TNF-a. Thus Hsp72 may have anti-inflammatory 
properties (Motta et at., 2007). Immunization of rats with M. tb Hsp72 also resulted 
in the induction of IL-10 (Prakken et at., 2001), and immunization of rats with an 
M. tb Hsp72 peptide (aa 234-252) suppressed the progression of arthritis. T cells 
derived from rats which were pre-treated with this peptide prior to stimulation with 
M. tb secreted excessive IL-10. In vivo administration of an anti-IL-10 antibody 
partly reduced the effect of the Hsp72 peptide against arthritis progression (Tanaka 
et a!., 1999). A similar study by Wendling et al. (2000) also revealed that T cells 
from rats which were immunised with specific M. tb peptides which corresponded to 
rat Hsp72 (GenBank accession no. Q07439) produced large amounts of IL-10
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when re-stimulated with specific peptides in vivo. This evidence demonstrates that 
Hsp72 has anti-inflammatory activity, especially in the absence of LPS.
More recently, another study has demonstrated that cytokine stimulation by Hsp72, 
could be reduced using anti-Hsp72 antibodies in THP-1 and U937 cell lines (El 
Mezayen et al., 2007). This study did not use recombinant protein to stimulate, but 
instead used pre-stimulated necrotic cell lysate (NCL) which contained cell derived 
Hsp72. NCL was applied directly to cell cultures, or pre-incubated with antibodies to 
Hsp72 then applied to cells in con-junction with LPS. They showed that non­
recombinant Hsp72 induced cytokine production could be reduced using these 
antibodies.
The possible mechanisms of extra-cellular Hsp72 are discussed further in relation 
to the immune response.
1.8 The role of Hsp72 within the immune system
Since Hsp72 is found in the extra-cellular matrix, and is implicated as being a 
significant marker of some disease states, such as infection (Njemini et al., 2003b), 
atherosclerosis (Lamb, El-Sankary & Ferns, 2002; Svensson et al., 2006), 
Alzheimer’s disease (Hamos et al., 1991; Yoo et al., 2001), Huntington’s disease 
(Hay et al., 2004), sickle cell anaemia (Adewoye et al., 2005), and vascular disease 
(Wright et al., 2000), it might have a functional role. The functional role of Hsp72 
could be as an inflammatory danger signal to the immune system (Campisi et al., 
2003; Vega et al., 2008; Williams & Ireland, 2008).
1.9 Recognition of Hsp72 by the immune system
The Danger model allows for recognition of endogenous self molecules as markers 
of tissue damage or cellular stress which activate the immune system. These have 
now been termed damage-associated molecular patterns (DAMPs) (Bianchi, 2007). 
Hsp72 is a candidate for one of these danger signals. In the innate response, 
Hsp72 is able to bind PRRs and TLRs to stimulate NF-k(B activation resulting in the 
release of cytokines and nitric oxide (NO) and up-regulating the expression of co­
stimulatory molecules and MHC II (Asea et al., 2000b; Basu et al., 2000; Basu & 
Matsutake, 2004; Binder, Vatner & Srivastava, 2004; Knowlton, 2006; Panjwani, 
Popova & Srivastava, 2002). In the adaptive response, Hsp-peptide complexes are 
readily taken up by APCs and internalised. The peptides are presented to MHC 
class I and MHC class II molecules and transported for recognition by T cells (Basu 
& Matsutake, 2004; Park et al., 2006a). Hsp72 has also been found in a 
membrane-bound form which externalises a specific epitope (TKD) found only on
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tumour cells which acts as a receptor for NK cells by binding to NK cells, possibly 
via Fc receptors on NK cells. The TKD peptide was found to bind to NK cells 
resulting in the up-regulation of CD94 which is associated with lytic activity against 
tumours expressing membrane-bound Hsp72, and stimulates migration of NK cells 
(Botzler et a/., 1998; Gastpar et al., 2004; Multhoff, 2007; Vega et al., 2008). 
Therefore, Hsps such as Hsp72 appear to have a dual role in activating the immune 
system (Figure 1.5).
1.10 Stimulation of the innate immune response by Hsp72
Hsp72 is known to strongly activate the immune system, resulting in the secretion 
of cytokines. It is thought they are able to do this by binding to receptors on the cell 
surface, much in the same way as PAMPs are recognised by PRRs (Calderwood et 
al., 2007; Takeda et al., 2003; Triantafilou & Triantafilou, 2002). These receptors 
may recognise Hsp72, Hsp72-peptide complexes, or just the peptide which is 
bound to Hsp72 (Basu et al., 2001; Binder et al., 2004). These PRRs are thought to 
include the following described here (Figure 1.6).
1.10.1 CD91
CD91 is an oxidized low density lipid (oxLDL) binding protein found on the surface 
of membranes of APCs involved in receptor-mediated endocytosis. It was first 
described as a common receptor to Hsp 60, 72, Gp96 and calreticulin by Binder et 
al. (2000). It does appear to have an important role in antigen presentation by Hsp, 
as it has been shown that in vitro blocking experiments which utilised a CD91 
receptor associated protein (RAP), there was a strong inhibition of Hsp72 to human 
macrophages, and a weak inhibition of binding to DCs (Delneste et al., 2002). RAP 
has also been reported to inhibit binding of Hsp72 to peripheral blood mononuclear 
cells (PBMCs) (Martin et al., 2003). Other studies have doubted the binding ability 
of CD91 with Hsp72, as one study demonstrated that Hsp72 which was free in 
solution showed little difference in binding ability between cells with or without 
CD91 expression (Theriault et al., 2005).
16











Upregulation of co-stimulatory 
molceules (CD markers) 
and MHC II
IL4 'W  TNF-n
Cytokine release
Figure 1.5: Interaction of Hsps with receptors of the adaptive and innate 
immune system.
In the adaptive immune response, Hsp-peptide complexes are internalised by 
endocytosis and are processed and presented on MHC molecules of APCs. In the 
innate immune response, Hsps bind to signalling receptors which activate NF-k(3 
and result in release of cytokines, chemokines and nitric oxide (NO), and 
expression of CD markers and MHC II.
(Adapted from Binder et al., 2004; Motta et al., 2007; El Mezayen et al., 2007).
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Figure 1.6: Cell surface receptors involved in the immune functions of extra­
cellular Hsp72.
The scavenger receptors LOX-1 and CD91 are shown to either stimulate activation 
of NF-kP or internalise via endocytosis. Activation through TLR-7 is as yet 
unknown. All other receptors are thought to exclusively mediate cell signalling and 
activation of NF-<p.
(Adapted from Binder et al., 2000; Pockley et al., 2003; Janeway Jr. et al., 2005; 




CD40 is a co-stimulatory protein found on APCs which is a member of the TNF-a 
receptor family. When stimulated it binds to CD40L on activated T cells, which 
leads to an increase in expression of CD40 on APCs (O'Sullivan & Thomas, 2003). 
CD40 was initially identified as a receptor for mycobacterial Hsp72 through use of 
competitive binding studies with anti-CD40 antibodies (Wang et al., 2001b). Becker 
et al. (2002) demonstrated that murine Hsp72 could also bind to recombinant CD40 
in cell lysates. The binding of mammalian Hsp72 to CD40 was demonstrated by 
Millar et al. (2003) by showing that bone marrow-derived DCs require CD40 for the 
Hsp72-induced secretion of IL-12. Bone marrow-derived DCs from chimeric mice 
which lacked CD40 did not produce IL-12 when challenged with Hsp72, whereas 
CD40 expressing DCs from control mice (C57BL/6J) did (Millar et al., 2003).
1.10.3 CD14
CD 14 is a receptor found on the surface of macrophages, and other APCs, and can 
also be found in a soluble form. Its primary function is to bind LPS in conjunction 
with TLR-4 and MD-2 as part of an LPS signalling receptor cluster, but only in the 
presence of Ips binding protein (Heidenreich, 1999). It was originally postulated as 
a receptor for Hsp72 by Asea et al. (2000b) who demonstrated that Hsp72 binding 
to CD14 resulted in an up-regulation of TNF-a, IL-1p and IL-6. However, they also 
found another Hsp72 signalling pathway which was independent of CD14 and led 
to an increase in TNF- a only. Another study by the same group showed that NF-kP 
activation was enhanced in response to Hsp72, and that the enhancement was 
increased following transfection of HEK293 cells with CD14 (Asea et al., 2002a). In 
contrast, it has been demonstrated that Hsp72 did not bind to CD 14 in transfected 
CHO cells using flow cytometry analysis (Delneste et al. 2002).
1.10.4 CD36
CD36 is a member of the class B scavenger receptor family, and also binds oxLDL, 
like CD91 and LOX-1 (Pluddemann, Neyen & Gordon, 2007). On macrophages, 
CD36 has been reported to form part of a receptor complex (CD36-aV/33 complex) 
which is involved in the stimulation of phagocytosis (Bottcher et al., 2006). It has yet 
to be demonstrated as a receptor for Hsp72, but it has been shown to bind gp96 
(Binder et al., 2004). Delneste et al. (Delneste et al., 2002) did not show any 
binding of Hsp72 to CD36 in transfected CHO cells using flow cytometry analysis.
19
1.10.5 TLR-2/TLR-4
TLR-2 and TLR-4 are members of the TLR family of receptor proteins which act as 
PRRs recognising PAMPs, leading to downstream activation of NF-«p and 
interference response factor (IRF) signalling pathways, and the production of 
cytokines and adhesion molecules which mediate innate and adaptive immunity in 
response to inflammation (Takeda et a/., 2003). TLR-2 and/or TLR-4 have been 
reported by several groups to be receptors for Hsp60, Hsp72, Gp96 and HMGB-1 
(Ohashi et at., 2000). TLR-2/TLR-4 is involved in the CD14 dependent stimulation 
by Hsp72 described by Asea et at. (2002). Dybdahl et at. (2002) demonstrated that 
Hsp72 could stimulate the production of TNF-a from macrophages derived from 
C3H/HeN mice but not C3H/HeJ. When Hsp72 was pre-incubated with antibody to 
TLR-4, the production of TNF-a and IL-6 from human adherent monocytes was 
abrogated. Antibody to TLR-2 had no effect.
1.10.6 TLR-7
TLR-7 is known to recognise single-stranded RNA (ssRNA) within endosomes as 
part of the innate immune response to viruses (Krieg, 2007; Triantafilou et at., 
2005). A recent study by Wang et al. (2006) demonstrated that the phagocytic 
response to Hsp72 in wild-type murine macrophages was significantly increased 
when compared to TLR-7 deficient mice (C57BL/6). They also demonstrated that 
when RAW264.7 cells were transfected with small interfering RNA (siRNA) for 
TLR-7, phagocyitc activity and TNF-a release was reduced compared to RAW264.7 
cells transfected with an empty vector (control). Presence of TLR-7 and Hsp72 
within the lipid raft region of macrophages membranes was verified by western blot. 
As Hsp72 in this study was able to stimulate phagocytosis through TLR-7, it may 
indicate that when Hsp72 is released from necrotic cells, it is able to act as a 
chemokine (Asea, 2006; Asea et al., 2000a; Asea et al., 2000b) when receptors 
from APCs, such as TLR-7, are bound by it.
1.10.7 LOX-1
LOX-1 is a Class E scavenger receptor which binds oxLDL, but has been found to 
bind with high affinity to Hsp72 (Binder et al., 2004; Delneste et al., 2002; Theriault, 
Adachi & Calderwood, 2006; Theriault et al., 2005). LOX-1 is known to be involved 
in cross-presentation of antigens and Hsp72 is thought to bind LOX-1, possibly in a 
peptide-bearing manner, and is internalised by endocytosis leading to stimulation of
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the adaptive immune response via MHC I (Binder et a/., 2004; Calderwood et al., 
2007; Delneste etal., 2002; Inoue & Sawamura, 2007).
1.11 High mobility group box protein-1 (HMGB-1)
The Danger model postulates that damaged cells release their contents into the 
extra-cellular milieu which contain endogenous danger signals that are capable of 
stimulating an immune response (Bianchi, 2007; Palumbo et al., 2007; Williams & 
Ireland, 2008). Hsp72 has already been discussed as a candidate signal but there 
are likely others, one of which is HMGB-1.
HMGB-1 is a 25 kDa nuclear protein consisting of two DNA-binding domains, 
known as HMG box A and B, and an acidic tail which interacts with the HMG boxes, 
possibly regulating their molecular interactions (Andersson et al., 2002; Bianchi & 
Manfredi, 2007; Knapp et al., 2004; Thomas, 2001; Wang et al., 2007) (Figure 1.7). 
HMGB-1 proteins are highly conserved, and in mammals are virtually identical. It is 
generally found within the nucleus but can also be found in the cytosol, external 
membranes and within the extra-cellular milieu (Bonaldi et al., 2002; El Gazzar, 
2007; Thomas, 2001; Zetterstrom et al., 2002). Within the box A region there is a 
heparin binding domain (aa 6-12) which is similar in sequence to a number of 
heparin binding proteins (Cardin & Weintraub, 1989), and a region which functions 
to stabilise amyloid fibrils (Takata et al., 2003). The complete box A region is 
capable of being a RAGE antagonist (Bianchi & Manfredi, 2007). The box B region 
contains the pro-inflammatory region of HMGB-1 (aa 89-108), and part of box B 
along with part of the connecting segment before the acidic tail is able to bind 
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Figure 1.7: Structure of HMGB-1 protein.
(Adapted from Thomas, 2001; Bianchi & Manfredi, 2007; Takata et al., 
2003Huttunen etal., 2002; Li etal., 2003).
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1.12 Regulation of HMGB-1
The regulation of HMGB-1 is not very well understood. Only very recently has it 
been demonstrated that expression of HMGB-1 may be activated by the JAK/STAT 
pathway (Liu et al., 2007). This study showed that when murine macrophages were 
stimulated with LPS, HMGB-1 expression was increased and this correlated with 
the activation of JAK/STAT. This activation was suppressed when specific inhibitors 
of JAK2, STAT1 or STAT3 were applied, and HMGB-1 expression was reduced. To 
determine whether this mechanism was responsible for the secretion of TNF-a 
following challenge with HMGB-1, HMGB-1 was applied to macrophages and 
induced secretion of TNF-a. Using the JAK/STAT inhibitors prior to HMGB-1 
treatment resulted in a significant decrease in TNF-a expression (Liu et al., 2007). 
TNF-a, which is secreted by activated immune cells also leads to the up-regulation 
of HMGB-1 (Wang et al., 1999).
1.13 Intra-cellular functions of HMGB-1
Within the cell HMGB-1 is transiently bound to chromatin and functions as a DNA 
chaperone by promoting DNA-protein interactions (Bonaldi et al., 2002). It regulates 
transcription by bending DNA to enable binding of transcription factors (Thomas, 
2001). HMGB-1 also binds non-specifically to the minor groove within DNA to 
induce these changes. These structural changes allow DNA to bind and interact 
with various proteins, such as p53, NF-xp, steroid hormone receptors and other 
homeobox-containing proteins (Bianchi, 2007).
HMGB-1 is also found at the periphery of the cell membrane in cells that are motile 
or can be activated, such as macrophages (Rouhiainen et al., 2004). It is thought 
that HMGB-1 is translocated into the cytoplasm by lysosomal exocytosis prior to 
release into the extra-cellular milieu (Gardella et al., 2002).
1.14 Mechanisms of HMGB-1 release from cells
HMGB-1 is released from necrotic cells in a passive manner (Scaffidi et al., 2002), 
and, like Hsp72 has been found to be released via a non-classical secretory 
pathway, despite lacking a peptide leader sequence (Bell et al., 2006; Gardella et 
al., 2002; Rouhiainen etal., 2004) (Figure 1.8).
The release of HMGB-1 from necrotic cells has been demonstrated to induce the 
inflammatory response, including release of pro-inflammatory cytokines and
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migration of immune cells to sites of inflammation (Degryse et al., 2001; Palumbo et 
al., 2007; Yang et al., 2006). Scaffidi et al. (2002) demonstrated that macrophages 
incubated with necrotic cells induced NF-k(3 activation and release of TNF-a. 
Incubation with apoptotic cells did not, and it was found that HMGB-1 in apoptotic 
cells is tightly bound to chromatin due to hypoacetylation of histones (Scaffidi et al., 
2002). The release of HMGB-1 from necrotic cells therefore leads to inflammation 
and tissue regeneration by attracting dendritic cells (DCs) and neutrophils, and the 
activation of stem cells (Palumbo et al., 2007).
HMGB-1 has also been found to be actively secreted from immune cells in a non- 
classical manner by lysosomes (Gardella et al., 2002). This mechanism of HMGB-1 
release is associated with the late onset of chronic inflammation. This study 
showed that HMGB-1 relocates to the periphery of the cell membrane in response 
to 18 h incubation with LPS, and is secreted following a short co-incubation (10 
min) with lysophosphatidylcholine (LPC). LPC is a bioactive lipid which is generated 
by inflamed cells (Gilon & Henquin, 2001).
One report has implicated that HMGB-1 is also released during apoptosis (Bell et 
al., 2006). Jurkat cells were treated with apoptosis inducers and HMGB-1 release 
was determined by western blot. HMGB-1 was found to be present in supernatants 
after 30 h following treatment with all apoptosis inducers tested. Another study 
reported that RAW264.7 cells could release HMGB-1 through apoptosis when 
stimulated with LPS for 20 h, and that when stimulated with polyinosinic- 
polycytidylic acid (poly(l:C)), release from apoptotic cells was dependent on IFN-a. 
Anti-IFN-a antibodies prevented HMGB-1 release (Jiang, Bell & Pisetsky, 2007). 
Late-stage apoptosis is also termed as secondary necrosis, whereby apoptotic 
bodies become permeable and release their contents. Apoptotic bodies are known 
to retain fragments of chromatin and it is likely that HMGB-1 bound to this 
chromatin is released following permeabilisation (Widlak et al., 2002).
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Figure 1.8: Proposed mechanisms of HMGB-1 release from cells.
(A) HMGB-1 released by necrosis; (B) release by endolysosomes which fuse with 
the cell membrane; (C) release by apoptotic bodies during late stage apoptosis. 
(Adapted from Scaffidi et al., 2002; Gardella et a!., 2002; Bell et a!., 2006).
1.15 Extra-cellular functions of HMGB-1
Extra-cellular HMGB-1 acts as a late inflammatory mediator of endotoxin lethality 
leading to sepsis (Qin et al., 2006; Wang et al., 1999) and is found at increased 
levels in serum from patients with sepsis (Gaini et al., 2007a; Gaini et al., 2007b), 
and pancreatitis (Sawa et al., 2006; Yamada et al., 2003). Studies have shown that 
extra-cellular HMGB-1 functions to stimulate the release of pro-inflammatory 
cytokines such as TNF-a and IL-1-p, but suppress mRNA transcription of anti­
inflammatory cytokines IL-10 and TGF-(3 (El Gazzar, 2007). TGF-(3 has many 
functions in controlling cell cycle, survival and proliferation, and is a known inducer 
of apoptosis (Schuster & Krieglstein, 2002). IL-10 is able to suppress cytokine 
release from activated macrophages (Gazzinelli et al., 1996; Janeway Jr et al., 
2005a; Malefyt et al., 1991). This suggests that increasing levels of HMGB-1 
actively down-regulate anti-inflammatory, and, encourage pro-inflammatory 
responses, leading to systemic inflammation (Wang et al., 2001a).
In Balb/C mice, elevated serum levels of HMGB-1 are associated with lethality 
following LPS infection. This effect could be suppressed and mortality reduced 
following injection with anti-HMGB-1 antibodies (Wang et al., 1999). Similar studies
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have also shown the attenuating effects of anti-HMGB-1 antibodies on cytokine 
secretion in other models (El Gazzar, 2007; Sawa et al., 2006). Sawa et al., (2006) 
induced pancreatitis in C3H/HeN mice and following administration of anti-HMGB-1 
found that anti-HMGB-1 attenuated the onset of pancreatitis and associated organ 
dysfunction. An in vitro study by El Mezayen et al. (2007) demonstrated that 
cytokine stimulation by HMGB-1 could be reduced using anti-HMGB-1 antibodies in 
THP-1 and U937 cell lines which were stimulated with NCL containing HMGB-1 in 
con-junction with LPS. They showed that HMGB-1 induced cytokine production 
could be reduced using these antibodies.
Migration of some immune cells in response to HMGB-1 has been reported in some 
cells types. In DCs, HMGB-1 has been found to stimulate the expression of the 
chemokine receptors, CCR7 and CXCR4. When DCs were stimulated with LPS in 
the presence of anti-HMGB-1 antibodies, the expression of these receptors was 
reduced resulting in the reduced migration of DCs to the receptor ligands CCL19 
and CXCL12 (Dumitriu et al., 2007). Migration of fibroblasts to HMGB-1 was 
demonstrated by Palumbo et al. (2007) to be dependent on activation of NF-kP by 
HMGB-1 which could be blocked by pre-incubating fibroblasts with 
ribobenzimidazole (DRB), an inhibitor of transcription.
Chemotaxis of DCs in response to HMGB-1 was demonstrated by Yang et al. 
(2007) who showed that migration of DCs could be induced by HMGB-1 in a dose 
dependent manner and that this migration is receptor mediated by the binding of 
HMGB-1 to the receptor of advanced glycation end products (RAGE).
In relation to intra-cellular Hsp72, IL-1p and TNF-a expression and release was 
reduced in RAW264.7 cells which were given a non-lethal heat shock (42.5°C, 1.5 
h) followed by 12 h recovery (37°C) prior to stimulation with HMGB-1. In RAW264.7 
cells which were transfected to over express Hsp72, cytokine secretion was also 
reduced following stimulation with HMGB-1. Elevated intra-cellular levels of Hsp72 
are known to inhibit NF-kP activation as a feedback response to a stressful insult 
which would lead to the release of HMGB-1 (Tang et al., 2007a; Weiss et al., 2007).
1.16 The role of HMGB-1 within the immune system
As HMGB-1 is implicated as being a mediator in the late inflammatory response 
and in many disease states, such as sepsis (Gaini et al., 2007b; Wang et al., 
2001a), arthritis (Kokkola et al., 2001), atherosclerosis (Kalinina et al., 2004), 
pancreatitis (Yasuda et al., 2007), and lung inflammation (Abraham et al., 2000), 
HMGB-1 must play a functional role in the immune response, and when found in
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the extra-cellular milieu is now widely regarded as a ‘danger signal’ (Bianchi, 2007; 
Harris & Raucci, 2006; Williams & Ireland, 2008).
1.17 Recognition of HMGB-1 by the immune system
HMGB-1 recognition by the immune system is similar to that previously described 
for Hsp72. In the innate immune response, HMGB-1 is released following cell 
damage, stimulation with LPS, and oxidative stress (Chen et al., 2004; Scaffidi et 
al., 2002; Tang et a/., 2007b). It is able to bind PRRs and TLRs leading to the 
stimulation of NF-k(3 activation and consequent up-regulation of cytokines 
(Andersson et at., 2000; O'Connor et at., 2003; Taniguchi et at., 2003; Wang et at., 
2001a), leading to further secretion of HMGB-1 (Kalinina et a!., 2004). The up- 
regulation and expression of CD markers following HMGB-1 stimulation leads to an 
adaptive response, whereby macrophages are activated (Fiuza et al., 2003; 
Rouhiainen et al., 2004) and DCs mature and migrate towards HMGB-1 (Dumitriu 
etal., 2007).
1.18 Stimulation of the innate immune response by HMGB-1
HMGB-1 is able to stimulate the immune response by binding certain cell receptors, 
leading to the up-regulation of cytokines. There are only three identified receptors 
for HMGB-1 to date: TLR-2, TLR-4 and RAGE (Huttunen et al., 2002; Park et al.,
2004). More recent studies suggest that TLR-9 (Tian et al., 2007) may be linked to 
HMGB-1 in association with FtAGE, although direct binding has not been 
elucidated. The effects of binding to the three known receptors are discussed here.
1.18.1 RAGE
The receptor for advanced glycation end products (RAGE) is a multi-ligand receptor 
belonging to the immunoglobulin family. It has been shown to bind s100 proteins, 
amyloid-p protein and HMGB-1 (Chavakis, Bierhaus & Nawroth, 2004; Huttunen et 
al., 2002; Schmidt et al., 2001). RAGE is found within the cell membrane but can 
also be found in a soluble form which blocks the action of RAGE ligands, such as 
HMGB-1 (Rong etal., 2004; Taniguchi etal., 2003).
When HMGB-1 binds to membrane-bound RAGE, it signals partly through the 
MAPK signalling pathway resulting in the secretion of more HMGB-1, and autocrine 
stimulation of HMGB-1 leads to signalling via NF-Kp signalling pathway, resulting in 
the release of pro-inflammatory cytokines (Lotze & Tracey, 2005; Park et al., 2003; 
Riuzzi, Sorci & Donato, 2006) (Figure 1.9).
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1.18.2 TLR-2/TLR-4
As described before, TLR-2 and TLR-4 are PRRs which when stimulated lead to 
downstream activation of NF-kP and interference response factor (IRF) signalling 
pathways, and the production of cytokines and adhesion molecules which mediate 
innate and adaptive immunity in response to inflammation (Takeda et al., 2003). 
HMGB-1 binds rapidly to TLR-2 and TLR-4 expressed on RAW264.7 cells when 
assessed by FRET analysis, and NF-kP activation is up-regulated in HEK-293 cells, 
through TLR-2 in a manner similar to the TLR-2-specific stimulus, Pam3CSK4 , and 
through TLR-4, similar to LPS (Park et al., 2006b; Park et al., 2004) (Figure 1.9).
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HMGB-1
Figure 1.9: Cell surface receptors involved in the immune functions of 
HMGB-1.
Extra-cellular HMGB-1 binds to TLR2 and TLR-4 and activates the MyD88- 
dependent NF-k(3 pathway leading to the release of pro-inflammatory responses. 
Binding through RAGE also follows the MyD88-dependent pathway but MAPK is 
also implicated whereby MAPK leads to NF-k(3 activation and the autocrine up- 
regulation of HMGB-1 which is in turn secreted externally and binds TLR-2, TLR-4 
and/or RAGE.
(Adapted from Lotze & Tracey, 2005; Park et al., 2006; Takeda et al., 2003; 
Huttunen et al., 2002; Taneguchi et al., 2003).
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1.19 Stimulation of the innate immune response by LPS
As previously described Hsp72 and HMGB-1 are able to stimulate the immune 
response through PRRs which include CD14, TLR-2 and TLR-4. This stimulation is 
very similar, if not identical to the immune response to LPS or other bacterial 
products.
LPS stimulates the production of cytokines and activation of the adaptive immune 
response by being presented to a complex receptor cluster on the surface of APCs 
by a lipopolysaccharide-binding protein (LBP) (Mathison et a!., 1992; Triantafilou et 
a!., 2001; Triantafilou & Triantafilou, 2002). LPS from Gram negative and 
lipoteichoic acid (LTA) from Gram positive bacteria are able to bind via this cluster 
which consists of CD14 and TLR-4 in association with MD-2. LPS binds directly to 
CD14 and is cross-linked specifically to TLR4 and MD-2, but only when co­
expressed with CD14 (Dauphinee & Karsan, 2006; Triantafilou & Triantafilou, 
2002). When bound, LPS activates NF-kP signalling pathway through MyD88, 
leading to the production of various cytokines, including IL-ip, IL-6 and TNF-a 
(Dauphinee & Karsan, 2006; Latz et at., 2002; Triantafilou & Triantafilou, 2002) 
(Figure 1.10).
TLR-2 binds Gram negative LPS, Gram positive LTA and petidoglycans, and also 
binds LPS-associated lipopeptides (Kurt-Jones et at., 2002; Means, Golenbock & 
Fenton, 2000; Zhang & Ghosh, 2001). Again, binding is associated with CD14 and 
activates NF-kP signalling pathway downstream of TLR-2, and is the same as for 
TLR-4 (Means et at., 2000) (Figure 1.10).
The immune system can also be stimulated by flagellin, the major component of 
flagellum of Gram negative bacteria which enables motility, such as in E. coli, 
(Hayashi et at., 2001). Flagellin is known to bind TLR-5 and stimulates the 














Figure 1.10: Stimulation of the immune response by various bacterial 
components.
(Adapted from Means et al., 2000; Hayashi et a/., 2001; Zhang et a!., 2001; Kurt- 
Jones et al., 2002; Smith et al., 2003).
30
1.20 Contamination of recombinant proteins by LPS
Many reports have suggested that Hsps, including Hsp72, and HMGB-1 can 
interact with receptors such as CD40, CD14 and TLR-2 and TLR-4 (Asea et al., 
2000b; Dybdahl et at., 2005; Park et at., 2004; Wang et at., 2001b; Yu et at., 2006). 
As these are known receptors for bacterial products, it has been suggested by 
others that the effects on the immune response by recombinant Hsps are the result 
of contamination with bacterial products (Bausinger et al., 2002; Gao & Tsan, 
2003a; Gao & Tsan, 2003b; Tsan & Gao, 2004a). This is potentially an issue with 
studies which have demonstrated an effect by Hsp72 which are recombinantly 
produced from E. coli (Asea et al., 2000a; Menoret, 2004; Valentis et al., 2008). 
Recombinant protein production usually involves transfecting E. coli with plasmid 
DNA containing the desired gene for the protein of interest. The gene also has a 
polyhistidine-tag (His-tag) codon encoded to allow downstream purification of the 
recombinant proteins. Following sufficient replication of E.coli, cells are harvested, 
centrifuged and lysed (usually with detergent or enzymes) before being applied to 
an immobilised metal affinity column. This affinity column is bound with either nickel 
or cobalt ions to which the His-tag binds and any unbound proteins are removed by 
washing with phosphate buffer. The recombinant protein of interest is then eluted 
with imidazole.
Bausinger et al. (2002) originally suggested that maturation of DCs was the result 
of LPS contamination in recombinant Hsp72 preparations. They showed that when 
LPS was reduced from these preparations by polymyxin B agarose, cytokine 
production was not induced, even in the presence of soluble CD14. Gao and Tsan 
(2003a) confirmed that removal of LPS by polymyxin B agarose abrogated any 
effect of Hsp72 on TNF-a secretion by RAW264.7 cells and that pre-incubation of 
cells with polymyxin B solution prior to challenge with Hsp72 gave similar results. 
Their study also indicated that the effect of boiling Hsp72 on TNF-a abrogation was 
due to the low level of LPS contaminant being heat sensitive. Similar experiments 
on recombinant Hsp60 demonstrated the same effect (Gao & Tsan, 2003b). In 
2004, Gao and Tsan published more evidence disputing the effects of Hsps on the 
immune response, through use of gene expression arrays on 96 cytokine genes in 
murine macrophages. Hsp72 and Hsp60 (5 pg/mL) were found to have no 
enhanced effect on gene expression over PBS treated cells, but LPS (1 ng/mL) 
enhanced expression markedly.
There are many studies which oppose this theory that contamination by bacterial 
products is solely responsible for activation of the immune response by Hsps. In 
2000, Kol et al. reported that pre-incubation of PBMCs with polymyxin B did not
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affect the production of IL-6 but pre-incubation with anti-CD14 antibodies or heat 
treatment did. They further demonstrated that Hsp60 could stimulate a CD14 
transfected human cell line (U373) but not a transfected rodent cell line (CHO). This 
suggests that another co-receptor may be involved in cytokine activation within 
rodent systems. It has been demonstrated that pre-incubating Hsps with anti-Hsp 
antibodies markedly reduces cytokine expression in a variety of systems. Retzlaff et 
al. (1994) showed that stimulation of IL-1(3 from BALB/c mice macrophages was 
significantly reduced when various Hsps were pre-incubated with neutralising 
antibodies prior to application on macrophages. Dybdahl et al. (2002) used 
antibodies to CD14 and TLR-4 on adherent monocytes which were able to inhibit 
TNF-a and IL-6 secretion in response to recombinant Hsp72. The use of antibodies 
in this way has been criticised as it is an indirect way of demonstrating binding of 
Hsps, as antibodies to receptors may just be blocking binding of LPS, and anti-Hsp 
antibodies (especially Hsp60) may interfere with Hsp-bound LPS to certain receptor 
complexes (Tsan & Gao, 2007). This is possible as there is growing evidence that 
some Hsps, including Hsp72 can bind LPS (Habich et al., 2005; Triantafilou et al., 
2001).
However, Svensson et al. (2006) applied Hsp72-rich supernatant from 
macrophages stimulated with oxLDL, to naive macrophages. IL-10 and IL-12 
secretion were increased from macrophages treated with this supernatant and the 
effect on secretion could be significantly reduced when the oxLDL supernatant was 
pre-incubated with neutralising anti-Hsp72 antibodies. Also reported is the effect of 
Hsp72 release into supernatant from transfected U937 cells, which was then 
applied to U937 cell cultures (Lee et al., 2006). Hsp72-rich supernatant was able to 
significantly increase expression of matrix metalloproteinase-9 (MMP-9) gene which 
plays a major role in migration of cells (Watanabe et al., 1993). This lead to an 
increase in the migration of U937 cells compared to treatment with supernatant 
from mock transfected cells. Pre-incubation of Hsp72-rich supernatant with anti- 
Hsp72 reduced the expression of MMP-9 and also the migration of U937 cells (Lee 
et al., 2006). More recently, another study has demonstrated that cytokine 
stimulation by Hsp72, or HMGB-1 could be reduced using anti- Hsp72 or HMGB-1 
antibodies in THP-1 and U937 cell lines (El Mezayen et al., 2007). This study did 
not use recombinant protein to stimulate, but instead used pre-stimulated necrotic 
cell lysate (NCL) which contained cell derived Hsp72 and HMGB-1. NCL was 
applied directly to cell cultures or pre-incubated with antibodies to Hsp72 or 
HMGB-1, then applied to cells in conjunction with LPS. They showed that non­
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recombinant Hsp72 and HMGB-1 induced cytokine production could be reduced 
using these antibodies.
Studies on the interaction between HMGB-1 and TLR-2/4 used either cell line 
expressed or purified porcine HMGB-1 (Park et al., 2004; Yu et al., 2006). Yu et al. 
(2006) added polymyxin B to the culture medium of cells prior to experiments and 
still demonstrated that HMGB-1 utilises TLR-2 and TLR-4 to induce TNF-a release 
which could be inhibited in a dose dependent manner with anti- TLR2 and TLR-4 
antibodies. Interestingly, they found that HMGB-1 acted through TLR-4 in human 
whole blood and primary macrophages, and through TLR-2 in RAW264.7 
macrophages and CHO cells over-expressing both TLRs. The reasons for this are 
not clear. Also, the study by El Mezayen et al. (2007) mentioned previously 
demonstrated that antibodies to HMGB-1 could reduce the stimulation of cytokines 
from human cell lines which were incubated with pre-stimulated NCL and LPS, thus 
showing that HMGB-1 itself does stimulate the innate immune response.
These data provide strong evidence that Hsp72 and HMGB-1 do play an important 
role within the immune response.
1.21 Measuring Hsp72
Hsp72 is widely regarded as a biomarker for stress in a variety of plant and animal 
systems (de Pomerai, 1996; Grosvik & Goksoyr, 1996; Ireland et al., 2004; Krasko 
et al., 1997; La Porte, 2005; Lewis et al., 1999; Nadeau et al., 2001; Pyza et al., 
1997; Schroder et al., 2000; Scofield, Bowyer & Duffy, 1999; Terry et al., 2006). 
There is growing evidence demonstrating that Hsp72 could be used as a marker of 
disease and disease progression (Adewoye et al., 2005; Dybdahl et al., 2005; Hay 
et al., 2004; Martin et al., 2003; Wright et al., 2000; Yasuda et al., 2006; Zhu et al., 
2003), and tissue damage following exercise (Madden et al., 2008). This is due to 
the presence of Hsp72 in the peripheral circulation and that it is found elevated in 
some disease states (Njemini et al., 2003b; Wright et al., 2000). It has also been 
demonstrated in vitro to be released under stress compared to controls (Guzhova 
et al., 2001; Luo etal., 2008; Mambula & Calderwood, 2006a).
The measurement of intra-cellular Hsp72 from tissue and cell extracts, and extra­
cellular Hsp72 in supernatants, plasma and serum have been reported using a 
variety of methods, such as densitometry, flow cytometry and ELISAs (Bachelet et 
al., 1998; Davies et al., 2006; Dybdahl et al., 2005; Fehrenbach et al., 2000; Lang 
et al., 2000; Njemini et al., 2003a; Njemini, Demanet & Mets, 2005; Theodorakis, 
Drujan & De Maio, 1999; Tong & Luo, 2000; Walsh et al., 2001). Densitometry is 
generally not a valid method of measurement of any protein as it measures
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differences in optical density between samples of interest, rather than 
measurement against known standards, and it is difficult to compare between 
film/blot due to inherent differences between exposures (Theodorakis et al., 1999). 
Also, densitometry measurements using western blots for Hsp72 in complex 
matrices do not account for the blocking of Hsp72 binding to nitrocellulose by other 
proteins of a similar molecular weight, such as albumin in serum and tissue culture 
supernatants (Mambula & Calderwood, 2006b; Park, Yeo & Park, 2006c). The 
same applies when using densitometry to distinguish between mRNA expression 
(Theodorakis et al., 1999; Tong & Luo, 2000). Therefore, densitometry should only 
be used as a qualitative measure of differences in Hsp72 levels between samples. 
Hsp72 ELISAs are reported to accurately measure Hsp72 protein levels in a variety 
of matrices (Njemini et al., 2005; Njemini et al., 2003b; Walsh et al., 2001; Wright et 
al., 2000). The commercial Hsp72 ELISAs are also reportedly extremely sensitive 
at quantifying Hsp72 in various matrices (Pockley et al., 1999; Walsh et al., 2001). 
They are indirect sandwich ELISAs which use a monoclonal capture antibody 
immobilised to the plastic surface of a treated ELISA plate. Antigen in the form of 
standards and unknown samples are then applied to the plate and any Hsp72 binds 
to the capture antibody. The bound Hsp72 is then detected by a primary rabbit anti- 
Hsp72 antibody which is subsequently bound by a horseradish peroxidise (HRP) 
conjugated anti-rabbit secondary antibody. The addition of an enzyme substrate 
enables the colorimetric detection of bound Hsp72 (Fukushima et al., 2005; Walsh 
et al., 2001; Zhu et al., 2003).
The commercially available ELISAs are costly and have recently been found to be 
unreliable in the determination of levels of Hsp72 in cell culture supernatants that 
contain serum, and serum or plasma samples. It is likely that in the studies 
quantifying Hsp72 in serum or tissue culture supernatants there are some non­
specific matrix problems, such as lipids or other proteins which either prevent 
Hsp72 binding to the bound antibody, or that Hsp72 is already peptide or antibody 
bound (Asea et al., 2000a; Child et al., 2006; Murray et al., 2001; Pockley et al., 
1998; Urbonaviciute et al., 2007). As a result, many studies have employed their 
own in-house ELISAs, although they are mainly based on those commercially 
available (Njemini et al., 2005; Njemini et al., 2003b; Pockley et al., 1998; Rea, 
McNerlan & Pockley, 2001). The reported levels of Hsp72 found in serum samples 
with these commercial or in-house methods are extremely varied. All the lower 
Hsp72 levels reported utilised a commercial Hsp72 ELISA (Stressgen Inc., EKS- 
700). Interestingly, the studies reporting high levels of Hsp72 in serum all perform 
ELISAs using the same components utilised by the commercially available ELISA.
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Therefore it cannot be assumed that measurements of Hsp72 in serum and cell 
culture supernatants which have been reported are accurate, although supporting 
the specificity of these antibodies are western blots that have been used to detect 
intra-cellular Hsp72 in cell extracts (Davies et al., 2006; Downs et al., 2002; Tavaria 
eta!., 1996; Tsuchiya etal., 2003).
Also, other studies measuring Hsp72 by ELISA in tissue culture supernatants do 
not use serum supplemented media when performing experiments which may 
result in inaccurate effects due to extra stress on cells (Mambula & Calderwood, 
2006b).
1.22 Aims and objectives
The role of extra-cellular Hsp72 is still not fully understood.
This thesis aims to examine aspects of the role for Hsp72 in being a danger signal 
to the innate immune system.
The objectives of this thesis are:
• To develop a method of measuring Hsp72, both intracellular and 
extracellular, from cell extracts and cell culture supernatants.
• To determine whether LPS contamination is responsible for the 
reported stimulation by recombinant Hsps.
• To determine the relative contributions of Hsp72 and LPS to the 
immune response.
• To determine the cell surface receptors Hsp72 can bind leading to 
stimulation of the immune system.
• To determine whether cell derived Hsp72 can stimulate an immune 
response in macrophages.






0.2 mL PCR tubes
Starlab (UK) Ltd. Part no. B1402-4300
0.6 mL Microcentrifuge tubes
Thermo Fisher Scientific Inc. Part no. TUL-918-010X
1.2 mL Micro dilution tubes
Starlab (UK) Ltd. Part no. E1730-9000
1.5 mL Microcentrifuge tubes
Thermo Fisher Scientific Inc. Part no. TUL-918-014G
12-well Cell Culture Plates
Thermo Fisher Scientific Inc. Part no. TKT-520-070H
25 cm2 Cell Culture Flasks
Thermo Fisher Scientific Inc. Part no. 136196
48-well Cell Culture Plates
Thermo Fisher Scientific Inc. Part no. TKT-522-070S
96-well Cell Culture Plates
Thermo Fisher Scientific Inc. Part no. DPS-130-01 ON
96-well TC-treated Black Clear Bottomed Plates
Thermo Fisher Scientific Inc. Part no. DPS-130-020K
96-well aluminium insert for Dri-Block
Thermo Fisher Scientific Inc. Part no. BLD-810-560Q
BD Eclipse Blood Collection Needle, 21 g
Southern Syringe Services Ltd. Part no. 368609
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BD Vacutainer One Use Holder
Southern Syringe Services Ltd. Part no. 364815
BD Vacutainer® Whole Blood Tube, K2EDTA, 10 mL
Southern Syringe Services Ltd. Part no. 367895
BD Vacutainer® Whole Blood Tube, K2EDTA, 6 mL
Southern Syringe Services Ltd. Part no. 367873
Bio-Rad ChemiDoc XRS Molecular Imaging System
Bio-Rad Laboratories Ltd. Part no. 170-8070
Bio-Tek Synergy™ HT Multi-Detection Microplate Reader
Labtech International Ltd. Part no. SIAFR
Bright-Line™ Haemocytometer
Sigma-Aldrich Ltd. Part no. Z359629
Circulating Water Bath
Wolf Laboratories Ltd. Part no. GD100-P5
Dynex Ultrawash PLUS™ Plate Washer
Jencons (Scientific) Ltd. Part no. 701-005
E100 Binocular Microscope
Jencons (Scientific) Ltd. Part no. 450-951
Extra Thick Blot Paper
Bio-Rad Laboratories Inc. Part no. 170-3965
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Hermle Z323K Refrigerated Centrifuge
VWR International Ltd. Part no. 521-0221
including:
Swing-out Rotor (8X15 mL)
Part no. 521-0189 
Fixed-angle Rotor (24 X 1.5 mL)
Part no. 521-0201 
Fixed-angle Rotor (8 X 50 mL)
Part no. 521-0194
High Speed Mini Orbital Shaker
Wolf Laboratories Ltd. Part no. SSM5
HTS Transwell-96 Well Permeable Support System
Thermo Fisher Scientific Inc. Part no. HTS-106-050J
Inverted TE2000-U Microscope System
Nikon Corporation Ltd.:
Eclipse TE2000-U Basic Unit
Part no. MEA51010
Eposcopic Fluorescence Attachment (Hg)
Part no. MEE54000
CFI Plan Fluor ELWD Objectives
Part nos. MRH38220/MRH38420/MRH18620
Hamamatsu Orca -  285 Digital CCD Camera
Part no. 1HMOC285




LMS Series 1 Cooled Incubator
Wolf Laboratories Ltd. Part no. 305
Mini Trans-Blot Electrophoretic Transfer Cell
Bio-Rad Laboratories Inc. Part no. 170-3930
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Mini-PROTEAN® II Electrophoresis Cell
Bio-Rad Laboratories Inc. Part no. 165-2940
Nitrocellulose Membrane, 0.45 pm
Bio-Rad Laboratories Inc. Part no. 162-0115
Non-binding 96-well plates
Thermo Fisher Scientific Inc. Part no. FB56426
Nunc Immuno Maxisorp 96-well plates
Thermo Fisher Scientific Inc. Part no. DIS-971-030J
PowerPac™ 3000 Power Supply
Bio-Rad Laboratories Inc. Part no. 165-5057
Sigma 1-14 Microcentrifuge
Wolf Laboratories Ltd. Part no. 10016
Slide-A-Lyzer Dialysis Cassette Kit, 10K MWCO
Pierce Biotechnology Inc. Part no. 66382
SwellGel® Blue albumin removal kit
Pierce Biotechnology Inc. Part no. 89845
Techne Dri-Block DB-3
Thermo Fisher Scientific Inc. Part no. BLD-715-010G
Temperature-controlled, stirred water bath, GD100-S5
Thermo Fisher Scientific Inc. Part no. BLE-650-010G
Ultrafree®-CL microcentrifuge filters, NMWL 100 kDa
Sigma-Aldrich Ltd. Part no. M-2286
Ultrafree®-CL microcentrifuge filters, NMWL 30 kDa
Sigma-Aldrich Ltd. Part no. M-1661
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Vortex mixer, mini
Thermo Fisher Scientific Inc. Part no. GBI-900-010E
Zeba™ desalt spin columns, 2 mL
Pierce Biotechnology Inc. Part no. 89889
Zeba™ desalt spin columns, 5 mL




Sigma-Aldrich Ltd. Part no. 320099-2.5L
Acrylamide
VWR International Ltd. Part no. 442994J
Agarose 1
Anachem Ltd. Part no. 0710-500G-R
e-Amino-n-caproic acid
Sigma-Aldrich Ltd. Part no. A-7824
Ammonium Persulphate
Sigma-Aldrich Ltd. Part no. A-3678
Antibiotic/Antimycotic Solution (100X)
Sigma-Aldrich Ltd. Part no. A-5955
Anti-FliC (flagellin) antibody
Cambridge Bioscience Ltd. Part no. 629701
Anti-mouse IgG (whole molecule)-Biotin antibody
Sigma Aldrich Ltd. Part no. A-6649
Anti-Mouse IgG (whole molecule)-Peroxidase antibody
Sigma-Aldrich Ltd. Part no. A-5278
Anti-Sheep IgG (whole molecule)-Peroxidase antibody
Sigma-Aldrich Ltd. Part no. A-3415
Benzamidine
Sigma-Aldrich Ltd. Part no. B-6506
Borrelia p41 recombinant flagellin of E. coli origin
Autogen Bioclear UK Ltd. Part no. ABC1111
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Bovine Serum Albumin
Sigma-Aldrich Ltd. Part no. A-7906
Bromophenol Blue
Thermo Fisher Scientific Inc. Part no. B/4630/44
Camptothecin
Sigma-Aldrich Ltd. Part no. C9911
CD14 (N-15) Blocking Peptide
Santa Cruz Biotechnology Inc. Part no. sc-6998-P
CD36 (N-15) Blocking Peptide
Santa Cruz Biotechnology Inc. Part no. sc-5522-P
CellTiter® Aqueous One Solution Cell Proliferation Assay
Promega UK Ltd. Part no. G3580
Coomassie (Bradford) Protein Assay Kit
Pierce Biotechnology Inc. Part no. 23200
DEGLKGKISEAD Custom-made Peptide
KJ Ross-Petersen, Denmark.
DEGLKGKISEAD-KLH Conjugated Custom-made Peptide
KJ Ross-Petersen, Denmark.
Dimethyl Sulfoxide
Sigma-Aldrich Ltd. Part no. D-2650
DL-Dithiothreitol
Sigma-Aldrich Ltd. Part no. D-0632
Escherichia coli DnaK Protein
Assay Designs Inc. Part no. SPP-630
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Escherichia coli GroEL Protein
Assay Designs Inc. Part no. SPP-610
Escherichia coli GroES Protein
Assay Designs Inc. Part no. SPP-620
Enzolyte™ Rh110 Caspase-3 Assay Kit
Anaspec Inc. Part no. 71141
Escherichia coli 0111:B4 Lipopolysaccharide
Sigma-Aldrich Ltd. Part no. L-4391
Ethylenediaminetetraacetic acid, anhydrous (EDTA)
Sigma-Aldrich Ltd. Part no. E-6758
Extravidin® peroxidise conjugate
Sigma Aldrich Ltd. Part no. E-2886
EZ-Link® NHS-PE04-Biotinylation Kit
Pierce Biotechnology Inc. Part no. 21455
Foetal Bovine Serum (FBS)
Cambrex Corporation. Part no. 14-810F
Glycine
VWR International Ltd. Part no. 101196X
HABA/Avidin Reagent
Sigma-Aldrich Ltd. Part no. H-2153
Histopaque®-1077 Hybri-max Solution
Sigma-Aldrich Ltd. Part no. H-8889
HMG1 (HMGB-1) Antibody
Assay Designs Inc. Part no. CSA-614
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Part no. H-4652
HMG-1 (HMGB-1) Human Protein
Sigma-Aldrich Ltd.
Human IL-1P (lnterleukin-1 beta) ELISA Ready-SET-Go! Kit
eBioscience Inc. Part no. 88-7010
Human IL-6 (lnterleukin-6) ELISA Ready-SET-Go! Kit
eBioscience Inc. Part no. 88-7066
Human IL-10 (Interleukin-10) ELISA Ready-SET-Go! Kit
eBioscience Inc. Part no. 88-7106
Human TNF-a (Tumor Necrosis Factor alpha) ELISA Ready-SET Go! Kit
eBioscience Inc. Part no. 88-7346
Hydrochloric Acid, 37%
Sigma-Aldrich Ltd. Part no. 320331
Imject® Alum
Pierce Biotechnology Inc. Part no. 77161
Immobilized TCEP Disulfide Reducing Gel
Pierce Biotechnology Inc. Part no. 77712
Imperial Protein Stain
Pierce Biotechnology Inc. Part no. 24615
L-Glutamine Solution (200 mM)
Cambrex Corporation. Part no. 17-605E
P-Mercaptoethanol
Thermo Fisher Scientific Inc. Part no. M/P200/05
2-Mercaptoethylamine HCI
Sigma-Aldrich Ltd. Part no. M-9768
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Methanol
VWR International Ltd. Part no. 152506X
Microlink™ Peptide Coupling Kit
Pierce Biotechnology Inc. Part no. 20485
N,N,N’,N’-Tetramethylethylenediamine (TEMED)
Sigma-Aldrich Ltd. Part no. T-9281
N’N’-Methylenebisacrylamide
VWR International Ltd. Part no. 4433003N
Phenylmethylsulfonyl fluoride
Sigma-Aldrich Inc. Part no. P-7626
Phorbol 12-Myristate 13-Acetate
Sigma-Aldrich Ltd. Part no. P-1585
Phosphate Buffered Saline without Ca++ or Mg++
Cambrex Corporation. Part no. BE17-516F
Polymixin B Solution
Sigma-Aldrich Ltd. Part no. 81271
Potassium Chloride
Sigma-Aldrich Ltd. Part no. P-5405
Potassium Dihydrogen Orthophosphate
VWR International Ltd. Part no. 102034B
Precision Plus9 Protein Dual Colour Standards
Bio-Rad Laboratories Inc. Part no. 161-0374
Precision Plus9 Protein Unstained Standards
Bio-Rad Laboratories Inc. Part no. 161-0363
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Protease Inhibitor Cocktail 100X
Sigma-Aldrich Ltd. Part no. P-8340
QCL-1000 Chromogenic LAL Endotoxin Detection Assay Kit
Cambrex Corporation. Part no. 50-647U
Recombinant Human Hsc70 (Hsp73) Protein
Assay Designs Inc. Part no. SPP-751
Recombinant Human Chaperonin 10 (Cpn10) Protein - Low Endotoxin
Assay Designs Inc. Part no. ESP-110
Recombinant Human Hsp70 (Hsp72) Protein, baculovirus expressed
Stressmarq Biosciences Inc. Part no. SPR-115
Recombinant Human Hsp70 (Hsp72) Protein
Assay Designs Inc. Part no. ESP-555
Recombinant Human Hsp70 (Hsp72) Protein - Low Endotoxin
Assay Designs Inc. Part no. NSP-555
Recombinant Human Hsp60 Protein - Low Endotoxin
Assay Designs Inc. Part no. NSP-540
RPMI-1640 Medium
Cambrex Corporation. Part no. BE12-702F
RPMI-1640 Medium, Phenol Red-Free
Cambrex Corporation. Part no. BE12-918F
Sheep IgG
Sigma-Aldrich Ltd. Part no. 1-5131
Sodium Acetate, trihydrate
VWR International Ltd. Part no. 27652.232
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Sodium Bicarbonate
Sigma-Aldrich Ltd. Part no. S-6297
Sodium Carbonate
Sigma-Aldrich Ltd. Part no. S-7795
Sodium Chloride
Sigma-Aldrich Ltd. Part no. S-7653
Sodium Deoxycholate
Sigma-Aldrich Ltd. Part no. D-6750
Sodium Dihydrogen Orthophosphate 1-hydrate
VWR International Ltd. Part no. 102454R
Sodium Dodecyl Sulphate
VWR International Ltd. Part no. 442444H
Sucrose
Sigma-Aldrich Ltd. Part no. S-7903
SwelIGel® Blue Albumin Removal Kit
Pierce Biotechnology Inc. Part no. 89845
SuperSignal® West Pico chemiluminescent substrate
Pierce Biotechnology Inc. Part no. 30477
TATDKSTGKAN Custom-made Peptide
KJ Ross-Petersen, Denmark.
TATDKSTGKAN-KLH Conjugated Custom-made Peptide
KJ Ross-Petersen, Denmark.
3,3\5,5’-Tetramethylbenzidine (TMB) Substrate
Cheshire Sciences (UK) Ltd. Part no. UP664781
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Thimerosal
Sigma-Aldrich Ltd. Part no. T-8784
TLR2 (N-17) Blocking Peptide
Santa Cruz Biotechnology Inc. Part no. sc-8689-P
TLR4 (C-18) Blocking Peptide
Santa Cruz Biotechnology Inc. Part no. sc-8694-P
TLR5 (N-15) Blocking Peptide
Santa Cruz Biotechnology Inc. Part no. sc-8695-P
TLR7 (H-20) Blocking Peptide
Santa Cruz Biotechnology Inc. Part no. sc-13208-P
Tris (hydroxymethyl)methylamine
VWR International Ltd. Part no. 443866G
Triton® X-100
Sigma-Aldrich Ltd. Part no. T-8787
Trypan Blue Solution (0.4%)
Sigma-Aldrich Ltd. Part no. T-8154
Tween® 20
Sigma-Aldrich Ltd. Part no. P-1379
U937 Human Cell Line
European Collection of Cell Cultures. Part no. 85011440
2.2.1 Hsp72 ELISA buffers
0.1 M Sodium bicarbonate buffer, pH 9.6
Sodium carbonate (10.6 g) and sodium bicarbonate (8.4 g) were added to 1 L of 
dH20  and pH adjusted to 9.6.
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0.15 M Phosphate buffered saline, pH 7.2 (PBS)
Sodium chloride (8.0 g), potassium chloride (0.2 g), potassium dihydrogen 
orthophosphate (0.24 g) and sodium dihydrogen orthophosphate (1.44 g) were 
added to 1 L of dH20  and pH adjusted to 7.2.
Blocking buffer
0.5 % (w/v) bovine serum albumin (BSA) was dissolved in PBS.
Wash Buffer
Phosphate buffered saline, pH 7.2 plus 0.05 % (v/v) Tween®20 and 0.01 % 
(w/v) thimerosal.
Detector antibody
The detector antibody was a kind gift from Dr Torsten Nygard, Faculty of 
Agricultural Sciences, Aarhus University, Denmark. It is a mouse monoclonal 
antibody raised against Bovine Hsp70 (H-9776, Sigma-Aldrich Ltd.) which is 
specific for Hsp72 and at a concentration of 1 mg/mL in PBS + 0.01 % (w/v) 
thimerosal.
1 M Phosphoric acid
Orthophosphoric acid (6.8 mL) was diluted with dH20  up to 100 mL.
2.2.2 Cell extraction buffer
Tris base (0.315 g), EDTA (0.004 g) and DL-dithiothreitol (0.01 g) was made up 
to 100 mL with dH20  and pH adjusted to 7.4. This was then supplemented with 
phenylmethylsulfonyl flouride (0.035 g), e-amino-n-caproic acid (0.065 g), 
benzamidine (0.016 g) and 0.1% (v/v) Triton X-100. This was prepared up to 
one month in advance and stored at 4°C.
2.2.3 SDS-PAGE buffers 
1.5 M Tris-HCI, pH 8.8
Tris base (18.5 g) was added to 40 mL of dH20  and pH adjusted to 8.8 then 
made up to 100 mL with dH20.
0.5 M Tris-HCI, pH 6.8
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Tris base (3.0 g) was added to 40 mL of dH20  and pH adjusted to 8.8 then 
made up to 100 mL with dH20.
Acrylamide-bis
Acrylamide (30.0 g)and N’N’ bismethylene acrylamide (0.8 g) was added to 
100 mL of dH20, stirred thoroughly then filtered through Whatman #1 filter 
paper.
10 % SDS solution
SDS (10.0 g) was added to 100 mL of dH20.
10 % Ammonium persulphate
Ammonium persulphate (0.1 g) was added to 1 mL of dH20. This was freshly 
prepared when required.
0.05 % Bromophenol blue
Bromophenol blue (0.01 g) was added to 20 mL of dH20.
Non-reducing sample buffer
Sucrose (2.4 g), 0.5 M Tris-HCI pH 6.8 (2.0 mL), 10 % SDS solution (2.0 mL), 
0.05 % bromophenol blue (0.4 mL) was added to 9.1 mL of dH20  and mixed 
thoroughly.
Reducing sample buffer
Non-reducing sample buffer plus DL-dithiothreitol (0.02 g).
Electrode buffer, pH 8.3
Tris base (5.4 g), glycine (25.92 g) and 10 % SDS solution (9.0 mL) was added 
to 900 mL of dH20  and stirred thoroughly. This was prepared a day prior to use 
and stored at 4°C.
2.2.4 Western blotting buffers
Transfer buffer
Tris base (3.03 g), glycine (14.4 g) and 200 mL methanol was made up to 1 L 
with dH20. This was prepared a day prior to use and stored at 4°C.
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Tris buffered saline (TBS)
Tris base (2.42 g) and NaCI (29.22 g) was added to 750 mL of dH20, pH 
adjusted to 7.5 then made up to 1 L with dH20.
Washing solution (TTBS)
Tween®20 (0.05 % v/v) was added to 500 mL of TBS and stirred thoroughly. 
Blocking solution
BSA (1 % w/v) was added to 50 mL of TBS and stirred thoroughly.
Antibody buffer
BSA (1 % w/v) was added to 100 mL of TTBS and stirred thoroughly.
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2.3 Methods
2.3.1 Screening of sheep serum for peptide-specific antibodies.
Peptides were coated onto Nunc Immuno Maxisorp 96-well plates, 100 pL per well 
at 5 pg/mL in 0.1 M sodium bicarbonate buffer and incubated overnight at 4°C. 
Plates were then washed three times with ELISA wash buffer using an automated 
plate washer and plates were blotted dry. Plates were then blocked with 250 pL per 
well blocking buffer and incubated at 25°C for 1 h. Plates were washed and dried 
as before. Serum from immunised sheep was diluted 1/100, 1/1000, and 1/10000 in 
PBS and applied to the plate at 100 pL per well. Control pre-immune serum was 
added at the same dilutions, as controls. The plate was then incubated at 37°C for 
1 h. Plates were washed and dried as before. An anti-sheep IgG peroxidase- 
labelled antibody was diluted 1/1000 with 0.5 % BSA (w/v) in wash buffer and 
applied to the plate at 100 pL per well and incubated for 1 h at 25°C. Plates were 
washed and dried as before and TMB substrate applied at 100 pL per well for 30 
min in the dark at 25°C. The reaction was stopped with 100 pL per well 
1 M phosphoric acid and the plates read at 450 nm using a microplate reader.
2.3.2 Reduction of disulfide bonds in peptides.
Reduction of disulfide bonds in peptides were performed using immobilized TCEP 
gel.
TCEP gel slurry (400 pL) was added to a Handee™ spin cup column and placed 
into a collection tube. The column was centrifuged at 50 g for 30 sec. Supernatant 
was discarded and the gel washed with 300 pL peptide coupling buffer (component 
of Microlink™ peptide coupling kit) by adding coupling buffer to the column, 
vortexing briefly and centrifuging at 50 g for 1 min. The gel was washed a total of 5 
times. Peptide was dissolved in 300 pL coupling buffer (1 mg/mL), added to the top 
of the gel and vortexed briefly before incubation for 60 min at 25°C. Reduced 
peptide sample was then collected by centrifugation at 50 g for 1 min.
The reduced sample was then used immediately for generating an affinity column 
using the Microlink™ peptide coupling kit.
2.3.3 Immobilization of peptide onto iodoacetyl gel.
Peptides with free, reduced sulfhydryl groups can be coupled to iodoacetyl gel to 
form an affinity substrate for purification of antibodies, lodoacetyl gel reacts with 
free sulfhydryl groups to form a stable thioether link on a 15-atom spacer which
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allows binding between peptide and antibody to be more efficient. The iodoacetyl 
gel was purchased pre-packed in spin columns for ease of use.
All reagents were brought to 25°C before use.
Peptide was dissolved in 300 pL of coupling buffer resulting in a peptide 
concentration of 1 mg/mL.
The column cap was loosened and base plug was removed, and the column placed 
into a collection tube which was then centrifuged at 1000 g for 2 min.
The cap was removed and plug reinserted, and the gel was re-suspended in 
300 pL of coupling buffer. The cap was loosened, plug removed and column placed 
in a collection tube then centrifuged at 1000 g for 2 min. Flow through was 
discarded. This step was repeated twice more.
The column was then plugged and 250 pL of peptide sample added directly to the 
gel; 5 pL of sample was retained for analysis. The cap was replaced and gel and 
sample mixed using a vortex at low speed. The column was then incubated 
overnight at 4°C followed by centrifugation at 1000 g for 1 min. The flow through 
was retained to determine coupling efficiency.
The column was then plugged, coupling buffer (300 pL) added and cap replaced. 
The column was gently inverted 10 times followed by centrifugation as before. This 
step was repeated twice more. Flow-through was retained to determine coupling 
efficiency.
The remaining active sites on the iodoacetyl gel were blocked by the addition of 
2 mg of L-cysteine in 200 pL of coupling buffer which was added to the gel, mixed 
gently and incubated for 60 min at room temperature with mixing every 15 minutes. 
The column was then centrifuged at 1000 g for 1 min and 300 pL of wash solution 
(1 M NaCI) added. The column was gently inverted 10 times followed by 
centrifugation as before. This step was repeated twice more.
PBS (300 pL) was added to the column, plug and cap replaced, and gently inverted 
10 times followed by centrifugation as before. This step was repeated twice more 
followed by the addition of 300 pL PBS containing 0.02 % (w/v) sodium azide. The 
column was then stored at 4°C until required for affinity purification of antibodies. 
Coupling efficiency was determined by comparing protein concentration of peptide 
sample prior to coupling, after coupling, and flow-through from wash steps.
2.3.4 Affinity purification of polyclonal antibodies.
Immobilized peptide and buffers were equilibrated to room temperature prior to use. 
Column cap and plug were removed and column centrifuged at 1000 g for 1 min 
and flow-through discarded. 300 pL of PBS was then added to the column and cap
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and plug replaced before mixing gently by inversion. Cap and plug were then 
removed and the column centrifuged as before and flow-through discarded. This 
step was repeated once more. The plug was then replaced and 250 pL of serum 
was added to the column and cap replaced; 5 pL of sample was retained for 
analysis. The column was then incubated overnight at 4°C. Cap and plug were 
removed and the column centrifuged at 1000 g for 1 min. Flow-through was 
retained for analysis. Wash solution was prepared by diluting original wash solution 
(1 M NaCI) 1:1 with dH20  containing 0.05 % (v/v) Tween®-20.The plug was then 
replaced and 300 pL diluted wash solution added. The cap was replaced and 
column gently inverted 10 times. The plug was then removed and column was 
centrifuged at 1000 g for 1 min. Flow-through was retained for analysis. This step 
was repeated twice more.
PBS (300 pL) was then added to the column and mixed as before. The column was 
then centrifuged as before and flow-through retained for analysis. This step was 
repeated twice more.
PBS (300 pL) was then added to the column in 100 pL increments down the sides 
of the column to wash the immobilized peptide gel down. The plug was then 
removed and the column centrifuged as before. Flow through was discarded. The 
plug was replaced and 100 pL of elution buffer was added to the column and was 
gently mixed by tapping on the bench top. The cap was replaced and the column 
was incubated at room temperature for 10 min. Following incubation the column 
cap and plug were removed and the column centrifuged at 1000 g for 1 min. Eluate 
was collected and immediately neutralised with 5 pL of 1 M Tris, pH 9.0. Elution 
steps were repeated four more times to ensure maximum elution of pure 
antibodies, followed by buffer exchange to PBS using desalting columns (Section 
2.3.4). The column was then regenerated by washing three times with 300 pL of 
coupling buffer followed by two washes with PBS. PBS containing 0.02 % (w/v) 
sodium azide (300 pL) was then added to the column and stored at 4°C until 
required for use again.
2.3.5 Buffer exchange and desalting of purified antibodies.
Buffer exchange and desalting of antibodies was performed using Zeba™ desalting 
spin columns.
Columns and buffers were brought to 25°C prior to use. The column bottom closure 
was twisted off and cap loosened then placed in a 15 mL collection tube. The 
column was centrifuged at 1000 g for 2 min to remove storage solution. PBS buffer 
(2.5 mL for 5 mL column, and 1 mL for 2 mL column) was then added dropwise to
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the column. The column was then centrifuged as before and buffer discarded. This 
was repeated 4 times to ensure complete removal of residual storage solution. 
Antibody sample (1 mL for 5 ml. column, and 500 pL for 2 mL column) was then 
pipetted slowly onto the centre of the resin bed followed by a stacker of ddH20 
(100 pL) to ensure maximal protein recovery. The column was then centrifuged at 
1000 g for 2 min and sample collected.
2.3.6 Biotinylation of antibodies
All reagents were brought to room temperature before use. IgG at a concentration 
of between 1-10 mg diluted in 0.5-2 mL of PBS was prepared. NHS-PE04-biotin 
was dissolved in 170 pL of dH20  to prepare a 20 mM solution. The appropriate 
volume of NHS-PE04-biotin was added to the IgG sample. The reaction was then 
incubated on ice for two hours and the biotinylated IgG sample was collected and 
desalted using desalting spin columns (See method 2.3.5).
2.3.7 Determination of biotin incorporation.
A generic HABA assay was used to determine the number of biotin molecules 
incorporated per antibody molecule.
HABA/avidin solution 45 pL was pipetted in triplicate onto a non-binding 96-well 
microtitre plate well and the absorbance was measured at 500 nm. The value was 
recorded as A 50o HABA/avidin. Then 5 pL of biotinylated antibody was added to 
each well containing the HABA/avidin solution and mixed briefly on a plate shaker. 
Absorbance was then measured multiple times at 500 nm until the signal was 
stable for at least 15 sec. This value was then recorded as A 50o HABA/avidin/biotin. 
The calculation to determine biotin incorporation was as follows:
Calculation 1 -  concentration of biotinylated protein in mM/mL
protein concentration (mg m) _ . ,mM protein per ml = ---- --^ \ f — f- ■ = Ca/c 1molecular weight of protein (mg mM)
Calculation 2 -  change in absorbance at 500 nm
a A 5oo = (>4500 HABAIavidin) -  (As oo H ABA!avidinlbiotin) = Calc 2
Calculation 3 -  concentration of mM biotin per mL
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mM biotin Calc 2 = Calc 3ml reaction mixture 34,000x0.5
Calculation 4 -  mM of biotin per mM of antibody
mM biotin per mM antibody = (Calc 3) x 10 x dilution factor Calc 1
2.3.8 Determination of protein concentration of samples.
Sample protein concentration was determined using a coomassie dye protein assay 
which is a modified version of the Bradford binding assay (Bradford, 1976). It 
utilises coomasie blue dye which binds to amino acid residues resulting in a shift in 
absorbance from 465 nm to 595 nm when protein is bound. This can be visualised 
as a colour change from brown to blue.
All protein concentrations were determined using the microplate method.
Protein standards (2 - 0.125 mg/mL) were prepared using bovine serum albumin 
(BSA) diluted in the appropriate buffer. Standards, zero control and samples (5 pL) 
were added in triplicate to a non-binding 96-well microtitre plate followed by the 
addition of 250 pL of dye reagent solution. The plate was then incubated at 25°C 
with shaking for 5 min. Absorbance was then measured at 595 nm. If sample 
concentrations were higher than within the working range of the assay, they were 
subsequently diluted in appropriate buffer until within range.
If sample concentrations were lower than the working range, the assay was 
modified as follows:
BSA standards were prepared within the range 100 - 3.125 pg/mL in appropriate 
buffer. Standards, zero control and samples (75 pL) were then dispensed onto a 
non-binding 96-well microtitre plate in triplicate followed by the addition of 75 pL of 
dye reagent concentrate. The plate was incubated at 25°C with shaking for 5 min 
and absorbance read at 595 nm.
2.3.9 Determination of IgG concentration.
Purified IgG concentration was measured using the method described in section
2.3.8 except that IgG from the appropriate animal species was used to generate the 
standards instead of BSA. All other conditions remained the same.
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2.3.10 SDS-PAGE electrophoresis.
Sodium dodecyl sulphate -  polyacrylamide electrophoresis (SDS-PAGE) was used 
to analyse cellular protein extracts, proteins released into the extra-cellular media, 
and to determine antibody purification techniques.
Following determination of protein or IgG concentration (Sections 2.3.8 - 2.3.9), all 
samples were adjusted in the appropriate buffer until all contained the same 
amount of protein. They were then diluted 1:1 with sample buffer (either reducing or 
non-reducing (Section 2.2.3).
All reduced samples were denatured by heating at 75°C for 10 min followed by 
cooling for 10 min prior to use.
Non-reduced samples were applied directly onto the gel.
Precision Plus® standards that do not require any pre-treatment were used as a 
molecular weight reference.
Samples were separated using homogenous percentage SDS-PAGE gels as 
described by Laemmli (1970) using the Bio-Rad mini-protean II electrophoresis 
apparatus. For all buffers required see section 2.2.3.
All samples were run using 10 % separating gels. The following method is for 
running two 1 mm spaced gels.
The 10 % separating gels were prepared by adding the following to a small side- 
arm flask: dH20  (6.05 ml_), 1.5M Tris-HCI, pH 8.8 (3.75 mL), 10% SDS solution 
(150 pL) and acrylamide-bis (5.0 mL). This was then degassed for 15 min before 
the addition of 10 % ammonium persulphate (50 pL) and TEMED (7.5 pL). The 
solution was then quickly pipetted between the glass plates until 2 cm from the top 
of the inner plate, then carefully overlaid with 1 mL of dH20  and allowed to 
polymerise for 1 h.
The dHzO was poured off and a 3 % stacking gel was prepared by adding the 
following to a small side-arm flask: dH20  (3.15 mL), 0.5 M Tris-HCI, pH 6.8 
(1.25 mL), 10 % SDS solution (50 pL) and acrylamide-bis (500 pL). This was then 
degassed for 15 min before the addition of 10 % ammonium persulphate (50 pL) 
and TEMED (5.0 pL). The well combs were put into place and the stacking gel 
solution poured and allowed to polymerise for 1 h. The well combs were then 
removed and the gel apparatus assembled and electrode buffer added to the inner 
reservoir and outer tank. Standards and samples were then loaded onto the 
stacking gel and the gel run at 200 V (constant voltage) until the bromophenol blue 
dye front was within 2 mm of the bottom of the separating gel. The gel was then
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carefully removed and either stained for total proteins or electro-transferred by 
western blotting onto nitrocellulose membrane for probing with specific antibodies.
2.3.11 SDS-PAGE total protein staining.
For visualisation of proteins on SDS-PAGE gels, Imperial protein stain which is a 
modified coomasie blue dye was used. Following SDS-PAGE, the gels were 
removed from the apparatus and washed three times with 100 mL dH20, with 
shaking, followed by staining with 20 mL per gel of protein stain for 1 h, with 
shaking. The stain was then poured off and the gel washed with 200 mL dH20  
which was replaced frequently to increase band intensity in relation to background. 
This was maximized by overnight washing with 200 mL dH20.
Stained gels were visualized and recorded using the Bio-Rad ChemiDoc imaging 
system.
2.3.12 Western blotting.
Following SDS-PAGE electrophoresis (Section 2.3.10), gels were subjected to 
electrophoretic transfer to nitrocellulose membrane by western blot using the 
Bio-Rad mini-trans blot apparatus. For all reagents required see section 2.2.4.
For each gel, pre-cut nitrocellulose membrane, pre-cut filter paper and sponges 
were soaked in transfer buffer. The transfer cassette was then assembled as 









When placing the membrane on top of the gel, care was taken to ensure there were 
no air bubbles in between and good contact was made. This was achieved by using 
a test tube as a rolling pin. The transfer cassette was then closed and placed within 
the blotting apparatus along with the cooling unit and that tank filled with transfer
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buffer. The transfer was run at 100 V (constant voltage) for 1 h. Following transfer 
the nitrocellulose blot was removed and immuno-stained using specific antibodies.
2.3.13 Immuno-staining of western blots.
For all buffers required see section 2.2.4. After western blotting electro transfer, the 
blot was blocked in blocking solution for 1 h at 25°C. Blocking solution was then 
poured off and the blot incubated with antigen specific antibody at the appropriate 
dilution in 50 mL of antibody buffer (Section 2.2.4) and incubated overnight at 4°C. 
Solution was then discarded and the blot washed three times with 50 mL washing 
solution before being incubated with appropriate dilution of secondary enzyme- 
labelled antibody or enzyme-labelled avidin in 50 mL antibody buffer for 1 h at 
25°C. The blot was washed five times with 50 mL washing solution then incubated 
with 2 mL Supersignal West Pico chemiluminescent substrate for 5 min, then 
visualised and recorded using the Bio-Rad ChemiDoc imaging system.
2.3.14 Optimisation of primary and secondary labelled antibody dilutions for 
Hsp72 ELISAs.
Nunc Immuno Maxisorp plates were used throughout ELISA development.
Primary antibody and secondary labelled antibody dilutions were optimised through 
use of checkerboard titrations to ensure optimal signal to noise ratio between the 
highest standard required and zero control.
Plates were coated overnight at 4°C with either DEG or TAT purified antibodies at 
2 pg/mL in 0.1 M sodium bicarbonate buffer. Plates were then washed three times 
with 350 pL/well wash buffer and blotted dry, before being blocked with 300 pL/well 
of 0.5 % (w/v) BSA in PBS and incubated at 25°C for 1 h. Plates were then washed 
three times as before and blotted dry. An appropriate high standard of pure Hsp72 
protein was prepared in the appropriate buffer, along with zero controls of buffer 
only. These were applied to the plates at 100 pL/well and sealed before incubation 
at 37°C for 2 h. Plates were then washed five times with 350 pL/well wash buffer 
with a 20 sec soak time between each wash, then blotted dry.
Primary antibody was serially diluted in 0.5 % (w/v) BSA in wash buffer at relevant 
dilutions, and 100 pL/well applied to the plates for 1 h at 37°C. Plates were then 
washed five times with 350 pL/well wash buffer with a 20 sec soak time between 
each wash, and then blotted dry. Secondary labelled antibody was serially diluted 
at relevant dilutions with 0.5 % (w/v) BSA in wash buffer was applied to the plates 
(100 pL/well) and incubated at 37°C for 1 h. The plates were then washed five 
times as before and blotted dry before the application of 100 pL/well TMB substrate
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for 45 min, with shaking, at 25°C in the dark. The reaction was stopped with the 
addition of 100 pL/well 1 M phosphoric acid. The plates were then read at 450 nm 
on a microplate reader.
2.3.15 Intra-assay variability of optimal Hsp72 ELISA conditions.
Intra-assay variability was determined by applying 6 replicates of each standard 
and zero control to the optimised ELISA.
2.3.16 Inter-assay variability of optimal Hsp72 ELISA conditions.
Inter-assay variability was determined by applying 2 replicates of each standard 
and zero control to five individual plates.
2.3.17 Recovery assays of Hsp72 spiked, and non-spiked cell extracts using 
an optimised Hsp72 ELISA.
Recovery of Hsp72 in cell extracts was determined by applying spiked or non- 
spiked samples to the optimised ELISA. Control (37°C) or heat-treated (40°C, 4 h) 
U937 cell extracts were diluted in extraction buffer to contain 100 pg/mL total 
protein and applied to the plate as non-spiked samples. Spiked samples were 
prepared by diluting cell extracts to contain 200 pg/mL total protein. This was then 
diluted 1:1 with extraction buffer containing 100, 50 and 10 ng/mL Hsp72 to result in 
cell extracts at 100 pg/mL total protein and spiked with 50, 25 and 5 ng/mL Hsp72.
2.3.18 Recovery assays of Hsp72 spiked, and non-spiked tissue extracts 
using an optimised Hsp72 ELISA.
Recovery of Hsp72 in tissue extracts was determined by applying spiked or non- 
spiked samples to the optimised ELISA. Tissue extracts (muscle and brain from the 
domestic Duroc pig) were diluted in extraction buffer to contain 10 pg/mL total 
protein and applied to the plate as non-spiked samples. Spiked samples were 
prepared by diluting cell extracts to contain 20 pg/mL total protein. This was then 
diluted 1:1 with extraction buffer containing 100, 50 and 10 ng/mL Hsp72 to result in 
cell extracts at 10 pg/mL total protein and spiked with 50, 25 and 5 ng/mL Hsp72.
2.3.19 Recovery assays of Hsp72 spiked, and non-spiked tissue culture 
supernatant using an optimised Hsp72 ELISA.
Recovery of Hsp72 from tissue culture supernatant was determined by applying 
spiked or non-spiked samples to the optimised ELISA. Spiked samples were 
prepared by adding pure Hsp72 to 10 % RPMI or 10 % RPMI from heat-treated
60
U937 cells (1 X 106/ml_, 42°C, 2 h) at 25, 10 and 2.5 ng/mL. Non-spiked 10 % 
RPMI was used as a 0 ng/mL control.
2.3.20 Albumin depletion from serum and tissue culture supernatant.
One disc of SwellGel® Blue per sample was placed in a mini-spin column and 
re-hydrated with 380 pL ddH20 and vortexed for 5 sec. The bottom closure of the 
mini-spin column was twisted off and the cap loosened, then the column placed in a 
2 mL collection tube and centrifuged at 12,000 g for 1 min. Flow through was 
discarded. Serum or supernatant (50 pL) was then added to the resin and 
incubated for 2 min. The column was then centrifuged as before and flow-through 
reapplied to the column for 2 min to ensure maximal albumin binding. The column 
was centrifuged as before and flow-through retained. The column was then 
discarded. If sample required more albumin removal, the sample was applied to a 
new SwellGel® column and the process repeated until all albumin was removed. 
Albumin removal was determined by SDS-PAGE electrophoresis (Section 2.3.10).
2.3.21 Cell culture conditions.
All culture and manipulation of cells was performed using aseptic technique in a 
Class II tissue culture hood. All cells were grown or incubated at 37°C in a 
humidified atmosphere under 5 % C02 unless stated otherwise.
2.3.22 Thawing of frozen cell lines.
RPMI-1640 medium was equilibrated at 37°C then supplemented with 10 % (v/v) 
foetal bovine serum (FBS) (10 % RPMI). Vials of cells were removed from liquid 
nitrogen and rapidly thawed at 37°C until almost completely thawed. Cell culture 
medium (9 mL) was dispensed into a 25 cm2 tissue culture flask and the thawed 
cell suspension was then dispensed into the flask and observed under an inverted 
light microscope for viability. The flask was then incubated at 37°C.
2.3.23 Growth of U937 cell line.
Human monocytic U937 cells were grown in 10% RPMI and maintained at a density 
of between approximately 2 - 9 X 105 cells/mL. Cells were passaged every 3-4 days 
and observed for viability using trypan blue exclusion (Section 2.3.24).
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2.3.24 Cell counting and viability testing.
Cell number and viability testing were performed using trypan blue dye exclusion. 
Routinely 500 pL of cell suspension was diluted 1:1 with trypan blue and incubated 
for 10 min. Viability and counts were carried out four times with 20 pL of cell/trypan 
blue suspension using a haemocytometer.
2.3.25 Freezing and storage of cell lines.
Cells were routinely frozen down to maintain minimal passaging of cells. 
Sub-confluent cells (~5 X 105 cells/mL) were transferred to a 15 mL centrifuge tube 
and centrifuged at 300 g for 3 min at 25°C. The medium was removed and the cell 
pellet re-suspended in 1 mL of ice-cold freeze medium (FBS supplemented with 
10% (v/v) sterile dimethyl sulfoxide) and transferred to a cryovial. Cryovials were 
incubated in vapour phase liquid nitrogen for at least 2 h and were then transferred 
to liquid nitrogen and stored until required.
2.3.26 Preparation of heat-inactivated FBS.
FBS was heat-inactivated to inactivate heat-labile components such as growth 
factors and complement proteins which may adversely affect experimental results. 
FBS was allowed to thaw at 37°C before being placed in a 56°C water bath for 
30 min. The FBS was swirled every 5 min during the 56°C incubation. After 30 min 
the FBS was removed and allowed to cool on ice.
2.3.27 Preparation of cell lines prior to experimental treatments.
Prior to treatments, U937 cells were centrifuged at 400 g, washed once with RPMI 
then re-suspended in phenol red free RPMI containing 10 % (v/v) heat-inactivated 
FBS (10 % HI-RPMI) plated out into 12-well cell culture plates at ~5 X 105 cells/mL 
(1 mL/well).
2.3.28 Transformation of U937 cells into U937 macrophages.
U937 cells were grown as described previously (Section 2.3.23). Prior to 
experimental treatments, cells were removed from flasks and viability tested as 
described in section 2.3.24. Cells in log phase of growth and at >95% viability were 
then centrifuged at 500 g for 3 min at 25°C and re-suspended at ~5 X 105 cells/mL 
in phenol red-free RPMI medium supplemented with 10% heat-inactivated FBS 
(10 % HI-RPMI), containing 10 ng/mL phorbol 12-myristate 13-acetate (PMA). Cells 
were plated out in 12-well cell culture plates at 1 mL/well and incubated for 48 h to 
enable differentiation of cells. After this time the media was removed and cells
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rinsed twice with 10 % HI-RPMI then 1 mL/well fresh 10% HI-RPMI media was 
added. U937 macrophages were then ready for experimental treatments.
U937 cells usually grow in a single cell suspension. When transformed with PMA, 
U937 cells became larger and began to adhere to the well surface within 24 hours, 
with some forming clusters. Within 48 hours the majority (>90%) of U937 cells 
adhered to the well surface and became granular with large lysosomes which is 
consistent with maturation of monocytes to macrophages (Figure 2.1).
Figure 2.1: Illustration of normal (A) and PMA transformed (B) U937 cells.
2.3.29 Isolation of peripheral blood mononuclear cells (PBMCs).
Venous whole blood was collected using K2EDTA vacutainers. Aliquots (3 mL) of 
whole blood were mixed by inversion with 5 mL of PBS without Ca++ or Mg++ in a 
15 mL centrifuge tube. Histopaque® (3 mL) was then carefully layered underneath 
the blood/PBS and centrifuged at 400 g for 30 min. With a Pasteur pipette the 
upper layer of plasma was removed to within 0.5 cm of the PBMC interface. 
PBMCs were then carefully transferred to a new 15 mL centrifuge tube with 10 mL 
PBS and mixed by inversion. This was centrifuged for 10 min at 250 g after which 
the supernatant was discarded. The pellet was re-suspended in 5 mL PBS and this 
was centrifuged for 10 min at 250 g after which the supernatant was removed and 
the step repeated once. PBMCs were then re-suspended in 10 % HI-RPMI (5 mL) 
followed by counting and viability testing using trypan blue exclusion (Section 
2.3.19). PBMCs were then diluted with 10 % HI-RPMI to adjust cell density to 
~1 X 106 cells/mL and plated out in 12-well cell culture plates at 1 mL/well. These 
were then incubated for 1 h prior to treatment.
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2.3.30 Determination of apoptosis by measurement of caspase-3.
Caspase-3 activity was determined using a fluorescence assay which measures 
caspase-3 and caspase-7. Caspase-3 plays an essential part in apoptosis and is 
common to most apoptotic pathways. It is an effector caspase which is cleaved and 
activated by granzyme B. Caspase-3 then activates a caspase proteolytic cascade 
leading to apoptosis. The assay kit used to measure caspase-3 activity utilises the 
synthetic peptide (Z-DEVD)2-Rh110 which, upon caspase-3 cleavage, generates 
the green fluorophore Rh110 (rhodamine 110). This green fluorescence can be 
detected at Aex 496 nm/Aem 520 nm using a fluorescence microplate reader. The 
assay also measures downstream caspase-7 as the substrate specificity for both 
caspases is the same.
Typically, 100 pL of cells (~5 x 104 per well) were plated out in a clear-bottomed 
black 96-well cell culture plate. Cells were then treated with 50 pL of test compound 
for the desired time. Caspase-3 substrate solution (40 pL, 1M DL-dithiothreitol 
(DTT); 1 mL assay buffer; 10.4 pL caspase-3 substrate) was then added to the 
plate at 50 pL caspase-3 substrate solution per well. The plate was incubated in the 
dark for 60 min at 25°C, and fluorescence intensity measured at Aex 496 nrn/Aem 520 
nm using a microplate reader.
2.3.31 Determination of necrosis by measurement of propidium iodide 
staining.
Typically, 100 pL of cells (~5 x 104 per well) were plated out in a clear-bottomed 
black 96-well cell culture plate. Included on the plate were positive controls 
consisting of ~5 x105 necrotic cells/mL; negative controls consisting of ~5 x104 per 
well of untreated cells; and background controls of media only. Cells were then 
treated with 10 pL of test compound for the desired time followed by the addition of 
100 pL/well of 5 pg/mL propidium iodide in PBS. The plate was then incubated for 
20 min in the dark at 25°C before fluorescence intensity was measured at 
Aex 535 nm/ Aem 617 nm using a microplate reader.
Necrotic cells were prepared by autoclaving 5 x 105 cells/mL in 10 % RPMI at 
121 °C. for 20 min.
2.3.32 Detection of endotoxin contamination by LAL assay.
Endotoxin concentrations can be measured by the Limulus amebocyte lysate (LAL) 
assay which utilises a purified enzymatic protein derived from the circulating 
amebocytes of the horsehose crab, Limulus polyphemus. Gram-negative endotoxin
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is able to catalyse the activation of the purified amebocyte protein and in the 
presense of p-nitroaniline (pNA) releases a yellow substrate which can be 
measured photometrically.
All materials used for the LAL assay were brought to room temperature before use 
and the assay was performed carefully to reduce the possibility of any external 
endotoxin contamination. All glassware and plastic consumables were sterilised 
before use. Endotoxin standards were prepared in the range 1 - 0.125 EU/mL with 
LAL reagent water. A sterile non-binding plate was pre-equilibrated to 37°C in a 
heating block. With the plate still on the heating block, standards, blank and 
samples were carefully pipetted in duplicate onto the plate at 50 pL per well. Then 
50 pL of prepared LAL protein extract was then added to each well and the plate 
gently tapped to enable mixing. The plate was then incubated for 10 min followed 
by the addition of 100 pL pre-warmed p-NA substrate solution and the plate tapped 
gently. The plate was then incubated for a further 6 min on the heating block 
followed by 100 pL of 25 % (v/v) acetic acid to stop the reaction. The plate was 
then read at 405 nm using a microplate reader.
2.3.33 Determination of IL-1P concentration by ELISA.
The concentration of IL-10 secretion was quantified by a commercially available 
enzyme linked immunosorbent assay (ELISA).
The ELISA format is an indirect sandwich assay that uses a plate bound antibody to 
capture antigen (in this case IL-1(B) in an unknown sample followed by a 
biotinylated detector antibody and, a peroxidise-labelled avidin. TMB substrate is 
then added to convert the peroxidase to a detectable colorimetric form which is 
converted to an absorbance value with a microplate reader at 450 nm. Using a 
defined set of IL-1 (3 standards unknown samples can be quantified.
An ELISA plate was coated with 100 pL/well of capture antibody in coating buffer at 
1/250 dilution. The plate was sealed and incubated at 4°C overnight. The plate was 
then washed five times with 250 pL/well wash buffer with a soak time between each 
wash of 1 min. The plate was then blotted dry and all wells were blocked with 200 
pL/well of 1X assay diluent and incubated for 1 h at 25°C. The plate was washed 
and blotted dry as before. Standards (0-500 pg/mL) were prepared by diluting IL-1 (3 
stock in 1X assay diluent. Samples were either applied directly to the plate or 
diluted, if required, in 1X assay diluent. Standards and samples were applied at 
100 pL/well to the appropriate wells, the plate sealed and incubated overnight at 
4°C. The plate was then washed and dried as before and 100 pL/well of
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biotinylated detector antibody diluted (1/250) in 1X assay diluent was added and 
incubated at 25°C for 1 h. The plate was then washed and dried as before and 100 
pL/well of peroxidase labelled avidin diluted (1/250) in 1X assay diluent was added 
and incubated at 25°C for 1 h. The plate was then washed seven times with a soak 
time of 1 min between washes and blotted dry. Substrate solution was then added 
to the plate (100 pL/well) and incubated for 15 min before the addition of 1M 
orthophosphoric acid (50 pL/well) to stop the reaction. The plate was then read at 
450 nm using a plate reader.
Absorbance values were then converted to IL-1p concentrations using Prism™
5.01 software.
2.3.34 Determination of IL-6 concentration by ELISA.
The concentration of IL-6 was determined using a commercially available indirect 
sandwich ELISA.
An ELISA plate was coated with 100 pL/well of capture antibody in coating buffer at 
1/250 dilution. The plate was sealed and incubated at 4°C overnight. The plate was 
then washed five times with 250 pL/well wash buffer with a soak time between each 
wash of 1 min. The plate was then blotted dry and all wells were blocked with 
200 pL/well of 1X assay diluent and incubated for 1 h at 25°C. The plate was 
washed and blotted dry as before. Standards (0 - 200 pg/mL) were prepared by 
diluting IL-6 stock in 1X assay diluent. Samples were either applied directly to the 
plate or diluted, if required, in 1X assay diluent. Standards and samples were 
applied at 100pl_/well to the appropriate wells, the plate sealed and incubated 
overnight at 4°C. The plate was then washed and dried as before and 100 pL/well 
of biotinylated detector antibody diluted (1/250) in 1X assay diluent was added and 
incubated at 25°C for 1 h. The plate was then washed and dried as before and 100 
pL/well of peroxidase labelled avidin diluted (1/250) in 1X assay diluent was added 
and incubated at 25°C for 1 h. The plate was then washed seven times with a soak 
time of 1 min between washes and blotted dry. Substrate solution was then added 
to the plate (100 pL/well) and incubated for 15 min before the addition of 1M 
orthophosphoric acid (50 pL/well) to stop the reaction. The plate was then read at 
450 nm using a plate reader.
Absorbance values were then converted to IL-6 concentrations using Prism™ 5.01 
software.
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2.3.35 Determination of TNF-a concentration by ELISA.
The concentration of TNF-a was determined using a commercially available indirect 
sandwich ELISA.
An ELISA plate was coated with 100 pL/well of capture antibody in coating buffer at 
1/250 dilution. The plate was sealed and incubated at 4°C overnight. The plate was 
then washed five times with 250 pL/well wash buffer with a soak time between each 
wash of 1 min. The plate was then blotted dry and all wells were blocked with 
200 pL/well of 1X assay diluent and incubated for 1 h at 25°C. The plate was 
washed and blotted dry as before. Standards (0-500 pg/mL) were prepared by 
diluting TNF- a stock in 1X assay diluent. Samples were either applied directly to 
the plate or diluted, if required, in 1X assay diluent. Standards and samples were 
applied at 100pL/well to the appropriate wells, the plate sealed and incubated 
overnight at 4°C. The plate was then washed and dried as before and 100 pL/well 
of biotinylated detector antibody diluted (1/250) in 1X assay diluent was added and 
incubated at 25°C for 1 h. The plate was then washed and dried as before and 
100 pL/well of peroxidase labelled avidin diluted (1/250) in 1X assay diluent was 
added and incubated at 25°C for 1 h. The plate was then washed seven times with 
a soak time of 1 min between washes and blotted dry. Substrate solution was then 
added to the plate (100 pL/well) and incubated for 15 min before the addition of 1M 
orthophosphoric acid (50 pL/well) to stop the reaction. The plate was then read at 
450 nm using a plate reader.
Absorbance values were then converted to TNF-a concentrations using Prism™
5.01 software.
2.3.36 Determination of IL-10 concentration by ELISA.
The concentration of IL-10 was determined using a commercially available indirect 
sandwich ELISA.
An ELISA plate was coated with 100 pL/well of capture antibody in coating buffer at 
1/250 dilution. The plate was sealed and incubated at 4°C overnight. The plate was 
then washed five times with 250 pL/well wash buffer with a soak time between each 
wash of 1 min. The plate was then blotted dry and all wells were blocked with 
200 pL/well of 1X assay diluent and incubated for 1 h at 25°C The plate was 
washed and blotted dry as before. Standards (0 - 200 pg/mL) were prepared by 
diluting IL-10 stock in 1X assay diluent. Samples were either applied directly to the 
plate or diluted, if required, in 1X assay diluent. Standards and samples were
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applied at 100pL/well to the appropriate wells, the plate sealed and incubated 
overnight at 4°C. The plate was then washed and dried as before and 100 pL/well 
of biotinylated detector antibody diluted (1/250) in 1X assay diluent was added and 
incubated at room temperature for 1 h. The plate was then washed and dried as 
before and 100 pL/well of peroxidase labelled avidin diluted (1/250) in 1X assay 
diluent was added and incubated at 25°C for 1 h. The plate was then washed seven 
times with a soak time of 1 min between washes and blotted dry. Substrate solution 
was then added to the plate (100 pL/well) and incubated for 15 min before the 
addition of 1M orthophosphoric acid (50 pL/well) to stop the reaction. The plate was 
then read at 450 nm using a plate reader.
Absorbance values were then converted to IL-10 concentrations using Prism™ 5.01 
software.
2.3.37 U937 macrophage migration assay.
U937 macrophages were prepared as in section 2.3.28, and harvested by scraping, 
then centrifuged at 500 g for 3 min at 25°C, and re-suspended in fresh 10% 
HI-RPMI at ~5 X 105 cells/mL. Macrophages (75 pL) were added to the upper 
compartment of a modified Boyden chamber (HTS Transwell® permeable support) 
and treatment (235 pL) added to the lower compartment (Figure 2.2). Migration of 
cells was monitored at 4 h. Migrated cells were counted and viability tested by 
trypan blue exclusion (Section 2.3.24) and photographed using the inverted 
TE2000-U microscope system.
2.3.38 Preparation of necrotic cell lysate (NCL).
U937 macrophages were prepared as described in section 2.3.28, in 25 cm3 flasks. 
Flasks were incubated at 40°C (heat-treated) for 4 h then media was removed and 
cells washed twice with 10 % HI-RPMI before being harvested by scraping in fresh 
media. Cells were then subjected to repeated (3 times) freezing with liquid nitrogen 
and thawing at 25°C, before centrifugation at 13 500 g for 30 min. Centrifugation 
was repeated once more to remove cell debris. The media containing intra-cellular 




Figure 2.2: illustration of a modified Boyden chamber used for U937 
macrophage migration assay.
(A) Macrophages are added to the top chamber, treatment to the bottom chamber.
(B) As treatment diffuses through pores macrophages are activated and begin to 
migrate through the pores. (C) As the macrophages are further stimulated, more 
migration occurs. (D) Following treatment, the number of cells which have migrated 
through the pores are counted. The microporous membrane pore size is 8.0 pm. 
U937 macrophages are approximately 15-20 pm.
69
2.3.39 Statistical analyses.
All statistical analyses were performed using Prism™ 5.01 (GraphPad Software 
Inc., San Diego, USA).
All data are represented as the mean ± standard error of the mean (SEM) unless 
stated otherwise in the figure legend. Numbers of replicates (n) are shown in 
parentheses in figure legends where appropriate.
Statistical significance of single variables was tested using the unpaired Student’s 
two-tailed t-test. Dose- or time- dependent effects were tested using one-way or 
two-way ANOVA, with appropriate post hoc multiple comparison test shown in 
parentheses in figure legends.
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Chapter 3
Design and Development of an ELISA for Measuring 
Inducible Hsp70 (Hsp72).
3.1 Introduction
The measurement of intra-cellular Hsp72 from tissue and cell extracts, and extra­
cellular Hsp72 in supernatants, plasma and serum have been reported using a 
variety of methods (Fehrenbach et al., 2000; Njemini et al., 2005; Njemini et a!., 
2003b; Walsh et al., 2001). Measurements have generally utilised ELISAs which 
reportedly accurately measure Hsp72 protein levels in a variety of matrices (Njemini 
et al., 2003a; Njemini et al., 2005; Walsh et al., 2001; Wright et al., 2000). The 
commercial Hsp72 ELISAs are indirect sandwich assays which use a monoclonal 
capture antibody immobilised to the plastic surface of a treated ELISA plate. 
Antigen in the form of standards and unknown samples are then applied to the 
plate and any Hsp72 binds to the capture antibody. The bound Hsp72 is then 
detected by a primary rabbit anti-Hsp72 antibody which is subsequently bound by a 
horseradish peroxidise conjugated anti-rabbit secondary antibody. The addition of 
an enzyme substrate enables the colorimetric detection of bound Hsp72 
(Fukushima et al., 2005; Walsh et al., 2001; Zhu et al., 2003) (Figure 3.1). Both of 
the antibodies used by the commercially available kits have been generated using 
peptide sequences from the human Hsp72 protein sequence HSPA1A (accession 
number M11717 (NCBI Database)).
The commercially available ELISAs are costly and have recently been found to be 
unreliable In the determination of levels of extra-cellular Hsp72 in cell culture 
supernatants that contain serum, and serum or plasma samples. This is likely due 
to matrix effects of samples containing large amounts of proteins and lipids which 
can interfere with protein detection in ELISAs (Murray et al., 2001). As a result, 
many studies have employed their own in-house ELISAs, although they are mainly 
based on those commercially available (Njemini et al., 2005; Njemini et al., 2003c; 
Pockley et al., 1998; Rea et al., 2001). Also, other studies measuring Hsp72 by 
ELISA in tissue culture supernatants do not use serum supplemented media when 
performing experiments which may result in inaccurate effects due to extra stress 
on cells (Mambula & Calderwood, 2006b). The reported levels of extra-cellular 
Hsp72 found in serum samples with the commercial or in-house methods are 
extremely varied (Table 3.1).
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All the lower Hsp72 levels reported utilised a commercial Hsp72 ELISA (Stressgen 
Inc.). Intrlguingly, the studies reporting high levels of Hsp72 in serum all perform 
ELISAs using the same components utilised by the commercially available ELISA. 
Therefore it cannot be assumed that measurements of Hsp72 in serum and cell 
culture supernatants which have been reported are accurate. An important aspect 
missing from all of these studies is a secondary detection method to support the 
detection of Hsp72 in complex matrices such as cell supernatants containing 
serum, and serum alone. Therefore there has been some concern about the ability 
of these ELISAs to acurately quantify extra-cellular Hsp72. Supporting the 
specificity of these antibodies are western blots that have been used to detect 
intra-cellular Hsp72 in cell extracts (Tsuchiya et al., 2003). Despite this, the broad 
range of Hsp72 levels reported suggests some matrix interference with the ELISA 
methods. Matrix interference is also likely to be the reason for the lack of secondary 
supporting evidence (Urbonaviciute et al., 2007).






(Njemini et al., 2005; Terry 
et al., 2006)
1 0 -2 0  000
Capture - Stressgen SPA-810 
Detector -  Stressgen SPA-812
(Pockley eta!., 1998) 2 0 -1 8  500
Capture - Stressgen SPA-810 
Detector -  Stressgen SPA-812
(Njemini etal., 2003b) 235 -  6 000
Capture - Stressgen SPA-810 
Detector -  Stressgen SPA-812
(Rea et al., 2001) 20 -  1 500
Capture - Stressgen SPA-810 
Detector -  Stressgen SPA-812
(Fukushima etal., 2005) 2 -1 3 0 Stressgen Kit
(Zhu et al., 2003) 0.2 -  30 Stressgen Kit
The aims of this chapter are:
• To produce antibodies specific to Hsp72.
• To develop a method of accurately detecting Hsp72 levels in different matrices 












Figure 3.1: Illustration of a commercial sandwich ELISA for the detection of 
Hsp72.
Plates are coated with an anti-Hsp72 capture antibody at 4°C overnight, followed by 
blocking of unbound sites with BSA. Standards, samples and controls are added to 
the plate and any Hsp72 present will bind to the antibody. Unbound proteins are 
then washed off and a secondary detector anti-Hsp72 antibody is added to the 
plate. This will bind to any Hsp72 present. Following washing of excess antibody, a 
species specific enzyme-labelled antibody is applied which binds to the Fc part of 
the detector antibody. Following washing of excess antibody substrate is then 
added to the plate for a specified time, during which the substrate is oxidised by 
hydrogen peroxide in the presence of the HRP on the enzyme-labelled antibody 
and a coloured product forms. The reaction is stopped by the addition of 1 M 
orthophosphoric acid and the plate is then read at 450 nm on a plate reader. The 
signal is directly proportional to the amount of Hsp72 present and unknown 
samples can be interpolated through use of the standard curve measurements.
73
3.2 Methods
3.2.1 Peptide selection and design.
Specific Hsp72 peptide sequences were selected from analysing the protein 
sequence for HSPA1A, accession number M11717 (NCBI Database). This 
sequence is 641 amino acids long (Figure 3.2). Two peptides were selected to raise 
antibodies specific for Hsp72 based on sequence position, hydrophilicity, 
antigenicity and surface probability using the analysis software Lasergene® v7.2 
components, EditSeq and Protean. EditSeq was used to format protein sequence 
information which could then be directly imported into Protean. Protean was used to 
determine hydrophilic and antigenic regions within the protein sequence as well as 
surface probability.
Selected peptides were then synthesised and used for screening, or conjugated to 
Keyhole Limpet Hemocyanin (KLH) for immunisation. KLH is widely used as a 
carrier protein for small peptides to enhance their immunogenicity and as it is 
derived from a mollusc, it is unlikely to produce cross reacting antibodies in 
mammalian species which interfere with typical target samples.
3.2.2 Preparation of peptides for immunisation.
Sheep polyclonal serum was supplied by MicroPharm UK Ltd.
Peptides were supplied pre-conjugated to KLH via an N-succinimidyl-3- 
maleimidobezoate cross-linker to an added cysteine residue at the N-terminus. The 
cross linker was covalently attached to the cysteine residue to ensure that the 
peptide antigen was not compromised.
The conjugated peptide was mixed with an adjuvant, Imject® Alum at 1 mg of 
peptide per mL of adjuvant. Peptides were separately pre-dissolved in PBS before 
the dropwise addition of adjuvant, which was then continually mixed by gentle 
rocking for 30 min. An adjuvant is used to generate an improved immune response 
to an antigen within the host by causing localisation of antigen for a prolonged 
period.
Primary immunisation of sheep required 1 mg of peptide, followed by three 
subsequent immunisations of 0.5 mg at weeks 4, 8 and 12. Bleeds for screening of 
antibodies are taken at weeks 6, 10 and 14 (~ 5 mL per bleed). Positive serum was 
collected from sacrificed sheep at week 14 (~ 300 mL per sheep).
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Figure 3.2: Amino acid sequence information for human Hsp72, HSPA1A.
Highlighted amino acids depict target peptides selected for polyclonal antibody 
generation (accession number M11717 (NCBI Database)).
3.2.3 Screening of sheep serum for peptide-specific antibodies.
For all buffers required for ELISAs, see section 2.2.1.
Serum from sheep immunized with either DEG or TAT peptides were screened by 
an ELISA as described in section 2.3.1.
3.2.4 Purification of polyclonal antibodies.
Antibodies specific to the two peptides were purified from serum using affinity 
columns. For the TAT peptide column, it was necessary to reduce disulfide bonds 
to free sulfhydryl groups within the peptide using TCEP prior to immobilization on 
the affinity column matrix.
Either TAT or DEG peptide was then immobilized onto an iodoacetyl gel to produce 
a peptide specific affinity column. Polyclonal sheep serum was then applied to the 
columns and peptide-specific antibodies were collected and desalted.
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Antibodies were then either stored at -20°C until required, or labelled with biotin as 
described in section 2.3.6 for use in western blots.
3.2.5 Specificity of peptide-specific antibodies to Hsp72.
The specificity of the peptide-specific antibodies to Hsp72 generated was tested by 
ELISA screening as described for bleed screening (Section 2.3.1) except that pure 
Hsp72 was used as plate coating (1 pg/mL in 0.1 M sodium bicarbonate buffer), 
and western blotting.
For western blotting, samples of pure human Hsc70 (1 pg/mL in PBS), pure human 
Hsp72 (1 pg/mL in PBS), pure rat Hsp72 (1 pg/mL in PBS), DnaK (1 pg/mL in 
PBS), 37°C treated U937 cellular extract (1 X 106 cells in 1 mL cell extraction 
buffer) and 42°C heat treated (4h) U937 cellular extract (1 X 106 cells in 1 mL cell 
extraction buffer) were all diluted 1:1 with SDS-PAGE reducing sample buffer and 
applied to a 10 % SDS-PAGE gel at 20 pL per well as described in sections 
2.3.10-11, followed by western blotting as described in sections 2.3.12-13, which 
were probed with 1:2000 dilution of either biotinylated peptide-specific antibody 
followed by incubation with 1:5000 dilution of peroxidase-labelled avidin.
3.2.6 Depletion of albumin using SwellGel® Blue (cibacron blue).
Depletion of albumin from samples was performed as described in section 2.3.20. 
For western blotting, samples of pure human Hsp72 (1 pg/mL), in PBS; in PBS with
2.5 % (w/v) BSA; in RPMI; in 10 % RPMI. Samples of PBS containing 1 pg/mL pure 
Hsp72, and 2.5 % (w/v) BSA or 10 % RPMI, were depleted twice with SwellGel® 
Blue.
Samples were then diluted 1:1 with SDS-PAGE reducing sample buffer and applied 
to a 10 % SDS-PAGE gel at 20 pL per well as described in section 2.3.10 followed 
by western blotting as described in sections 2.3.12-13, which were probed with 
1:2000 dilution of either biotinylated peptide-specific antibody followed by 
incubation with 1:5000 dilution of peroxidase-labelled avidin.
3.2.7 Optimisation of an ELISA for Hsp72 in cell and tissue extracts.
3.2.7.1 Optimisation of primary and secondary labelled antibody dilutions.
For tissue extracts, optimisation of primary and secondary antibodies was 
performed as described in section 2.3.14.
A pure Hsp72 standard for the ELISA was prepared in cell extraction buffer at 
100 ng/mL, and a negative control of extraction buffer only.
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Primary antibody was serially diluted at 1/1250, 1/2500, 1/5000, 1/10000 and 
1/20000 in 0.5 % (w/v) BSA in wash buffer. Secondary peroxidise-labelled antibody 
was serially diluted at 1/1250, 1/2500 and 1/5000 with 0.5 % (w/v) BSA in wash 
buffer.
3.2.7.2 Optimisation of standard curve range.
Optimisation of the standard curve range for measuring cell and tissue extracts was 
performed using standards prepared in extraction buffer, along with a zero control 
of extraction buffer only. The standard curve range was: 100, 50, 25,12.5, 6.25, 
3.125, 1.56, 0.78, 0.39, and 0 ng/mL. Standards were applied to the plates in 
triplicate.
3.2.7.3 Intra- and inter- assay variability of optimal ELISA conditions for cell 
and tissue extracts.
Intra-assay variability was determined by applying 6 replicates of each standard 
and zero to the optimised ELISA.
Inter-assay variability was determined by applying 2 replicates of each standard to 
five individual plates.
3.2.7.4 Recovery of Hsp72 in spiked cell and tissue extracts.
Cell and tissue extracts were applied to the optimised ELISA in triplicate, as 
described in sections 2.3.17 and 2.3.18.
3.2.8 Optimisation of an ELISA for Hsp72 in tissue culture supernatant.
3.2.8.1 Optimisation of primary and secondary labelled antibody dilutions.
For tissue culture supernatants, optimisation of primary and secondary antibodies 
was performed as described in section 2.3.14.
A pure Hsp72 standard at 100 ng/mL was prepared in 10 % RPMI, and a negative 
control of 10 % RPMI only.
Primary antibody was serially diluted at 1/500, 1/1000, 1/2000, 1/4000 and 1/8000 
in 0.5 % (w/v) BSA in wash buffer. Secondary peroxidase-labelled antibody was 
serially diluted at 1/1250, 1/2500 and 1/5000 with 0.5 % (w/v) BSA in wash buffer.
3.2.8.2 Optimisation of standard curve range.
Optimisation of the standard curve range for measuring Hsp72 in tissue culture 
supernatant was performed using standards prepared in 10 % RPMI, along with a 
zero control of 10 % RPMI only. The standard curve range was: 50, 25,12.5, 6.25,
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3.125, 1.56, 0.78, 0.39, 0.19 and 0 ng/mL. Standards were applied to the plates in 
triplicate.
3.2.8.3 Intra- and inter- assay variability of optimal ELISA conditions for tissue 
culture supernatant.
Intra-assay variability was determined by applying 6 replicates of each standard to 
the optimised ELISA.
Inter-assay variability was determined by applying 3 replicates of each standard to 
five individual plates.
3.2.8.4 Recovery of Hsp72 in spiked tissue culture supernatant.
Tissue culture supernatants were applied to the optimised ELISA in triplicate, as 
described in section 2.3.19.
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3.3 Results
3.3.1 Selection of peptides for generation of polyclonal antibodies.
The complete Hsp72 sequence (amino acids 1-641) was analysed for areas of 
hydrophilicity ( >0.5, Hopp-Woods plot), antigenicity (>1.0, Jameson-Wolf plot) and 
surface probability (Figure 3.3). Two short peptide sequences were selected which 
were both hydrophilic and antigenic in nature. These were:
TATDKSTGKAN, aa 489-499 (TAT)
DEGLKGKISEAD, aa 555-566 (DEG)
Both of these sequences are found in the peptide binding region of Hsp72. The 
sequence at aa 555-566 was also found to be within the peptide sequence which 
was used by Stressgen Inc. as an immunogen for a polyclonal rabbit antibody 
(Stressgen Inc., product SPA-811). Each peptide sequence was then analysed 
individually to ensure they remained hydrophilic and antigenic, and tertiary structure 
was not altered (Figures 3.4 and 3.5). These sequences were analysed for 
homology to Hsp72 using basic local alignment search tool for standard protein- 
protein sequences (BLASTp, NCBI). Both sequences were determined to be well 
conserved across a variety of species for Hsp72.
3.3.2 Screening of sheep sera at weeks 6,10 and 14.
Serum bleeds from sheep either immunised with DEG or TAT peptides were 
screened as described in section 2.3.1. Sera from DEG and TAT immunised sheep 
showed very significant increases at 6, 10 and 14 weeks when compared to pre- 
immune sera (P<0.05) but no significant differences between each post-immune 
sera. Typically for DEG immunised sheep serum absorbance values were between 
1.560 AU when diluted at 1/1000 and 1.341 AU when diluted at 1/10 000, 
compared to pre-immune serum which gave absorbance values of 0.591 and 0.167 
respectively. For TAT immunised sheep serum, absorbance values were between 
1.467 AU when diluted at 1/1000 and 1.306 AU when diluted at 1/10 000, 







0 = 0 □  DEGUCGWSEAD J’EPTTDE
TATDKSTGKAN
D=3 □  TATDKSTGKANPEPTIDE
Figure 3.3: Amino acid sequence of human Hsp72, HSPA1A from aa 438 - 641.
Blue plot - hydrophilicity; Pink plot - antigenicity; Yellow plot - surface probability. 
Chosen peptide sequence regions indicated in black.
Figure 3.4: Amino acid sequence of TAT peptide (Hsp72 aa 489-499).
Blue plot - hydrophilicity; Pink plot - antigenicity; Yellow plot - surface probability.
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Figure 3.5: Amino acid sequence of DEG peptide (Hsp72 aa 555-566).
Blue plot - hydrophilicity; Pink plot - antigenicity: Yellow plot - surface probability.
3.3.3 Cross-reactivity of sheep sera with either peptide.
When both TAT sheep serum and DEG pre-immune serum were tested against the 
DEG peptide there were no differences between either sera at any dilution (P=0.30) 
(Figure 3.7).
A similar result was obtained when DEG serum and TAT pre-immune serum were 
tested against the TAT peptide (P=0.13) (Figure 3.8).
3.3.4 Ability of sheep sera to recognise Hsp72 protein.
When tested for the ability to recognise Hsp72 protein, DEG serum gave higher 
absorbance values compared to TAT at all dilutions (Figure 3.9). When each sera 
were compared to pre-immune sera, DEG serum was significantly different when 
compared to pre-immune DEG serum (P<0.0001) and TAT serum was significantly 
different from pre-immune serum (P<0.0001) (Figure 3.9).
High absorbance values were obtained for both serum at 1/100 dilution (1.221 AU 
for DEG and 0.967 AU for TAT) and remained above the optimal value of 1.0 AU 
for DEG serum at 1/1000 (1.026 AU). However, TAT serum showed a significant 
reduction in absorbance value at 1/1000 (0.451 AU). Pre-immune serum 
absorbance values remained relatively high at 1/1000 dilution (0.387 AU for DEG 
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Figure 3.6: Screening of sheep serum for antibodies to DEG and TAT 
peptides by ELISA.
Plates were coated with either DEG or TAT peptide (5 pg/mL in PBS) and tested for 
specificity with either DEG or TAT sheep serum respectively. Data are presented as 
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Figure 3.7: Screening of cross reactivity of TAT sheep serum with DEG 
peptide by ELISA.
Plate was coated with 5 pg/mL DEG peptide in PBS and screened with TAT sheep 
serum (Week 14) and pre-immune bleed as a control. Data are presented as mean 
± SEM, n=3, CVs < 5%.
W eek 14 
Pre-im m une
Serum dilution, 1/X
Figure 3.8: Screening of cross reactivity of DEG sheep serum with TAT 
peptides by ELISA.
Plate was coated with 5 pg/mL TAT peptide in PBS and screened with DEG sheep 
serum (Week 14) and pre-immune bleed as a control. Data are presented as mean 
± SEM, n=3, CVs < 5%.
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DEG
Week 14 * * *
Pre-immune
TAT
W eek 14 * * *  
Pre-immune
Serum dilution, 1/X
Figure 3.9: Screening of DEG and TAT sheep serum for antibodies to Hsp72 
by ELISA.
Plates were coated with 1 pg/mL recombinant human Hsp72 in PBS and screened 
with DEG or TAT sheep serum (Week 14) and pre-immune sera as control. Data 
are presented as mean ± SEM, n=3. * Indicates significant difference between pre- 
and post- immune sera through use of two-way ANOVA: ***(P<0.0001).
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3.3.5 Purification of peptide specific antibodies from serum.
Purified peptide specific antibodies were eluted within fractions 2 to 5 (Figure 3.10). 
Strong doublet bands can be seen at approximately 150 kDa within these fractions 
along with more faint bands seen at approximately 100, 75 and 45 kDa which 
correspond to F(ab’)2, reduced IgG and Fab fragments respectively from pure 
sheep IgG (Figure 3.10).
A non-reducing SDS-PAGE gel of purified DEG and TAT antibodies showed only 
doublet bands at approximately 150 kDa indicating pure intact IgGs (Figure 3.11).
Purification of peptide specific antibodies from polyclonal sera resulted in an 
average yield of 1.545 mg/mL of pure antibodies for DEG peptide and 1.162 mg/mL 
of pure antibodies for TAT peptide.
Figure 3.10: Reducing SDS-PAGE of a typical affinity purification of peptide 
specific sheep antibodies from whole serum.
A 10 % gel was cast and loaded with the following under reduced conditions: Lane 
1 - molecular weight markers; Lane 2 - whole sheep serum; Lane 3 - unbound 
sheep serum; Lane 4 - 0.5 M NaCI wash #1; Lane 5 - 0.5 M NaCI wash #2; Lane 6 - 
0.5 M NaCI wash #3; Lane 7 - PBS wash #1; Lane 8 - fraction #1; Lane 9 - fraction 
#2; Lane 10 - fraction #3; Lane 11 - fraction #4; Lane 12 - fraction #5; Lane 13 - 
fraction #6. Gel was stained with Imperial protein stain and exposed according to 
ChemiDoc Quantity One® software standards for coomassie blue.
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Figure 3.11: Non-reducing SDS-PAGE of purified DEG and TAT antibodies 
following affinity purification.
A 10 % gel was cast and loaded with the following under non-reduced conditions: 
Lane 1 - molecular weight markers; Lanes 2 and 3 - pure mouse IgG; Lanes 4 and 
5 - pure DEG IgG; Lanes 6 and 7 - empty; Lanes 8 and 9 - pure TAT IgG. Gel was 
stained with Imperial protein stain and exposed according to ChemiDoc Quantity 
One® software standards for coomassie blue.
3.3.6 Specificity of peptide specific antibodies.
Western blots were probed with peptide specific antibodies for Hsp72 (Figure 3.12). 
Both DEG and TAT purified antibodies showed specific reactivity with pure Hsp72 
from human and rat, and with U937 cell extracts. No reactivity was seen with Hsc70 
or DnaK indicating that both DEG and TAT antibodies were specific to Hsp72 
(Figure 3.12).
3.3.7 Interference in the detection of Hsp72 by albumin in complex matrices.
Western blots probed with DEG antibody showed clear bands at approximately 
70 kDa in the PBS and RPMI samples containing Hsp72 (Lanes 2 and 4). Sample 
containing PBS and BSA showed no binding (Lane 1). Samples containing FBS or 
BSA and Hsp72 produced large smears from 50 to 70 kDa (Lanes 3, 5 and 8). 
RPMI samples containing albumin which had been depleted also produced smears 
but these were reduced slightly following repeated depletions (Lanes 6 and 7). 
RPMI samples containing 10 % FBS which had been depleted showed less 
smearing resulting in a relatively clear band at approximately 70 kDa following two 
depletions (Lanes 9 and 10)(Figure 3.13).
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Figure 3.12: SDS-PAGE gel (A) and western blots to determine specificity of 
DEG (B) and TAT (C) for Hsp72.
10 % gels were cast and loaded with the following: Lane 1 - molecular weight 
standards; Lane 2 - pure Hsc70; Lane 3 - pure human Hsp72 (Assay Designs); 
Lane 4 - pure human Hsp72 (Stressmarq); Lane 5 - empty; Lane 6 - pure rat Hsp72 
(Assay Designs); Lane 7 - pure DnaK (Assay Designs); Lane 8 - 4 h, 37°C U937 
cell extract; Lane 9 - 4 h, 42°C U937 cell extract. Blots were probed with either 
DEG-biotin or TAT-biotin at 1/5000 dilution followed by avidin at 1/5000 dilution. 
Blots were exposed for 240 sec.
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Figure 3.13: Western blot showing interference caused by albumin when 
detecting Hsp72 in complex matrices.
10 % gels were cast and loaded with the following: Lane 1 - PBS + 2.5 % BSA; 
Lane 2 - Hsp72 in PBS; Lane 3 - Hsp72 in PBS + 2.5 % BSA; Lane 4 - Hsp72 in 
RPMI; Lane 5 - Hsp72 in RPMI + 2.5 % BSA; Lane 6 - 1X albumin depleted Hsp72 
in RPMI + 2.5 % BSA; Lane 7 - 2X albumin depleted Hsp72 in RPMI + 2.5 % BSA; 
Lane 8 - Hsp72 in 10 % RPMI; Lane 9 - 1X albumin depleted Hsp72 in 10 % RPMI; 
Lane 10 - 2X albumin depleted Hsp72 in 10 % RPMI. Blot was probed with DEG- 
biotin at 1/5000 dilution followed by avidin at 1/5000 dilution. Blot was exposed for 
90 sec.
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3.3.8 Optimisation of an ELISA for Hsp72 in cell and tissue extracts.
3.3.8.1 Optimisation of a sandwich ELISA using various antibody 
combinations.
Using DEG as a capture antibody and TAT as a detector resulted in low 
absorbance values for the standards tested with no difference between 500 ng/mL 
Hsp72 and 0 ng/mL control (Figure 3.14A).
Using TAT as a capture antibody and DEG antibody as a detector also resulted in 
low absorbance values for the standards tested with low signal to noise ratios 
(Figure 3.14B).
Due to the low absorbance values obtained using DEG and TAT, optimisation with 
another antibody (TOR, a mouse monoclonal antibody raised against bovine 
Hsp70. See section 2.2.1) was attempted.
Using TOR as a capture antibody, again resulted in low absorbance values using 
either DEG or TAT as a detector (Figure 3.14C).
However, using DEG or TAT as a capture antibody and TOR as a detector resulted 
in very high absorbance values at both 500 and 100 ng/mL pure Hsp72 compared 
to 0 ng/mL (Figures 3.14 A and B). Therefore all subsequent optimisations were 
performed using TOR as a detector antibody.
3.3.8.2 Optimisation of primary and secondary labelled antibody dilutions.
Optimal primary antibody dilution for an ELISA using DEG antibody as a capture 
antibody was determined to be 1/5000, and the secondary antibody 1/2500 through 
use of a checkerboard titration (Figure 3.15). This was based on optimal signal to 
noise ratio using 100 ng/mL pure Hsp72 as signal (AU = 4.176) and 0 ng/mL as 
noise (AU = 0.088).
Optimisation of primary antibody dilution for an ELISA using TAT as a capture 
antibody was determined to be 1/5000, and the secondary antibody 1/5000 (Figure 
3.16).
As the optimised ELISA using DEG as a capture antibody had a lower background 
absorbance (AU = 0.088) than using TAT (AU = 0.261), all subsequent 
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Figure 3.14: Optimisation of capture and detector antibody combinations for 
use in a sandwich ELISA.
Plates were coated with 2 pg/mL capture antibody. Detector and secondary 
enzyme-labelled antibodies were at 1/5000 dilution.
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3.3.8.3 Optimisation of range of standards.
The detection range was determined to be 100 - 0.78125 ng/mL with a limit of 
detection of 0.78125 ng/mL Hsp72 (P<0.05) (Figure 3.17).
3.3.8.4 Intra- and inter- assay variability of optimal ELISA conditions for cell 
and tissue extracts.
Intra-assay variability of the optimised sandwich ELISA was determined by 
replicating six standard curves on one plate. CVs were less than 5 % (Figure 3.18). 
Inter-assay variability was determined by comparing five standard curves from 5 
individual plates. CVs were less than 11 % and there was a very high correlation 
between all curves (r= 0.948, P<0.001) (Figure 3.19)
3.3.8.5 Recovery of Hsp72 from spiked cell and tissue extracts.
Recovery of Hsp72 from spiked cell and tissue extracts was performed using 3 
different amounts of Hsp72 within the standard curve range.
The % recovery for cell extracts were all >90 %, although at the low concentration 
there was a slight over recovery (109 % for control + 5 ng/mL, and 103 % for 
treated + 5 ng/mL) (Table 3.2).
The % recovery of Hsp72 from tissue extracts were all >90 % except for muscle 
tissue spiked with 25 ng/mL Hsp72 which was 89 %. There was a slight over 
recovery when either muscle or brain were spiked with 5 ng/mL (113 and 106 % 
respectively), and brain spiked with 50 ng/mL Hsp72 (102%) (Table 3.3).
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Figure 3.15: Checkerboard titration optimisation of primary and secondary 
antibody dilutions of an ELISA for measuring Hsp72 in cell and tissue 
extracts using DEG as a capture antibody.
(A): Pure Hsp72 at 100 ng/mL; (B) Negative control. Primary antibody was diluted 
1/1250, 1/2500, 1/5000, 1/10000 and 1/20000. Secondary antibody was diluted at 
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Figure 3.16: Checkerboard titration optimisation of primary and secondary 
antibody dilutions of an ELISA for measuring Hsp72 in cell and tissue 
extracts using TAT as a capture antibody.
(A): Pure Hsp72 at 100 ng/mL; (B) Negative control. Primary antibody was diluted 
1/1250, 1/2500, 1/5000, 1/10000 and 1/20000. Secondary antibody was diluted at 
1/11250, 1/2500 and 1/5000. Plates were coated with 2 pg/mL TAT antibody.
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Figure 3.17: A typical standard curve obtained from an optimised ELISA for 
measuring Hsp72 in cell and tissue extracts using DEG as a capture antibody.
Primary antibody was diluted at 1/5000 and secondary antibody diluted at 1/2500. 
Plate was coated with 2 pg/mL DEG antibody. * (P<0.05), ** (P<0.01), ***




Figure 3.18: Intra-assay variability of an optimised ELISA for measuring 
Hsp72 in cell and tissue extracts.
Primary antibody was diluted at 1/5000 and secondary antibody diluted at 1/2500. 
Plate was coated with 2 pg/mL DEG antibody, n = 6, CVs <5 %. r2 = 0.9961.
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Figure 3.19: Inter-assay variability of an optimised ELISA for measuring 
Hsp72 in cell and tissue extracts.
Primary antibody was diluted at 1/5000 and secondary antibody diluted at 1/2500. 
Plate was coated with 2 pg/mL DEG antibody. CVs <11 %. *** (P<0.001), using 
Pearson correlation, r=  0.948.
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Table 3.2: Recovery of Hsp72 from spiked U937 cell extracts.
Sample Expected (ng/mL) Observed (ng/mL) Recovery (%)
Control (37°C) N/A 11.617 N/A
Control + 50 ng/mL 61.617 58.648 95 ± 0.2
Control + 25 ng/mL 36.617 33.229 91 ±0.5
Control + 5 ng/mL 16.617 18.106 109 ±0.8
Treated (40°C, 4 h) N/A 44.669 N/A
Treated + 50 ng/mL 94.669 92.137 97 ±0.6
Treated + 25 ng/mL 69.669 63.946 91 ±0.6
Treated + 5 ng/mL 49.669 51.205 103 ± 1.2
Note: n = 4. Recovery shown as % ± SEM.
Table 3.3: Recovery of Hsp72 from spiked tissue extracts from exercised 
Duroc pigs.
Sample Expected (ng/mL) Observed (ng/mL) Recovery (%)
Muscle N/A 4.694 N/A
Muscle + 50 ng/mL 54.694 52.445 96 ± 1.7
Muscle + 25 ng/mL 29.694 26.495 89 ± 1.2
Muscle + 5 ng/mL 9.694 10.955 113 ± 2.1
Brain N/A 18.011 N/A
Brain + 50 ng/mL 68.011 69.122 102 ±0.9
Brain + 25 ng/mL 43.011 40.956 95 ± 2.3
Brain + 5 ng/mL 23.011 24.318 106 ±2.6
Note: n = 4. Recovery shown as % ± SEM.
Note: Exercise consisted of treadmill exercise increasing speed from 0.4 km/h up to 
an average 5.2 km/h by increments of 0.4 km/h every 2 minutes until maximum 
capacity for the individual pig. This speed was maintained until the individual animal 
was exhausted, which was assessed by uncoordinated breathing and movements.
97
3.3.9 Optimisation of an ELISA for Hsp72 in tissue culture supernatant.
3.3.9.1 Optimisation of primary and secondary labelled antibody dilutions.
Optimal primary antibody dilution for an ELISA measuring Hsp72 in tissue culture 
supernatant was determined to be 1/1000, and the secondary antibody 1/1250 
through use of a checkerboard titration (Figure 3.20). This was based on optimal 
signal to noise ratio using 100 ng/mL pure Hsp72 as signal (AU = 2.568) and 
0 ng/mL as noise (AU = 0.113).
3.3.9.2 Optimisation of range of standards.
The detection range was determined to be 50 - 0.39 ng/mL with a limit of detection 
of 0.39 ng/mL Hsp72 (P<0.001) (Figure 3.21).
3.3.9.3 Intra- and inter- assay variability of optimal ELISA conditions for tissue 
culture supernatant.
Intra-assay variability of the optimised sandwich ELISA was determined by 
replicating six standard curves on one plate. CVs were less than 5 % (Figure 3.22). 
Inter-assay variability was determined by comparing five standard curves from 5 
individual plates. CVs were less than 11 % and there was a very high correlation 
between all curves (r= 0.998, P<0.0001) (Figure 3.23).
3.3.9.4 Recovery of Hsp72 from spiked tissue culture supernatant.
The % recovery of Hsp72 from tissue culture supernatant were all >100 % but 
below 120 % (Table 3.4).
Recovery (%) was within the acceptable limits of 80-120 %.
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Figure 3.20: Checkerboard titration optimisation of primary and secondary 
antibody dilutions of an ELISA measuring Hsp72 in tissue culture 
supernatant.
(A): Pure Hsp72 at 100 ng/mL; (B) Negative control. Primary antibody was diluted 
1/500, 1/1000, 1/2000, 1/4000 and 1/8000. Secondary antibody was diluted at 
1/1250, 1/2500 and 1/5000. Plates were coated with 2 pg/mL DEG antibody.
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Figure 3.21: A typical standard curve obtained from an optimised ELISA for 
measuring Hsp72 in tissue culture supernatant.
Primary antibody was diluted at 1/1000 and secondary antibody diluted at 1/1250. 
Plate was coated with 2 pg/mL DEG antibody. * (P<0.05), ** (P<0.01), *** 
(P<0.001), using one-way ANOVA with Dunnett’s post hoc test, ns indicates no 
significant difference.
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Figure 3.22: Intra-assay variability of an optimised ELISA for measuring 
Hsp72 in tissue culture supernatant.
Primary antibody was diluted at 1/1000 and secondary antibody diluted at 1/1250. 
Plate was coated with 2 |jg/mL DEG antibody, n = 6, CVs <5 %. i2 = 0.9998.
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Figure 3.23: Inter-assay variability of an optimised ELISA for measuring 
Hsp72 in tissue culture supernatant.
Primary antibody was diluted at 1/1000 and secondary antibody diluted at 1/1250. 
Plate was coated with 2 pg/mL DEG antibody. CVs <11 %. *** (P<0.0001), using 
Pearson correlation, r = 0.998.
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Table 3.4: Recovery of Hsp72 from spiked control or heat-treated tissue 
culture supernatant.
Sample Expected (ng/mL) Observed (ng/mL) Recovery (%)
Control (10 % RPMI) N/A 0.062 N/A
25 ng/mL spike 25.062 26.943 107 ±3.1
10 ng/mL spike 10.062 11.186 111 ±2.0
2.5 ng/mL spike 2.562 2.711 102 ± 1.6
Heat-treated (42°C, 2 h) N/A 0.619 N/A
25 ng/mL spike 25.619 28.176 109 ±2.6
10 ng/mL spike 10.619 10.943 103 ± 1.2
2.5 ng/mL spike 3.119 3.314 106 ±3.7
Note: n = 4. Recovery shown as %  ± SEM.
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3.4 Discussion
The aims of this chapter were to produce antibodies specific to Hsp72 and develop 
a method of detecting and quantifying Hsp72 in different media such as cell and 
tissue extracts, and tissue culture supernatant.
Two polyclonal antibodies were produced from sheep by immunisation with 
conjugated peptide sequences from the N-terminal region of the human sequence 
for Hsp72, HSPA1A (accession number M11717 (NCBI Database)). Both 
antibodies were easily purified by affinity purification. The antibodies were found to 
be highly specific for Hsp72 and did not cross react with Hsc70 or DnaK as 
determined by western blotting. Both antibodies were also capable of detecting 
single bands in cellular extracts. When applied to western blots of spiked tissue 
culture supernatant containing 10 % (v/v) FBS, or spiked PBS containing
2.5 % (w/v) BSA, clear bands were not visible due to the effect of albumin which is 
abundant in serum and has a molecular weight of 66 kDa. Albumin could be 
removed from samples by repeated depletion by SwellGel® Blue but this is 
extremely costly. However, removal of most albumin from 10 % RPMI spiked with 
Hsp72 did result in a fairly clear band at approximately 70 kDa which was 
determined to be Hsp72. This ‘blocking’ effect of albumin when using western blots 
for the identification of Hsp72 is probably the main reason there are no publications 
showing western blots of Hsp72 in serum or tissue culture supernatant containing 
FBS.
These antibodies were applied to an ELISA for use in quantifying Hsp72. An 
indirect sandwich ELISA format was determined to be the most suitable format due 
to the ability to detect a particular protein from complex matrices, such as tissue 
culture supernatant supplemented with FBS, or serum (Jeney et al., 1999; Njemini 
et al., 2005), and an amplification of signal by using a secondary enzyme-labelled 
detector antibody. As both antibodies were raised in sheep, they could not be 
optimised for use together for ELISA development due to non-specific binding 
between the antibodies which could not be reduced. Steric hindrance was probably 
a factor as the peptide regions the antibodies were raised against are relatively 
close together within the substrate binding region, and therefore the detecting 
antibody could not bind to relevant epitope on Hsp72 (Kent, Ryan & Siegel, 1978). 
Therefore, a specific mouse monoclonal antibody (TOR) for Hsp72 was utilised 
which was able to detect an undetermined epitope of Hsp72 which was accessible 
in the sandwich ELISA format (Figure 3.24). Usually, sandwich ELISAs employ the
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use of a monoclonal antibody as the capture antibody which is plate bound, and a 
detector antibody from a polyclonal source, such as goat or rabbit. However, it was 
found that the monoclonal antibody was unable to efficiently detect Hsp72 when 
plate bound and therefore the ELISAs were optimised using the affinity purified 
polyclonal DEG antibody as the capture. The polyclonal antibody had a better 
avidity to Hsp72 in PBS, extraction buffer and supplemented tissue culture 
supernatant. This suggested that the epitope recognised by the monoclonal anti- 
Hsp72 antibody is either within the ATPase domain which is inaccessible when 
bound to ATP, or that binding of Hsp72 to either of the polyclonal antibodies results 
in bound ATP being released from Hsp72 that results in the epitope for the 
monoclonal antibody being revealed (Botzler et al., 1998).
When developing the ELISAs for quantifying Hsp72, it was necessary to optimise 
conditions for detection within cell or tissue extracts independently from the 
conditions required for detection within tissue culture supernatant.
The ELISA for quantifying Hsp72 within extracts was found to be highly specific and 
sensitive enough to quantify Hsp72 down to as little as 0. 78125 ng/mL Hsp72 in 
samples containing as little as 10 pg/mL total protein and is comparable to the 
commercially available kit. Also, the ELISA was able to detect and quantify Hsp72 
from species other than human as demonstrated by the use of Duroc pig tissue.
The ELISA for quantifying Hsp72 within tissue culture supernatant was also found 
to be highly specific and was more sensitive than the ELISA for extracts, being able 
to detect as little as 0.39 ng/mL Hsp72 within a complex matrix such as 10 % RPMI.
Quantification of Hsp72 in serum/plasma was not a primary requirement of this 
thesis. It would require a large number of healthy volunteers for collection of 
serum/plasma for use in the optimisation of such an ELISA. The serum/plasma 
would by used as a buffer for the reference standard curve for quantification to 
minimise possible matrix differences between the detection of analyte in the matrix 
for standards and analyte in the matrix for samples (Njemini et al., 2005; Njemini et 
al., 2003b). As the ELISA is able to quantify Hsp72 in 10 % RPMI, it is probable that 
the ELISA could be applied to quantifying Hsp72 within serum and/or plasma 
samples, as other studies have shown this is possible (Hunter-Lavin et al., 2004; 
Njemini et al., 2005; Pockley et al., 1998). Further work by other researchers, in- 
house, have demonstrated that levels of Hsp72 release from in vitro cultures are 
within the limits of the ELISA for supernatants. For example, various 2 h heat-shock 
and ABC transport inhibitor treatments give values of Hsp72 release between 5.12 
(± 0.79) and 45.9 (± 3.81) ng/mL (personal communication, Leoni, 2007).
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In conclusion, the development of ELISAs capable of quantifying Hsp72 from cell 
and tissue extracts, and within tissue culture supernatant was successful and are 
more cost effective than those commercially available. They can be utilised for use 
in determining the effects of various potential stressors on the intra-cellular 
production, and extra-cellular levels of Hsp72.
The DEG antibody produced here is used in chapters 5 and 6 for western blotting 
and as a neutralising antibody for blocking experiments.
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KEY: Non-specific binding 
block
Y DEG/TAT sheep anti-Hsp72
TOR mouse anti-Hsp72





Figure 3.24: Illustration of an optimised indirect sandwich ELISA for the 
quantification of Hsp72 from cell and tissue extracts, and tissue culture 
supernatant.
Plates are coated with an anti-Hsp72 capture antibody at 4°C overnight, followed by 
blocking of unbound sites with BSA. Standards, samples and controls are added to 
the plate and any Hsp72 present will bind to the antibody. Unbound proteins are 
then washed off and a secondary detector anti-Hsp72 antibody is added to the 
plate. This will bind to any Hsp72 present. Following washing of excess antibody, a 
species specific enzyme-labelled antibody is applied which binds to the Fc part of 
the detector antibody. Following washing of excess antibody substrate is then 
added to the plate for a specified time, during which the substrate is oxidised by 
hydrogen peroxide in the presence of the HRP on the enzyme-labelled antibody 
and a coloured product forms. The reaction is stopped by the addition of 1 M 
orthophosphoric acid and the plate is then read at 450 nm on a plate reader. The 
signal is directly proportional to the amount of Hsp72 present and unknown 
samples can be interpolated through use of the standard curve measurements.
Chapter 4
The effects of recombinant heat shock proteins on cytokine 
secretion from peripheral blood mononuclear cells and U937 
macrophages.
4.1 Introduction
Extra-cellular heat shock proteins have been reported to have a stimulatory effect 
on the innate immune system (Asea, 2006; Asea et ai, 2000b; Campisi & Fleshner, 
2003; Guzhova et ai, 1998; Milani et ai, 2002; Svensson et al., 2006). These 
effects Include the secretion of many cytokines, both pro-and anti-inflammatory 
(Campisi et al., 2003; El Mezayen et al., 2007; Moré, Breloer & von Bonin, 2001; 
Retzlaff et al., 1994; Singh-Jasuja et al., 2000; Svensson et al., 2006). Most of 
these studies employed the use of recombinant proteins expressed in transfected 
E. coli. More recently it has been reported that these innate immune responses 
may actually be due to contamination of these proteins by LPS, or possibly flagellin 
(Bausinger et al., 2002; Gao & Tsan, 2003a; Gao & Tsan, 2003b; Gao & Tsan, 
2004; Kol et al., 2000; Tsan & Gao, 2004a; Ye & Gan, 2007).
Gao and Tsan (2004) utilised highly purified recombinant human (rh) Hsp72 and 
Hsp60 and subjected murine macrophages to a 4 h incubation with 5 pg/mL of 
either stress protein or LPS (1 ng/mL) and performed gene array expression on a 
number of common cytokines. They reported there was no increased expression of 
any of these cytokines in response to rhHsp72 or rhHsp60 in contrast to incubation 
with LPS. A time course experiment measuring IL-1(B also showed no expression. 
However, Kol et al. (2000) stimulated cytokine production from U373 cell line with 
Hsp60 and the effect was completely abrogated by heat treatment which suggested 
no LPS contamination present as LPS is heat labile. Campisi et al. (2003) also 
demonstrated that even in the presence of polymixin B, Hsp72 could stimulate 
TNF-a, IL-1p and IL-6 secretion from rat splenocytes and macrophages. More 
recently, it has been suggested that Hsp72 can activate macrophages, especially 
when in a membrane bound form (Vega etal., 2008).
Svensson et al. (2006) observed that supernatant from stimulated peripheral blood 
mononuclear cells (PBMCs), which contained released Hsp72, resulted in a 3-fold 
increase in IL-1(3 and IL-12 secretion in naive macrophages that could be blocked 
by anti-Hsp72 antibodies.
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The aim of this chapter is to determine whether recombinant heat shock proteins 




All preparations and cell culture experiments were carried out within a Class II 
tissue culture hood.
4.2.1 Preparation of cells for treatment.
U937 macrophages were prepared as in section 2.3.28. PBMCs were isolated and 
prepared for treatment as in section 2.3.29.
4.2.2 Preparation of heat shock proteins for experiments.
Heat shock proteins used for experiments were: Hsp72, low endotoxin Hsp72, 
DnaK, Hsp60, GroEL, Cpn10, GroES. Proteins were diluted in 10 % HI-RPMI to 
give 10 000, 1000 and 100 ng/mL stock solutions.
For heat-treated stress protein treatments, stock solutions were heated at 75°C for 
20 min and allowed to cool prior to use.
4.2.3 Preparation of LPS for experiments.
LPS from E. coli 0111:B4 was reconstituted in 10 % HI-RPMI at 1 mg/mL and 
allowed to dissolve. LPS was then further diluted in 10 % HI-RPMI to give 1 pg/mL 
stock solution.
4.2.4 Determination of endotoxin content of heat shock proteins.
Endotoxin content of 1000 ng/mL native or denatured heat shock proteins was 
determined using the Limulus Amebocyte Lysate assay as described in section 
2.3.32.
4.2.5 Treatment of cells with native or denatured heat shock proteins.
Native or denatured heat shock proteins were applied to cells at 1/10 dilution 
(100 pL protein stock to 900 pL 10 % HI-RPMI) so that cells were treated with 
1000, 100 and 10 ng/mL stress protein. Cells were then incubated for 24 h.
4.2.6 Time course experiments with native or denatured, Hsp72 or low 
endotoxin Hsp72.
Native or denatured Hsp72 or low endotoxin Hsp72 were applied to U937 
macrophages at 1/10 dilution (100 pL protein stock to 900 pL 10 % HI-RPMI) so 
that cells were treated with 1000 ng/mL heat shock protein. Cells were then 
incubated for up to 6 h.
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4.2.7 Treatment of U937 macropahges for 4 h, with Hsp72 and polymyxin B.
Hsp72 (1000 ng/mL) or LPS (100 ng/mL) was pre-incubated with or without 
20 pg/mL polymyxin B before being added to U937 macrophages for 4 h.
4.2.8 Cell counts and viability tests by trypan blue exclusion.
Following treatment, cells were re-suspended into the media by repeated pipetting. 
Cells were then counted and assessed by trypan blue exclusion (Section 2.3.24).
4.2.9 Determination of apoptosis.
Cells were plated onto a black 96 well cell culture plate and treated with stress 
proteins or LPS and cells were then analysed for apoptosis by caspase 3/7 
detection (Section 2.3.30).
4.2.10 Determination of necrosis.
Following treatments, necrosis was determined by propidium iodide (Section 
2.3.31).
4.2.11 Measurement of secreted cytokines.
Following treatment, media was removed from the wells and clarified by 
centrifugation at 400 g for 5 min and transferred to a clean 1.5 mL microcentrifuge 
tube. Media was then either used fresh or frozen at -70°C until required. Secretion 




4.3.1 Endotoxin contamination of recombinant heat shock proteins 
determined by LAL assay.
Endotoxin contamination of recombinant heat shock proteins was determined as 
endotoxin units (EU) per pg of protein. All heat shock proteins, whether native or 
denatured had less than 0.075 EU per pg except for native and denatured, DnaK 
(2.344 and 2.274 EU per pg respectively) and GroEL (0.396 and 0.239 EU per pg 
respectively). None of the proteins tested showed any significant difference from 




Figure 4.1: Endotoxin contamination of recombinant heat shock proteins in 
native and denatured forms.
Native and denatured heat shock proteins were applied to a LAL assay at 1 pg/mL 
in 10% HI-RPMI. Data are presented as mean ± SEM, n = 4. Significance shown as 
difference from 10% HI-RPMI using two-way ANOVA with Bonferroni’s post hoc 
test: * (P<0.05), ** (P<0.01), *** (P<0.001).
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4.3.2 Cytokine secretion from PBMCs following 24 h incubation with native 
or denatured heat shock proteins.
Cytokine secretion from PBMCs following treatments with native or denatured heat 
shock proteins are presented in Figures 4 .2 -4.13 and Tables 4.1 -  4.17.
4.3.2.1 Treatment of PBMCs with native or denatured Hsp72 or DnaK.
Following incubation of PBMCs with Hsp72 for 24 h, an almost 4-fold increase 
(P<0.001) in IL-1P secretion was seen at 100 ng/mL native Hsp72 (2049.210 
pg/mL) compared to denatured Hsp72 (601.144 pg/mL) (Figure 4.2A). A 4-fold 
increase (P<0.001) was also observed at 1000 ng/mL native Hsp72 when 
compared to denatured Hsp72 (405.545 and 7.184 pg/mL respectively) (Figure 
4.2A). IL-6 secretion increased almost 2-fold when incubated with 10 ng/mL native 
Hsp72 (31.352 pg/mL) compared to denatured Hsp72 (17.101 pg/mL) although this 
was not significant (Figure 4.3A). IL-6 secretion increased more than 3-fold 
(P<0.001) when incubated with native Hsp72 compared to denatured Hsp72 at 
100 ng/mL (2874.279 and 798.760 pg/mL respectively), and 3-fold (P<0.001) when 
incubated with 1000 ng/mL (4370.564 and 1915.391 pg/mL respectively) (Figure 
4.3A). TNF-a secretion increased 2-fold (P<0.05) when PBMCs were incubated 
with 10 ng/mL native Hsp72 compared with denatured Hsp72 (97.288 and 39.732 
pg/mL respectively) (Figure 4.4A). TNF-a increased over 2-fold (P<0.001) when 
incubated with 100 ng/mL native Hsp72 (781.203 pg/mL) compared to denatured 
Hsp72 (362.789 pg/mL), and also increased nearly 3-fold (P<0.001) when 
incubated with 1000 ng/mL native compared to denatured Hsp72 (2298.341 and 
816.756 pg/mL respectively) (Figure 4.4A). IL-10 secretion increased over 40-fold 
(P<0.001) when PBMCs were incubated with 100 ng/mL native Hsp72 (136.370 
pg/mL) compared to denatured Hsp72 (3.024 pg/mL), and increased nearly 10-fold 
(P<0.001) when incubated with 1000 ng/mL native Hsp72 compared to the 
denatured form (558.350 and 59.007 pg/mL respectively) (Figure 4.5A).
All cytokine responses were dose dependent at 1000 and 100 ng/mL native Hsp72 
(P<0.01 -  0.001), but only TNF-a was dose dependent at 10 ng/mL (P<0.05) when 
compared to untreated control cells (Table 4.1). A significant correlation was seen 
between TNF-a and all other cytokines (t2 = 0.941 -  0.996, P<0.01) and between 
IL-1 p and IL-10 {r2 = 0.999, P<0.01) (Table 4.2).
Cytokine responses were dose dependent when treated with denatured 
1000 ng/mL Hsp72 (P<0.001), but only IL-6 and TNF-a were dose dependent when 
incubated with 100 ng/mL (P<0.001). No significant difference was observed with 
10 ng/mL treatment (Table 4.1). Significant correlations were seen between IL-13
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and IL-10 (r2 = 1.000, P<0.01), and between IL-6 and TNF-a (r2 = 1.000, P<0.01) 
(Table 4.2).
When incubated with 10 ng/mL native DnaK, IL-ip secretion increased over 20-fold 
(P<0.001) compared to denatured DnaK (164.730 and 7.435 pg/mL respectively) 
Figure 4.2B). A 15-fold increase (P<0.001) was observed with 100 ng/mL native 
compared to denatured DnaK (1012.419 and 69.688 pg/mL respectively), and an 
almost 3-fold increase (P<0.001) was seen when incubated with 1000 ng/mL native 
DnaK (2247.721 pg/mL) compared to denatured DnaK (891.625 pg/mL) (Figure 
4.2B). IL-6 secretion increased nearly 40-fold (P<0.001) when incubated with 
10 ng/mL native DnaK compared to denatured DnaK (1066.259 and 28.298 pg/mL 
respectively); nearly 5-fold (P<0.01) with 100 ng/mL native (2404.094 pg/mL) 
compared to denatured (522.136 pg/mL), but were not significantly different when 
incubated with 1000 ng/mL native DnaK compared to the denatured form (4617.849 
and 4298.035 pg/mL) (Figure 4.3B). TNF-a secretion increased over 2-fold 
(P<0.01) when incubated with 10 ng/mL native DnaK compared to denatured DnaK 
(584.657 and 263.869 pg/mL respectively) (Figure 4.4B). A 2-fold increase 
(P<0.001) in TNF-a was observed when incubated with 100 ng/mL native 
compared to denatured DnaK (1036.363 and 347.935 pg/mL respectively), and 
there was an increase (P<0.001) incubated with 1000 ng/mL native or denatured 
DnaK (6584.202 and 5925.299 pg/mL respectively) (Figure 4.4B). IL-10 increased 
8-fold (P<0.05) following incubation with 10 ng/mL native DnaK compared to 
denatured DnaK (42.755 and 7.345 pg/mL respectively); a 34-fold increase 
(P<0.001) was observed following incubation with 100 ng/mL native 
(442.932 pg/mL) compared to the denatured form (13.996 pg/mL); a 2-fold increase 
(P<0.001) in IL-10 secretion was seen when incubated with 1000 ng/mL native 
DnaK compared to denatured DnaK (750.417 and 336.107 pg/mL respectively) 
(Figure 4.5B).
All cytokine responses were dose dependent at all when incubated with native 
DnaK (P<0.05 -0.001) (Table 4.1). Significant correlations were observed between 
IL-1 (3, IL-6 and IL-10 ( f  = 0.988, P<0.01) (Table 4.2).
Cytokine responses were dose dependent when treated with denatured 
1000 ng/mL DnaK (P<0.001), but only IL-6 and TNF-a were dose dependent when 
incubated with 100 ng/mL (P<0.01 -  0.001). No significant differences were 
observed with 10 ng/mL treatment except for TNF-a (P<0.05) (Table 4.1). 










Figure 4.2: Effect on IL-1 secretion by PBMCs when incubated for 24 h with 
Hsp72 (A) or DnaK (B), in native or denatured (de) forms.
Data are presented as mean ± SEM, n = 4. * Indicates significant difference 
between mean concentration points through use of two-way ANOVA with 










Figure 4.3: Effect on IL-6 secretion by PBMCs when incubated for 24 h with 
Hsp72 (A) or DnaK (B), in native or denatured (de) forms.
Data are presented as mean ± SEM, n = 4. * Indicates significant difference 
between mean concentration points through use of two-way ANOVA with 















Figure 4.4: Effect on TNF-a secretion by PBMCs when incubated for 24 h with 
Hsp72 (A) or DnaK (B), in native or denatured (de) forms.
Data are presented as mean ± SEM, n = 4 . * Indicates significant difference 
between mean concentration points through use of two-way ANOVA with 







Figure 4.5: Effect on IL-10 secretion by PBMCs when incubated for 24 h with 
Hsp72 (A) or DnaK (B), in native or denatured (de) forms.
Data are presented as mean ± SEM, n = 4. * Indicates significant difference 
between mean concentration points through use of two-way ANOVA with 
Bonferroni’s multiple comparison post hoc test: * (P<0.05), ** (P<0.01),
*** (P<0.001).
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Table 4.1: Dose responses of cytokine secretion by PBMCs incubated for 24 h 
with native or denatured, Hsp72 or DnaK.
Significance shown as difference between treatments using one-way ANOVA with 
Bonferroni’s multiple comparison post hoc test.
Concentration of Treatment (ng/mL)
T reatment 10 vs. 0 100 vs. 10 1000 vs. 100
Hsp72 Significance
IL-ip ns P>0.05 ** P<0.01 *** P<0.001
IL-6 ns P>0.05 *** P<0.001 *** P<0.001
TNF-a * P<0.05 *** P<0.001 *** P<0.001
IL-10 ns P>0.05 *** P<0.001 *** P<0.001
deHsp72
IL-1p ns P>0.05 ns P>0.05 *** P<0.001
IL-6 ns P>0.05 *** P<0.001 *** P<0.001
TNF-a ns P>0.05 *** P<0.001 *** P<0.001
IL-10 ns P>0.05 ns P>0.05 ** P<0.01
DnaK
IL-1P * P<0.05 *** P<0.001 *** P<0.001
IL-6 ** P<0.01 *** P<0.001 *** P<0.001
TNF-a * P<0.05 ** P<0.01 *** P<0.001
IL-10 ** P<0.01 *** P<0.001 *** P<0.001
deDnaK
IL-1 P ns P>0.05 ns P>0.05 *** P<0.001
IL-6 ns P>0.05 * P<0.05 *** P<0.001
TNF-a * P<0.05 ** P<0.01 •k irk P<0.001
IL-10 ns P>0.05 ns P>0.05 •kkk P>0.001
Note: ns = not significant
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Table 4.2: Correlation between cytokine secretion by PBMCs when incubated 
for 24 h with native or denatured, Hsp72 or DnaK.
Significance shown following Pearson correlation: * (P<0.05); ** (P<0.01)
Hsp72 IL-1 P IL-6 TNF-a IL-10
IL-1P 0.890 0.991** 0.999**
IL-6 0.890 0.941* 0.910
TNF-a 0.991** 0.941* 0.996**
IL-10 0.999** 0.910 0.996**
.
deHsp72 IL-1 P IL-6 TNF-a IL-10
IL-1p 0.910 0.910 1.000**
IL-6 0.910 1.000** 0.920
TNF-a 0.910 1.000** 0.910
IL-10 1.000** 0.920 0.910
DnaK IL-1 P IL-6 TNF-a IL-10
IL-1 p 0.988** 0.939 0.988**
IL-6 0.988** 0.920 0.978*
TNF-a 0.939 0.920 0.876
IL-10 0.988** 0.978* 0.876
deDnaK IL-1 P IL-6 TNF-a IL-10
IL-1 p 0.999** 0.999** 0.999**
IL-6 0.999** 0.996** 0.996**
TNF-a 0.999** 0.996** 1.000**
IL-10 0.999** 0.996** 1.000**
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4.3.2.2 Treatment of PBMCs with native or denatured Hsp60 or GroEL.
Incubation of PBMCs with 100 ng/mL native Hsp60 resulted in a 60-fold increase 
(P<0.001) in IL-ip secretion compared to incubation with denatured Hsp60 
(188.399 and 3.158 pg/mL respectively) (Figure 4.6A). A 13-fold increase 
(P<0.001) was also observed when incubated with 1000 ng/mL native Hsp60 
(2007.328 pg/mL) compared to incubation with the denatured form (152.586 pg/mL) 
(Figure 4.6A). IL-6 secretion increased 70-fold (P<0.001) when incubated with 
100 ng/mL native Flsp60 compared to denatured Hsp60 (1488.644 and 
21.173 pg/mL respectively), and increased 2-fold (P<0.001) when incubated with 
1000 ng/mL native (4069.630 pg/mL) compared to denatured Hsp60 
(2014.229 pg/mL) (Figure 4.7A). Incubation with 100 ng/mL native Hsp60 resulted 
in a 10-fold increase in TNF-a (P<0.001) in comparison to denatured Hsp60 
(554.023 and 54.586 pg/mL respectively); TNF-a also increased nearly 3-fold 
(P<0.001) when incubated with native Hsp60 compared to the denatured form 
(2525.781 and 975.481 pg/mL respectively) (Figure 4.8A). IL-10 secretion 
increased almost 6-fold (P<0.001) following incubation with 100 ng/mL native 
Hsp60 (69.007 pg/mL) when compared to denatured Hsp60 (12.026 pg/mL), 
followed by a 44-fold increase when incubated with 1000 ng/mL Hsp60 compared 
to the denatured form (397.218 and 44.238 pg/mL respectively) (Figure 4.9A).
All cytokine responses were dose dependent in PBMCs that were incubated with 
100 and 1000 ng/mL (P<0.001) native Hsp60 but were not significant when 
incubated with 10 ng/mL compared to untreated cells. Significant correlations were 
observed amongst all cytokines (r2 = 0.960 -  0.999, P<0.05 -  0.01) (Table 4.4). 
IL-ip and TNF-a responses were only dose dependent when PBMCs were treated 
with 1000 ng/mL denatured Hsp60 (P<0.001), compared to untreated cells. IL-6 
and IL-10 secretion were also dose dependent at 100 ng/mL (P<0.05). No 
significance in cytokine response was observed when PBMCs were incubated with 
10 ng/mL denatured Hsp60 (fable 4.3). Significant correlations were observed 
amongst all cytokines (r2 = 0.973 -  1.000, P<0.05 -  0.01) (Table 4.4).
Following incubation of PBMCs with GroEL, IL-1p secretion increased 2-fold when 
incubated with 10 ng/mL native GroEL compared to the denatured form (4.206 and 
2.339 pg/mL respectively) although this was not significant; a 4-fold increase 
(P<0.001) was observed when incubated with 100 ng/mL native compared to 
denatured (221.981 and 54.332 pg/mL respectively); and a nearly 4-fold increase 
(P<0.001) was seen at 1000 ng/mL native GroEL compared to the denatured form 
(1839.356 and 542.800 pg/mL respectively) (Figure 4.6B). IL-6 secretion increased
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2-fold following incubation with 10 ng/mL native GroEL (19.137 pg/mL) compared to 
denatured GroEL (8.449 pg/mL) although this was not significant; a 20-fold 
increase (P<0.001) was observed when incubated with 100 ng/mL native compared 
to denatured form (2517.183 and 127.036 pg/mL respectively); an significant 
increase (P<0.001) was also seen when incubated with 1000 ng/mL native GroEL 
compared to denatured (4770.412 and 4197.884 pg/mL respectively) (Figure 4.7B). 
TNF-a secretion from PBMCs increased 2-fold following incubation with 10 ng/mL 
native GroEL compared to the denatured form (74.081 and 36.948 pg/mL 
respectively) but this was not significant; a 3-fold increase (P<0.01) was observed 
when incubated with 100 ng/mL native GroEL (541.955 pg/mL) compared to 
denatured GroEL (167.841 pg/mL); a significant increase (P<0.001) was also seen 
when incubated with 1000 ng/mL native GroEL compared to denatured (2419.952 
and 1967.859 pg/mL respectively) (Figure 4.8B). Secretion of IL-10 increased 
almost 2-fold (P<0.001) when PBMCs were incubated with 100 ng/mL GroEL 
compared to denatured GroEL (75.183 and 39.655 pg/mL respectively), and 
increased over 2-fold (P<0.001) following incubation with 1000 ng/mL native GroEL 
(578.758 pg/mL) compared to the denatured form (283.360 pg/mL) (Figure 4.9B).
All cytokine responses were dose dependent (P<0.001) when incubated with 100 or 
1000 ng/mL native GroEL when compared to untreated PBMCs. No significant 
difference was seen when incubated with 10 ng/mL GroEL. Significant correlations 
were seen between TNF-a and all other cytokines (r2 = 0.944 -  0.996, P<0.05 -  
0.01) and between IL-1 p and IL-10 (r2 = 1.000, P<0.01) (Table 4.4).
A dose response was seen for IL-1 (3 secretion when incubated with denatured 
GroEL at 100 and 1000 ng/mL (P<0.001) but not at 10 ng/mL. A dose response 
(P<0.001) was only seen when incubated with 1000 ng/mL denatured GroEL for 
IL-6 and TNF-a secretion when compared to untreated PBMCs (Table 4.3). 










Figure 4.6: Effect on IL-ip secretion by PBMCs when incubated for 24 h with 
Hsp60 (A) or GroEL (B), in native or denatured (de) forms.
Data are presented as mean ± SEM, n = 4. * Indicates significant difference 
between mean concentration points through use of two-way ANOVA with 










Figure 4.7: Effect on IL-6 secretion by PBMCs when incubated for 24 h with 
Hsp60 (A) or GroEL (B), in native or denatured (de) forms.
Data are presented as mean ± SEM, n = 4. * Indicates significant difference 
between mean concentration points through use of two-way ANOVA with 










Figure 4.8: Effect on TNF-a secretion by PBMCs when incubated for 24 h with 
Hsp60 (A) or GroEL (B), in native or denatured (de) forms.
Data are presented as mean ± SEM, n = 4. * Indicates significant difference 
between mean concentration points through use of two-way ANOVA with 









Figure 4.9: Effect on IL-10 secretion by PBMCs when incubated for 24 h with 
Hsp60 (A) or GroEL (B), in native or denatured (de) forms.
Data are presented as mean ± SEM, n = 4. * Indicates significant difference 
between mean concentration points through use of two-way ANOVA with 
Bonferroni’s multiple comparison post hoc test: * (P<0.05), ** (P<0.01),
*** (P<0.001).
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Table 4.3: Dose responses of cytokine secretion by PBMCs incubated for 24 h 
with native or denatured, Hsp60 or GroEL.
Significance shown as difference between treatments using one-way ANOVA with 
Bonferroni’s multiple comparison post hoc test.
Concentration of Treatment (ng/mL)
Treatment 10 vs. 0 100 vs. 10 1000 vs. 100
Hsp60 Significance
IL-1P ns P>0.05 *** P<0.001 *** P<0.001
IL-6 ns P>0.05 ** P<0.01 *** P<0.001
TNF-a ns P>0.05 *** P<0.001 *** P<0.001
IL-10 ns P>0.05 *** P<0.001 *** P<0.001
deHsp60
IL-1p ns P>0.05 ns P>0.05 *** P<0.001
IL-6 ns P>0.05 * P<0.05 *** P<0.001
TNF-a ns P>0.05 ns P>0.05 *** P<0.001
IL-10 ns P>0.05 * P<0.05 *** P<0.001
GroEL
IL-1p ns P>0.05 *** P<0.001 *** P<0.001
IL-6 ns P>0.05 *** P<0.001 *** P<0.001
TNF-a ns P>0.05 ** P<0.01 *** P<0.001
IL-10 ** P<0.01 *** P<0.001 *** P<0.001
deGroEL
IL-1p ns P>0.05 *** P<0.001 *** P<0.001
IL-6 ns P>0.05 ns P>0.05 *** P<0.001
TNF-a ns P>0.05 ns P>0.05 *** P<0.001
IL-10 ns P>0.05 *** P<0.001 *** P<0.001
Note: ns = not significant
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Table 4.4: Correlation between cytokine secretion by PBMCs when incubated 
for 24 h with native or denatured, Hsp60 or GroEL.
Significance shown following Pearson correlation: * (P<0.05); ** (P<0.01)
Hsp60 IL-1 p IL-6 TNF-a IL-10
IL-1p 0.960* 0.993** 0.997**




IL-10 0.997** 0.978* 0.999**
deHsp60 IL-1 P IL-6 TNF-a IL-10
IL-1 p 1.000** 1.000** 0.973*
IL-6 1.000** 1.000** 0.974*
TNF-a 1.000** 1.000** 0.976*
IL-10 0.973* 0.974* 0.976*
GroEL IL-1 p IL-6 TNF-a IL-10
IL-1 P : 0.911 0.996** 1.000**
IL-6 0.911 0.944* 0.911
TNF-a 0.996** 0.944* \ , : 0.996**
IL-10 1.000** 0.911 0.996**
deGroEL IL-1 P IL-6 TNF-a IL-10
IL-1 p 0.998** 1.000** 0.999**




IL-10 0.999** 0.995** 0.998**
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4.3.2.3 Treatment of PBMCs with native or denatured Cpn10 or GroES.
Following incubation of PBMCs with Cpn10 for 24 h, there were no significant 
differences in IL-1 (3 secretion at any concentration of native Cpn10 compared to 
denatured Cpn10 (Figure 4.1 OA). IL-6 secretion increased when incubated with 
100 ng/mL native Cpn10 compared to the denatured form (9.467 and 6.922 pg/mL 
respectively) although this was not significant; a 2-fold increase (P<0.001) in IL-6 
secretion was observed when incubated with 1000 ng/mL native Cpn10 
(19.101 pg/mL) compared to denatured Cpn10 (10.485 pg/mL) (Figure 4.11 A). 
There were no significant differences in TNF-a secretion following incubation with 
native Cpn10 compared to denatured Cpn10 at any concentration (Figure 4.12A). 
IL-10 secretion increased almost 4-fold (P<0.001) following 100 ng/mL treatment 
with native Cpn10 compared denatured Cpn10 (9.810 and 2.715 pg/mL 
respectively), and increased almost 4-fold (P<0.001) following incubation with 
1000 ng/mL Cpn10 compared to the denatured form (11.323 and 3.266 pg/mL 
respectively) (Figure 4.13A).
IL-1 (3, IL-6 and IL-10 secretion from cells treated with native Cpn10 was dose 
dependent at 100 and 1000 ng/mL when compared to untreated cells (P<0.05 - 
P<0.001). IL-1 p, IL-6 and IL-10 secretion from cells treated with denatured Cpn10 
was dose dependent at 1000 ng/mL (P<0.05 -P<0.001). IL-1 p secretion was also 
significant at 100 ng/mL denatured Cpn10 (P<0.01). There were no significant 
differences observed for TNF-a secretion at any dose for either native or denatured 
Cpn10 (Table 4.5). There was a significant correlation between IL-1 (3 and IL-10 
secretion when incubated with native Cpn10 (r2 = 0.961, P<0.05), and denatured 
Cpn10 (r2 = 0.995, P<0.01) (Table 4.6).
PBMCs incubated with 100 ng/mL native GroES showed a significant increase 
(P<0.05) in IL-1 (3 secretion when compared to denatured GroES (4.961 and 
3.535 pg/mL respectively; a 3-fold increase (P<0.001) was seen at 1000 ng/mL 
native GroES compared to denatured GroES (12.910 and 4.165 pg/mL 
respectively) (Figure 4.10B). IL-6 secretion increased almost 3-fold (P<0.001) when 
incubated with 10 ng/mL native GroES (19.137 pg/mL) compared to the denatured 
form (7.665 pg/mL); a 2-fold increase (P<0.001) was observed at 100 ng/mL native 
compared to denatured GroES (22.191 and 11.502 pg/mL respectively), and also at 
1000 ng/mL native compared to denatured GroES (25.244 and 13.476 pg/mL 
respectively) (P<0.001) (Figure 4.11B). TNF-a increased significantly (P<0.05) 
when incubated with 10 ng/mL native GroES (60.156 pg/mL) compared to the 
denatured form (42.518 pg/mL); secretion increased at 100 ng/mL native GroES
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when compared to denatured GroES (63.868 and 49.015 pg/mL respectively) 
although this was not significant; TNF-a increased significantly (P<0.05) when 
incubated with 1000 ng/ml_ native GroES (80.723 pg/mL) compared to the 
denatured form (60.156 pg/mL) (Figure 4.12B). An almost 2-fold increase (P<0.01) 
in IL-10 secretion was observed following treatment with 10 ng/mL native GroES 
(2.474 pg/mL) compared to denatured GroES (1.921 pg/mL); 100 ng/mL native 
compared to the denatured form (4.290 and 2.711 pg/mL respectively, P<0.001); 
and with 1000 ng/mL native GroES compared to denatured GroES (7.846 and 
4.220 pg/mL respectively, P<0.001) (Figure 4.13B).
Cytokine secretion was dose dependent (P<0.05 -P<0.001) when cells were treated 
with native GroES compared to untreated cells, except for IL-1p and IL-10 
secretion at 10 ng/mL which were not significant (Table 4.5). Significant correlations 
were seen between IL-1P and IL-10 following incubation with native GroES (r2 = 
0.983, P<0.05), and IL-6 and TNF-a {r2= 0.960, P<0.05) (Table 4.6).
When treated with denatured GroES, secretion of all cytokines were dose 
dependent at 1000 ng/mL (P<0.05 -P<0.001). IL-6 and IL-10 were also dose 
dependent (P<0.05 -0.01) when treated with 100 ng/mL denatured GroES (Table 
4.5). Significant correlations were seen between IL-113, TNF-a and IL-10 following 
incubation with denatured GroES (r2= 0.957 -  0.074, P<0.05), and IL-6 and TNF-a 
{r2= 0.961, P<0.05) (Table 4.6).
4.3.2.4 Cell viability and cell death in PBMCs following treatment with native 
and denatured heat shock proteins.
There was no significant change in cell number or viability (0.91 x 106 cells/mL) 
when compared to seeding density (1 x 106 cells/mL) although cell counts were 
reduced. No significant cell death by apoptosis or necrosis was detected for any 
treatment when compared to untreated cells, and all were significantly different 
from the positive controls for either apoptosis or necrosis (Table 4.7). A decrease in 
cell number was observed when treated with either native or denatured DnaK, and 
GroEL, as well as a small increase in apoptosis and necrosis, although these were 









Figure 4.10: Effect on IL-1P secretion by transformed PBMCs when incubated 
for 24 h with Cpn10 (A) or GroES (B), in native or denatured (de) forms.
Data are presented as mean ± SEM, n = 4. * Indicates significant difference 
between mean concentration points through use of two-way ANOVA with 






Figure 4.11: Effect on IL-6 secretion by PBMCs when incubated for 24 h with 
Cpn10 (A) or GroES (B), in native or denatured (de) forms.
Data are presented as mean ± SEM, n = 4. * Indicates significant difference 
between mean concentration points through use of two-way ANOVA with 












Figure 4.12: Effect on TNF-a secretion by PBMCs when incubated for 24 h 
with Cpn10 (A) or GroES (B), in native or denatured (de) forms.
Data are presented as mean ± SEM, n = 4. * Indicates significant difference 
between mean concentration points through use of two-way ANOVA with 










Figure 4.13: Effect on IL-10 secretion by PBMCs when incubated for 24 h with 
Cpn10 (A) or GroES (B), in native or denatured (de) forms.
Data are presented as mean ± SEM, n = 4. * Indicates significant difference 
between mean concentration points through use of two-way ANOVA with 
Bonferroni’s multiple comparison post hoc test: * (P<0.05), ** (P<0.01),
*** (P<0.001).
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Table 4.5: Dose responses of cytokine secretion by PBMCs incubated for 24 h 
with native or denatured, Cpn10 or GroES.
Significance shown as difference between treatments using one-way ANOVA with 
Bonferroni’s multiple comparison post hoc test.
Concentration of Treatment (ng/mL)
T reatment 10 vs. 0 100 vs. 10 1000 vs.100
Cpn10 Significance
IL-1p ns P>0.05 ** P<0.01 *** P<0.001
IL-6 ns P>0.05 * P<0.05 ** P<0.01
TNF-a ns P>0.05 ns P>0.05 ns P>0.05
IL-10 ns P>0.05 *** P<0.001 *** P<0.001
deCpnIO
IL-1P ns P>0.05 ** P<0.01 *** P<0.001
IL-6 ns P>0.05 ns P>0.05 * P<0.05
TNF-a ns P>0.05 ns P>0.05 ns P>0.05
IL-10 ns P>0.05 ns P>0.05 ** P<0.01
GroES
IL-1 p ns P>0.05 * P<0.05 *** P<0.001
IL-6 *** P<0.001 *** P<0.001 *** P<0.001
TNF-a * P<0.05 * P<0.05 ** P<0.01
IL-10 ns P>0.05 *** P<0.001 *** P<0.001
deGroES
IL-1 P ns P>0.05 ns P>0.05 * P<0.05
IL-6 ns P>0.05 * P<0.05 ** P<0.01
TNF-a ns P>0.05 ns P>0.05 * P<0.05
IL-10 ns P>0.05 ** P<0.01 *** P<0.001
Note: ns = not significant
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Table 4.6: Correlation between cytokine secretion by PBMCs when incubated 
for 24 h with native or denatured, Cpn10 or GroES.
Significance shown following Pearson correlation: * (P<0.05); ** (P<0.01)
Cpn10 IL-1 P IL-6 TNF-a IL-10
IL-1P 0.942 0.644 0.961*
IL-6 0.942 0.799 0.827
TNF-a 0.644 0.799 0.409
IL-10 0.961* 0.827 0.409 |
deCpnIO IL-1 p IL-6 TNF-a IL-10
IL-ip 0.735 0.592 0.995**
IL-6 0.735 0.823 0.801
TNF-a 0.592 0.823 0.650
IL-10 0.995** 0.801 0.650
GroES IL-1 P IL-6 TNF-a IL-10
IL-1 p 0.673 0.849 0.983*
IL-6 0.673 0.960* 0.714
TNF-a 0.849 0.960* 0.863
IL-10 0.983* 0.714 0.863
deGroES IL-1 P IL-6 TNF-a IL-10
IL-1 p 0.904 0.957* 0.974*
IL-6 0.904 0.961* 0.826
TNF-a 0.957* 0.961* 0.938
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4.3.3 Cytokine secretion from U937 macrophages following 24 h incubation 
with native or denatured stress proteins.
Cytokine secretion from U937 macrophages following treatments with stress 
proteins are presented in Figures 4.14 -  4.25 and Tables 4.8 -  4.14.
4.3.3.1 Treatment of U937 macrophages with native or denatured, Hsp72 or 
DnaK.
Following incubation of U937 macrophages with Hsp72, a 2-fold increase in IL-1(3 
secretion was seen with 100 ng/mL native Hsp72 (8.090 pg/mL) compared to 
denatured Hsp72 (4.906 pg/mL), although this was not significant. A 12-fold 
increase (P<0.001) was seen at 1000 ng/mL native Hsp72 (76.850 pg/mL) 
compared with denatured Hsp72 (6.035 pg/mL) (Figure 4.14A). IL-6 levels 
increased 30-fold (P<0.001) after 24 h when incubated with 1000 ng/mL native 
Hsp72 (69.062 pg/mL) compared to denatured Hsp72 (2.154 ng/mL) (Figure 
4.15A). Secretion of TNF-a increased 4-fold following incubation with 10 ng/mL 
Hsp72 (6.455 pg/mL) compared to denatured Hsp72 (28.988 pg/mL). TNF-a levels 
also increased 4-fold (P<0.001) when incubated with 100 ng/mL native Hsp72 
compared to the denatured form (45.428 and 11.939 pg/mL respectively), and 
increased over 6-fold (P<0.001) following treatment with 1000 ng/mL native Hsp72 
(338.369 pg/mL) when compared to denatured Hsp72 (52.817 pg/mL) (Figure 
4.16A). IL-10 increased 200-fold (P<0.001) when incubated with native Hsp72 
compared to denatured Hsp72 (129.098 and 0.640 pg/mL respectively), and 
increased 15-fold (P<0.001) following incubation with 1000 ng/mL native 
(301.906 pg/mL) compared to denatured Hsp72 (21.774 pg/mL) (Figure 4.17A). 
Cytokine secretion from cells treated with native Hsp72 was dose dependent at 10, 
100 and 1000 ng/mL when compared to untreated cells (P<0.05 -  0.001), except 
for IL-6 and IL-10 at 10 ng/mL which were not significant (Table 4.8). Significant 
correlation was seen between all cytokines (r2 = 0.995 -  1.000, P<0.01) except for 
IL-10 (Table 4.9).
No significant differences were seen in relation to dose for denatured Hsp72 except 
for TNF-a secretion at 100 and 1000 ng/mL (P<0.05 and P<0.01 respectively) 
(Table 4.8). There was no significant correlation between any cytokine when 
incubated with denatured Hsp72 (Table 4.9).
IL-1|3 increased 6-fold (P<0.0)1) following incubation with 100 ng/mL native DnaK 
compared to denatured DnaK (31.778 and 7.540 pg/mL respectively), and 4-fold 
(P<0.001) at 1000 ng/mL (218.973 and 57.395 pg/mL respectively) (Figure 4.14B).
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IL-6 secretion increased significantly (P<0.001) following incubation with 
1000 ng/ml_ native DnaK compared to denatured DnaK (157.922 and 
143.424 pg/mL respectively) (Figure 4.15B). A significant increase (P<0.01) in 
TNF-a secretion from cells was observed when treated 1000 ng/mL native DnaK 
compared to denatured DnaK (593.236 and 539.368 pg/mL respectively) (Figure 
4.16B). IL-10 secretion increased 38-fold (P<0.001) following incubation with 
10 ng/mL native DnaK compared to denatured DnaK (38.998 and 1.179 pg/mL 
respectively); a 25-fold increase (P<0.001) was observed when incubated with 
100 ng/mL native DnaK compared to denatured form (270.009 and 10.522 pg/mL 
respectively); and increased 2-fold (P<0.001) following incubation with 1000 ng/mL 
native DnaK (436.974 pg/mL) compared to denatured DnaK (277.607 pg/mL) 
(Figure 4.17B).
Cytokine secretion from cells treated with native or denatured DnaK was dose 
dependent at 10, 100 and 1000 ng/mL (P<0.05 -P0.001) when compared to 
untreated cells, except for IL-6 secretion when treated with 10 ng/mL denatured 
DnaK which was not significant (Table 4.8).
Correlation was observed between TNF-a and all other cytokines (r2 = 0.957 -  
0.979, P<0.05) when treated with native DnaK, and between IL-1 (3 and IL-6 (r2 = 









Figure 4.14: Effect on IL-ip secretion by U937 macrophages when incubated 
for 24 h with Hsp72 (A) or DnaK (B), in native or denatured (de) forms.
Data are presented as mean ± SEM, n = 4. * Indicates significant difference 
between mean concentration points through use of two-way ANOVA with 










Figure 4.15: Effect on IL-6 secretion by U937 macrophages when incubated 
for 24 h with Hsp72 (A) or DnaK (B), in native or denatured (de) forms.
Data are presented as mean ± SEM, n = 4. * Indicates significant difference 
between mean concentration points through use of two-way ANOVA with 










Figure 4.16: Effect on TNF-a secretion by U937 macrophages when incubated 
for 24 h with Hsp72 (A) or DnaK (B), in native or denatured (de) forms.
Data are presented as mean ± SEM, n = 4 . * Indicates significant difference 
between mean concentration points through use of two-way ANOVA with 








Figure 4.17: Effect on IL-10 secretion by U937 macrophages when incubated 
for 24 h with Hsp72 (A) or DnaK (B), in native or denatured (de) forms.
Data are presented as mean ± SEM, n = 4. * Indicates significant difference 
between mean concentration points through use of two-way ANOVA with 
Bonferroni’s multiple comparison post hoc test: * (P<0.05), ** (P<0.01),
*** (P<0.001).
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Table 4.8: Dose responses of cytokine secretion by U937 macrophages 
incubated for 24 h with native or denatured, Hsp72 or DnaK.
Significance shown as difference between treatments using one-way ANOVA with 
Bonferroni’s multiple comparison post hoc test.
Concentration of Treatment (ng/mL)
T reatment 10 vs. 0 100 vs. 10 1000 vs. 100
Hsp72 Significance
IL-1 p * P<0.05 ** P<0.01 *** P<0.001
IL-6 ns P>0.05 * P<0.05 *** P<0.001
TNF-a *** P<0.001 *** P<0.001 *** P<0.001
IL-10 ns P>0.05 *** P<0.001 *** P<0.001
deHsp72
IL-1 p ns P>0.05 ns P>0.05 ns P>0.05
IL-6 ns P>0.05 ns P>0.05 ns P>0.05
TNF-a ns P>0.05 * P<0.05 *** P<0.001
IL-10 ns P>0.05 ns P>0.05 *** P<0.001
DnaK
IL-1 p ** P<0.01 *** P<0.001 *** P<0.001
IL-6 * P<0.05 *** P<0.001 *** P<0.001
TNF-a *** P<0.001 *** P<0.001 *** P<0.001
IL-10 *** P<0.001 *** P<0.001 *** P<0.001
deDnaK
IL-1 p * P<0.05 ** P<0.01 *** P<0.001
IL-6 ns P>0.05 *** P<0.001 *** P<0.001
TNF-a *** P<0.001 *** P<0.001 *** P<0.001
IL-10 ns P>0.05 ns P>0.05 *** P<0.001
Note: ns = not significant
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Table 4.9: Correlation between cytokine secretion by U937 macrophages 
when incubated for 24 h with native or denatured, Hsp72 or DnaK.
Significance shown following Pearson correlation: * (P<0.05); ** (P<0.01)
Hsp72 IL-1 p IL-6 TNF-a IL-10
IL-1P 0.995** 1.000** 0.935
IL-6 0.995** 0.996** 0.915
TNF-a 1.000** 0.996** 0.938
IL-10 0.935 0.915 0.938
deHsp72 IL-1 P IL-6 TNF-a IL-10
IL-1p 0.880 0.850 0.580
IL-6 0.880 0.930 0.660
TNF-a 0.850 0.930 0.890
IL-10 0.580 0.660 0.890
DnaK IL-1 P IL-6 TNF-a IL-10
IL-1p 0.999** 0.957* 0.882
IL-6 0.999** 0.966* 0.899
TNF-a 0.957* 0.966* 0.979*
IL-10 0.882 0.899 0.979*
deDnaK IL-1 P IL-6 TNF-a IL-10
IL-1P 0.992** 0.922 0.996**
IL-6 0.992** 0.949* 0.990**
TNF-a 0.922 0.949* 0.898
IL-10 0.996** 0.990** 0.898
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4.3.3.2 Treatment of U937 macrophages with native or denatured Hsp60 or 
GroEL.
Incubation of U937 macrophages with native Hsp60 resulted in an increase of IL-ip 
secretion at 100 ng/mL native Hsp60 compared to denatured Hsp60 (12.038 pg/mL 
and 8.299 pg/mL respectively), although this was not significant. There was a 3.5- 
fold increase in IL1 -(3 secretion at 1000 ng/mL native Hsp60 (53.053 pg/mL) 
compared to denatured Hsp60 (14.563 pg/mL) (P<0.001) (Figure 4.18A). Secretion 
of IL-6 increased 3-fold (P<0.001) when incubated with 10 ng/mL native Hsp60 
compared to the denatured form (3.016 and 1.102 pg/mL respectively) followed by 
a 2-fold increase (P<0.001) at 100 ng/mL native Hsp60 (5.713 pg/mL) compared to 
denatured Hsp60 (2.356 pg/mL) (P<0.05), and increased 6-fold at 1000 ng/mL 
native Hsp60 compared to denatured Hsp60 (35.434 pg/mL and 6.421 pg/mL 
respectively, P<0.001) (Figure 4.19A). TNF-a secretion increased almost 20-fold 
(P<0.01) following incubation with 10 ng/mL native Hsp60 (19.148 pg/mL) 
compared to denatured Hsp60 (1.732 pg/mL), followed by a nearly 5-fold increase 
(P<0.001) at 100 ng/mL (45.798 pg/mL native and 9.102 pg/mL denatured) and a 
5-fold increase (P<0.001) at 1000 ng/mL (276.411 pg/mL native and 56.049 pg/mL 
denatured) (Figure 4.20A). Secretion of IL-10 increased 16-fold (P<0.001) after 
incubation with 100 ng/mL Hsp60 compared to denatured Hsp60 (59.906 and 
3.043 pg/mL respectively), and a 10-fold increase (P<0.001) was observed when 
incubated with 1000 ng/mL native compared to denatured Hsp60 (286.818 and 
26.243 pg/mL respectively) (Figure 4.21A).
Cytokine secretion from cells treated with native or denatured Hsp60 were dose 
dependent at 10, 100 and 1000 ng/mL (P<0.05 -P<0.001) when compared to 
untreated cells, except for IL-ip and TNF-a when treated with 10 ng/mL denatured 
Hsp60 which were not significant (Table 4.10).
There was a significant correlation between all cytokines when treated with native 
Hsp60 (r2 = 0.993 -  1.000, P<0.01). When treated with denatured Hsp60 there was 
a significant correlation between IL-6 and all other cytokines (r2 = 0.969 -  0.980, 
P<0.05), and between TNF and IL-10 (r2= 0.999, P<0.01) (Table 4.11).
IL-ip increased 5-fold (P<0.001) following incubation with native GroEL compared 
to denatured GroEL at 1000 ng/mL (64.677 and 12.996 pg/mL respectively). No 
significant differences were seen at other concentrations (Figure 4.18B). IL-6 
secretion increased 2-fold (P<0.001) when incubated with 100 ng/mL native GroEL 
(11.145 pg/mL) compared to denatured GroEL (5.198 pg/mL) and also increased at 
1000 ng/mL (49.230 pg/mL and 33.961 pg/mL respectively, P<0.001) (Figure
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4.19B). TNF-a secretion increased significantly (P<0.001) from cells treated with 
1000 ng/mL native GroEL compared to denatured GroEL (459.852 pg/mL and 
360.298 pg/mL respectively) (Figure 4.20B). A 6-fold (P<0.001) increase of IL-10 
secretion was observed following incubation with 100 ng/mL GroEL (95.975 pg/mL) 
compared to the denatured form (16.231 pg/mL), and a 3-fold increase following 
incubation with 1000 ng/mL native compared to denatured GroEL (420.020 and 
137.439 pg/mL respectively) (Figure 4.21 B).
Cytokine secretion from cells treated with native and denatured GroEL were dose 
dependent at 10, 100 and 1000 ng/mL (P<0.05 -P<0.001) when compared to 
untreated cells, except for IL-6 secretion when treated with 10 ng/mL native or 
denatured GroEL which were not significant (Table 4.10).
Significant correlation was observed between all cytokines when treated with native 
GroEL (r2 = 0.984 -  1.000, P<0.05 -  0.01). A significant correlation was also seen 
between IL-6 and TNF-a (r2 = 0.998, P<0.01), and IL-6 and IL-10 (r2 = 0.999, 









Figure 4.18: Effect on IL-1p secretion by U937 macrophages when incubated 
for 24 h with Hsp60 (A) or GroEL (B), in native or denatured (de) forms.
Data are presented as mean ± SEM, n = 4. * Indicates significant difference 
between mean concentration points through use of two-way ANOVA with 







Figure 4.19: Effect on IL-6 secretion by U937 macrophages when incubated 
for 24 h with Hsp60 (A) or GroEL (B), in native or denatured (de) forms.
Data are presented as mean ± SEM, n = 4. * Indicates significant difference 
between mean concentration points through use of two-way ANOVA with 








Figure 4.20: Effect on TNF-a secretion by U937 macrophages when incubated 
for 24 h with Hsp60 (A) or GroEL (B), in native or denatured (de) forms.
Data are presented as mean ± SEM, n = 4. * Indicates significant difference 
between mean concentration points through use of two-way ANOVA with 









Figure 4.21: Effect on IL-10 secretion by U937 macrophages when incubated 
for 24 h with Hsp60 (A) or GroEL (B), in native or denatured (de) forms.
Data are presented as mean ± SEM, n = 4. * Indicates significant difference 
between mean concentration points through use of two-way ANOVA with 
Bonferroni’s multiple comparison post hoc test: * (P<0.05), ** (P<0.01),
*** (P<0.001).
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Table 4.10: Dose responses of cytokine secretion by U937 macrophages 
incubated for 24 h with native and denatured Hsp60 and GroEL.
Significance shown as difference between treatments using one-way ANOVA with 
Bonferroni’s multiple comparison post hoc test.
Concentration of Treatment (ng/mL)
Treatment 10 vs. 0 100 vs. 10 1000 vs. 100
Hsp60 Significance
IL-1 p ** P<0.01 *** P<0.001 *** P<0.001
IL-6 *** P<0.001 *** P<0.001 *** P<0.001
TNF-a *** P<0.001 *** P<0.001 *** P<0.001
IL-10 ns P>0.05 *** P<0.001 *** P<0.001
deHsp60
IL-1 p ns P>0.05 ** P<0.01 *** P<0.001
IL-6 *** P<0.001 *** P<0.001 *** P<0.001
TNF-a ns P>0.05 * P<0.05 *** P<0.001
IL-10 ns P>0.05 * P<0.05 *** P<0.001
GroEL
IL-1 p * P<0.05 ** P<0.01 *** P<0.001
IL-6 ns P>0.05 *** P<0.001 *** P<0.001
TNF-a *** P<0.001 *** P<0.001 *** P<0.001
IL-10 ns P>0.05 *** P<0.001 *** P<0.001
deGroEL
IL-1 p * P<0.05 ** P<0.01 *** P<0.001
IL-6 ns P>0.05 * P<0.05 *** P<0.001
TNF-a ** P<0.01 *** P<0.001 *** P<0.001
IL-10 ns P>0.05 *** P<0.001 *** P<0.001
Note: ns = not significant
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Table 4.11: Correlation between cytokine secretion by U937 macrophages 
when incubated for 24 h with native or denatured, Hsp60 or GroEL.
Significance shown following Pearson correlation: * (P<0.05); ** (P<0.01)
Hsp60 IL-1 P IL-6 TNF-a IL-10
IL-1p 0.999** 0.998** 0.994**
IL-6 0.999** 1.000** 0.993**
TNF-o 0.998** 1.000** 0.995**
IL-10 0.994** 0.993** 0.995**
deHsp60 IL-1 P IL-6 TNF-a IL-10
IL-1P 0.980* 0.912 0.901
IL-6 0.980* ' M l 0.975* 0.969*
TNF-a 0.812 0.975* 0.999**
IL-10 0.901 0.969* 0.999**
GroEL IL-1 P IL-6 TNF-a IL-10
IL-1P 0.990** 1.000** 0.988*
IL-6 0.990** 0.987* 1.000**
TNF-a 1.000** 0.987* 0.984*
IL-10 0.988* 1.000** 0.984*
deGroEL IL-1 P IL-6 TNF-a IL-10
IL-1 p 0.844 0.846 0.823
IL-6 0.844 0.998** 0.999**
TNF-a 0.846 0.998** 0.997**
IL-10 0.823 0.999** 0.997**
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4.3.3.3 Treatment of U937 macrophages with native or denatured Cpn10 or 
GroES.
When incubated with native Cpn10, there was no significant difference in IL-1(3 
secretion at any dose when compared to denatured Cpn10 (Figure 4.22A). IL-6 
secretion increased significantly (P<0.01) when U937 macrophages were incubated 
with 100ng/ml_ native Cpn10 compared to denatured Cpn10 (4.302 and 
3.303 pg/mL respectively); secretion increased significantly (P<0.001) when 
incubated with 1000 ng/ml_ native (7.628 pg/mL) compared to the denatured form 
(4.453 pg/mL) (Figure 4.23A). TNF-a secretion increased 2-fold (P<0.001) when 
incubated with 10 ng/mL native Cpn10 compared to denatured Cpn10 (4.573 and 
2.345 pg/mL respectively), which increased 3-fold (P<0.001) when treated with 100 
ng/mL (8.594 and 2.600 pg/mL respectively), followed by a 4-fold increase 
(P<0.001) in secretion when treated with 1000 ng/mL native Cpn10 compared to 
denatured Cpn10 (11.876 and 2.680 pg/mL respectively) (Figure 4.24A). IL-10 
increased 10-fold (P<0.001) following incubation with 100 ng/mL native compared 
to denatured Cpn10 (0.356 and 0.038 pg/mL respectively), and an almost 6-fold 
(P<0.001) increase following 1000 ng/mL native Cpn10 (0.703 pg/mL) compared to 
the denatured form (0.120 pg/mL) (Figure 4.25A).
Cytokine secretion from cells treated with native and denatured Cpn10 was dose 
dependent at 10, 100 and 1000 ng/mL when compared to untreated cells (P<0.05 - 
P0.001) (Table 4.12).
A significant correlation was observed between IL-1 (3 and IL-10 when treated with 
either native (r2 = 0.961, P<0.05) or denatured (r2 = 0.995, P<0.01) Cpn10 (Table 
4.13).
Following incubation of U937 macrophages when treated with native GroES, IL-1 (3 
secretion increased significantly (P<0.001) compared to denatured GroES at 
10 ng/mL (8.888 and 7.163 pg/mL respectively); secretion was significantly 
increased (P<0.001) following incubation with 100 ng/mL native GroES 
(9.613 ng/mL) compared to the denatured form (8.104 pg/mL). No significant 
increase was seen when incubated with 1000 ng/mL (Figure 4.22B). IL-6 secretion 
increased significantly (P<0.01) when incubated with 100 ng/mL native GroES 
(2.794 pg/mL) compared to denatured GroES (2.109 pg/mL) and was increased 
0.5-fold (P<0.001) when treated with 1000 ng/mL native GroES compared to 
denatured GroES (6.325 and 4.188 pg/mL respectively) (Figure 4.23B). There was 
a 2-fold increase (P<0.001) of TNF-a secretion when cells were treated with 
10 ng/mL native GroES compared to denatured GroES (4.410 and 1.199 pg/mL
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respectively), which increased 4-fold (P<0.001) when treated with 100 ng/mL 
(9.283 and 1.918 pg/mL respectively), followed by an 8-fold increase (P<0.001) in 
secretion when treated with 1000 ng/mL native GroES compared to denatured 
GroES (16.526 and 2.352 pg/mL respectively) (Figure 4.24B). Incubation 
with100 ng/mL native GroES resulted in a significant (P<0.001) increase in IL-10 
secretion compared to denatured GroES (0.442 and 0.000 pg/mL respectively), and 
a 4-fold (P<0.001) increase following incubation with 1000 ng/mL native compared 
to denatured GroES (0.937 and 0.120 pg/mL respectively) (Figure 4.25B).
Cytokine secretion from cells treated with native and denatured GroES was dose 
dependent at 10, 100 and 1000 ng/mL when compared to untreated cells (P<0.05 - 
P<0.001) , except for TNF-a secretion when treated with 10 ng/mL denatured 
GroES which was not significant (Table 4.12).
Significant correlation between IL-1 p and IL-10 (r2 = 0.983, P<0.05), and IL-6 and 
TNF-a (r2 = 0.960, P<0.05) was observed following treatment with native GroES. 
There was correlation between IL-1 (3, TNF-a and IL-10 (r2 = 0.957 -  0.974, 
P<0.05), and between IL-6 and TNF-a (r2 = 0.961, P<0.05) following treatment with 
denatured GroES (Table 4.13).
4.3.3.4 Cell viability and cell death in U937 macrophages following treatment 
with native and denatured heat shock proteins.
There was no significant change in cell number or viability (4.66 x 105 cells/mL) 
when compared to seeding density (5 x 105 cells/mL) although cell counts were 
reduced. No significant cell death by apoptosis or necrosis was detected for any 
treatment when compared to untreated cells, and all were significantly different 








Figure 4.22: Effect on IL-1P secretion by U937 macrophages when incubated 
for 24 h with Cpn10 (A) or GroES (B), in native or denatured (de) forms.
Data are presented as mean ± SEM, n = 4. * Indicates significant difference 
between mean concentration points through use of two-way ANOVA with 
Bonferroni’s multiple comparison post hoc test: * (P<0.05), ** (P<0.01),
*** (P<0.001).
156
Figure 4.23: Effect on IL-6 secretion by U937 macrophages when incubated 
for 24 h with Cpn10 (A) or GroES (B), in native or denatured (de) forms.
Data are presented as mean ± SEM, n = 4. * Indicates significant difference 
between mean concentration points through use of two-way ANOVA with 










Figure 4.24: Effect on TNF-a secretion by U937 macrophages when incubated 
for 24 h with Cpn10 (A) or GroES (B), in native or denatured (de) forms.
Data are presented as mean ± SEM, n = 4. * Indicates significant difference 
between mean concentration points through use of two-way ANOVA with 










Figure 4.25: Effect on IL-10 secretion by U937 macrophages when incubated 
for 24 h with Cpn10 (A) or GroES (B), in native or denatured (de) forms.
Data are presented as mean ± SEM, n = 4. * Indicates significant difference 
between mean concentration points through use of two-way ANOVA with 
Bonferroni’s multiple comparison post hoc test: * (P<0.05), ** (P<0.01),
*** (P<0.001).
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Table 4.12: Dose responses of cytokine secretion by U937 macrophages 
incubated for 24 h with native or denatured, Cpn10 or GroES.
Significance shown as difference between treatments using one-way ANOVA with 
Bonferroni’s multiple comparison post hoc test.
Concentration of Treatment (ng/mL)
Treatment 10 vs. 0 100 vs. 10 1000 vs. 100
Cpn10 Significance
IL-1 p *** P<0.001 *** P<0.001 *** P<0.001
IL-6 *** P<0.001 *** P<0.001 *** P<0.001
TNF-a *** P<0.001 *** P<0.001 *** P<0.001
IL-10 ns P>0.05 *** P<0.001 *** P<0.001
deCpnIO
IL-1 p *** P<0.001 *** P<0.001 *** P<0.001
IL-6 *** P<0.001 *** P<0.001 *** P<0.001
TNF-a *** P<0.001 *** P<0.001 *** P<0.001
IL-10 ns P>0.05 ns P>0.05 *** P<0.001
GroES
IL-1 p *** P<0.001 *** P<0.001 *** P<0.001
IL-6 *** P<0.001 *** P<0.001 *** P<0.001
TNF-a *** P<0.001 *** P<0.001 *** P<0.001
IL-10 ns P>0.05 *** P<0.001 *** P<0.001
deGroES
IL-1 p *** P<0.001 *** P<0.001 *** PC0.001
IL-6 *** P<0.001 *** P<0.001 *** P<0.001
TNF-a ns P>0.05 *** P<0.001 *** P<0.001
IL-10 ns P>0.05 ns P>0.05 *** P<0.001
Note: ns = not significant
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Table 4.13: Correlation between cytokine secretion by U937 macrophages 
when incubated for 24 h with native or denatured, Cpn10 or GroES.
Significance shown following Pearson correlation: * (P<0.05); ** (P<0.01)
Cpn10 IL-1 P IL-6 TNF-a IL-10
IL-1P 0.888 0.914 0.722
IL-6 0.888 0.985* 0.932
TNF-o 0.914 0.985* 0.940
IL-10 0.722 0.932 0.940 IMMI
deCpnIO IL-1 P IL-6 TNF-a IL-10
IL-1p 0.984* 0.989* 0.685
IL-6 0.984* 0.966* 0.774
TNF-a 0.989* 0.966* 0.588
IL-10 0.685 0.774 0.999** ■
GroES IL-1 P IL-6 TNF-a IL-10
IL-1P 0.733 0.771 0.655
IL-6 0.733 0.994** 0.984*
TNF-a 0.771 0.994** 0.985*
IL-10 0.655 0.984* 0.985*
deGroES IL-1p IL-6 TNF-a IL-10
IL-1 p 0.909 0.883 0.599
IL-6 0.909 0.958 0.866
TNF-a 0.883 0.958 0.757
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4.3.4 Effects on U937 macrophages following a time course of treatments 
with native or denatured, Hsp72 or low endotoxin (LE) Hsp72.
Cytokine secretion from U937 macrophages following treatments are presented in 
Figures 4.26 -  4.29 and Table 4.15.
Following a time course, IL-1 (3 secretion increased in a time dependent manner from 
U937 macrophages when treated with either Hsp72 (12.545 pg/mL) or LE-Hsp72 
(11.984 pg/mL), when compared to 0 h (4.813 pg/mL). Significant differences were 
observed at 3 h (11.929 and 9.242 pg/mL respectively) and 4 h (12.720 and 
9.753 pg/mL respectively) between, Hsp72 or LE-Hsp72 (Figure 4.26A). There was 
no difference over time between either, denatured Hsp72, or denatured LE-Hsp72 
(Figure 4.26B). IL-6 secretion also increased in a time dependent manner with 
significant differences seen between Hsp72 and LE-Hsp72 at 4 h (26.319 and 
21.480 pg/mL, P<0.01), 5 h (39.916 and 31.075 pg/mL, P0.001), and 6 h (44.699 
and 39.900 pg/mL, P<0.001) (Figure 4.27A). There was no difference at any time 
between denatured, Hsp72 or LE-Hsp72 at any time point (Figure 4.27B). TNF-a 
secretion increased in a time dependent manner reaching a peak at 6 h for both 
Hsp72 and LE-Hsp72 (716.870 and 604.050 pg/mL respectively). Significant 
differences (P<0.01 -  0.001) were observed between Hsp72 and LE-Hsp72 at all 
time points except at 0 h (Figure 4.28A). There was an increase in TNF-a secretion 
over time following incubation with both denatured forms but these were not 
significantly different from 0 h (Figure 4.28B). IL-10 secretion increased in a time 
dependent manner that peaked at 6 h for both Hsp72 and LE-Hsp72 (75.775 and 
66.898 pg/mL respectively). Significant differences were observed after 3 h until 6 h 
between Hsp72 and LE-Hsp72 (P<0.05 -  0.001) (Figure 4.29A). There was no 
difference between 0 h and any time point following incubation with denatured forms 
of Hsp72 and LE-Hsp72 (Figure 4.29B).
Significant correlation was ooserved between all cytokines over time when 
incubated with Hsp72 (r2 = 0.830 -  1.000, P<0.05 -  0.01) and LE-Hsp72 (r2 = 








Figure 4.26: Time course of IL-1p secretion by U937 macrophages treated with 
1000 ng/mL Hsp72 or low endotoxin (LE) Hsp72 in native (A) or denatured 
form (B).
U937 macrophages were treated with 1000 ng/mL Hsp72 from 0-6 h. U937 
macrophages were treated with 100 ng/ml LPS from 0-6 h. Data are presented as 
mean ± SEM, n = 4. Significance shown as difference from 0 h using two-way 









Figure 4.27: Time course of IL-6 secretion by U937 macrophages treated with 
1000 ng/mL Hsp72 or low endotoxin (LE) Hsp72 in native (A) or denatured 
form (B).
U937 macrophages were treated with 1000 ng/ml Hsp72 from 0-6 h. Data are 
presented as mean ± SEM, n = 4. Significance shown as difference from 0 h using 









Figure 4.28: Time course of TNF-a secretion by U937 macrophages treated 
with 1000 ng/mL Hsp72 or low endotoxin (LE) Hsp72 in native (A) or denatured 
form (B).
U937 macrophages were treated with 1000 ng/ml Hsp72 from 0-6 h. Data are 
presented as mean ± SEM, n = 4. Significance shown as difference from 0 h using 






Figure 4.29: Time course of IL-10 secretion by U937 macrophages treated with 
1000 ng/mL Hsp72 or low endotoxin (LE) Hsp72 in native (A) or denatured 
form (B).
U937 macrophages were treated with 1000 ng/ml Hsp72 from 0-6 h. Data are 
presented as mean ± SEM, n = 4. Significance shown as difference from 0 h using 
two-way ANOVA with Bonferroni’s multiple comparison post hoc test: * (P<0.05), ** 
(P<0.01), *** (P<0.001).
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Table 4.15: Correlation between cytokines secreted by U937 macrophages 
when incubated for up to 6 h with native Hsp72.
Significance shown following Pearson correlation: * (P<0.05); ** (P<0.01)
Hsp72 IL-1p IL-6 TNF-a IL-10
IL-1p 0.830* 0.980** 0.830*
IL-6 0.830* ^ ----- 0.890** 1.000**
TNF-a 0.980** 0.890** 0.890**
IL-10 0.830* 1.000** 0.890**
LE-Hsp72 IL-1p IL-6 TNF-a IL-10
IL-1p 0.930** 0.990** 0.930**
IL-6 0.930** 0.900** 1.000**
TNF-a 0.990** 0.900** 0.900**
IL-10 0.930** 1.000** 0.900**
________________
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4.3.5 Effect on cytokine secretion from U937 macrophages following 4 h 
treatment with Hsp72 or LPS, pre-incubated with polymyxin B.
Cytokine secretion from U937 macrophages following treatments are presented in 
Figures 4.30 -  4.33 and Table 4.16.
Following incubation with Hsp72, IL-1(3, IL-6, TNF-a and IL-10 secretion were 
significantly decreased when pre-incubated with polymyxin B compared to no 
polymyxin B (IL-1(B: 11.021 and 14.939 pg/mL respectively, P<0.05; IL-6: 21.945 
and 26.738 pg/mL respectively, P<0.001; TNF-a: 529.203 and 618.647 pg/mL 
respectively, P<0.001; IL-10: 242.079 and 415.763 pg/mL respectively, P<0.001) 
(Figures 4.30-4.33).
A significant decrease in all cytokine secretion was seen when LPS was pre- 
incubated with polymyxin B (IL-1(3: 10.684 and 33.070 pg/mL respectively, P<0.001; 
IL-6: 75.188 and 1576.964 pg/mL respectively, P<0.001; TNF-a: 382.900 and 
9793.075 pg/mL respectively, P<0.001; IL-10: 293.218 and 1381.471 pg/mL 
respectively, P<0.001) (Figures 4.30 -  4.33).
No significant differences were observed when HI-RPMI was pre-incubated with 
polymyxin B.
When pre-incubated with polymyxin B, Hsp72 resulted in significant increases 
(P<0.05 -  0.001) in cytokine secretion when compared to HI-RPMI which was 
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Figure 4.30: Secretion of IL-1p by U937 macrophages treated with Hsp72 or 
LPS with or without polymyxin B for 4 h.
U937 macrophages were treated with 1000 ng/ml Hsp72 or 100 ng/mL LPS either 
with or without pre-incubation with 20 pg/mL polymyxin B. Data are presented as 
mean ± SEM, n = 4. Significance shown as difference from HI-RPMI using two-way 
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Figure 4.31: Secretion of IL-6 by U937 macrophages treated with Hsp72 or LPS 
with or without polymyxin B for 4 h.
U937 macrophages were treated with 1000 ng/ml Hsp72 or 100 ng/mL LPS either 
with or without pre-incubation with 20 pg/mL polymyxin B. Data are presented as 
mean ± SEM, n = 4. Significance shown as difference from HI-RPMI using two-way 
ANOVA with Bonferroni’s multiple comparison post hoc test: * (P<0.05), ** (P<0.01), 
*** (P<0.001).
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Figure 4.32: Secretion of TNF-a by U937 macrophages treated with Hsp72 or 
LPS with or without polymyxin B for 4 h.
U937 macrophages were treated with 1000 ng/ml Hsp72 or 100 ng/mL LPS either 
with or without pre-incubation with 20 pg/mL polymyxin B. Data are presented as 
mean ± SEM, n = 4. Significance shown as difference from HI-RPMI using two-way 
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Figure 4.33: Secretion of IL-10 by U937 macrophages treated with Hsp72 or 
LPS with or without polymyxin B for 4 h.
U937 macrophages were treated with 1000 ng/ml Hsp72 or 100 ng/mL LPS either 
with or without pre-incubation with 20 pg/mL polymyxin B. Data are presented as 
mean ± SEM, n = 4. Significance shown as difference from HI-RPMI using two-way 
ANOVA with Bonferroni’s multiple comparison post hoc test: * (P<0.05), ** (P<0.01), 
*** (P<0.001).
Table 4.16: Significant differences in cytokine secretion between HI-RPMI (no 
treatment) and Hsp72, or LPS that were pre-incubated with polymyxin B.
Significance shown as difference from HI-RPMI using one-way ANOVA with 
Bonferroni’s multiple comparison post hoc test.
IL-10 IL-6 TNF-a IL-10
Hsp72 * (P<0.05) ***(P<0.001) ***(P<0.001) * (P<0.05)
LPS * (P<0.05) ***(P<0.001) ***(P<0.001) * (P<0.05)
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4.4 Discussion
The aim of this chapter was to determine whether recombinant heat shock proteins 
are able to induce cytokine expression and production, or if the effect is due to LPS 
contamination.
A number of recombinant heat shock proteins were applied to PBMCs or U937 
macrophages, in native or denatured forms. It was found that all native proteins 
caused a dose dependent stimulation of pro- and anti- inflammatory cytokines in 
both cell types. When Hsp72 and Hsp60 were applied to U937 macrophages, there 
was a high correlation between cytokines secreted when stimulated with the native 
form compared to the denatured form which suggests that at least some heat shock 
proteins are capable of stimulating an immune response independently of LPS. This 
is in agreement with other studies (Kol et al., 2000; Svensson et al., 2006). 
However, as the stimulation of cytokines was not completely abrogated by 
denaturation, it is possible that there is an LPS component to some of the activity. 
Kol et al. (2000) demonstrated that any activity could be abrogated by boiling 
recombinant proteins. The experiments described here only used a relatively mild 
denaturation compared to boiling as proteins are able to be denatured at lower 
temperatures than boiling, and boiling has been demonstrated to reduce the ability 
of LPS to stimulate cytokine secretion by as much as 90% (Gao, Wang & Tsan, 
2006). Also, as demonstrated by LAL assay, the only recombinant heat shock 
proteins found to contain any detectable LPS were DnaK and GroEL. When these 
proteins were denatured, this LPS contamination was only marginally reduced. This 
evidence suggests that at least some heat shock proteins are able to stimulate 
cytokine secretion.
When recombinant human proteins were used, there was a reduced cytokine 
response when compared to the equivalent bacterial protein. This is likely to be 
partially due to LPS contamination, but also the recognition of a foreign protein by 
immune cells. For example, human Hsp72 and the E. coli equivalent, DnaK, are 
both known to activate cytokine synthesis (Vabulas et al., 2002; Wang et al., 2005), 
but Hsp72 appears to be able to bind a number of receptors, including CD14 (Asea 
et al., 2000b), TLR2/4 (Asea et al., 2002), LOX-1 (Delneste, 2004) and CD40 
(Becker, Hartl & Wieland, 2002) whereas DnaK only appears to bind CD40 (Nolan et 
al., 2004).
Recombinant human Hsp60 was able to stimulate pro- and anti- inflammatory 
cytokines, as was GroEL, both of which are known to stimulate pro-inflammatory 
cytokines (Graham et al., 2004) (More et al., 2001). The response of Hsp60 could
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be due to Hsp60 being bound to LPS, as it has been demonstrated that Hsp60 is 
able to bind LPS through a distinct region (aa 354-365) which has the motif LKGK 
(Habich et al., 2004; Habich et a/., 2005). Interestingly, Hsp72 also contains this 
LKGK motif (aa 558-561) but there have been no studies reporting whether this may 
be an LPS-binding region. It is therefore possible that Hsp72 may act as an LPS- 
binding protein (LBP). Some studies have shown that the cell surface receptor for 
LPS involves a complex of which Hsp72 is a component which is indirect evidence 
that Hsp72 can bind to LPS (Triantafilou et al., 2001; Triantafilou & Triantafilou, 
2002).
The cytokine responses to Cpn10 and GroES were very low when compared to the 
other heat shock proteins, although a dose dependent increase was observed for 
both proteins. Again, this could be due to LPS contamination as secretion was 
reduced following denaturation, but it has recently been suggested that Cpn10 
functions to increase the anti-inflammatory cytokine IL-10 by inhibiting the activation 
of NF-kP by LPS (Johnson et al., 2005). The results here are not comparative with 
this study as their study utilised 100 pg/mL Cpn10 which is at least 100-fold higher 
than the concentrations used here.
A higher correlation between cytokines secreted was seen when U937 
macrophages were incubated over a short time course with Hsp72 or LE-Hsp72, 
than at 24 h which demonstrated that the cytokines measured here are upregulated 
quickly following stimulation with Hsp72. As there was no difference between Hsp72 
and LE-Hsp72, it is likely that Hsp72 itself can stimulate the cytokine response.
As Hsp72 is able to bind CD40, this leads to stimulation of the pro-inflammatory 
cytokine TNF-a (Becker et al., 2002). Secretion of TNF-a in turn initiates the 
stimulation of the anti-inflammatory cytokine IL-10, which acts to inhibit the 
production of TNF-a, as well as IL-1 p and IL-6 (Moore et al., 2001). Hsp72 is 
therefore likely to be involved in the pro-inflammatory modulation of the immune 
response, although it has recently been suggested that an LPS-free preparation of 
Mycobacterial Hsp70 does not stimulate pro-inflammatory cytokines but stimulates 
IL-10 (Motta et al., 2007). Interestingly, when either Hsp72 or LE-Hsp72 was 
denatured, the only cytokine secreted was TNF-a, which is the primary immune 
response when stimulated with LPS. The abrogation of IL-10 secretion when Hsp72 
was denatured may indicate that the primary function of extra-cellular Hsp72 is anti­
inflammatory which is in agreement with the work by Motta et al. (2007), and has 
been previously suggested by others (Prakken et al., 2001).
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LPS contamination of recombinant Hsp72 was further investigated by pre-incubating 
Hsp72 with polymyxin B which is a potent inhibitor of LPS activation. When LPS 
(100 ng/mL) was pre-incubated with polymyxin B, there was a significant reduction 
in the secretion of cytokines from U937 macrophages. Pre-incubation of Hsp72 also 
resulted in a significant decrease in secretion. However, this reduction, although 
significant, did not abrogate secretion completely and was still significantly higher 
than untreated U937 macrophages. This again suggests that Hsp72 has the ability 
to stimulate cytokine secretion of immune cells independently of LPS.
The results found in this chapter conclude that many recombinant heat shock 
proteins, especially Hsp72, are able to stimulate a cytokine response which is likely 
to be independent of LPS.
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Chapter 5
The effect of blocking peptides on Hsp72 stimulation of 
cytokine production by, and migration of, U937 
macrophages.
5.1 Introduction
The previous chapter determined that recombinant Hsp72 is able to stimulate an 
immune response from PBMCs and U937 macrophages independently from LPS. 
Hsp72 is reported to illicit this response via several receptors on the cell surface 
such as CD14 (Asea et al., 2000b), CD40 (Becker et al., 2002; Millar et al., 2003; 
Nolan et al., 2004), CD91 (Binder et al., 2000), the toll-like receptors TLR-2 (Asea et 
al., 2000b; Asea eta!., 2002), TLR-4 (Asea et al., 2002), TLR-7 (Wang etal., 2006b) 
and, the scavenger receptors LOX-1 (Delneste et al., 2002)and SREC-1 (Theriault 
et al., 2006). It has also been demonstrated that a peptide sequence homologous to 
Hsp72 (aa 329-338) is able to bind to the cytoplasmic domain of macrophage 
scavenger receptors, including CD36 (Nakamura etal., 2002).
As some of these receptors are also LPS-binding receptors (Triantafilou & 
Triantafilou, 2002) (Sondermann et al., 2000), it is plausible that any immune 
response may be due to contamination of Hsp72 by LPS. More recently, it has been 
proposed that flagellin may actually be a contaminating stimulant (Ye & Gan, 2007) 
which is supposedly specific for TLR-5 (Smith et al., 2003). The previous chapter 
however, demonstrates that although there may be some contaminating LPS 
present in recombinant Hsp72 preparations, there is a marked effect of Hsp72 on 
the stimulation of pro- and anti- inflammatory cytokines.
Hsp72 has been shown to interact with lipid raft-associated TLR-7 and can stimulate 
enhancement of macrophage phagocytosis in conjunction with TLR-7 (Wang et al., 
2006b). Also, Hsp72 which is localised at the cell surface has been shown to induce 
migration of human NK cells through a specific epitope, TKD (Gastpar et al., 2004). 
Extra-cellular Hsp72 could therefore act as a chemokine through binding to a 
number of cell surface receptors and stimulating pro- and anti- inflammatory 
cytokine release, leading to migration of phagocytic cells, which would correlate with 
Hsp72 being an endogenous danger signal (Campisi et al., 2003; Vega et al., 2008; 
Williams & Ireland, 2008).
The aim of this chapter is to determine whether Hsp72 cytokine stimulation can be 
abrogated through use of blocking peptides to a number of cell surface receptors, 
and if this has any effect on Hsp72 induced cell migration.
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5.2 Methods
All preparations and cell culture experiments were carried out within a Class II tissue 
culture hood.
5.2.1 Preparation of cells for treatment.
U937 macrophages were prepared as in section 2.3.28.
5.2.2 Preparation of Hsp72 for experiments.
Hsp72 was diluted in 10 % HI-RPMI to give 10 000 ng/mL stock solutions.
5.2.3 Preparation of peptides for blocking experiments.
Recombinant peptides derived from TLR-2, TLR-4, TLR-5, TLR-7, CD14 and CD36 
were diluted in 10 % HI-RPMI to give 20 pg/mL stock solutions.
5.2.4 Treatment of U937 macrophages with Hsp72 pre-treated with blocking 
peptides.
Hsp72 (1000 ng/mL in 10 % HI-RPMI) was pre-treated with blocking peptides for 
TLR-2, TLR-4, TLR-5, TLR-7, CD14 and CD36 at 20, 10, 5, 2, and 1 pg/mL for 1 h 
before being applied to U937 macrophages for 4 h.
5.2.5 Measurement of secreted cytokines.
Following treatment, media was removed from the wells and clarified by 
centrifugation at 400 g for 5 min and transferred to a clean 1.5 mL micro-centrifuge 
tube. Media was then either used fresh or frozen at -70°C until required. Secretion 
of TNF-a and IL-10 were measured as described in sections 2.3.35 - 2.3.36.
5.2.6 Effect on migration of U937 macrophages by Hsp72 and blocking 
peptides.
Migration of U937 macrophages was determined as in section 2.3.37.
Hsp72 (1000 ng/mL in 10 % HI-RPMI) was pre-treated with blocking peptides for 
TLR-2, TLR-4, TLR-5, TLR-7, CD14 and CD36 at 20 pg/mL for 1 h, then added to 
the lower chamber for 4 h. Hsp72 (1000 ng/mL) in 10 % HI-RPMI or 10 % HI-RPMI 
only were used as controls.
178
5.2.7 Treatment of Hsp72 with anti-flagellin antibody.
Hsp72 (1000 ng/mL) was incubated with 5 pg/mL anti-flagellin antibody for 1 h 
before being applied to U937 macrophages for 4 h. Hsp72 only or anti-flagellin 
antibody only were applied to U937 macrophages as control samples.
5.2.8 Western blots of Hsp72 and flagellin.
Serial dilutions of Hsp72 and a flagellin control (1 pg/mL) were run on SDS-PAGE 
followed by western blot as described in sections 2.3.10 and 2.3.12-13 and probed 
with either anti-Hsp72 or anti-flagellin.
5.2.9 Cell counts and viability tests by trypan blue exclusion.
Following treatment, cells were re-suspended into the media by repeated pipetting. 




5.3.1 Effect on cytokine secretion and cell migration following treatment of 
U937 macrophages with Hsp72, pre-treated with blocking peptides.
5.3.1.1 Effect of TLR-2 blocking peptide.
When Hsp72 was pre-incubated with a peptide of TLR-2 before being applied to 
U937 macrophages, TNF-a and IL-10 secretion was significantly reduced (P<0.01) 
when Hsp72 was blocked with 20 pg/mL of TLR-2 peptide compared to Hsp72 only 
(Figures 5.1A-B). TNF-a secretion was reduced by 1 %, from 626.028 to 618.540 
pg/mL, and IL-10 by 3 %, from 368.987 to 357.915 pg/mL. No other significant 
decrease was observed.
Migration of U937 macrophages was significantly reduced (P<0.001) when Hsp72 
was pre-incubated with TLR-2 peptide (4.564 X 103 cells/mL) compared to Hsp72 
alone (4.465 X 103 cells/mL respectively). Both were significantly different from 
control samples (P<0.001) (Figure 5.2).
5.3.1.2 Effect of TLR-4 blocking peptide.
Following pre-incubation of Hsp72 with a TLR-4 peptide, cytokine secretion was 
significantly reduced (P<0.001) in a concentration dependent manner at 20 and 10 
pg/mL peptide for both TNF-a (527.424 and 605.714 pg/mL respectively) and IL-10 
(172.917 and 295.874 pg/mL respectively), and a significant reduction (P<0.05) in 
IL-10 secretion was also seen when blocked with 5 pg/mL (356.788 pg/mL) (Figures 
5.3A-B).
Migration of U937 macrophages was significantly reduced (P<0.001) when Hsp72 
was pre-incubated with TLR-4 peptide (3.328 X 103 cells/mL) compared to Hsp72 
alone (4.465 X 103 cells/mL respectively). Both were significantly different from 
control samples (P<0.001) (Figure 5.4).
5.3.1.3 Effect of TLR-5 blocking peptide.
TNF-a secretion was significantly reduced (P<0.001) in a concentration dependent 
manner when Hsp72 was pre-incubated with TLR-5 peptide at all concentrations 
(151.417, 225.450, 461.556, 567.644 and 604.899 pg/mL at respective 
concentrations: 20, 10, 5, 2 and 1 pg/mL TLR-5 peptide) (Figure 5.5A). IL-10 
secretion was also significantly reduced (P<0.001) in a concentration dependent 
manner at all concentrations (51.382, 72.456, 104.496, 291.935 and 332.551 pg/mL 
at respective concentrations of 20, 10, 5, 2 and 1 pg/mL TLR-5 peptide) (Figure 
5.5B).
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Migration of U937 macrophages was significantly reduced (P<0.001) when Hsp72 
was pre-incubated with TLR-5 peptide (3.435 X 103 cells/mL) compared to Hsp72 
alone (4.465 X 103 cells/mL respectively). Both were significantly different from 
control samples (P<0.001) (Figure 5.6).
5.3.1.4 Effect of TLR-7 blocking peptide.
When Hsp72 was pre-incubated with a peptide of TLR-7 before being applied to 
U937 macrophages, TNF-a was not significantly reduced at any concentration of 
TLR-7 peptide (Figure 5.7A). In contrast, IL-10 secretion was significantly reduced 
(P<0.001) in a concentration dependent manner when Hsp72 was blocked with all 
concentrations (226.458, 290.867, 305.534, 326.092 and 348.207 pg/mL at 
respective concentrations of 20, 10, 5, 2 and 1 pg/mL TLR-7 peptide) compared to 
Hsp72 only (368.987 pg/mL)(Figure 5.7B).
Migration of U937 macrophages was reduced when Hsp72 was pre-incubated with 
TLR-7 peptide although this was not significantly different from Hsp72 alone (4.320 
and 4.465 X 103 cells/mL respectively). Both were significantly different from control 
samples (P<0.001) (Figure 5.8).
5.3.1.5 Effect of CD14 blocking peptide.
Following pre-incubation of Hsp72 with a CD14 peptide, cytokine secretion was 
significantly reduced (P<0.001) in a concentration dependent manner at 20, 10 and 
5 pg/mL peptide for both TNF-a (335.035, 381.683 and 506.346 pg/mL respectively) 
and IL-10 (99.797, 231.434 and 307.925 pg/mL respectively), and a significant 
reduction (P<0.05) in IL-10 secretion was also seen when blocked with 2 pg/mL 
(357.164 pg/mL) (Figures 5.9A-B).
Migration of U937 macrophages was significantly reduced (P<0.001) when Hsp72 
was pre-incubated with CD14 peptide (2.985 X 103 cells/mL) compared to Hsp72 
alone (4.465 X 103 cells/mL respectively). Both were significantly different from 
control samples (P<0.001) (Figure 5.10).
5.3.1.6 Effect of CD36 blocking peptide.
TNF-a secretion was significantly reduced (P<0.001) in a concentration dependent 
manner when Hsp72 was pre-incubated with CD36 peptide at all concentrations 
(63.886, 139.566, 331.689, 484.954 and 580.636 pg/mL at respective
concentrations of 20, 10, 5, 2 and 1 pg/mL CD36 peptide) (Figure 5.11 A). IL-10 
secretion was also significantly reduced (P<0.001) in a concentration dependent 
manner at all concentrations (54.315, 82.312, 133.380, 263.049 and 350.299 pg/mL
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at respective concentrations of 20, 10, 5, 2 and 1 pg/mL CD36 peptide) (Figure 
5.11B).
Migration of U937 macrophages was significantly reduced (P<0.001) when Hsp72 
was pre-incubated with CD36 peptide (2.535 X 103 cells/mL) compared to Hsp72 
alone (4.465 X 103 cells/mL respectively). Both were significantly different from 
control samples (P<0.001) (Figure 5.12).
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Figure 5.1: Effect on cytokine secretion from U937 macrophages by Hsp72 
pre-incubated with different concentrations of a TLR-2 blocking peptide.
(A) Effect on TNF-a, and (B) IL-10. Hsp72 (1000 ng/mL was pre-incubated for 1 h 
with TLR-2 blocking peptide before being applied to macrophages for 4 h. Hsp72, or 
peptide (20 pg/mL) only were used as controls. Data are presented as mean ± SEM, 













Figure 5.2: Effect on cell migration of U937 macrophages by Hsp72 pre­
incubated with a TLR-2 blocking peptide.
Hsp72 (1000 ng/mL was pre-incubated for 1 h with TLR-2 blocking peptide 
(20 pg/mL) before being applied to the lower chamber of the Boyden chamber. 
U937 macrophages (5 X 105 cells/mL) were applied to the upper chamber and the 
plate was incubated for 4 h. Cells within the lower chamber were counted. Data are 
presented as mean ± SEM, n=4. * Indicates significant difference, compared to 
Hsp72 only, through use of one-way ANOVA with Bonferroni’s multiple comparison 
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Figure 5.3: Effect on cytokine secretion from U937 macrophages by Hsp72 
pre-incubated with different concentrations of a TLR-4 blocking peptide.
(A) Effect on TNF-a, and (B) IL-10. Hsp72 (1000 ng/mL was pre-incubated for 1 h 
with TLR-4 blocking peptide before being applied to macrophages for 4 h. Hsp72, or 
peptide (20 pg/mL) only were used as controls. Data are presented as mean ± SEM, 




Figure 5.4: Effect on cell migration of U937 macrophages by Hsp72 pre­
incubated with a TLR-4 blocking peptide.
Hsp72 (1000 ng/mL was pre-incubated for 1 h with TLR-2 blocking peptide 
(20 pg/mL) before being applied to the lower chamber of the Boyden chamber. 
U937 macrophages (5 X 105 cells/mL) were applied to the upper chamber and the 
plate was incubated for 4 h. Cells within the lower chamber were counted. Data are 
presented as mean ± SEM, n=4. * Indicates significant difference, compared to 
Hsp72 only, through use of one-way ANOVA with Bonferroni’s multiple comparison 
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Figure 5.5: Effect on cytokine secretion from U937 macrophages by Hsp72 
pre-incubated with different concentrations of a TLR-5 blocking peptide.
(A) Effect on TNF-a, and (B) IL-10. Hsp72 (1000 ng/mL was pre-incubated for 1 h 
with TLR-5 blocking peptide before being applied to macrophages for 4 h. Hsp72, or 
peptide (20 pg/mL) only were used as controls. Data are presented as mean ± SEM, 
























Figure 5.6: Effect on cell migration of U937 macrophages by Hsp72 pre­
incubated with a TLR-5 blocking peptide.
Hsp72 (1000 ng/mL was pre-incubated for 1 h with TLR-5 blocking peptide 
(20 pg/mL) before being applied to the lower chamber of the Boyden chamber. 
U937 macrophages (5 X 105 cells/mL) were applied to the upper chamber and the 
plate was incubated for 4 h. Cells within the lower chamber were counted. Data are 
presented as mean ± SEM, n=4. * Indicates significant difference, compared to 
Hsp72 only, through use of one-way ANOVA with Bonferroni’s multiple comparison 
post hoc test: * (P<0.05), ** (P<0.01), *** (P<0.001).
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Figure 5.7: Effect on cytokine secretion from U937 macrophages by Hsp72 
pre-incubated with different concentrations of a TLR-7 blocking peptide.
(A) Effect on TNF-a, and (B) IL-10. Hsp72 (1000 ng/mL was pre-incubated for 1 h 
with TLR-7 blocking peptide before being applied to macrophages for 4 h. Hsp72, or 
peptide (20 pg/mL) only were used as controls. Data are presented as mean ± SEM, 
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Figure 5.8: Effect on cell migration of U937 macrophages by Hsp72 pre­
incubated with a TLR-7 blocking peptide.
Hsp72 (1000 ng/mL was pre-incubated for 1 h with TLR-7 blocking peptide 
(20 pg/mL) before being applied to the lower chamber of the Boyden chamber. 
U937 macrophages (5 X 105 cells/mL) were applied to the upper chamber and the 
plate was incubated for 4 h. Cells within the lower chamber were counted. Data are 
presented as mean ± SEM, n=4. * Indicates significant difference, compared to 
Hsp72 only, through use of one-way ANOVA with Bonferroni’s multiple comparison 
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Figure 5.9: Effect on cytokine secretion from U937 macrophages by Hsp72 
pre-incubated with different concentrations of a CD14 blocking peptide.
(A) Effect on TNF-a, and (B) IL-10. Hsp72 (1000 ng/mL was pre-incubated for 1 h 
with CD14 blocking peptide before being applied to macrophages for 4 h. Hsp72, or 
peptide (20 pg/mL) only were used as controls. Data are presented as mean ± SEM, 



















Figure 5.10: Effect on cell migration of U937 macrophages by Hsp72 pre­
incubated with a CD14 blocking peptide.
Hsp72 (1000 ng/mL was pre-incubated for 1 h with CD14 blocking peptide 
(20 pg/mL) before being applied to the lower chamber of the Boyden chamber. 
U937 macrophages (5 X 105 cells/mL) were applied to the upper chamber and the 
plate was incubated for 4 h. Cells within the lower chamber were counted. Data are 
presented as mean ± SEM, n=4. * Indicates significant difference, compared to 
Hsp72 only, through use of one-way ANOVA with Bonferroni’s multiple comparison 
post hoc test: * (P<0.05), ** (P<0.01), *** (P0.001).
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Figure 5.11: Effect on cytokine secretion from U937 macrophages by Hsp72 
pre-incubated with different concentrations of a CD36 blocking peptide.
(A) Effect on TNF-a, and (B) IL-10. Hsp72 (1000 ng/mL was pre-incubated for 1 h 
with CD36 blocking peptide before being applied to macrophages for 4 h. Hsp72, or 
peptide (20 pg/mL) only were used as controls. Data are presented as mean ± SEM, 

















Figure 5.12: Effect on cell migration of U937 macrophages by Hsp72 pre­
incubated with a CD36 blocking peptide.
Hsp72 (1000 ng/mL was pre-incubated for 1 h with CD36 blocking peptide 
(20 pg/mL) before being applied to the lower chamber of the Boyden chamber. 
U937 macrophages (5 X 105 cells/mL) were applied to the upper chamber and the 
plate was incubated for 4 h. Cells within the lower chamber were counted. Data are 
presented as mean ± SEM, n=4. * Indicates significant difference, compared to 
Hsp72 only, through use of one-way ANOVA with Bonferroni’s multiple comparison 
post hoc test: * (P<0.05), ** (P<0.01), *** (P<0.001).
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5.3.2 Determination of flagellin contamination of recombinant Hsp72.
Since the cytokine response of U937 macrophages to Hsp72 appears to be partially 
blocked by the TLR-5 peptide, it was necessary to determine if recombinant Hsp72 
was contaminated with flagellin, as TLR-5 is reported to be a specific receptor for 
flagellin (Smith et al., 2003).
When Hsp72 was pre-incubated with anti-flagellin, there was no significant 
difference in TNF-a or IL-10 secretion when compared to Hsp72 alone (Figure 5.13) 
When Hsp72 was probed with anti-flagellin by western blot, no flagellin could be 
detected (Figure 5.14).
Treatment
Figure 5.13: Effect on cytokine secretion from U937 macrophages by Hsp72, 
or Hsp72 pre-incubated with an anti-flagellin antibody.
Hsp72 (1000 ng/mL was pre-incubated for 1 h with anti-flagellin (5 pg/mL) before 
being applied to macrophages for 4 h. Data are presented as mean ± SEM, n=4.
* (P<0.05), ** (P<0.01), *** (P<0.001), using one-way ANOVA with Bonferroni’s 
multiple comparison post hoc test.
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Figure 5.14: Western blots to determine contamination of recombinant Hsp72 
with flagellin.
10 % gels were cast and loaded with the following: Lanes 1 and 6 - 25 ng pure 
human Hsp72; Lanes 2 and 7-12.5 ng pure human Hsp72; Lanes 3 and 8 - 6.25 ng 
pure human Hsp72; Lanes 4 and 9 - 3.125 ng pure human Hsp72; Lanes 5 and 10 - 
25 ng pure E. coli derived flagellin. Blots were probed with either: (A) DEG-biotin at 
1/5000 dilution followed by avidin at 1/5000 dilution or, (B) anti-flagellin at 1/1000 
dilution followed by anti-mouse IgG HRP-conjugate at 1/1000 dilution. Blots were 
exposed for 120 sec.
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5.4 Discussion
The aim of this chapter was to determine whether the stimulatory effect of Hsp72 on 
immune function could be abrogated by utilising blocking peptides to several cell 
surface receptors which are known to bind Hsp72.
It was shown that Hsp72 alone could induce TNF-a and IL-10 secretion and 
stimulate migration of U937 macrophages. Some of the blocking peptides were 
found to be able to prevent this stimulation, but there was no complete abrogating 
effect. These effects could be due to effective blocking of Hsp72 to the relevant 
receptors, or that binding of Hsp72 to certain peptides can block the binding of 
Hsp72 to other receptors.
TLR-2 blocking peptides could only block the effect of Hsp72 on macrophage 
activity at the highest concentration of blocking peptide used, which suggests that 
Hsp72 does not bind avidly to TLR-2 which is in agreement with other studies 
(Theriault et at., 2005). Hsp72 activation of an immune response was blocked in a 
dose dependent manner by all other known Hsp72 receptor peptides which 
correlates with findings by others that Hsp72 can bind a variety of cell surface 
receptors (Asea et at., 2000b; Basu et at., 2000; Becker et at., 2002; Millar et at., 
2003; Nolan et at., 2004; Wang etal., 2006b).
TLR-4 and CD14 blocking also resulted in a reduction of cytokine secretion in a 
dose dependent manner. This is suggestive that Hsp72 can bind to TLR-4 and 
CD 14 as other groups have shown (Asea et at., 2000b; Asea et at., 2002). This may 
be the result of LPS contamination as suggested by other studies (Tsan & Gao, 
2004a; Tsan & Gao, 2004b) although other proteins, such as Hsp60, have been 
shown to bind CD14 independently of LPS (Kol et at., 2000).
Blocking of CD36 resulted in the highest rate of cytokine reduction. CD36 is a class 
B scavenger receptor and can bind many ligands, including oxLDL, which is known 
to bind to other receptors such as LOX-1. LOX-1 is also a receptor known to interact 
with Hsp72 (Delneste et at., 2002). On macrophages, CD36 has been reported to 
form part of a receptor complex (CD36-aV(33 complex) which is involved in 
phagocytosis (Bottcher et at., 2006). Therefore, it may be that Hsp72 is an 
endogenous signal which promotes chemotaxis leading to phagocytosis of cellular 
debris from necrotic cells.
As stimulatory activity was effectively blocked by a TLR-5 peptide, and it has been 
suggested that flagellin could be a contaminating component of recombinant Hsp72 
(Ye & Gan, 2007), the effect of pre-incubating Hp72 with an anti-flagellin antibody on 
cytokine secretion, or probing by western blot was investigated. None of these two 
methods demonstrated any contamination by flagellin, as cytokine activity was not
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affected and there was no binding by anti-flagellin. Ye et at. (2007) have 
demonstrated that very low levels of flagellin are required to stimulate activation of 
NF-kP which does suggest that there may be enough flagellin present in 
recombinant Hsp72 preparations. Conversely, in the same paper, they do show a 
stimulatory effect of Mycobacterial Hsp72 on NF-kP avtivity which shows that even if 
flagellin is present in E. coli Hsp72, it is likely that Hsp72 is also able to stimulate an 
immune response.
Interestingly, the use of a TLR-7 blocking peptide effectively reduced only IL-10 
secretion, and not TNF-a. Binding of TLR-7 by Hsp72 has only been reported by 
one other group as a mechanism which enhances phagocytosis (Wang et at., 
2006b). Migration of U937 macrophages was not reduced compared to Hsp72 only 
treated cells. This may indicate that migration of macrophages is dependent on the 
secretion of TNF-a rather than IL-10. As the binding appears to block only IL-10 
secretion, it may indicate that the anti-inflammatory effect of Hsp72 leading to 
stimulation of IL-10 is modulated through TLR-7.
Further work needs to be done to determine exactly which receptors are being 
bound by Hsp72, or if the response is due to the blocking of Hsp72 to other 
receptors. Although this is not the case for TLR-7, as blocking with this peptide 
resulted in only IL-10 secretion abrogation, demonstrating that other receptors must 
be involved.
From the work in this chapter it is likely that Hsp72 is able to bind a number of 
receptors present on the cell surface of U937 macrophages although the types of 
receptors present was not determined. This is based on the partial blocking of 
cytokine secretion from U937 macrophages by Hsp72. As these peptides were 
produced against hydrophilic regions of receptors, it is likely that Hsp72 is able to 
bind these regions of the receptors tested here. The receptors tested here are all 
members of the super immunoglobulin family. This may suggest that these 
receptors have the ability to bind a wide variety of molecules and able to recognise 
‘dangerous’ molecules present in the extra-cellular milieu.
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Chapter 6
Interactions between extra-cellular Hsp72 and HMGB-1 on the 
stimulation of U937 macrophages.
6.1 Introduction
The previous chapter demonstrated that Hsp72 is able to act as an endogenous 
danger signal by stimulating the production of pro- and anti- inflammatory cytokines, 
and the migration of macrophages when bound to cell surface receptors. Several 
other endogenous danger signals have been proposed (Bianchi & Manfredi, 2007), 
such as HMGB-1. HMGB-1 is a nuclear protein that acts as a DNA chaperone under 
normal conditions and is associated with chromatin. It is released by necrotic or 
damaged cells and stimulates a pro-inflammatory response, but remains bound to 
chromatin in cells undergoing apoptosis (Scaffidi et al., 2002), although it has 
recently been shown to be released during late apoptosis (Bell etal., 2006). It is also 
actively secreted by viable cells (Gardella et al., 2002). Hsp72 is known to be 
released by necrosis (Daniels et al., 2004; Saito et al., 2005; Todryk et al., 1999), 
not apoptosis (Srivastava, 2003), although it has been shown to be actively secreted 
(Kalinina et al., 2004; Mambula & Calderwood, 2006a; Mambula & Calderwood, 
2006b).
Although both proteins are implicated as danger signals, they have different effects 
on other cells and tissues. Extra-cellular Hsp72 appears to have a regulatory role 
(Van Molle et al., 2002) by binding to cell surface receptors and through 
internalisation (Guzhova et al., 2001; Guzhova et al., 1998), leading to the secretion 
of pro- and anti- inflammatory cytokines (Luo et al., 2008; Njemini et al., 2007a), 
whereas HMGB-1 induces fever and inflammation in low doses (O'Connor et al., 
2003; Wang et al., 1999) and is able to effectively inhibit secretion of IL-10 (Fiuza et 
al., 2003). HMGB-1 is thought to contribute to autoimmune reactions in lupus 
through stimulation of IFN-y secretion from dendritic cells (Tian et al., 2007), and 
anti-HMGB-1 treatment is able to prevent LPS-induced fever or sepsis (Qin et al., 
2006; Wang etal., 1999).
As both proteins can be found within the extra-cellular milieu, and Hsp72 is known to 
interact with HMGB-1 within the nucleus (Tang et al., 2007a; Tang et al., 2007b) it is 
plausible that the presence of extra-cellular Hsp72 may interact with HMGB-1, and 
abrogate or inhibit some of the effects of HMGB-1, and vice versa. Therefore the 




All preparations and cell culture experiments were carried out within a Class II tissue 
culture hood.
6.2.1 Preparation of cells for treatment.
U937 macrophages were prepared as in section 2.3.28.
6.2.2 Preparation of Hsp72, HMGB-1 and LPS for experiments.
Hsp72, Bac-Hsp72 and HMGB-1 were diluted in 10 % HI-RPMI to give 10 000 
ng/mL stock solutions. LPS from E. coli 0111 :B4 was reconstituted in 10 % HI-RPMI 
at 1 mg/mL and allowed to dissolve. LPS was then further diluted in 10 % HI-RPMI 
to give 1 pg/mL stock solution.
6.2.3 Treatment of U937 macrophages with mixtures of Hsp72, HMGB-1 and 
LPS.
Hsp72 (1000 ng/mL), HMGB-1 (1000 ng/mL) and LPS (100 ng/mL) were applied 
separately or as mixtures to U937 macrophages and incubated for 4 h.
6.2.4 Time course treatment of U937 macrophages with different 
concentrations of LPS.
U937 macrophages (5 X105 U937 macrophages) were incubated with 10 000, 1000, 
100 and 10 ng/mL LPS for up to 5 h.
6.2.5 Treatment of U937 macrophages with Hsp72 and/or HMGB-1, with or 
without anti-Hsp72 and/or anti-HMGB-1 antibodies.
Hsp72 (1000 ng/mL) and/or HMGB-1 (1000 ng/mL) were applied directly to cells, or 
were pre-incubated with 1 pg/mL of anti-Hsp72 and/or anti-HMGB-1, for 1 h prior to 
being applied at 1 mL per well (5 X105 U937 macrophages) for 4 h.
6.2.6 Effect on migration of U937 macrophages by Hsp72 and/or HMGB-1, 
with or without anti-Hsp72 and/or anti-HMGB-1 antibodies.
Migration of U937 macrophages was determined as in section 2.3.37.
Hsp72 and/or HMGB-1, with or without anti-Hsp72 and/or anti-HMGB-1 were added 
to the lower chamber as described and incubated for 4 h.
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6.2.7 Treatment of U937 macrophages with heat-treated NCL, with or without 
anti-Hsp72 and/or anti-HMGB-1 antibodies.
Heat-treated NCL (Section 2.3.38) were pre-incubated with 1 pg/mL of anti-Hsp72 
and/or anti-HMGB-1 for 1 h prior to being applied at 1 mL per well (5 X105 U937 
macrophages) for 4 h.
6.2.8 Effect on migration of U937 macrophages by NCL, with or without anti- 
Hsp72 and/or anti-HMGB-1 antibodies.
Migration of U937 macrophages was determined as in section 2.3.37.
Necrotic cell lysate, with or without anti-Hsp72 and/or anti-HMGB-1 were added to 
the lower chamber as described and incubated for 4 h.
6.2.9 Treatment of U937 macrophages with Bac-Hsp72, and/or HMGB-1.
Baculovirus expressed recombinant Hsp72 (Bac-Hsp72), at 1000, 500, 250 and 125 
ng/mL, was applied to U937 macrophages with or without, HMGB-1 at 1000, 500 
and 100 ng/mL, and incubated for 4 h.
6.2.10 Effect on migration of U937 macrophages by Bac-Hsp72, and/or 
HMBG-1.
Migration of U937 macrophages was determined as in section 2.3.37.
Bac-Hsp72 and HMGB-1 were added to the lower chamber as described. 
Bac-Hsp72, at 1000, 500, 250 and 125 ng/mL, was applied to U937 macrophages 
with or without, HMGB-1 at 1000, 500 and 100 ng/mL, and incubated for 4 h.
6.2.11 Measurement of secreted cytokines.
Following treatment, media was removed from the wells and clarified by 
centrifugation at 400 g for 5 min and transferred to a clean 1.5 mL micro-centrifuge 
tube. Media was then either used fresh or frozen at -70°C until required. Secretion 
of TNF-a and IL-10 were measured as described in sections 2.3.35 - 2.3.36.
6.2.12 Cell counts and viability tests by trypan blue exclusion.
Following treatment, cells were re-suspended into the media by repeated pipetting. 




6.3.1 Effect on cytokine secretion following treatment of U937 macrophages 
with mixtures of Hsp72, HMGB-1 and LPS.
Following treatment of U937 macrophages with Hsp72 (1000 ng/mL), TNF-a 
secretion increased 50-fold (P<0.001) compared to untreated macrophages 
(631.404 and 12.677 pg/mL respectively). IL-10 secretion also increased over 3-fold 
(P<0.001) when compared to untreated macrophages (326.106 and 97.839 pg/mL 
respectively) (Figure 6.1 A).
A similar increase in TNF-a was seen following treatment with HMGB-1 
(1000 ng/mL) (679.852 pg/mL, P<0.001) (Figure 6.1A), but IL-10 secretion was 
abrogated (92.270 pg/mL) and not significantly different from untreated 
macrophages (Figure 6.1 A).
When macrophages were treated with both Hsp72 and HMGB-1, a 120-fold 
increase (P<0.001) in TNF-a was observed (1526.435 pg/mL), and there was a 2- 
fold increase (P<0.001) in IL-10 secretion (215.297 pg/mL) when compared to 
untreated macrophages (Figure 6.1 A).
When the same treatments were applied to U937 macrophages, with added LPS 
(100 ng/mL), a similar trend in cytokine secretion was observed: TNF-a secretion 
increased significantly (P<0.001) with LPS and Hsp72, compared to LPS only 
treated macrophages (13016.020 and 10032.150 pg/mL respectively). IL-10 
secretion also increased (P<0.0001) when compared to LPS treated macrophages 
(1860.653 and 1372.494 pg/mL respectively) (Figure 6.1B).
A similar increase in TNF-a was seen following treatment with LPS and HMGB-1 
(17954.710 pg/mL, P<0.001), but IL-10 secretion was significantly decreased 
(784.467 pg/mL, P<0.001) compared to LPS treated macrophages (Figure 6.1 B). 
When macrophages were treated with LPS and, both Hsp72 and HMGB-1, a 2-fold 
increase (P<0.001) in TNF-a was observed (21149.150 pg/mL), but IL-10 secretion 
was significantly decreased (P<0.001) when compared to LPS treated macrophages 
(1255.950 and 1372.494 pg/mL respectively) (Figure 6.1 B).
There were no differences in cell viability or counts following any 4 h treatment 
compared to untreated macrophages (Table 6.1).
U937 macrophages treated with different doses of LPS over a 5 h time course 







□  LPS+Hsp72 
H  LPS+HMGB-1
^  LPS+Usp72+HMGB-1
Figure 6.1: Effect on cytokine secretion following 4 h treatment of U937 
macrophages with (A) Hsp72 and/or HMGB-1, and (B) LPS and, Hsp72 and/or 
HMGB-1.
Hsp72 and HMGB-1 concentrations were 1000 ng/mL. LPS concentration was 100 
ng/mL. Data are presented as mean ± SEM, n = 4. * Indicates significant difference 
between mean concentration points, compared to untreated cells, through use of 
one-way ANOVA with Bonferroni’s multiple comparison post hoc test: * (P<0.05), ** 
(P<0.01), *** (P<0.001).
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Table 6.1: Cell counts and viability of U937 macrophages following 4 h 
treatment with Hsp72 and/or HMGB-1, and LPS with or without Hsp72 and/or 
HMGB-1.
T reatment Viable cell count (x 10s)
Untreated 4.95 ±0.05
Hsp72 4.93 ± 0.07
HMGB-1 4.94 ± 0.04
Hsp72+HMGB-1 4.92 ± 0.04
LPS 4.95 ± 0.06
LPS+Hsp72 4.95 ± 0.02
LPS+HMGB-1 4.93 ± 0.04
LPS+Hsp72+HMGB-1 4.92 ± 0.04





Figure 6.2: Effect on cytokine secretion by U937 macrophages following 5 h 
time course of LPS at different concentrations.
(A) TNF-a secretion, (B) IL-10 secretion. Data are presented as mean ± SEM, n = 4. 
* Indicates significant difference between dose curves through use of one-way 
ANOVA with Bonferroni’s multiple comparison post hoc test: * (P<0.05), ** (P<0.01), 
*** (P<0.001).
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6.3.2 Effect on cytokine secretion and cell migration following treatment of 
U937 macrophages with Hsp72, and/or HMGB-1, pre-incubated with anti- 
Hsp72, and/or anti-HMGB-1.
When Hsp72 was pre-incubated with anti-Hsp72 before being applied to U937 
macrophages, there were significant (P<0.001) reductions in both TNF-a 
(109.596 pg/mL) and IL-10 (164.681 pg/mL) secretion for both treatments when 
compared to cells treated with Hsp72 only (631.404 and 326.106 pg/mL respectively 
for TNF-a and IL-10) (Figure 6.3).
Migration of U937 macrophages increased over 3-fold (P<0.001) in response to 
Hsp72 compared to control cells (4.465 and 1.388 X 103 cells/mL respectively). This 
migration was significantly reduced when Hsp72 was pre-incubated with anti-Hsp72 
(3.547 X 103 cells/mL, P<0.001) compared to Hsp72, but was still significantly 
different from control cells (Figure 6.4).
When incubated with Hsp72, and/or anti-Hsp72, there was a high correlation 
between TNF-a and migration (r2 = 0.675), although the correlation was higher for 
IL-10 and migration (/2 -  0.799).
When HMGB-1 was pre-incubated with anti-HMGB-1 before being applied to U937 
macrophages there was a significant reduction in TNF-a (158.370 pg/mL, P<0.001) 
compared to HMGB-1 only (679.852 pg/mL) (Figure 6.3A). There was a significant 
increase of IL-10 secretion (101.551 pg/mL, P<0.05) compared to HMBG-1 only 
(92.270 pg/mL), although neither was significantly different from untreated cells 
(Figure 6.3B).
Migration of U937 macrophages increased over 3-fold (P<0.001) in response to 
HMGB-1 compared to control cells (4.798 and 1.388 X 103 cells/mL respectively). 
Migration was significantly reduced when HMGB-1 was pre-incubated with anti- 
HMGB-1 (3.108 X 103 cells/mL, P<0.001) compared to HMGB-1, but was still 
significantly different from control cells (Figure 6.4).
When incubated with HMGB-1, and/or anti-HMGB-1, there was a high correlation 
between TNF-a and migration (r2 = 0.900), and a low correlation between IL-10 and 
migration (r2 = 0.350).
When a mixture of both Hsp72 and HMGB-1 was pre-incubated with antibodies to 
the respective proteins there was a significant reduction in secretion of TNF-a 
(109.921 pg/mL, P<0.001) compared to Hsp72/HMGB-1 only (1526.435 pg/mL) 
(Figure 6.3A). There was a significant decrease in IL-10 secretion (178.224 pg/mL,
207
P<0.001) when a mixture of both Hsp72 and HMGB-1 was pre-incubated with 
antibodies compared to Hsp72/HMGB-1 only (215.297 pg/mL) (Figure 6.3B). 
Migration of U937 macrophages increased over 4-fold (P<0.001) in response to 
Hsp72/HMGB-1 compared to control cells (5.660 and 1.388 X 103 cells/mL 
respectively). Migration was significantly reduced when Hsp72/HMGB-1 was pre- 
incubated with anti-Hsp72/HMGB-1 (2.590 X 103 cells/mL, P<0.001) compared to 
Hsp72/HMGB-1, but was still significantly different from control cells (Figure 6.4). 
When incubated with Hsp72/HMGB-1, and/or anti- Hsp72/HMGB-1, there was a 
high correlation between TNF-a and migration (i2 = 0.950), and a high correlation 








Figure 6.3: Effect on cytokine secretion from U937 macrophages incubated 
with Hsp72, HMGB-1, or mixtures of Hsp72/HMGB-1, with or without anti- 
Hsp72 and/or anti-HMGB-1.
(A) TNF-a secretion, (B) IL-10 secretion. Data are presented as mean ± SEM, n = 4. 
* Indicates significant difference between untreated and treated cells, through use of 





Figure 6.4: Effect on migration of U937 macrophages incubated with Hsp72, 
HMGB-1, or mixtures of Hsp72/HMGB-1, with or without anti-Hsp72 and/or 
anti-HMGB-1.
Data are presented as mean ± SEM, n = 4. * Indicates significant difference 
between treated and untreated cells, through use of one-way ANOVA with 
Bonferroni’s multiple comparison post hoc test: * (P<0.05), ** (P<0.01),
*** (P<0.001).
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6.3.3 Effect on cytokine secretion and cell migration following treatment of 
U937 macrophages with heat-treated NCL, pre-incubated with anti- 
Hsp72, and/or anti-HMGB-1.
Heat-treated NCL (See section 2.3.38) pre-incubated with anti-Hsp72, when applied 
to U937 macrophages resulted in a significant (P<0.001) decrease in TNF-a 
(468.030 pg/mL) and IL-10 (173.904 pg/mL) secretion when compared to cells 
treated with NCL only (777.916 and 214.094 pg/mL respectively) (Figure 6.5).
Cell migration was reduced significantly when NCL was pre-incubated with anti- 
Hsp72 (7.497 from 8.292 X 103 cells/mL, P<0.001) (Figure 6.6).
When heat-treated NCL pre-incubated with anti-HMGB-1 was applied to U937 
macrophages there was a significant reduction in both TNF-a (P<0.001) and IL-10 
(P<0.01) secretion (422.156 and 201.596 pg/mL respectively), compared to NCL 
treatment alone (Figure 6.5).
Cell migration was reduced significantly when NCL was pre-incubated with anti- 
HMGB-1 (7.257 X 103 cells/mL, P<0.001) (Figure 6.6).
NCL which was pre-incubated with both anti- Hsp72 and HMGB-1 then applied to 
U937 macrophages resulted in a significant decrease (P<0.001) of TNF-a secretion 
(383.405 pg/mL) and IL-10 secretion (167.352 pg/mL) compared to NCL treatment 
alone (Figure 6.5).
Cell migration was reduced significantly when NCL was pre-incubated with anti- 
Hsp72/HMGB-1 (7.025 X 103 cells/mL, P<0.001) (Figure 6.6).
When incubated with NCL, and/or anti- Hsp72/HMGB-1, there was a high correlation 
between TNF-a and migration (r2 = 0.778), and a high correlation between IL-10 and 
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Untreated NCL NCL+anti-Hsp72 NCL+anti-HMGB-1 NCL+antibodies
Treatment, 4 h
Figure 6.5: Effect on cytokine secretion from U937 macrophages incubated 
with NCL, with or without anti-Hsp72 and/or anti-HMGB-1.
(A) TNF-a secretion, (B) IL-10 secretion. Data are presented as mean ± SEM, n = 4. 
* Indicates significant difference between mean concentration points, compared to 
NCL only, through use of one-way ANOVA with Bonferroni’s multiple comparison 
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Control NCL NCL+anti-Hsp72 NCL+anti-HMGB-1 NCL+antibodies
Treatment, 4 h
Figure 6.6: Effect on migration of U937 macrophages incubated with NCL, with 
or without anti-Hsp72 and/or anti-HMGB-1.
Data are presented as mean ± SEM, n = 4. * Indicates significant difference 
between mean concentration points, compared to NCL only, through use of one-way 
ANOVA with Bonferroni’s multiple comparison post hoc test * (P<0.05), ** (P<0.01), 
*** (P<0.001).
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6.3.4 Effect of varying Hsp72 concentrations with fixed HMGB-1 on cytokine 
secretion from, and migration of, U937 macrophages.
Following treatment of U937 macrophages with varying concentrations of Hsp72 
with a fixed concentration of HMGB-1 (1000 ng/mL), there was a dose dependent 
decrease in TNF-a secretion (1607.835 -  679.699 pg/mL) which peaked when 
incubated with 1000 ng/mL of Hsp72/HMGB-1 (1607.835 pg/mL) and was significant 
at each dose except for 15.625 ng/mL. There was also a dose dependent decrease 
in IL-10 secretion (234.824 -  24.737 pg/mL) which peaked at 1000 ng/mL 
Hsp72/HMGB-1 (234.824 pg/mL) and was significant at each dose except for 
15.625 ng/mL. There was a high correlation between TNF-a and IL-10 (r2 = 0.984) 
(Figure 6.7).
Cell migration was not dose dependent except for those treated with Hsp72 at 
1000 ng/mL (5.660 X 103 cells/mL) and 500 ng/mL (5.417 X 103 cells/mL). Migration 
correlated highly with TNF-a (/2 = 0.962), and IL-10 (r2 = 0.956) (Figure 6.8).
Following treatment of varying concentrations of Hsp72 only there was again a dose 
dependent response of both cytokines, although TNF-a secretion was lower and 
IL-10 secretion was higher than when incubated with Hsp72/HMGB-1. There was a 
high correlation between TNF-a and IL-10 (r2 = 0.931) (Figure 6.9).
Cell migration was dose dependent between 1000 -  250 ng/mL Hsp72 only (4.465 -  
2.247 X 103 cells/mL). Migration correlated highly with TNF-a (r2 = 0.966), and IL-10 
(r2 = 0.962) (Figure 6.10).
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1000 500 250 125 6Z5 31.25 15.625
Hsp72 concentration (ng/mL) + HMGB-1 (1000 ng/mL)
■0
0
Figure 6.7: Effect of varying Hsp72 concentrations with fixed HMGB-1 on 
cytokine secretion from U937 macrophages.
HMGB-1 concentration was 1000 ng/mL. Data are presented as mean ± SEM, n =
4. TNF-a is represented by (•) is depicted on the left Y-axis; IL-10 is represented by 
(■) on the right Y-axis. * indicates significant difference between mean concentration 
points, compared to HMGB-1 only, through use of one-way ANOVA with 
Bonferroni’s multiple comparison post hoc test:* (P<0.05), ** (P<0.01),
*** (P<0.001). r2, Pearson correlation.
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1000 500 250 125 62.5 31.25 15.625 0
Hsp72 concentration (ng/mL) + HMGB-1 (1000 ng/mL)
Figure 6.8: Effect of varying Hsp72 concentrations with fixed HMGB-1 on 
migration of U937 macrophages.
HMGB-1 concentration was 1000 ng/mL. Data are presented as mean ± SEM, n =
4. * Indicates significant difference between mean concentration points of Hsp72, 
compared to HMGB-1 only, through use of one-way ANOVA with Bonferroni’s 
multiple comparison post hoc test: * (P<0.05), ** (P<0.01), *** (P<0.001).
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Hsp72 concentration, ng/ml
Figure 6.9: Effect of varying Hsp72 concentrations on cytokine secretion from 
U937 macrophages.
Data are presented as mean ± SEM, n = 4. TNF-a is represented by (•) is depicted 
on the left Y-axis; IL-10 is represented by (■) on the right Y-axis. * indicates 
significant difference between mean concentration points, compared to 0 ng/mL 
only, through use of one-way ANOVA with Bonferroni’s multiple comparison post 
hoc test:* (P<0.05), ** (P<0.01), *** (P<0.001). i2, Pearson correlation.
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Hsp72 concentration, ng/ml
Figure 6.10: Effect of varying Hsp72 concentrations on migration of U937 
macrophages.
Data are presented as mean ± SEM, n = 4. * indicates significant difference between 
mean concentration points, compared to 0 ng/mL only, through use of one-way 
ANOVA with Bonferroni’s multiple comparison post hoc test:* (P<0.05), ** (P<0.01), 
*** (P<0.001).
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6.3.5 Effect of varying HMGB-1 concentrations with fixed Hsp72 on cytokine 
secretion from, and migration of, U937 macrophages.
Following treatment of U937 macrophages with varying concentrations of HMGB-1 
with a fixed concentration of Hsp72 (1000 ng/mL), there was a dose dependent 
decrease in TNF-a secretion (1455.885 -  633.382 pg/mL) which peaked when 
incubated with 1000 ng/mL of HMGB-1/Hsp72 (1455.855 pg/mL) but was only 
significantly decreased until dose 125 ng/mL (666.729, P<0.01). There was also a 
dose dependent increase in IL-10 secretion (194.979 -  387.641 pg/mL) which was 
highest at 1000 ng/mL HMGB-1 only (387.641 pg/mL) and was significantly different 
(P<0.001) at each dose. There was a low correlation between TNF-a and IL-10 
(r2 = 0.656) (Figure 6.11).
Cell migration was dose dependent between 1000 -  500 ng/mL HMGB-1 (5.660 -  
4.817 X 103 cells/mL). Migration correlated well with TNF-a (/2 -  0.823), but was 
lower with IL-10 (r2 = 0.557) (Figure 6.12).
Following treatment of varying concentrations of HMGB-1 only there was a dose 
dependent response of TNF-a between 1000 -  62.5 ng/mL only (P<0.001 - <0.05). 
All other doses were not significantly different from each other. There were no 
significant differences in dose response for IL-10 at any concentration of HMGB-1. 
There was a low correlation between TNF-a and IL-10 (t2 = 0.507) (Figure 6.13).
Cell migration was dose dependent between 1000 -  62.5 ng/mL HMGB-1 (4.798 -  
1.718 X 103 cells/mL). Migration correlated well with TNF-a (/2 -  0.895), and with 
IL-10 (r2 = 0.891) (Figure 6.14).
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r2 =  0.656
HMGB-1 concentration (ng/mL) + Hsp72 (1000 ng/mL)
Figure 6.11: Effect of varying HMGB-1 concentrations with fixed Hsp72 on 
cytokine secretion from U937 macrophages.
Hsp72 concentration was 1000 ng/mL. Data are presented as mean ± SEM, n = 4. 
TNF-a is represented by (•) is depicted on the left Y-axis; IL-10 is represented by 
(■) on the right Y-axis. * indicates significant difference between mean concentration 
points, compared to 0 ng/mL only, through use of one-way ANOVA with Bonferroni’s 
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Figure 6.12: Effect of varying HMGB-1 concentrations with fixed Hsp72 on 
migration of U937 macrophages.
Hsp72 concentration was 1000 ng/mL. Data are presented as mean ± SEM, n = 4.
* indicates significant difference between mean concentration points, compared to 
Hsp72 only, through use of one-way ANOVA with Bonferroni’s multiple comparison 







Figure 6.13: Effect of varying HMGB-1 concentrations on cytokine secretion 
from U937 macrophages.
Data are presented as mean ± SEM, n = 4. TNF-a is represented by (•) is depicted 
on the left Y-axis; IL-10 is represented by (■) on the right Y-axis. * indicates 
significant difference between mean concentration points, compared to 0 ng/mL 
only, through use of one-way ANOVA with Bonferroni's multiple comparison post 
hoc test:* (P<0.05), ** (P<0.01), *** (P<0.001). t2, Pearson correlation.
NB: Significant differences for TNF-a are indicated above curve and IL-10 
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Figure 6.14: Effect of varying HMGB-1 concentrations with on migration of 
U937 macrophages.
Data are presented as mean ± SEM, n = 4. * indicates significant difference between 
mean concentration points, compared to 0 ng/mL only, through use of one-way 
ANOVA with Bonferroni’s multiple comparison post hoc test:* (P<0.05), ** (P<0.01), 
*** (P<0.001).
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6.3.6 Effect on cytokine secretion and cell migration following treatment of 
U937 macrophages with mixtures of Bac-Hsp72, and HMGB-1.
When U937 macrophages were incubated with Bac-Hsp72 only, there was a dose 
dependent decrease in the secretion of TNF-a between 1000 -  125 ng/mL Bac- 
Hsp72 (226.149 -  25.099 pg/mL, P<0.001). There was also a dose dependent 
decrease in IL-10 secretion between 1000 -  125 ng/mL Bac-Hsp72 (151.642 -  
28.566 pg/mL, P<0.001). Cytokine secretion correlated highly (r2 = 0.978) (Figure 
6.15).
Cell migration was dose dependent between 1000 -  500 ng/mL Bac-Hsp72 (2.107 -  
1.634 X 103 cells/mL). Migration correlated highly with TNF-a (r2 = 0.992), and with 
IL-10 (r2 = 0.947) (Figure 6.16).
When Bac-Hsp72 was incubated with 1000 ng/mL HMGB-1 there was a dose 
dependent decrease in TNF-a secretion between 1000 -  250 ng/mL Bac-Hsp72 
(1042.048 -  651.737 pg/mL, P<0.001 -  0.05). IL-10 secretion was completely 
abrogated by 1000 ng/mL HMGB-1. Cytokine secretion correlated well (r2 = 0.771) 
(Figure 6.17).
Cell migration was dose dependent between 1000 -  250 ng/mL Bac-Hsp72 (6.211 -  
5.121 X 103 cells/mL). Migration correlated highly with TNF-a (r2 = 0.960), but was 
lower with IL-10 (r2 = 0.891) (Figure 6.18).
Following incubation with Bac-Hsp72 and 500 ng/mL HMGB-1, a dose dependent 
decrease in TNF-a secretion was observed between 1000 -  500 ng/mL Bac-Hsp72 
(398.608 -  190.793 pg/mL). Secretion of IL-10 was only dose dependent at 
1000 ng/mL Bac-Hsp72 (48.000 pg/mL, P0.001). All other doses were completely 
abrogated by 500 ng/mL HMGB-1. Secretion of TNF-a and IL-10 correlated highly 
(r2 = 0.972) (Figure 6.19).
Cell migration was dose dependent between 1000 -  500 ng/mL Bac-Hsp72 (4.519 -  
4.137 X 103 cells/mL). Migration correlated highly with TNF-a (r2 = 0.848), but was 
lower with IL-10 (r2 = 0.719) (Figure 6.20).
Incubation with Bac-Hsp72 with 100 ng/mL HMGB-1 resulted in a dose dependent 
decrease of TNF-a secretion between all doses (237.960 -  77.402 pg/mL, P<0.001). 
IL-10 secretion was also dose dependent between 1000 -  250 ng/mL Bac-Hsp72 
(79.990 -  30.667 pg/mL, P<0.001 -  0.01). Secretion of TNF-a and IL-10 correlated 
highly (a2 = 0.951) (Figure 6.21).
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Cell migration was dose dependent between 1000 -  500 ng/mL Bac-Hsp72 (2.892 -  
2.336 X 103 cells/mL). Migration correlated highly with TNF-a (r2 = 0.984), and with 









Figure 6.15: Effect on cytokine secretion following treatment of U937 
macrophages with Bac-Hsp72.
Data are presented as mean ± SEM, n = 4. TNF-a is represented by (•) is depicted 
on the left Y-axis; IL-10 is represented by (■) on the right Y-axis. * indicates 
significant difference between mean concentration points, compared to 0 ng/mL 
only, through use of one-way ANOVA with Bonferroni’s multiple comparison post 








Figure 6.16: Effect of varying Bac-Hsp72 concentrations on migration of U937 
macrophages.
Data are presented as mean ± SEM, n = 4. * indicates significant difference between 
mean concentration points, compared to 0 ng/mL only, through use of one-way 
ANOVA with Bonferroni’s multiple comparison post hoc test:* (P<0.05), ** (P<0.01), 
*** (P<0.001).
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Figure 6.17: Effect on cytokine secretion following treatment of U937 
macrophages with Bac-Hsp72 and 1000 ng/mL HMGB-1.
Data are presented as mean ± SEM, n = 4. TNF-a is represented by (•) is depicted 
on the left Y-axis; IL-10 is represented by (■) on the right Y-axis. * indicates 
significant difference between mean concentration points, compared to HMGB-1 
only, through use of one-way ANOVA with Bonferroni’s multiple comparison post 
hoc test:* (P<0.05), ** (P<0.01), *** (P<0.001). i2, Pearson correlation.
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Figure 6.18: Effect of Bac-Hsp72 with 1000 ng/mL HMGB-1 on migration of 
U937 macrophages.
Data are presented as mean ± SEM, n = 4. * indicates significant difference between 
mean concentration points, compared to HMGB-1 only, through use of one-way 
ANOVA with Bonferroni’s multiple comparison post hoc test:* (P<0.05), ** (P<0.01), 
*** (P<0.001).
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Bac-Hsp72 concentration (ng/mL) + HMGB-1 (500 ng/mL)
Figure 6.19: Effect on cytokine secretion following treatment of U937 
macrophages with Bac-Hsp72 and 500 ng/mL HMGB-1.
Data are presented as mean ± SEM, n = 4. TNF-a is represented by (•) is depicted 
on the left Y-axis; IL-10 is represented by (■) on the right Y-axis. * indicates 
significant difference between mean concentration points, compared to HMGB-1 
only, through use of one-way ANOVA with Bonferroni’s multiple comparison post 
hoc test:* (P<0.05), ** (P<0.01), *** (P<0.001). r2, Pearson correlation.
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Figure 6.20: Effect of Bac-Hsp72 with 500 ng/mL HMGB-1 on migration of U937 
macrophages.
Data are presented as mean ± SEM, n = 4. * indicates significant difference between 
mean concentration points, compared to HMGB-1 only, through use of one-way 
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Figure 6.21: Effect on cytokine secretion following treatment of U937 
macrophages with Bac-Hsp72 and 100 ng/mL HMGB-1.
Data are presented as mean ± SEM, n = 4. TNF-a is represented by (•) is depicted 
on the left Y-axis; IL-10 is represented by (■) on the right Y-axis. * indicates 
significant difference between mean concentration points, compared to HMGB-1 
only, through use of one-way ANOVA with Bonferroni’s multiple comparison post 
hoc test:* (P<0.05), ** (P<0.01), *** (P<0.001). i2, Pearson correlation.
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Bac-Hsp72 concentration (ng/mL) + HMGB-1 (100 ng/mL)
Figure 6.22: Effect of Bac-Hsp72 with 100 ng/mL HMGB-1 on migration of U937 
macrophages.
Data are presented as mean ± SEM, n = 4. * indicates significant difference between 
mean concentration points, compared to HMGB-1 only, through use of one-way 




This chapter aimed to determine if Hsp72 was able to abrogate or inhibit the effects 
of HMGB-1 on the immune response.
Firstly, Hsp72 is able to stimulate the secretion of TNF-a and IL-10, whereas 
HMGB-1 only stimulates TNF-a secretion. HMGB-1 is known to abrogate IL-10 
(Andersson et al., 2000; Fiuza et ai, 2003). However, when both Hsp72 and HMGB- 
1 were applied together, there was a significant increase in TNF-a, but also, IL-10 
secretion was significantly higher than HMGB-1 treated, or, untreated samples. It 
therefore suggests that Hsp72 is able to stimulate IL-10 secretion despite the 
presence of HMGB-1, and supports a role for Hsp72 as a modulatory chemokine 
and danger signal.
When Hsp72 or HMGB-1 was added to LPS a similar, but amplified pattern of 
cytokine release occurred. This amplification could not be achieved through the 
addition of more LPS suggesting that receptors other than CD14 and TLR-2/4 are 
involved in the stimulation of the immune response by Hsp72 and HMGB-1. The 
effect could not due to potential contamination by LPS.
Hsp72 and HMGB-1 have previously been reported to be able to stimulate migration 
of immune cells (Dumitriu et al., 2007; Gastpar et al., 2004; Palumbo et a!., 2007; 
Rouhiainen et al., 2004; Yang et al., 2006), and neutralising antibodies have been 
shown to inhibit cytokine secretion (El Mezayen et al., 2007). The results here 
support both of these findings. When Hsp72 was pre-incubated with anti-Hsp72, 
there was an overall reduction of cytokine secretion and migration of macrophages 
was reduced and the correlation between migration and cytokines was high. There 
was a reduction of cytokine secretion and migration of macrophages when HMGB-1 
was pre-incubated with anti-HMGB-1, but in contrast to Hsp72 migration was 
positively correlated with TNF-a, and inversely with IL-10. However, when both 
Hsp72 and HMGB-1 were applied to macrophages, there was a high positive 
correlation between migration and both cytokines. Pre-incubation with antibodies to 
both proteins reduced migration and cytokine secretion. This again suggests that 
Hsp72 is able to counteract some of the pro-inflammatory effects of HMGB-1 by 
stimulating IL-10 secretion.
To determine whether Hsp72 and HMGB-1 from necrotic cells were able to 
significantly affect cytokine secretion and migration of macrophages, NCL was pre- 
incubated with anti-Hsp72 and/or anti-HMGB-1. NCL was able to stimulate secretion 
of TNF-a and IL-10 and resulted in significantly more migration than either Hsp72 or 
HMGB-1. When antibodies were applied there was a significant reduction in 
cytokine secretion and migration of macrophages. There was less of an effect than
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expected when anti-HMGB-1 was applied but this is possibly due to the treatment 
for heat-treated NCL not resulting in large enough levels of HMGB-1 being 
produced, or that the antibody used did not effectively block binding of HMGB-1 to 
cell surface receptors. The same could be applied to the Hsp72 antibody used. Also, 
there was a higher correlation between migration and IL-10 than there was for 
migration and TNF-a further supporting Hsp72 as a modulatory chemokine. 
However, as the reduction, although significant, was slight there must be other 
signals from necrotic cells which stimulate migration of, and cytokine release from 
macrophages (Gallucci, Lolkema & Matzinger, 1999; Shi & Rock, 2002; Shi, Zheng 
& Rock, 2000).
Migration of macrophages when incubated with Hsp72 and/or HMGB-1 was always 
significantly higher than untreated macrophages. HMGB-1 treatment resulted in 
higher migration levels than Hsp72, and appears to be highly correlated with TNF-a 
secretion. HMGB-1 is known to induce migration of immune cells (Rouhiainen et at., 
2004) and increase levels of TNF-a (Yu et al., 2006). Migration in relation to Hsp72 
was highly correlated with both TNF-a and IL-10. However, the number of migrating 
macrophages was much less than with HMGB-1, possibly indicating that the 
stimulation of IL-10 reduced the number of migrating macrophages. This data 
correlates well with the ability of IL-10 to reduce migration of immune cells. The use 
of a certified endotoxin-free recombinant Hsp72 expressed in Baculovirus induced 
less TNF-a and IL-10 than Hsp72 expressed in E. coli, and less migrating 
macrophages. Again, the correlation was high between both cytokines and migration 
of macrophages.
The results from varying concentrations of either Bac-Hsp72 with a fixed 
concentration HMGB-1, or vice versa demonstrated that the presence of Hsp72 
could effectively reduce the number of migrating macrophages. It is possible this 
was due to an increased secretion of IL-10 when there was less HMGB-1 present, 
or due there being less TNF-a produced overall.
It is possible therefore that immediately following a mild stress, leading to the 
necrosis of a small number of cells, that increased levels of extra-cellular Hsp72 
may modulate a particular immune response in the presence of low levels of extra­
cellular HMGB-1, whereas higher levels of HMGB-1 associated with further necrosis 





The immune system is known to respond to exogenous molecules derived from 
pathogens, and it has also been shown to respond to endogenous molecules, 
leading to autoimmune diseases (Brudzynski, 1993; Brudzynski et al., 1992). In 
recent years it has been recognised that many endogenous, or ‘self molecules can 
also modulate an immune response, as a result of injury or tissue damage, such as 
necrosis. This response can be pro- or anti- inflammatory depending on the stimulus 
or damage and is hypothesised by the Danger model (Gallucci et al., 1999; 
Matzinger, 1994; Matzinger, 2007; Seong & Matzinger, 2004). The Danger model 
postulates that abnormal cell death (necrosis) resulting from infection or other 
damage, is recognised by the immune system as a danger, and therefore stimulates 
an immune response. The stimulus comprises DAMPs, which are released by cells 
undergoing necrosis, but not apoptosis (Bianchi, 2007; El Mezayen et al., 2007; 
Gallucci et al., 1999; Shi et al., 2000), or PAMPs which are bacterial products such 
as LPS (Seong & Matzinger, 2004). Cells undergoing necrosis passively release 
their intra-cellular contents due to loss of membrane integrity, whereas apoptotic 
cells retain their contents within membrane-bound vesicles which display phagocytic 
signals, such as phosphatidylserine (PS), to induce phagocytosis before membrane 
integrity of the vesicles is lost. PS is usually found on the cytosolic side of the cell 
membrane. If apoptotic cells are not efficiently cleared, vesicle membranes become 
impaired and secondary necrosis occurs. Secondary necrosis also leads to release 
of DAMPs (Adams, 2003; Bell et al., 2006; Kono & Rock, 2008; Martin et al., 1995) 
(Figure 7.1).
These stimulating DAMPs include Hsp72 and HMGB-1 (Basu et al., 2000; Bianchi, 
2007; Campisi eta!., 2003; Degryse et al., 2001; Dumitriu et al., 2007; Kono & Rock, 
2008; Saito et al., 2005; Scaffidi et al., 2002; Vega et al., 2008; Williams & Ireland, 
2008).
Hsp72 has been shown in vitro to be released by passive or active mechanisms 
(Bausero et al., 2005; Evdonin et al., 2006b; Mambula & Calderwood, 2006a; Zhu et 
al., 2003). Extra-cellular Hsp72 has been shown to stimulate an immune response in 
vitro, through the release of cytokines (Asea, 2006; Asea et al., 2002; Luo et al., 
2008; Marcatili et al., 1997), and elevated levels of Hsp72 have also been
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determined in vivo in relation to certain inflammatory situations (Adewoye et al., 
2005; Madden et al., 2008; Rea et al., 2001; Walsh et al., 2001; Wright et al., 2000). 
This indicates that elevated levels of extra-cellular Hsp72 may modulate part of the 
inflammatory immune response.
The basal and elevated levels of Hsp72 reported by these studies vary widely 
depending upon the method used (Njemini et al., 2005). Most of the studies which 
reported relatively low levels of Hsp72 utilised a commercial ELISA kit (Stressgen 
Inc.) (Fukushima eta!., 2005; Walsh et al., 2001; Zhu et al., 2003). Studies reporting 
high levels of Hsp72 utilised an ELISA developed in-house (Njemini et al., 2005; 
Njemini et al., 2003b; Pockley et al., 1998; Wright et al., 2000). The levels reported 
in serum (up to 18.5 pg/mL, Pockley et al., 1998) would imply a massive amount of 
tissue damage or active release of Hsp72. There are similar issues regarding values 
of Hsp60 found in serum which are directly related to the type of ELISA used 
(Lewthwaite et al., 2002; Niizeki et al., 2008). Only one of these articles reports the 
actual absorbance values obtained from a standard curve using an in-house ELISA 
(Pockley et al., 1998), and the absorbance value for the top end of the standard 
curve (20 pg/mL Hsp72) was reported as less than 0.3 AU when measured at 405 
nm. When optimising an ELISA the maximum absorbance, as determined by the top 
standard, should always be between 1.0 and 3.0 AU when using a colourimetric 
substrate (R&D Systems Inc., 2002). This does imply that the high levels of Hsp72 
reported are the result of a relatively flat slope with a low correlation value (r) 
(although this was not reported), and are therefore not particularly accurate. The 
commercial ELISA kit generates a standard curve which results in the top standard 
(50 ng/mL Hsp72) giving an absorbance value of over 1.5 AU. One issue with the 
commercial ELISA is that it contains a diluent for producing standards and samples 
(if required). The constituents of this diluent are unknown and are not necessarily 
appropriate for use in some matrices, such as serum or cell culture supernatant. 
Matrix interference is known to occur in many sample types, including serum, such 
as abundant proteins and lipids, which can interfere with binding to the molecule of 
interest. To reduce the possibility of inaccurate results, protein standards used in 
ELISAs should be diluted in a solution identical to that of unknown samples, such as 
cell culture supernatant. In chapter 3, an in-house ELISA for Hsp72 was developed 
using an affinity-purified polyclonal antibody targeted to a specific epitope found only 
in Hsp72. Through optimisation, this in-house ELISA was found to be sensitive, and 
is able to determine accurate levels of intra-cellular Hsp72 in cellular extracts, and 
extra-cellular Hsp72 in cell culture supernatants. When measuring cell culture 
supernatant containing 10 % (v/v) FCS, there was a significant reduction in signal
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compared to PBS or extraction buffer, due to interference from serum components. 
It was demonstrated by western blot that this interference was mainly due to the 
presence of albumin, which could be depleted using cibacron blue. Although the 
ELISA was not required for any further work for this thesis, it was useful in 
confirming the type of concentrations present within, and being released from cells. 
Also, the antibodies developed are also applicable for use in western blots and as 
neutralising antibodies for use in blocking experiments in chapters 5 and 6.
The ELISA is currently being applied to clinical samples such as tissue and serum 
from leukaemic patients, to determine the if Hsp72 is a significant marker of disease 
progression, and it is also being applied to tissue and serum samples from pigs to 
determine stress levels in housed animals. In order to determine quantification os 
Hsp72 within serum samples rather than pattern analysis, it would be necessary to 
optimise the ELISA for use with serum samples. This would probably include re­
optimisation of antibody concentrations in order to be able to detect Hsp72 within 
the complex matrix of serum and also determine whether serum samples would be 
required to be diluted for optimal detection.
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Figure 7.1: The discrimination between necrotic and apoptotic cells by the 
immune system.
A normal cell will usually contain DAMPs within the cell interior. A cell undergoing 
apoptosis retains membrane integrity so DAMPs remain hidden from the immune 
system and are phagocytosed. If an apoptotic cell is not efficiently cleared then 
secondary necrosis will occur, and like necrosis, cellular contents are released, 
including DAMPs. DAMPs are then recognised by an immune cell, such as a 
macrophage or DC, resulting in an inflammatory response.
(Adapted from Bell etal., 2006; Bianchi, 2007; Gallucci, Lolkema & Matzinger, 1999; 
Kono & Rock, 2008).
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The second objective of this thesis was to determine whether LPS contamination is 
responsible for the reported stimulation by recombinant Hsps. This is an important 
aspect relating to a number of previous studies which have demonstrated the 
stimulatory effects of extra-cellular Hsp72, and other Hsps (Asea, 2006; Asea et al., 
2000b; Campisi & Fleshner, 2003; Guzhova et al., 1998; Milani et al., 2002; Retzlaff 
et al., 1994; Svensson et al., 2006). There are also a small number of reports 
demonstrating a lack of stimulation of Hsp72 and attributed the stimulation to LPS 
contamination (Bausinger et al., 2002; Gao & Tsan, 2003a; Gao & Tsan, 2003b; 
Gao & Tsan, 2004; Tsan & Gao, 2004a), and maybe other microbial products such 
as flagellin (Ye & Gan, 2007). The results from this thesis demonstrated that 
recombinant human Hsp72 is able to activate the immune system independently of 
LPS or flagellin (Chapters 4, 5 and 6), although the presence of both human Hsp72 
and LPS together results in an enhanced stimulatory effect (Chapter 6) which has 
been reported by others (El Mezayen et al., 2007). A comparative study of native 
and mildly denatured Hsps demonstrated that denaturation resulted in a reduction in 
cytokine responses in PBMCs and U937 macrophages, except for DnaK and GroEL, 
and Cpn10 and GroES (Chapter 4). DnaK and GroEL were the only two proteins 
which were shown to contain large amounts of endotoxin contamination as 
determined by LAL assay, and denaturation did not significantly reduce LPS 
detection. The levels of cytokine secretion from Cpn10 and GroES were significantly 
lower than all the other proteins tested. The human Hsp72 data corresponds well 
with data by others who demonstrated that human Hsp72 is able to stimulate 
cytokine production independently of LPS contamination (Svensson et al., 2006). 
Some studies which demonstrate that LPS is responsible for the stimulation of pro- 
inflammatory cytokines are convincing (Gao & Tsan, 2003a; Gao & Tsan, 2003b; 
Gao & Tsan, 2004; Tsan & Gao, 2004a). However, it is important to remember that 
the Danger model indicates that the signals stimulating the immune response can 
be endogenous or ‘self as wen as foreign. The studies by Gao and Tsan have all 
demonstrated the effects of human recombinant Hsp72 on murine models, and 
therefore demonstrating the effects of a foreign intra-cellular molecule, rather than 
an endogenous one. As endogenous Hsp72 regulates an anti-inflammatory 
response when intra-cellular, the presence of an exogenous protein in the extra­
cellular milieu may send a signal to the immune system that the foreign invader is 
damaged and is being adequately dealt with by other immune cells in the area, and 
therefore does not require a pro-inflammatory response. However, if the exogenous 
protein is found in the presence of LPS, which is found externally on the bacterial 
cell wall, the immune response would be stimulated but directed towards LPS rather
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than the exogenous protein. This is supported by evidence that LPS-free 
Mycobacterial tuberculosis (Mt) Hsp72 does not induce pro-inflammatory cytokine 
TNF-a secretion, or DC maturation, but induces the secretion of IL-10, whereas LPS 
contaminated Mt Hsp72 does induce TNF-a secretion and DC maturation (Motta et 
a/., 2007).
The report by Bausinger et al. (2002) demonstrated that human Hsp72 could not 
induce pro-inflammatory cytokine secretion in human-derived DCs. The data 
presented in this thesis is not directly comparable to their data as different cell types 
may elicit different responses. Bausinger et al. (2002) discredit work by Basu et al. 
(2000) by suggesting that DC maturation was only stimulated by using large 
quantities of Hsp72 (200 pg/mL). However Basu et al. (2000) demonstrated cytokine 
stimulation from macrophages, further supporting the evidence that comparing 
responses of different cell types is not appropriate when suggesting that 
recombinant Hsp72 only stimulates an immune response due to LPS contamination. 
In the innate immune response, cytokine release would occur within a few hours 
(Janeway Jr et al., 2005c). Experiments by Bausinger et al. (2002) used a fixed time 
of 18 h to demonstrate that DCs do not induce cytokine secretion and therefore do 
not lead to maturation of DCs but do not demonstrate an actual lack of maturation. 
Experiments by Basu et al. (2000) used a fixed time of 20 h and demonstrated that 
DCs expressed antigen-presenting and co-stimulatory molecules following 
incubation with Hsp72. Therefore it is possible that DCs secrete cytokines within a 
few hours of exposure to Hsp72, leading to the expression of antigen-presenting 
and co-stimulatory molecules.
With regards to flagellin contamination of Hsp72, data shown here (Chapter 5) does 
not show any contamination. The only published report of flagellin being responsible 
for the effect of Hsp72 stimulation of the immune response, does not actually 
demonstrate flagellin contamination of Hsp72 but rather reports that Burkhoderia 
pseudomallei (Bp) recombinant Hsp72 expressed in E. coli lacking the flagellin gene 
do not activate NF-k(3 activity whereas BpHsp72 expressed in E. coli containing the 
flagellin gene does, in a similar way to MtHsp72, and flagellin itself (Ye & Gan, 
2007).
Data from this thesis also demonstrated that human Hsp72 expressed in a 
Baculovirus system, which is certified endotoxin-free, is able to stimulate both 
TNF-a and IL-10 secretion (Chapter 6), which supports endogenous Hsp72 as a 
danger signal (Campisi eta!., 2003; Matzinger, 1998; Williams & Ireland, 2008).
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The third objective of this thesis was to determine the relative contributions of Hsp72 
and LPS to the immune response. Relating to the studies regarding LPS 
contamination, data shown in this thesis demonstrates that LPS is able to stimulate 
cytokine secretion, and that Hsp72 alone is also able to stimulate cytokine secretion. 
In chapter 6 of this thesis, LPS was shown to induce secretion of TNF-a and IL-10, 
and that this secretion was dependent on time rather than dose. Hsp72 was also 
shown to stimulate the production of these cytokines. When Hsp72 was added to 
LPS (100 ng/mL), the secretion was significantly increased. This increase could not 
be attributed to LPS contamination as LPS was shown not to increase cytokine 
secretion between different concentrations at 4 h. These data are in direct 
accordance with others who demonstrated that endogenous Hsp72 enhances the 
immune response to LPS (Campisi & Fleshner, 2003). Campisi & Fleshner (2003) 
clearly showed that endogenous rat Hsp72 is able to stimulate a modest secretion of 
pro-inflammatory cytokines. LPS from E. coli stimulated the secretion significantly 
more than Hsp72, and this effect was stimulated significantly further by the addition 
of Hsp72 to LPS. Again, this data shows the importance of using same species 
Hsp72 as the model system being used.
The fourth objective of this thesis was to determine the cell surface receptors 
required for Hsp72 stimulation of the immune system. In chapter 5 of this thesis, it 
was demonstrated that, through use of blocking peptides corresponding to certain 
cell receptors, that the secretion of both TNF-a and IL-10, and migration of 
macrophages by endogenous Hsp72 could be reduced. Using a blocking peptide 
corresponding to a region of the TLR-2 receptor, Hsp72 induced cytokine secretion 
was only partially reduced when using a high concentration of peptide (20 pg/mL), 
and migration was significantly reduced, although the reduction was rather small. 
This would indicate that Hsp72 does not avidly bind TLR-2 peptide which is in 
agreement with Theriault et al. (2005) who failed to show any binding of Hsp72 to 
TLR-2 by TLR-2 over-expressing HEK293 cells, although Asea et al. (2002) 
demonstrated that HEK293 cells which were co-transfected with TLR-2 and CD14 
were able to bind Hsp72. This may indicate that U937 macrophages do not normally 
express TLR-2, although the presence of TLR-2 and TLR-4 has been demonstrated 
by others (Greene et al., 2004). It could also suggest that the peptide for TLR-2 did 
not prevent binding of Hsp72 to its functional receptors on U937 macrophages. 
Cytokine secretion of macrophages following incubation with Hsp72 and TLR-4, 
TLR-5, CD14 or CD36 blocking peptides resulted in a dose dependent reduction in 
cytokine secretion. Migration of macrophages was also significantly reduced when
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incubated with each peptide although migration was still significantly different from 
un-stimulated macrophages. This data suggested that either Hsp72 was stimulating 
cytokine secretion through these relative receptors, or that Hsp72 bound by these 
peptides was unable to bind its functional cell surface receptors. Also, the lack of 
complete abrogation of migration indicates that Hsp72 was able to bind other cell 
signalling receptors. The reduction in an immune response when using a TLR-5 
peptide was unexpected. It does imply that the recombinant Hsp72 used is likely to 
be contaminated with flagellin, as has been suggested by Ye et al. (2007). However, 
the use of neutralising antibodies to flagellin did not result in a change in cytokine 
secretion compared to Hsp72 alone, and western blotting did not show any 
contamination. If flagellin was present, it may suggest that the antibody was unable 
to bind its flagellin epitope as it may be bound by Hsp72. It was also demonstratesd 
that Hsp72 potentially binds CD36. As CD36 is a receptor involved in signalling of 
phagocytosis, it is probable that the presence of endogenous Hsp72, from necrotic 
cells, binds to CD36 alerting the immune system to necrotic or damaged cells which 
require clearing (Bottcher et al., 2006). These data indicating Hsp72 binding to 
CD36 contrast with results reported by Delneste et al. (2002) who demonstrated that 
Hsp72 is unable to bind transfected CHO cells. This report though does not indicate 
whether the Hsp72 used corresponds to human Hsp72 or hamster Hsp72, although 
in the same article they demonstrate binding of Hsp72 to scavenger receptors on 
human DCs, which does suggest that they utilised human Hsp72 in the experiments 
performed with CHO cells. However, the data in this thesis is comparable to studies 
by others demonstrating binding of a sequence homologous to Hsp72 (aa 329-338) 
bound to the cytoplasmic domain of macrophage scavenger receptors, including 
CD36 (Nakamura et al., 2002). These data again demonstrate the requirement that 
Hsp72 treatment is from the same species as the model system being used when 
describing the effects of Hsp72 on the immune system in relation to the Danger 
model (Kono & Rock, 2008; Matzinger, 1998; Matzinger, 2002).
Interestingly, the use of a TLR-7 blocking peptide with Hsp72 only reduced the 
stimulation of IL-10 and not TNF-a, or migration of macrophages. This effect on 
IL-10 secretion was dose dependent. This may indicate that when endogenous 
Hsp72 is bound to TLR-7, it signals the anti-inflammatory part of the immune 
response regulated by extra-cellular Hsp72. TLR-7 is found within the membranes of 
endosomes, although it was recently reported to be found in the lipid raft domain on 
the surface of RAW264.7 macrophages (Wang et al., 2006b). However, their 
method for surface staining of cells states that cells were fixed then stained with 
anti-TLR-7 antibodies. It is generally accepted for surface staining of cells that they
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are stained prior to being fixed, as fixation can interfere with membrane staining. As 
TLR-7 has only been reported to reside within endosomes (Means et al., 2000; 
Smits et al., 2008; Takeda et al., 2003; Triantafilou et a/., 2005), and would therefore 
only be found in the extra-cellular milieu following necrosis, then the data presented 
in chapter 5 may demonstrate that when Hsp72 is bound to TLR-7 following 
necrosis that Hsp72 is unable to stimulate IL-10 through other receptors. One such 
receptor en shown to stimulate IL-10 secretion by Hsp72 is epidermal growth factor 
receptor (EGFR). Epidermal growth factor (EGF) binds to EGFR and stimulates the 
MAPK/ERK activation pathway leading to the production of IL-10. Extra-cellular 
Hsp72 has been found to activate EGFR in association with TLR-2/TLR-4 in A431 
cells (Evdonin et al., 2006a). Evdonin et al. (2006) also demonstrated that media 
from heat-treated cells containing secreted Hsp72 was able to stimulate activation of 
EGFR, whereas media from control cells lacking Hsp72 did not. Pure Hsp72 
(100 ng/mL) was also able to activate EGFR. In theory this could mean that extra­
cellular Hsp72 up-regulates IL-10 through activation of MAPK/ERK by binding to 
EGFR, and that this can be blocked specifically by a peptide corresponding to a 
region of TLR-7, or that this particular peptide binds to the region of Hsp72 which 
would normally bind EGFR but does not block the other receptor binding regions of 
Hsp72 which up-regulate TNF-a secretion through NF-k(3 activation. TLR-7 mRNA 
expression has been found to be increased in THP-1 cells following treatment with 
LPS or live E. coli (Zarember & Godowski, 2002). This could indicate that TLR-7 is 
not only a receptor for ssRNA from viruses which activates through MyD88/IRF7 
leading to the production of IFN-a, but can also be stimulated by Hsp72 leading to 
the production of IL-10. IL-10 stimulation by imidazoquinoline, a TLR-7 antagonist, 
has been reported in murine bone marrow-derived DCs, possibly through JAK/STAT 
activation (Samarasinghe et al., 2006).
Also, many other proteins have been shown to activate the immune response 
through the same PRRs as LPS. For example, HMGB-1 has been found to signal 
through TLR-2 and TLR-4, although the pattern of cytokine production is different to 
that of LPS in that IL-10 is not up-regulated (El Gazzar, 2007; Park et al., 2006b; Yu 
et al., 2006). Also, TLR-2 has been demonstrated to be stimulated by endotoxin-free 
lipoproteins (Aliprantis et al., 1999), and TLR-4 deficient mice were not responsive 
to Hsp60 whereas TLR-4 positive mice were (Ohashi et al., 2000), which 
demonstrates that molecules other than LPS are able to stimulate an immune 
response through TLR-2 and TLR-4.
The binding of endogenous molecules to PRRs which are the same as PRRs 
recognised by bacteria may suggest the presence of some bacterial products.
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However, it has been suggested that the immune system may have evolved to be 
able to recognise a wide variety of danger signals rather than foreign molecules 
through PRRs, and that invading pathogens have evolved to bind to these 
(Matzinger, 2002). This is a possibility as is has been found that CD14 deficient 
mice were more resistant to Gram negative bacteria or LPS than CD14 positive 
mice, demonstrating that in order for bacteria to stimulate an immune response and 
infect the host, it must be able to bind to certain PRRs (Haziot et al., 1996) (Figure 
7.2).
The fifth objective was to determine whether cell derived Hsp72 can stimulate an 
immune response in macrophages. Data in chapter 6 demonstrated that through 
use of neutralising antibodies to Hsp72, the stimulation of TNF-a and IL-10 could be 
reduced. When anti-Hsp72 was used in conjunction with necrotic cell lysate (NCL) 
from heat-treated U937 macrophages, cytokine secretion was also significantly 
reduced, and migration of U937 was reduced compared to NCL only treated 
macrophages. Although secretion of cytokines and migration of macrophages was 
significantly reduced compared to NCL only, cytokine secretion and migration was 
still significantly different from control, untreated macrophages demonstrating that 
there are many other stimulatory factors from necrotic cells which are able to 
stimulate an immune response. This data is in accordance with similar work by El 
Mezayen et al. (2007) who demonstrated that the use of anti-Hsp72 antibodies 
attenuated the cytokine response of THP-1 cells when cells were incubated with 
NCL and LPS. Other known stimulators originating from necrotic cells include uric 
acid, chromatin, and nucleosomes (Decker et al., 2005; Gallucci et al., 1999; Hu et 
























Figure 7.2: Signalling receptors utilised by Hsp72, HMGB-1, and bacterial 
components.
Hsp72 can stimulate the immune response through various receptors. It has 
common receptors with both LPS and HMGB-1 for which they may all compete. 
(Adapted from Lotze & Tracey, 2005; Park et a/., 2006; Takeda et a/., 2003; 
Huttunen et al., 2002; Taneguchi et al., 2003; Means et al., 2000; Hayashi et at., 
2001; Zhang et al., 2001; Kurt-Jones et al., 2002 Pockley et al., 2003; Janeway Jr. 
et al., 2005; Pockley et al., 2007; Calderwood et al., 2007; Wang et al., 2006; Motta 
et al., 2007; Samarasinghe et al., 2006; Zarember et al., 2002, and data 
demonstrated in this thesis).
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The sixth objective of this thesis was to assess how Hsp72 may interact with other 
elements of the Danger model. HMGB-1 is another candidate danger signal as both 
Hsp72 and HMGB-1 have clear intra-cellular roles, and both are known to interact 
strongly with the immune system following necrosis, they also appear to play 
different roles extra-cellularly. For example, Hsp72 has been shown to stimulate the 
production of pro- and anti- inflammatory cytokines from a monocytes and 
macrophages (Asea et al., 2000b; Basu et al., 2000; Svensson et al., 2006), and 
the maturation of DCs (Wang et al., 2005). In comparison, HMGB-1 has also been 
shown to stimulate TNF-a, IL-1 and IL-6 from monocytes and macrophages 
(Andersson et al., 2000; O'Connor et al., 2003; Taniguchi et al., 2003), and can 
induce the migration of DCs (Degryse et al., 2001; Dumitriu et al., 2007; Yang et al., 
2006). In contrast, Hsp72 has been shown to have a protective role in the extra­
cellular milieu by binding to cell surfaces and through internalisation (Guzhova et 
al., 2001; Guzhova et al., 1998), whereas HMGB-1 can induce fever and is fatal at 
low doses in mouse and rat model systems (O'Connor et al., 2003; Wang et al., 
1999). Intra-cellularly, up-regulation of Hsp72 has been shown to prevent the 
release of HMGB-1 by binding HMGB-1 and inhibiting translocation through the 
chromosome region maintenance 1 (CRMIndependent nuclear export pathway 
ultilised by HMGB-1, and also reduced the secretion of pro-inflammatory cytokine 
release by inhibiting MAPK and NF-k(3 signalling pathways (Tang et al., 2007b; 
Tang et al., 2007c). As there is a definite relationship between the two proteins 
within the cell, it is possible that there may be an association outside the cell. A 
possible relationship between Hsp72 and HMGB-1 was investigated in chapter 6 of 
this thesis.
Firstly it was demonstrated that whilst both proteins stimulated a secretion of TNF-a 
from macrophages, Hsp72 also up-regulated IL-10 secretion whereas HMGB-1 did 
not. In the presence of both proteins, macrophages secreted significantly more 
TNF-a and IL-10 secretion was significantly up-regulated but was reduced 
compared to Hsp72 alone. This suggested that Hsp72 is able to up-regulate an 
anti-inflammatory response despite the presence of HMGB-1. Similar, but amplified 
results were obtained when either or both proteins were incubated with LPS. In the 
presence of neutralising antibodies, there was a significant reduction in TNF-a and 
IL-10 secretion. Migration of U937 macrophages was also increased in the 
presence of Hsp72 and HMGB-1, or both. Antibodies reduced this migration but this 
was still significantly different from untreated cells, suggesting that the antibodies 
did not sufficiently block binding of either Hsp72 or HMGB-1. Migration also
247
correlated well with TNF-a secretion which is a well known function of TNF-a 
(deJong et at., 1996; Janeway Jr et at., 2005c; Katerinaki et at., 2003).
Neutralising antibodies to Hsp72 and HMGB-1 were also shown to reduce cytokine 
secretion and migration of macrophages when stimulated in the presence of NCL, 
further supporting the presence of both proteins having an effect on the immune 
system when released from necrotic cells (Basu et at., 2000; El Mezayen et at., 
2007; Scaffidi et at., 2002). A relationship between Hsp72 and HMGB-1 was 
investigated by varying the concentrations of each protein in the presence of a fixed 
amount of the other. It was found that Hsp72 was able to up-regulate IL-10 in the 
presence of HMGB-1 providing there was always more Hsp72 present than HMGB- 
1, and that migration of cells was highly correlated with TNF-a secretion. If more 
HMGB-1 was present than Hsp72, IL-10 secretion was always reduced which may 
be a consequence of higher levels of TNF-a being present.
It is possible therefore that during early stages of infection, for instance, that 
cytokine secretion is stimulated by an invading pathogen leading to the up- 
regulation of intra-cellular Hsp72. This in turn prevents HMGB-1 release and down- 
regulates TNF-a secretion. If the result is cell necrosis, then larger amounts of 
Hsp72 than HMGB-1 would be released, which would potentially try to counteract 
the effects of the invading pathogen by modulating the immune response and up- 
regulation of anti-inflammatory cytokines. Hsp72 possibly does this by competing 
with bacterial components for certain PRRs on cell surfaces. However, if there is 
insufficient Hsp72 released following necrosis then the invading pathogen would be 
able to over-stimulate the up-regulation of TNF-a, which in turn up-regulates 
HMGB-1 over Hsp72, leading to the onset of sepsis.
In conclusion, the ideas presented in this discussion are summarised in a simplified 
form in Figure 7.3. Endogenous extra-cellular Hsp72 has an integral role within the 
immune system by modulating cytokine responses through binding of various cell 
surface receptors. In terms of relating endogenous Hsp72 to the Danger model, it is 
important to use same species Hsp72 as the model system being used, as the 
model system may not respond to other species Hsp72 in the same manner. The 
data presented in this thesis has demonstrated that endogenous Hsp72 is able to 
stimulate the immune system by itself, and that the response is not solely due to 
LPS contamination of recombinant protein preparations. In fact Hsp72 augments 
the response to LPS. In the presence of another endogenous danger signal, 
HMGB-1, relative amounts of Hsp72 were shown to augment a pro-inflammatory 
response whilst being able to maintain an anti-inflammatory response
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demonstrating modulation. As HMGB-1 is a late mediator of the immune response, 
initial increased levels of Hsp72 would be able to modulate the immune response, 
unless in the presence of increased necrosis caused by infection. It was 
demonstrated that extra-cellular Hsp72 can interact with extra-cellular HMGB-1 by 
inhibiting some of the pro-inflammatory responses of HMGB-1, in a similar way to 
that seen within the nucleus. The relative amounts of each protein found in the 
extra-cellular milieu may determine the type of inflammatory immune response 
generated, whether it be protective modulation (higher levels of Hsp72 over HMGB- 
1), pro-inflammatory (higher levels of HMGB-1 over Hsp72), or chronic pro- 
inflammatory (high levels of HMGB-1, low levels of Hsp72 and infection) (Figure 
7.3).
The proportion of these different DAMPs or PAMPs will have different qualitative 
effects on the response and this may well be modulated by imposition of an extra 
bacterial infection (or other stressor) at different points in this continuum and may 
significantly alter the inflammatory response. In the most severe case, this can lead 









Figure 7.3: Relative differences in inflammatory responses of the immune 
system.
The stressor could be an infection. This will result in the release of DAMPs or 




Extension of the work presented in this thesis would take two main routes. These 
routes would involve a complete analysis of:
a) the cell surface receptors involved in binding Hsp72; b) the signalling pathways 
involved in Hsp72 mediated signal transduction.
This may include antagonising receptor binding through use of antibodies directed 
towards the receptors themselves rather than the use of receptor peptides 
sequences. Such an approach could use the macrophage system used in this 
thesis and then could be applied further to transfected cell systems whereby cells 
are transfected with genes that up or down regulate certain receptors. Analysis of 
cytokine secretion and/or direct binding of Hsp72 to receptors through flow 
cytometry or fluorescence microscopy could be utilised.
As Hsp72 has been shown to bind a number of receptors which are able to be 
bound by other molecules, affinity characteristics could be elucidated via the use of 
binding kinetics systems, such as Biacore. Biacore utilises surface plasmon 
resonance (SPR) which is used to measure the adsorption of material onto a metal 
planar surface which can be coated with molecules of choice. As the binding of 
Hsp72 with receptors and other molecules is not covalent it could be displaced by 
another with a higher affinity. This may be difficult to assess as no sensor chips are 
yet available which offer correct orientation of molecules binding to the sensor chip 
surface. This work would require design and optimisation of receptor-based chips.
It would also be useful to elucidate the signalling pathways used by Hsp72 in terms 
of pro- and/or anti- inflammatory responses as binding to different receptors 
probably signal through different downstream pathways which lead to different 
inflammatory responses. As Hsp72 has been shown to up-regulate the secretion of 
IL-10, a potent anti-inflammatory cytokine, it may be useful to determine which 
pathway stimulates its release and manipulate it in such a way that would be of 
therapeutic use in controlling pro-inflammatory conditions. Chemical inhibitors 
and/or siRNA (small interfering RNA) would be used to specifically inhibit signalling 
elements. For example, blocking phosphorylation of MAP kinase along the MyD88 
dependent pathway which leads to up-regulation of IFNs rather than TNF-a, IL-1(B 
and IL-6. Specific inhibitors are available for all the major signalling pathways 
allowing a complete analysis of how responses to Hsp72 are mediated. As Hsp72 
is able to modulate the pro-inflammatory cytokine response of HMGB-1 by up- 
regulating IL-10 secretion, then Hsp72 must be able to signal through a MyD88- 
independent pathway. Determining this could be useful in determining future 




Abraham, E., Arcaroli, J., Carmody, A., Wang, H. C. & Tracey, K. J. (2000). Cutting 
edge: HMG-1 as a mediator of acute lung inflammation. Journal of Immunology, 
165(6), 2950-2954.
Abulafia-Lapid, R., Elias, D., Raz, I., Keren-Zur, Y., Atlan, H. & Cohen, I. R. (1999). 
T cell proliferative responses of type 1 diabetes patients and healthy individuals to 
human hsp60 and its peptides. Journal of Autoimmunity, 12, 121-129.
Adams, J. M. (2003). Ways of dying: multiple pathways to apoptosis. Genes & 
Development, 17, 2481-2495.
Adewoye, A. H., Klings, E. S., Farber, H. W., Palaima, E., Bausero, M. A., 
McMahon, L., Odhiambo, A., Surinder, S., Yoder, M., Steinberg, M. H. & Asea, A.
(2005). Sickle cell vaso-occlusive crisis induces the release of circulating serum 
heat shock protein-70. American Journal of Hematology, 78(3), 240-242.
Aliprantis, A. O., Yang, R. B., Mark, M. R., Suggett, S., Devaux, B., Radolf, J. D., 
Klimpel, G. R., Godowski, P. & Zychlinsky, A. (1999). Cell activation and apoptosis 
by bacterial lipoproteins through toll-like receptor-2. Science, 285(5428), 736-739.
Andersson, U., Erlandsson-Harris, H., Yang, H. & Tracey, K. J. (2002). HMGB1 as 
a DNA-binding cytokine. Journal of Leukocyte Biology, 72(6), 1084-1091.
Andersson, U., Wang, H., Palmblad, K., Aveberger, A. C., Bloom, O., Harris, H. E., 
Janson, A., Kokkola, R., Zhang, M., Yang, H. & Tracey, K. J. (2000). High mobility 
group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human 
monocytes. The Journal of Experimental Medicine, 192(4), 565-570.
Arai, M. & Kuwajima, K. (2000). Role of the molten globule state in protein folding. 
Advances in Protein Chemistry, Vol 53, 53, 209-282.
251
Arispe, N., Doh, M. & De Maio, A. (2002). Lipid interaction differentiates the 
constitutive and stress-induced heat shock proteins Hsc70 and Hsp70. Cell Stress 
& Chaperones, 7(4), 330-338.
Asea, A. (2006). Initiation of the immune response by extracellular hsp72: 
chaperokine activity of hsp72. Current Immunology Reviews, 2, 209-215.
Asea, A., Kabingu, E., Stevenson, M. A. & Calderwood, S. K. (2000a). HSP70 
peptide-bearing and peptide-negative preparations act as chaperokines. Cell Stress 
& Chaperones, 5(5), 425-431.
Asea, A., Kraeft, S. K., Kurt-Jones, E. A., Stevenson, M. A., Chen, L. B., Finberg, 
R. W., Koo, G. C. & Calderwood, S. K. (2000b). Hsp70 stimulates cytokine 
production through a CD14-dependent pathway, demonstrating its dual role as a 
chaperone and cytokine. Nature Medicine, 6(4), 435-442.
Asea, A., Rehli, M., Kabingu, E., Boch, J. A., Bare, O., Auron, P. E., Stevenson, M. 
A. & Calderwood, S. K. (2002). Novel signal transduction pathway utilized by 
extracellular hsp70 - role of toll-like receptor (TLR) 2 and TLR4. The Journal of 
Biological Chemistry, 277(17), 15028-15034.
ATt-Ai'ssa, S., Pandard, P., Magaud, H., Arrigo, A. P., Thybaud, E. & Porcher, J. M.
(2003). Evaluation of an in vitro hsp70 induction test for toxicity assessment of 
complex mixtures: comparison with chemical analyses and ecotoxicity tests. 
Ecotoxicology and Environmental Safety, 54(1), 92-104.
Bachelet, M., Mariethoz, E., Banzet, N., Souil, E., Pinot, F., Polla, C. Z., Durand, P., 
Bouchaert, I. & Polla, B. S. (1998). Flow cytometry is a rapid and reliable method 
for evaluating heat shock protein 70 expression in human monocytes. Cell Stress & 
Chaperones, 3(3), 168-176.
Baretto, A., Gonzalez, J. M., Kabingu, E., Asea, A. & Fiorentino, S. (2003). Stress- 
induced release of HSC70 from human tumors. Cellular Immunology, 222, 97-104.
Basu, S., Binder, R. J., Ramalingam, T. & Srivastava, P. K. (2001). CD91 is a 
common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. 
Immunity, 14(3), 303-313.
252
Basu, S., Binder, R. J., Suto, R., Anderson, K. M. & Srivastava, P. K. (2000). 
Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a 
partial maturation signal to dendritic cells and activate the NF-kB pathway. 
International Immunology, 12(11 ), 1539-1546.
Basu, S. & Matsutake, T. (2004). Heat shock protein-antigen presenting cell 
interactions. Methods, 32(1), 38-41.
Bausero, M. A., Gastpar, R., Multhoff, G. & Asea, A. (2005). Alternative mechanism 
by which IFN-g enhances tumor recognition: active release of heat shock protein 
72. The Journal of Immunology, 175, 2900-2912.
Bausinger, H., Lipsker, D., Ziylan, U., Manié, S., Briand, J. P., Cazenave, J. P., 
Muller, S., Haeuw, J. F., Ravanat, C., de la Salle, H. & Hanau, D. (2002). 
Endotoxin-free heat-shock protein 70 fails to induce APC activation. European 
Journal of Immunology, 32, 3708-3713.
Becker, T., Hartl, F. U. & Wieland, F. (2002). CD40, an extracellular receptor for 
binding and uptake of Hsp70-peptide complexes. The Journal of Cell Biology, 
158(7), 1277-1285.
Bell, C. W., Jiang, W., Reich, C. F. & Pisetsky, D. S. (2006). The extracellular 
release of HMGB1 during apoptotic cell death. American Journal of Physiology - 
Cell Physiology, 291(6), C1318-C1325.
Bianchi, M. E. (2007). DAMPs, PAMPs and alarmins: all we need to know about 
danger. Journal of Leukocyte Biology, 81(1), 1-5.
Bianchi, M. E. & Manfredi, A. A. (2007). High-mobility group box 1 (HMGB1) protein 
at the crossroads between innate and adaptive immunity. Immunological Reviews, 
220(1), 35-46.
Binder, R. J., Han, D. K. & Srivastava, P. K. (2000). CD91: a receptor for heat 
shock protein gp96. Nature Immunology, 1(2), 151-155.
Binder, R. J., Vatner, R. & Srivastava, P. (2004). The heat-shock protein receptors: 
some answers and more questions. Tissue Antigens, 64(4), 442-451.
253
Bonaldi, T., Längst, G., Strohner, R., Becker, P. B. & Bianchi, M. E. (2002). The 
DNA chaperone HMGB1 facilitates ACF/CHRAC-dependent nucleosome sliding. 
The EMBO Journal, 21(24), 6865-6873.
Boorstein, W. R., Ziegelhoffer, T. & Craig, E. A. (1994). Molecular evolution of the 
hsp70 multigene family. Journal of Molecular Evolution, 38, 1-17.
Bosco, M. C., Espinoza-Delgado, I., Rowe, T. K., Malabarba, M. G., Longo, D. L. & 
Varesio, L. (1997). Functional role for the myeloid differentiation antigen CD14 in 
the activation of human monocytes by IL-2. The Journal of Immunology, 159(6), 
2922-2931.
Böttcher, A., Gaipl, U. S., Furnrohr, B. G., Herrmann, M., Girkontaite, I., Kalden, J. 
R. & Voll, R. E. (2006). Involvement of phosphatidylserine, alpha v beta 3, CD14, 
CD36, and complement C1q in the phagocytosis of primary necrotic lymphocytes 
by macrophages. Arthritis and Rheumatism, 54(3), 927-938.
Botzler, C., Li, G., Issels, R. D. & Multhoff, G. (1998). Definition of extracellular 
localized epitopes of Hsp70 involved in an NK immune response. Cell Stress & 
Chaperones, 3(1), 6-11.
Boyce, M. & Yuan, J. (2006). Cellular response to endoplasmic reticulum stress: a 
matter of life and death. Cell Death and Differentiation, 13, 363-373.
Bradford, M. M. (1976). Rapid and sensitive method for quantitation of microgram 
quantities of protein utilizing principle of protein-dye binding. Analytical 
Biochemistry, 72(1-2), 248-254.
Broquet, A. H., Thomas, G., Masliah, J., Trugnan, G. & Bachlet, M. (2003). 
Expression of the molecular chaperone Hsp70 in detregent-resistant microdomians 
correlates with its membrance delivery and release. The Journal of Biological 
Chemistry, 278(24), 21601-21606.
Brudzynski, K. (1993). Insulitis-caused redistribution of heat-shock protein HSP60 
inside beta-cells correlates with induction of HSP60 autoantibodies. Diabetes, 
42(6), 908-913.
254
Brudzynski, K., Martinez, V. & Gupta, R. S. (1992). Secretory granule autoantigen 
in insulin-dependent Diabetes-mellitus is related to 62 kDa heat-shock protein 
(HSP60). Journal of Autoimmunity, 5(4), 453-463.
Bukau, B. & Horwich, A. L. (1998). The Hsp70 and Hsp60 chaperone machines. 
Cell, 92(3), 351-366.
Calderwood, S. K., Theriault, J., Gray, P. J. & Gong, J. (2007). Cell surface 
receptors for molecular chaperones. Methods, 43(3), 199-206.
Campisi, J. & Fleshner, M. (2003). Role of extracellular hsp72 in acute stress- 
induced potentiation of innate immunity in active rats. Journal of Applied 
Physiology, 94(1), 43-52.
Campisi, J., Leem, T. H. & Fleshner, M. (2003). Stress-induced extracellular Hsp72 
is a functionally significant danger signal to the immune system. Cell Stress & 
Chaperones, 8(3), 272-286.
Cardin, A. D. & Weintraub, H. J. R. (1989). Molecular modeling of protein- 
glycoaminoglycan interactions. Arteriosclerosis, 9(1), 21-32.
Chavakis, T., Bierhaus, A. & Nawroth, P. P. (2004). RAGE (receptor for advanced 
glycation end products): a central player in the inflammatory response. Microbes 
and Infection, 6(13), 1219-1225.
Chen, G., Li, J., Ochani, M., Rendon-Mitchell, B., Qaing, X., Susarala, S., Ulloa, L., 
Yang, H., Fan, S., Goyert, S. M., Wang, P., Tracey, K. J., Sama, A. E. & Wang, H.
(2004). Bacterial endotoxin stimulates macrophages to release HMGB1 partly 
through CD14- and TNF- dependent mechanisms. Journal of Leukocyte Biology, 
76(5), 994-1001.
Chen, H., Wu, Y., Zhang, Y., Jin, L., Luo, L., Xue, B., Lu, C., Zhang, X. & Yin, Z.
(2006). Hsp70 inhibits lipopolysaccharride-induced NF-kB activation by interacting 
with TRAF6 and inhibiting its ubiquitination. FEBS Letters, 580, 3145-3152.
255
Child, D. F., Hudson, P. R., Hunter-Lavin, C., Mukhergee, S., China, S., Williams, 
C. P. & Williams, J. H. H. (2006). Birth defects and anti-heat shock protein 70 
antibodies in early pregnancy. Cell Stress & Chaperones, 11(1), 101-105.
Cotto, J. J., Kline, M. & Morimoto, R. I. (1996). Activation of heat shock factor 1 
DNA binding precedes stress-induced serine phosphorylation - Evidence for a 
multistep pathway of regulation. Journal of Biological Chemistry, 271(7), 3355- 
3358.
Currie, S., Moyes, C. D. & Tufts, B. L. (2000). The effects of heat shock and 
acclimation temperature on hsp70 and hsp30 mRNA expression in rainbow trout: in 
vivo and in vitro comparisons. Journal of Fish Biology, 56, 398-408.
Daniels, G. A., Sanchez-Perez, L., Diaz, R. M., Kottke, T., Thompson, J., Lai, M. Y., 
Gough, M., Karim, M., Bushell, A., Chong, H., Melcher, A., Harrington, K. & Vile, R. 
G. (2004). A simple method to cure established tumors by inflammatory killing of 
normal cells. Nature Biotechnology, 22(9), 1125-1132.
Dauphinee, S. M. & Karsan, A. (2006). Lipopolysaccharide signaling in endothelial 
cells. Laboratory Investigation, 86(1), 9-22.
Davies, E. L., Bacelar, M., Marshall, M. J., Johnson, E., Wardle, T. D., Andrew, S. 
M. & Williams, J. H. H. (2006). Heat shock proteins form part of a danger signal 
cascade in response to lipopolysaccharide and GroEL. Clinical and Experimental 
Immunology, 145(1), 183-189.
De los Rios, P., Ben-Zvi, A., Slutsky, O., Azem, A. & Goloubinoff, P. (2006). Hsp70 
chaperones accelerate protein translocation and the unfolding of stable protein 
aggregates by entropic pulling. Proceedings of the National Academy of Sciences 
of the United States of America, 103(16), 6166-6171.
de Pomerai, D. I. (1996). Heat-shock proteins as biomarkers of pollution. Human 
and Experimental Toxicology, 15, 279-285.
256
Decker, P., Singh-Jasuja, H., Haager, S., Kotter, I. & Rammensee, H. G. (2005). 
Nucleosome, the main autoantigen in systemic lupus erythematosus, induces direct 
dendritic cell activation via a MyD88-independent pathway: Consequences on 
inflammation. Journal of Immunology, 174(6), 3326-3334.
Degryse, B., Bonaldi, T., Scaffidi, P., Muller, S., Resnati, M., Sanvito, F., Arrigoni, 
G. & Bianchi, M. E. (2001). The high mobility group (HMG) boxes of the nuclear 
protein HMG1 induce chemotaxis and cytoskeleton reorganisation in rat smooth 
muscle cells. Journal of Cell Biology, 152(6), 1197-1206.
deJong, A. L., Green, D. M., Trial, J. & Birdsall, H. H. (1996). Focal effects of 
mononuclear leukocyte transendothelial migration: TNF-alpha production by 
migrating monocytes promotes subsequent migration of lymphocytes. Journal of 
Leukocyte Biology, 60(1), 129-136.
Delneste, Y. (2004). Scavenger receptors and heat-shock protein-mediated antigen 
cross-presentation. Biochemical Society Transactions, 32(4), 633-635.
Delneste, Y., Magistrelli, G., Gauchat, J. F., Haeuw, J. F., Aubry, J. P., Nakamura, 
K., Kawakami-Honda, N., Goetsch, L., Sawamura, T., Bonnefoy, J. Y. & Jeannin, P. 
(2002). Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. 
Immunity, 17(3), 353-362.
Ding, X. Z., Fernandez-Prada, C. M., Bhattacharjee, A. K. & Hoover, D. L. (2001). 
Over-expression of Hsp-70 inhibits bacterial lipopolysaccharide-induced production 
of cytokines in human monocyte-derived macrophages. Cytokine, 16(6), 210-219.
Downs, C. A., Fauth, J. E., Halas, J. C., Dustan, P., Bemiss, J. & Woodley, C. M. 
(2002). Oxidative stress and seasonal coral bleaching. Free Radical Biology and 
Medicine, 33(4), 533-543.
Dumitriu, I. E., Bianchi, M. E., Bacci, M., Manfredi, A. A. & Rovere-Querini, P.
(2007). The secretion of HMGB1 is required for the migration of maturing dendritic 
cells. Journal of Leukocyte Biology, 81(1), 84-91.
257
Dybdahl, B., Wahba, A., Lien, E., Flo, T. H., Waage, A., Qureshi, N., Sellevold, O. 
F. M., Espevik, T. & Sundan, A. (2002). Inflammatory response after open heart 
surgery: release of heat-shock protein 70 and signaling through toll-like receptor-4. 
Circulation, 105(6), 685-690.
Dybdahl, B., Slordahl, S. A., Waage, A., Kierulf, P., Espevik, T. & Sundan, A.
(2005). Myocardial ischaemia and the inflammatory response: release of heat 
shock protein 70 after myocardial infarction. Heart, 91(3), 299-304.
El Gazzar, M. (2007). HMGB1 modulates inflammatory responses in LPS-activated 
macrophages. Inflammation Research, 56(4), 162-167.
El Mezayen, R., El Gazzar, M., Seeds, M. C., McCall, C. E., Dreskin, S. C. & 
Nicolls, M. R. (2007). Endogenous signals released from necrotic cells augment 
inflammatory responses to bacterial endotoxin. Immunology Letters, 111(1), 36-44.
Evdonin, A. L., Guzhova, I. V., Margulis, B. A. & Medvedeva, N. D. (2006a). 
Extracellular heat shock protein 70 mediates heat stress-induced epidermal growth 
factor receptor transactivation in A431 carcinoma cells. Febs Letters, 580(28-29), 
6674-6678.
Evdonin, A. L., Martynova, M. G., Bystrova, O. A., Guzhova, I. V., Margulis, B. A. & 
Medvedeva, N. D. (2006b). The release of hsp70 from A431 carcinoma cells is 
mediated by secretory-like granules. European Journal of Cell Biology, 85, 443- 
455.
Fehrenbach, E., Passek, F., Niess, A. M., Pohla, H., Weinstock, C., Dickhuth, H. H. 
& Northoff, H. (2000). HSP expression in human leukocytes is modulated by 
endurance exercise. Medicine and Science in Sports and Exercise, 32(3), 592-600.
Fiuza, C., Bustin, M., Talwar, S., Tropea, M., Gerstenberger, E., Shelhamer, J. H. & 
Suffredini, A. F. (2003). Inflammation-promoting activity of HMGB1 on human 
microvascular endothelial cells. Blood, 101(7), 2652-2660.
258
Fukushima, A., Kawahara, H., Isurugi, C., Syoji, T., Oyama, R., Sugiyama, T. & 
Horiuchi, S. (2005). Changes in serum levels of heat shock protein 70 in preterm 
delivery and pre-eclampsia. Journal of Obstetrics and Gynaecology Research, 
31(1), 72-77.
Gaini, S., Koldkjaer, O. G., Moller, H. J., Pedersen, C. & Pedersen, S. S. (2007a). A 
comparison of high-mobility group-box 1 protein, lipopolysaccharide-binding protein 
and procalcitonin in severe community-acquired infections and bacteraemia: A 
prospective study. Critical Care, 11(4), 10.
Gaini, S., Pedersen, S. S., Koldkjaer, O. G., Pedersen, C. & Moller, H. J. (2007b). 
High mobility group box-1 protein in patients with suspected community-acquired 
infections and sepsis: a prospective study. Critical Care, 11(2).
Gallucci, S., Lolkema, M. & Matzinger, P. (1999). Natural adjuvants: endogenous 
activators of dendritic cells. Nature Medicine, 5(11), 1249-1255.
Gallucci, S. & Matzinger, P. (2001). Danger signals: SOS to the immune system. 
Current Opinion in Immunology, 13(1), 114-119.
Gao, B. & Tsan, M. F. (2003a). Endotoxin contamination in recombinant human 
heat shock protein 70 (Hsp70) preparation is responsible for the induction of tumor 
necrosis factor a release by murine macrophages. The Journal of Biological 
Chemistry, 278(1), 174-179.
Gao, B. & Tsan, M. F. (2003b). Recombinant human heat shock protein 60 does 
not induce the release of tumor necrosis factor a from murine macrophages. The 
Journal of Biological Chemistry, 278(25), 22523-22529.
Gao, B. & Tsan, M. F. (2004). Induction of cytokines by heat shock proteins and 
endotoxin in murine macrophages. Biochemical and Biophysical Research 
Communications, 317, 1149-1154.
Gao, B. C., Wang, Y. & Tsan, M. F. (2006). The heat sensitivity of cytokine-inducing 
effect of lipopolysaccharide. Journal of Leukocyte Biology, 80(2), 359-366.
259
Gardella, S., Andrei, C., Ferrera, D., Lotti, L. V., Torrisi, M. R., Bianchi, M. E. & 
Rubartelli, A. (2002). The nuclear protein HMGB1 is secreted by monocytes via a 
non-classical, vesicle-mediated secretory pathway. EMBO Reports, 3(10), 995- 
1001.
Garrido, C., Gurbuxani, S., Ravagnan, L. & Kroemer, G. (2001). Heat shock 
proteins: Endogenous modulators of apoptotic cell death. Biochemical and 
Biophysical Research Communications, 286(3), 433-442.
Gastpar, R., Gross, C., Rossbacher, L., Ellwart, J., Riegger, J. & Multhoff, G. 
(2004). The cell surface-localized heat shock protein 70 epitope TKD induces 
migration and cytolytic activity selectively in human NK cells. The Journal of 
Immunology, 172(2), 972-980.
Gazzinelli, R. T., Wysocka, M., Hieny, S., SchartonKersten, T., Cheever, A., Kuhn, 
R., Muller, W., Trinchieri, G. & Sher, A. (1996). In the absence of endogenous IL- 
10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune 
response dependent on CD4(+) T cells and accompanied by overproduction of IL- 
12, IFN-gamma, and TNF-alpha. Journal of Immunology, 157(2), 798-805.
Gebauer, M., Zeiner, M. & Gehring, U. (1997). Proteins interacting with the 
molecular chaperone hsp70/hsc70: physical associations and effects on refolding 
activity. FEBS Letters, 417, 109-113.
Gething, M. J. & Sambrook, J. (1992). Protein folding in the cell. Nature, 355(6355), 
33-45.
Gilon, P. & Henquin, J. C. (2001). Mechanisms and physiological significance of the 
cholinergic control of pancreatic beta-cell function. Endocrine Reviews, 22(5), 565- 
604.
Gouwy, M., Struyf, S., Proost, P. & van Damme, J. (2005). Synergy in cytokine and 
chemokine networks amplifies the inflammatory response. Cytokine and Growth 
Factor Review, 16(6), 561-580.
Graham, G. M., Farrar, M. D., Cruse-Sawyer, J. E., Holland, K. T. & Ingham, E. 
(2004). Proinflammatory cytokine production by human keratinocytes stimulated
260
with Propionibacterium acnés and P-acnes GroEL. British Journal of Dermatology, 
150(3), 421-428.
Greene, C. M., McElvaney, N. G., O'Neill, S. J. & Taggart, C. C. (2004). Secretory 
leucoprotease inhibitor impairs toll-like receptor 2-and 4-mediated responses in 
monocytic cells. Infection and Immunity, 72(6), 3684-3687.
Grosvik, B. E. & Goksoyr, A. (1996). Biomarker protein expression in primary 
cultures of salmon (salmo salar L.) hepatocytes exposed to environmental 
pollutants. Biomarkers, 1,45-53.
Gutsmann, T., Müller, M., Carroll, S. F., MacKenzie, R. C., Wiese, A. & Seydel, U. 
(2001). Dual role of lipopolysaccharide (LPS)-binding protein in neutralization of 
LPS and enhancement of LPS-induced activation of mononuclear cells. Infection 
and Immunity, 69(11), 6942-6950.
Guzhova, I., Kislyakova, K., Moskaliova, O., Fridlanskaya, I., Tytell, M., Cheetham, 
M. & Margulis, B. (2001). In vitro studies show that Hsp70 can be released by glia 
and that exogenous Hsp70 can enhance neuronal stress tolerance. Brain 
Research, 914, 66-73.
Guzhova, I. V., Arnholdt, A. C. V., Darieva, Z. A., Kinev, A. V., Lasunskaia, E. B., 
Nilsson, K., Bozhkov, V. M., Voronin, A. P. & Margulis, B. A. (1998). Effects of 
exogenous stress protein 70 on the functional properties of human promonocytes 
through binding to cell surface and internalization. Cell Stress & Chaperones, 3(1), 
67-77.
Habich, C., Baumgart, K., Kolb, H. & Burkart, V. (2002). The receptor for heat 
shock protein 60 on macrophages is saturable, specific, and distinct from receptors 
for other heat shock proteins. The Journal of Immunology, 168, 569-576.
Habich, C., Kempe, K., Burkart, V., van der Zee, R., Lillicrap, M., Gaston, H. & 
Kolb, H. (2004). Identification of the heat shock protein 60 epitope involved in 
receptor binding on macrophages. FEBS Letters, 568, 65-69.
261
Habich, C., Kempe, K., van der Zee, R., Rümenapf, R., Akiyama, H., Kolb, H. & 
Burkart, V. (2005). Heat shock protein 60: specific binding of lipopolysaccharide. 
The Journal of Immunology, 174, 1298-1305.
Hall, T. J. (1994). Role of hsp70 in cytokine production. Experientia, 50(11-12), 
1048-1053.
Hamilton, K. L , Mbai, F. N., Gupta, S. & Knowlton, A. A. (2004). Estrogen, heat 
shock proteins, and NF kappa B in human vascular endothelium. Arteriosclerosis 
Thrombosis and Vascular Biology, 24(9), 1628-1633.
Hamos, J. E., Oblas, B., Pulaskisalo, D., Welch, W. J., Bole, D. G. & Drachman, D. 
A. (1991). Expression of hest-shock proteins in Alzheimer's disease. Neurology, 
41(3), 345-350.
Harris, H. E. & Raucci, A. (2006). Alarmin(g) news about danger. EMBO Reports, 
7(8), 774-778.
Hartl, F. U. (1996). Molecular chaperones in cellular protein folding. Nature, 381, 
571-580.
Hartl, F. U. & Hayer-Hartl, M. (2002). Protein folding - Molecular chaperones in the 
cytosol: from nascent chain to folded protein. Science, 295(5561), 1852-1858.
Hay, D. G., Sathasivam, K., Tobaben, S., Stahl, B., Marber, M., Mestril, R., Mahal, 
A., Smith, D. L , Woodman, B. & Bates, G. P. (2004). Progressive decrease in 
chaperone protein levels in a mouse model of Huntington's disease and induction 
of stress proteins as a therapeutic approach. Human Molecular Genetics, 13(13), 
1389-1405.
Hayashi, F., Smith, K. D., Ozinsky, A., Hawn, T. R., Yi, E. C., Goodlett, D. R., Eng,
J. K., Akira, S., Underhill, D. M. & Aderem, A. (2001). The innate immune response 
to bacterial flagellin is mediated by Toll-like receptor 5. Nature, 410(6832), 1099- 
1103.
262
Haziot, A., Ferrero, E., Kontgen, F., Hijiya, N., Yamamoto, S., Silver, J., Stewart, C.
L. & Goyert, S. M. (1996). Resistance to endotoxin shock and reduced 
dissemination of gram-negative bacteria in CD14-deficient mice. Immunity, 4(4), 
407-414.
Heidenreich, S. (1999). Monocyte CD14: a multifunctional receptor engaged in 
apoptosis from both sides. Journal of Leukocyte Biology, 65(6), 737-743.
Hightower, L. E. & Guidon Jr, P. T. (1989). Selective release from cultured 
mammalian cells of heat-shock (stress) proteins that resemble glia-axon transfer 
proteins. Journal of Cellular Physiology, 138, 257-266.
Hu, D. E., Moore, A. M., Thomsen, L. L. & Brindle, K. M. (2004). Uric acid promotes 
tumor immune rejection. Cancer Research, 64(15), 5059-5062.
Hunter-Lavin, C., Davies, E. L., Bacelar, M. M. F. V. G., Marshall, M. J., Andrew, S.
M. & Williams, J. H. H. (2004). Hsp70 release from peripheral blood mononuclear 
cells. Biochemical and Biophysical Communications, 324, 511-517.
Huttunen, H. J., Fages, C., Kuja-Panula, J., Ridley, A. J. & Rauvala, H. (2002). 
Receptor for advanced glycation end products-binding COOH-terminal motif of 
amphoterin inhibits invasive migration and metastasis. Cancer Research, 62(16), 
4805-4811.
Huttunen, H. J. & Rauvala, H. (2004). Amphoterin as an extracellular regulator of 
cell motility: from discovery to disease. Journal of Internal Medicine, 255(3), 351- 
366.
Inoue, N. & Sawamura, T. (2007). Lectin-like oxidized LDL receptor-1 as 
extracellular chaperone receptor: its versatile functions and human diseases. 
Methods, 43(3), 218-222.
Ireland, H. E., Harding, S. J., Bonwick, G. A., Jones, M., Smith, C. J. & Williams, J. 
H. H. (2004). Evaluation of heat shock protein 70 as a biomarker of environmental 
stress in Fucus serratus and Lemna minor. Biomarkers, 9(2), 139-155.
263
Janeway, C. A. (1989). Approaching the asymptote - Evolution and revolution in 
immunology. Cold Spring Harbor Symposia on Quantitative Biology, 54, 1-13.
Janeway Jr, C. A., Travers, P., Walport, M. & Shlochik, M. J. (2005a). T-cell 
mediated immunity. In E. Lawrence, G. Bushell & M. Morales (Eds.), 
Immunobiology. Abingdon: Garland Science Publishing.
Janeway Jr, C. A., Travers, P., Walport, M. & Shlomchik, M. J. (2005b). Basic 
concepts in immunology. In E. Lawrence, G. Bushell & M. Morales (Eds.), 
Immunobiology. Abingdon: Garland Science Publishing.
Janeway Jr, C. A., Travers, P., Walport, M. & Shlomchik, M. J. (2005c). Innate 
Immunity. In E. Lawrence, G. Bushel & M. Morales (Eds.), Immunobiology. 
Abingdon: Garland Science Publishing.
Jeney, C., Dobay, O., Lengyel, A., Adam, E. & Nasz, I. (1999). Taguchi optimisation 
of ELISA procedures. Journal of Immunological Methods, 223, 137-146.
Jiang, W. W., Bell, C. W. & Pisetsky, D. S. (2007). The relationship between 
apoptosis and high-mobility group protein 1 release from murine macrophages 
stimulated with lipopolysaccharide or polyinosinic-polycytidylic acid. Journal of 
Immunology, 178(10), 6495-6503.
Johnson, B. J., Le, T. T. T., Dobbin, C. A., Banovic, T., Howard, C. B., Flores, F. d. 
M. L., Vanags, D., Naylor, D. J., Hill, G. R. & Suhrbier, A. (2005). Heat shock 
protein 10 inhibits lipopolysaccharide-induced inflammatory mediator production. 
The Journal of Biological Chemistry, 280(6), 4037-4047.
Kaczorowski, D. J., Mollen, K. P., Edmonds, R. & Billiar, T. R. (2008). Early events 
in the recognition of danger signals after tissue injury. Journal of Leukocyte Biology, 
83(3), 546-552.
Kalinina, N., Agrotis, A., Antropova, Y., DiVitto, G., Kanellakis, P., Kostolias, G., 
Ilyinskaya, O., Tararak, E. & Bobik, A. (2004). Increased expression of the DNA- 
binding cytokine HMGB1 in human atherosclerotic lesions: role of activated 
macrophages and cytokines. Arteriosclerosis, Thrombosis, & Vascular Biology., 
24(12), 2320-2325.
264
Kaplan, M. J., Lewis, E. E., Shelden, E. A., Somers, E., Pavlic, R., McClune, W. J. 
& Richardson, B. C. (2002). The apopotic hands TRAIL, TWEAK, and Fas ligand 
mediate monocyte death induced by autologous lupus T cells. The Journal of 
Immunology, 169, 6020-6029.
Katerinaki, E„ Evans, G. S., Lorigan, P. C. & MacNeil, S. (2003). TNF-alpha 
increases human melanoma cell invasion and migration in vitro: the role of 
proteolytic enzymes. British Journal of Cancer, 89(6), 1123-1129.
Kent, S. P., Ryan, K. H. & Siegel, A. L. (1978). Steric hindrance as a factor in 
reaction of labelled antibody with cell-surface antigenic determinants. Journal of 
Histochemistry & Cytochemistry, 26(8), 618-621.
Knapp, S., Muller, S., Digilio, G., Bonaldi, T., Bianchi, M. E. & Musco, G. (2004). 
The long acidic tail of high mobility group box 1 (HMGB1) protein forms an 
extended and flexible structure that interacts with specific residues within and 
between the HMG boxes. Biochemistry, 43(38), 11992-11997.
Knowlton, A. A. (2006). NFkB, heat shock proteins, HSF-1, and inflammation. 
Cardiovascular Research, 69, 7-8.
Kokkola, R., Palmblad, K., Andersson, A., Jonsson, C., Sundberg, E., Tracey, K. J., 
Andersson, U. & Harris, H. E. (2001). HMG-1 - A new cytokine in arthritis. Arthritis 
and Rheumatism, 44(9), S113-S113.
Kokkola, R., Sundberg, E., Ulfgren, A. K., Palmblad, K., Li, J., Wang, H., Ulloa, L., 
Yang, H., Yan, X. J., Furie, R., Chiorazzi, N., Tracey, K. J., Andersson, U. & Harris, 
H. E. (2002). High mobility group box chromosomal protein 1 - A novel 
proinflammatory mediator in synovitis. Arthritis and Rheumatism, 46(10), 2598- 
2603.
Kol, A., Lichtman, A. H., Finberg, R. W., Libby, P. & Kurt-Jones, E. A. (2000). 
Cutting Edge: Heat shock protein (Hsp) 60 activates the innate immune response: 
CD14 is an essential receptor for hsp60 activation of mononuclear cells. The 
Journal of Immunology, 164, 13-17.
265
Kono, H. & Rock, K. L. (2008). How dying cells alert the immune system to danger. 
Nature Reviews Immunology, 8(4), 279-289.
Krasko, A., Scheffer, U., Koziol, C., Pancer, Z., Batel, R., Badria, F. A. & Müller, W. 
E. G. (1997). Diagnosis of sublethal stress in the marine sponge Geodia cydonium: 
application of the 70 kDa heat-shock protein and a novel biomarker, the Rab GDP 
dissociation inhibitor, as probes. Aquatic Toxicology, 37, 157-168.
Krieg, A. M. (2007). The toll of too much TLR7. Immunity, 27(5), 695-697.
Krska, J., Elthon, T. & Blum, P. (1993). Monoclonal antibody recognition and fuction 
of a DNAK (hsp70) epitope found in gram-negative bacteria. Journal of 
Bacteriology, 175(20), 6433-6440.
Kurt-Jones, E. A., Mandell, L , Whitney, C., Padgett, A., Gosselin, K., Newburger, 
P. E. & Finberg, R. W. (2002). Role of Toll-like receptor 2 (TLR2) in neutrophil 
activation: GM-CSF enhances TLR2 expression and TLR2-mediated interleukin 8 
responses in neutrophils. Blood, 100(5), 1860-1868.
La Porte, P. F. (2005). Mytilus trossulus hsp70 as a biomarker for arsenic exposure 
in the marine environment: Laboratory and real-world results. Biomarkers, 10(6), 
417-428.
Lamb, D. J., El-Sankary, W. & Ferns, G. A. A. (2002). Molecular mimicry in 
atherosclerosis: a role for heat shock proteins in immunisation. Atherosclerosis, 
167, 177-185.
Lancaster, G. L. & Febbraio, M. A. (2005). Exosome-dependent trafficking of 
HSP70: a novel seceretory pathway for cellular stress proteins. Journal of 
Biological Chemistry, 280(24), 23349-23355.
Lang, D., Hubrich, A., Dohle, F., Terstesse, M., Saleh, H., Schmidt, M., Pauels, H. 
G. & Heidenreich, S. (2000). Differential expression of heat shock protein 70 
(hsp70) in human monocytes rendered apoptotic by IL-4 or serum deprivation. 
Journal of Leukocyte Biology., 68, 729-736.
266
Latz, E., Visintin, A., Lien, E., Fitzgerald, K. A., Monks, B. G., Kurt-Jones, E. A., 
Golenbock, D. T. & Espevik, T. (2002). Lipopolysaccharide rapidly traffics to and 
from the golgi apparatus with the toll-like receptor 4-MD-2-CD14 complex in a 
process that is distnct from the initiation of signal transduction. The Journal of 
Biological Chemistry, 277(49), 47834-47843.
Lee, K. J., Kim, Y. M., Kim, D. Y., Jeoung, D., Han, K., Lee, S. T., Lee, Y. S., Park,
K. H., Park, J. H., Kim, D. J. & Hahn, J. H. (2006). Release of heat shock protein 70 
(hsp70) and the effects of extracellular hsp70 on matric metalloproteinase-9 
expression in human monocytic U937 cells. Experimental and Molecular Medicine, 
38(4), 364-374.
Lehner, T., Wang, Y., Whittall, T., McGowan, E., Kelly, C. G. & Singh, M. (2004). 
Functional domains of HSP70 stimulate generation of cytokines and chemokines, 
maturation of dendritic cells and adjuvanticity. Biochemical Society Transactions, 
32(4), 629-632.
Lewis, S., Handy, R. D., Cordi, B., Billinghurst, Z. & Depldge, M. H. (1999). Stress 
proteins (Hsp's): methods of detection and their use as an environmental 
biomarker. Ecotoxicology, 8, 351-368.
Lewthwaite, J., Owen, N., Coates, A., Henderson, B. & Steptoe, A. (2002). 
Circulating human heat shock protein 60 in the plasma of British civil servants. 
Circulation, 106(2), 196-201.
Li, J. H., Kokkola, R., Tabibzadeh, S., Yang, R. K., Ochani, M., Qiang, X. L., Harris, 
H. E., Czura, C. J., Wang, H. C., Ulloa, L., Wang, H., Warren, H. S., Moldawer, L.
L. , Fink, M. P., Andersson, U., Tracey, K. J. & Yang, H. (2003). Structural basis for 
the proinflammatory cytokine activity of high mobility group box 1. Molecular 
Medicine, 9(1-2), 37-45.
Liu, H., Yao, Y. M., Yu, Y., Dong, N., Yin, H. N. & Sheng, Z. Y. (2007). Role of 
Janus kinase/signal transducer and activator of transcription pathway in regulation 
of expression and inflammation-promoting activity of high mobility group box protein 
1 in rat peritoneal macrophages. Shock, 27(1), 55-60.
267
Liu, Y., Liu, W., Song, X. D. & Zuo, J. (2005). Effect of 
GRP75/mthsp70/PBP74/mortalin overexpression on intracellular ATP level, 
mitochondrial membrane potential and ROS accumulation following glucose 
deprivation in PC12 cells. Molecular and Cellular Biochemistry, 268(1-2), 45-51.
Lotze, M. T. & Tracey, K. J. (2005). High-mobility group box 1 protein (HMGB): 
Nuclear weapon in the immune arsenal. Nature Reviews Immunology, 5(4), 331- 
342.
Luo, X. J., Zuo, X. X., Zhang, B., Song, L„ Wei, X., Zhou, Y. & Xiao, X. Z. (2008). 
Release of heat shock protein 70 and the effects of extracellular heat shock protein 
70 on the production of IL-10 in fibroblast-like synoviocytes. Cell Stress & 
Chaperones, 13(3), 365-373.
MacKenzie, A., Wilson, H. L., Kiss-Toth, E., Dower, S. K., North, R. A. & 
Surprenant, A. (2001). Rapid secretion of interleukin-1 beta by microvesicle 
shedding. Immunity, 15(5), 825-835.
Madden, L. A., Sandstrom, M. E., Lovell, R. J. & McNaughton, L. (2008). Inducible 
heat shock protein 70 and its role in preconditioning and exercise. Amino Acids, 
34(4), 511-516.
Malefyt, R. D., Abrams, J., Bennett, B., Figdor, C. G. & Devries, J. E. (1991). 
Interleukin-10(IL-10) inhibits cytokine synthesis by human monocytes - an 
autoregulatory role of IL-10 produced by monocytes. Journal of Experimental 
Medicine, 174(5), 1209-1220.
Mallouk, Y., Vayssier-Taussai, M., Bonventre, J. V. & Polla, B. S. (1999). Heat 
shock protein 70 and ATP as partners in cell homeostasis (Review). International 
Journal of Molecular Medicine, 4(5), 463-474.
Mambula, S. S. & Calderwood, S. K. (2006a). Heat induced release of hsp70 from 
prostate carcinoma cells involves both active secretion and passive release from 
necrotic cells. International Jounal of Hyperthermia, 22(7), 575-585.
268
Mambula, S. S. & Calderwood, S. K. (2006b). Heat shock protein 70 is secreted 
from tumor cells by a nonclassical pathway involving lysosomal endosomes. The 
Journal of Immunology, 177(11), 7849-7857.
Marcatili, A., Cipollaro de l'Ero, G., Galdiero, M., Folgore, A. & Petrillo, G. (1997). 
TNF-a, IL-1 a, IL-6 and ICAM-1 expression in human kératinocytes stimulated in 
vitro with Escherichia coli heat-shock proteins. Microbiology, 143, 45-53.
Martin, C. A., Carsons, S. E., Kowalewski, R., Bernstein, D., Valentino, M. & 
Santiago-Schwarz, F. (2003). Aberrant extracellular and dendritic cell (DC) surface 
expression of heat shock protein (hsp)70 in the rheumatoid joint: Possible 
mechanisms of hsp/DC-mediated cross-priming. Journal of Immunology, 171(11), 
5736-5742.
Martin, S. J., Reutelingsperger, C. P. M., McGahon, A. J., Rader, J. A., van Schie,
R. C. A. A., LaFace, D. M. & Green, D. R. (1995). Early redistribution of plasma 
membrane phosphatidylserine is a general feature of apoptosis regardless of 
theinitiating stimulus: inhibition by overexpression of Bcl-2 and Abl. Journal of 
Experimental Medicine, 182, 1545-1556.
Mathison, J. C., Tobias, P. S., Wolfson, E. & Ulevitch, R. J. (1992). Plasma 
lipopolysaccharide (LPS)-binding protein. The Journal of Immunology, 149(1), 200- 
206.
Matzinger, P. (1994). Tolerance, danger, and the extended family. Annual Review 
of Immunology, 12, 991-1045.
Matzinger, P. (1998). An innate sense of danger. Seminars in Immunology, 10(5), 
399-415.
Matzinger, P. (2002). The Danger Model: a renewed sense of self. Science, 
296(5566), 301-305.
Matzinger, P. (2007). Friendly and dangerous signals: is the tissue in control. 
Nature Immunology, 8(1), 11-13.
269
Mayer, M. P. & Bukau, B. (1998). Hsp70 chaperone systems: Diversity of cellular 
functions and mechanism of action. Biological Chemistry, 379(3), 261-268.
Means, T. K., Golenbock, D. T. & Fenton, M. J. (2000). The biology of Toll-like 
receptors. Cytokine & Growth Factor Reviews, 11(3), 219-232.
Milani, V., Noessner, E., Ghose, S., Kuppner, M., Ahrens, B., Scharner, A., 
Gastpar, R. & Issels, R. D. (2002). Heat shock protein 70: role in antigen 
presentation and immune stimulation. International Jounal of Hyperthermia, 18(6), 
563-575.
Millar, D. G., Garza, K. M., Odermatt, B., Elford, A. R., Ono, N., Li, Z. & Ohashi, P.
S. (2003). Hsp70 promotes antigen-presenting cell function and converts T-cell 
tolerance to autoimmunity in vivo. Nature Medicine, 9(12), 1469-1476.
Moore, K. W., Malefyt, R. D., Coffman, R. L. & O'Garra, A. (2001). Interleukin-10 
and the interleukin-10 receptor. Annual Review of Immunology, 19, 683-765. 
Morimoto, R. I. (1993). Cells in stress: Transcriptional activation of heat shock 
genes. Science, 259(5100), 1409-1410.
Moré, S. H., Breloer, M. & von Bonin, A. (2001). Eukaryotic heat shock proteins as 
molecular links in innate and adaptive immune responses: Hsp60-mediated 
activation of cytotoxic T cells. International Immunology, 13(9), 1121-1127.
Motta, A., Schmitz, C., Rodrigues, L., Ribeiro, F., Teixeira, C., Detanico, T., Bonan, 
C., Zwickey, H. & Bonorino, C. (2007). Mycobacterium tuberculosis heat-shock 
protein 70 impairs maturation of dendritic cells from bone marrow precursors, 
induces interleukin-10 production and inhibits T-cell proliferation in vitro. 
Immunology, 121(4), 462-472.
Multhoff, G. (2007). Heat shock protein 70 (Hsp70): Membrane location, export and 
immunological relevance. Methods, 43(3), 229-237.
Murray, K. S., Rouse, J. C., Tangarone, B. S., Peterson, K. A. & Van Cleave, V. H. 
(2001). Identification of human serum interferants in the recombinant P-selectin 
glycoprotein ligand-1 clinical ELISA using MALDI MS and RP-HPLC. Journal of 
Immunological Methods, 255(1-2), 41-56.
270
Menoret, A. (2004). Purification of recombinant and endogenous hsp70s. Methods, 
32, 7-12.
Menoret, A., Chaillot, D., Callahan, M. & Jacquin, C. (2002). Hsp70, an 
immunological actor playing with the intracellular self under oxidative stress. 
International Jounal of Hyperthermia, 18(6), 490-505.
Nadeau, D., Corneau, S., Plante, I., Morrow, G. & Tanguay, R. M. (2001). 
Evaluation of Hsp70 as a biomarker of effect of pollutants on the earthworm 
Lumbricus terrestris. Cell Stress & Chaperones, 6(2), 153-163.
Nakamura, T., Hinagata, J., Tanaka, T., Imanishi, T., Wada, Y., Kodama, T. & Doi,
T. (2002). HSP90, HSP70, and GAPDH directly interact with the cytoplasmic 
domain of macrophage scavenger receptors. Biochemical and Biophysical 
Research Communications, 290(2), 858-864.
Neupert, W. & Brunner, M. (2002). The protein import motor of mitochondria. 
Nature Reviews Molecular Cell Biology, 3(8), 555-565.
Nickel, W. (2003). The mystery of nonclassical protein secretion - A current view on 
cargo proteins and potential export routes. European Journal of Biochemistry, 
270(10), 2109-2119.
Niizeki, T„ Takeishi, Y., Watanabe, T., Nitobe, J., Miyashita, T., Miyamoto, T., 
Kitahara, T., Suzuki, S., Sasaki, T., Bilim, O., Ishino, M. & Kubota, I. (2008). 
Relation of serum heat shock protein 60 level to severity and prognosis in chronic 
heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. American 
Journal of Cardiology, 102(5), 606-610.
Nilsen, N. J., Deininger, S., Nonstad, U., Skjeldal, F., Husebye, H., Rodionov, D., 
von Aulock, S., Hartung, T., Lien, E., Bakke, O. & Espevik, T. (2008). Cellular 
trafficking of lipoteichoic acid and Toll-like receptor 2 in relation to signalling; role of 
CD14 and CD36. Journal of Leukocyte Biology, 84(1), 280-291.
271
Njemini, R., Demanet, C. & Mets, T. (2003a). Determination of intracellular heat 
shock protein 70 using a newly developed cell lysate immunometric assay. Journal 
of Immunological Methods, 274, 271-279.
Njemini, R., Demanet, C. & Mets, T. (2005). Comparison of two ELISAs for the 
determination of Hsp70 in serum. Journal of Immunological Methods, 306(1-2), 
176-182.
Njemini, R., Lambert, M., Demanet, C., Kooijman, R. & Mets, T. (2007). Basal and 
infection-induced levels of heat shock proteins in human aging. Biogerontology, 
8(3), 353-364.
Njemini, R., Lambert, M., Demanet, C. & Mets, T. (2003b). Elevated serum heat- 
shock protein 70 levels in patients with acute infection: use of an optimized 
enzyme-linked immunosorbent assay. Scandinavian Journal of Immunology, 58, 
664-669.
Njemini, R., Lambert, M., Demanet, C., Vanden Abeele, M., Vandebosch, S. & 
Mets, T. (2003c). The induction of heat shock protein 70 in peripheral mononuclear 
blood cells in elderly patients: a role for inflammatory markers. Human Immunology, 
64, 575-585.
Nolan, A., Weiden, M. D., Hoshino, Y. & Gold, J. A. (2004). CD40 but not CD154 
knockout mice have reduced inflammatory response in polymicrobial sepsis: a 
potential role for Escherichia coli heat shock protein 70 in cd40-mediated 
inflammation in vivo. Shock, 22(6), 538-542.
O'Connell, R. M., Doyle, S. E., Miranda, G. A., Vaidya, S. A., Chow, E. K., Liu, P. 
T., Suzuki, S., Suzuki, N., Modlin, R. L., Yeh, W. C., Lane, T. F. & Cheng, G. 
(2004). Toll-like receptors: Regulators of macrophage phagocytosis. Bologna: 
Medimond Publishing Co.
O'Connor, K. A., Hansen, M. K., Pugh, C. R., Deak, M. M., Biedenkapp, J. C., 
Milligan, E. D., Johnson, J. D., Wang, H., Maier, S. F., Tracey, K. J. & Watkins, L. 
R. (2003). Further characterization of high mobility group box 1 (HMGB1) as a 
proinflammatory cytokine: central nervous system effects. Cytokine, 24(6), 254-265.
272
O'Sullivan, B. & Thomas, R. (2003). Recent advances on the role of CD40 and 
dendritic cells in immunity and tolerance. Current Opinion in Hematology, 10(4), 
272-278.
Oehler, R., Pusch, E., Zellner, M., Dungel, P., Hergovics, N., Homoncik, M., 
Eliasen, M. M., Brabec, M. & Roth, E. (2001). Cell type-specific variations in the 
induction of hsp70 in human leukocytes by feverlike whole body hyperthermia. Cell 
Stress & Chaperones, 6(4), 306-315.
Ohashi, K., Burkart, V., Flohe, S. & Kolb, H. (2000). Cutting edge: Heat shock 
protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. The 
Journal of Immunology, 164(2), 558-561.
Palumbo, R., Galvez, B. G., Pusterla, T., De Marchis, F., Cossu, G., Marcu, K. B. & 
Bianchi, M. E. (2007). Cells migrating to sites of tissue damage in response to the 
danger signal HMGB1 require NF-kB activation. The Journal of Cell Biology, 
179(1), 33-40.
Panjwani, N. N., Popova, L. & Srivastava, P. K. (2000). Production of chemokines 
by hsp70 and gp96 stimulated antigen presenting cells. Cell Stress & Chaperones, 
5(4), 392-392.
Panjwani, N. N., Popova, L. & Srivastava, P. K. (2002). Heat shock proteins gp96 
and hsp70 activate the release of nitric oxide by APCs. Journal of Immunology, 
168(6), 2997-3003.
Park, J. E., Facciponte, J., Chen, X., MacDonald, I., Repasky, E. A., Manjili, M. H., 
Wang, X. Y. & Subjeck, J. R. (2006a). Chaperoning function of stress protein 
grp170, a member of the hsp70 superfamily, is responsible for its immunoadjuvant 
activity. Cancer Research, 66(2), 1161-1168.
Park, J. S., Arcaroli, J., Yum, H. K., Yang, H., Wang, H. C., Yang, K. Y., Choe, K. 
H., Strassheim, D., Pitts, T. M., Tracey, K. J. & Abraham, E. (2003). Activation of 
gene expression in human neutrophils by high mobility group box 1 protein. 
American Journal of Physiology-Cell Physiology, 284(4), C870-C879.
273
Park, J. S., Gamboni-Robertson, F., He, Q. B., Svetkauskaite, D., Kim, J. Y., 
Strassheim, D., Sohn, J. W., Yamada, S., Maruyama, I., Banerjee, A., Ishizaka, A. 
& Abraham, E. (2006b). High mobility group box 1 protein interacts with multiple 
Toll-like receptors. American Journal of Physiology-Cell Physiology, 290(3), C917- 
C924.
Park, J. S., Svetkauskaite, D., He, Q. B., Kim, J. Y., Strassheim, D., Ishizaka, A. & 
Abraham, E. (2004). Involvement of toll-like receptors 2 and 4 in cellular activation 
by high mobility group box 1 protein. Journal of Biological Chemistry, 279(9), 7370- 
7377.
Park, S. N., Yeo, S. W. & Park, K. H. (2006c). Serum heat shock protein 70 and its 
correlation with clinical characteristics in patients with sudden sensorineural hearing 
loss. Laryngoscope, 116(1), 121-125.
Peetermans, W. E., Raats, C. J. I., Langermans, J. A. M. & Van Furth, R. (1994). 
Mycobacterial heat-shock protein 65 induces proinflammatory cytokines but does 
not activate human mononuclear phagocytes. Scandinavian Journal of 
Immunology, 39, 613-617.
Pike, L. J. (2004). Lipid rafts: heterogeneity on the high seas. Biochemical Journal, 
378, 281-292.
Pluddemann, A., Neyen, C. & Gordon, S. (2007). Macrophage scavenger receptors 
and host-derived ligands. Methods, 43, 207-217.
Pockley, A. G. (2003). Heat shock proteins as regulators of the immune response. 
The Lancet, 362, 469-476.
Pockley, A. G., Bulmer, J., Hanks, B. M. & Wright, B. H. (1999). Identification of 
human heat shock protein 60 (Hsp60) and anti-Hsp60 antibodies in the peripheral 
circulation of normal individuals. Cell Stress & Chaperones, 4(1), 29-35.
Pockley, A. G., Shepherd, J. & Corton, J. M. (1998). Detection of heat shock protein 
70 (hsp70) and anti-hsp70 antibodies in the serum of normal individuals. 
Immunological Investigations, 27(6), 367-377.
274
Prakken, B. J., Wending, U., van der Zee, R., Rutten, V. P. M, G., Kuis, W. & van 
Eden, W. (2001). Induction of IL-10 and inhibition of experimental arthritis are 
specific features of microbial heat shock proteins that are absent fro other 
evolutionarily conserved immunodominant proteins. The Journal of Immunology, 
167, 4147-4153.
Prohaszka, Z. & Fust, G. (2004). Immunological aspects of heat-shock proteins - 
the optimum stress of life. Molecular Immunology, 41,29-44.
Pyza, E., Mak, P., Kramarz, P. & Laskowski, R. (1997). Heat shock proteins 
(HSP70) as biomarkers in ecotoxicological studies. Ecotoxicology and 
Environmental Safety, 38, 244-251.
Qin, S., Wang, H., Yuan, R., Li, H., Ochani, M., Ochani, K., Rosas-Ballina, M., 
Czura, C. J., Huston, J. M., Miller, E., Lin, X., Sherry, B., Kumar, A., LaRosa, G., 
Newman, W., Tracey, K. J. & Yang, H. (2006). Role of HMGB1 in apoptosis- 
mediated sepsis lethality. The Journal of Experimental Medicine, 203(7), 1637- 
1642.
R&D Systems Inc. ELISA Development Guide. pp1-16. 
http://www.rndsystems.com/DAM_public/5670.pdf
Ran, R., Lu, A., Zhang, L., Tang, Y., Zhu, H., Xu, H., Feng, Y., Han, C., Zhou, G., 
Rigby, A. C. & Sharp, F. R. (2004). Hsp70 promotes TNF-mediated apoptosis by 
binding IKKy and impairing NF-k(3 survival signaling. Genes and Development, 18, 
1466-1481.
Rapaport, D., Mayer, A., Neupert, W. & Lill, R. (1998). cis and trans sites of the 
TOM complex of mitochondria in unfolding and initial translocation of preproteins. 
Journal of Biological Chemistry, 273(15), 8806-8813.
Rea, I. M., McNerlan, S. & Pockley, A. G. (2001). Serum heat shock protein and 
anti-heat shock protein antibody levels in aging. Experimental Gerontology, 36, 
341-352.
275
Reines, B. P. (2001). Bystanders or bad seeds? Many autoimmune-target cells may 
be transforming to cancer and signalling "danger" to the immune system. 
Autoimmunity, 33(2), 121-134.
Retzlaff, C., Yamamoto, Y., Hoffman, P. S., Friedman, H. & Klein, T. W. (1994). 
Bacterial heat shock proteins directly induce cytokine mRNA and interleukin-1 
secretion in macrophage cultures. Infection and Immunity, 62(12), 5689-5693.
Ritossa, F. (1962). New puffing pattern induced by temperature shock and DNP in 
Drosophila. Experientia, 18(12), 571-573.
Riuzzi, F., Sorci, G. & Donato, R. (2006). The amphoterin (HMGB1)/receptor for 
advanced glycation end products (RAGE) pair modulates myoblast proliferation, 
apoptosis, adhesiveness, migration, and invasiveness - Functional inactivation of 
rage in L6 myoblasts results in tumor formation in vivo. Journal of Biological 
Chemistry, 281(12), 8242-8253.
Rong, L. L., Trojaborg, W., Qu, W., Kostov, K., Du Yan, S., Gooch, C., Szabolcs,
M., Hays, A. P. & Schmidt, A. M. (2004). Antagonism of RAGE suppresses 
peripheral nerve regeneration. Faseb Journal, 18(15), 1812-1817.
Rouhiainen, A., Kuja-Panula, J., Wilkman, E., Pakkanen, J., Stenfors, J., Tuominen, 
R. K., Lepantalo, M., Carpen, O., Parkkinen, J. & Rauvala, H. (2004). Regulation of 
monocyte migration by amphterin (HMGB1). Blood, 104(4), 1174-1182.
Ruchalski, K., Mao, H. P., Li, Z. J., Wang, Z. Y., Gillers, S., Wang, Y. H., Mosser, D. 
D., Gabai, V., Schwartz, J. H. & Borkan, S. C. (2006). Distinct hsp70 domains 
mediate apoptosis-inducing factor release and nuclear accumulation. Journal of 
Biological Chemistry, 281(12), 7873-7880.
Rudiger, S., Buchberger, A. & Bukau, B. (1997). Interaction of Hsp70 chaperones 
with substrates. Nature Structural Biology, 4(5), 342-349.
Saito, K., Dai, Y. & Ohtsuka, K. (2005). Enhanced expression of heat shock 
proteins in gradually dying cells and their release from necrotically dead cells. 
Experimental Cell Research, 310(1), 229-236.
276
Samarasinghe, R., Tailor, P., Tamura, T., Kaisho, T., Akira, S. & Ozato, K. (2006). 
Induction of an anti-inflammatory cytokine, IL-10, in dendritic cells after toll-like 
receptor signaling. Journal of Interferon and Cytokine Research, 26(12), 893-900.
Sarge, K. D., Murphy, S. P. & Morimoto, R. I. (1993). Activation of heat-shock gene- 
transcription by heat-shock factor-1 involves oligomerization, acquisition of DNA- 
binding activity, and nuclear-localization and can occur in the absence of stress. 
Molecular and Cellular Biology, 13(3), 1392-1407.
Sawa, H., Ueda, T., Takeyama, Y., Yasuda, T., Shinzeki, M., Nakajima, T. & 
Kuroda, Y. (2006). Blockade of high mobility group box-1 protein attenuates 
experimental severe acute pancreatitis. World Journal of Gastroenterology, 12(47), 
7666-7670.
Scaffidi, P., Misteli, T. & Bianchi, M. E. (2002). Release of chromatin protein 
HMGB1 by necrotic cells triggers inflammation. Nature, 418(6894), 191-195.
Schmidt, A. M., Du Yan, S., Yan, S. F. & Stern, D. M. (2001). The multiligand 
receptor RAGE as a progression factor amplifying immune and inflammatory 
responses. Journal of Clinical Investigation, 108(7), 949-955.
Schröder, H. C., Batel, R., Hassanein, H. M. A., Lauenroth, S., Jenke, H. S., Simat, 
T., Steinhart, H. & Müller, W. E. G. (2000). Correlation between the level of the 
potential biomarker, heat-shock protein, and the occurrence of DNA damage in the 
dab, Limanda limanda: a field study in the North Sea and the English Channel. 
Marine Environmental Research, 49(3), 201-215.
Schuster, N. & Krieglstein, K. (2002). Mechanisms of TGF-beta-mediated 
apoptosis. Cell and Tissue Research, 307(1), 1-14.
Scofield, E., Bowyer, R. T. & Duffy, L. K. (1999). Baseline levels of Hsp 70, a stress 
protein and biomarker, in halibut from the Cook Inlet region of Alaska. The Science 
of The Total Environment, 226(1), 85-88.
Seong, S. Y. & Matzinger, P. (2004). Hydrophobicity: an ancient damage- 
associated molecular pattern that initiates innate immune responses. Nature 
Reviews Immunology, 4(6), 469-478.
277
Shi, Y. & Rock, K. L. (2002). Cell death releases endogenous adjuvants that 
selectively enhance immune surveillance of particulate antigens. European Journal 
of Immunology, 32(1), 155-162.
Shi, Y., Zheng, W. Y. & Rock, K. L. (2000). Cell injury releases endogenous 
adjuvants that stimulate cytotoxic T cell responses. Proceedings of the National 
Academy of Sciences of the United States of America, 97(26), 14590-14595.
Shi, Y. H., Mosser, D. D. & Morimoto, R. I. (1998). Molecular chaperones as HSF1- 
specific transcriptional repressors. Genes & Development, 12(5), 654-666.
Singh-Jasuja, H., Scherer, H. U., Hilf, N., Arnold-Schild, D., Rammensee, H. G., 
Toes, R. E. M. & Schild, H. (2000). The heat shock protein gp96 induces maturation 
of dendritic cells and down-regulation of its receptor. European Journal of 
Immunology, 30(8), 2211-2215.
Smith, K. D., Andersen-Nissen, E., Hayashi, F., Strobe, K., Bergman, M. A., Barrett, 
S. L. R., Cookson, B. T. & Aderem, A. (2003). Toll-like receptor 5 recognizes a 
conserved site on flagellin required for protofilament formation and bacterial 
motility. Nature Immunology, 4(12), 1247-1253.
Smits, E. L. J. M., Ponsaerts, P., Berneman, Z. N. & Van Tendeloo, V. F. I. (2008). 
The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. 
Oncologist, 13(8), 859-875.
Sondermann, H., Becker, T., Mayhew, M., Wieland, F. & Hartl, F. U. (2000). 
Characterization of a receptor for heat shock protein 70 on macrophages and 
monocytes. Biological Chemistry, 381, 1165-1174.
Sriram, M., Osipiuk, J., Freeman, B. C., Morimoto, R. I. & Joachimiak, A. (1997). 
Human Hsp70 molecular chaperone binds two calcium ions within the ATPase 
domain. Structure, 5(3), 403-414.
Srivastava, P. (2002). Roles of heat-shock proteins in innate and adaptive 
immunity. Nature Reviews Immunology, 2(3), 185-194.
278
Srivastava, P. K. (2003). Hypothesis: Controlled necrosis as a tool for 
immunotherapy of human cancer. Cancer Immunity, 3, 4-7.
Stewart, G. R. & Young, D. B. (2004). Heat-shock proteins and the host-pathogen 
interaction during bacterial infection. Current Opinion in Immunology, 16, 506-510.
Sugawara, S., Arakaki, R., Rikiishi, H. & Takada, H. (1999). Lipoteichoic acid acts 
as an antagonist and agonist of lipopolysaccharide on human gingival firbroblasts 
and monocytes in a CD14-dependent manner. Infection and Immunity, 67(4), 1623- 
1632.
Svensson, P. A., Asea, A., Englund, M. C. O., Bausero, M. A., Jernas, M., Wiklund, 
O., Ohlsson, B. G., Carlsson, L. M. S. & Carlsson, B. (2006). Major role of HSP70 
as a paracrine inducer of cytokine production in human oxidized LDL treated 
macrophages. Atherosclerosis, 185, 32-38.
Takata, K., Kitamura, Y., Kakimura, J., Shibagaki, K., Tsuchiya, D., Taniguchi, T., 
Smith, M. A., Perry, G. & Shimohama, S. (2003). Role of high mobility group 
protein-1 (HMG1) in amyloid-beta homeostasis. Biochemical and Biophysical 
Research Communications, 301(3), 699-703.
Takeda, K., Kaisho, T. & Akira, S. (2003). Toll-like receptors. Annual Review of 
Immunology, 21, 335-376.
Tanaka, S., Kimura, Y., Mitani, A., Yamamoto, G., Nishimura, H., Spallek, R., 
Singh, M., Noguchi, T. & Yoshikai, Y. (1999). Activation of T cells recognizing an 
epitope of heat-shock protein 70 can protect against rat adjuvant arthritis. Journal of 
Immunology, 163(10), 5560-5565.
Tang, D., Kang, R., Xiao, W., Wang, H., Calderwood, S. K. & Xiao, X. (2007a). The 
anti-inflammatory effects of heat shock protein 72 involve inhibition of high-mobility- 
group box 1 release and proinflammatory function in macrophages. The Journal of 
Immunology, 179(2), 1236-1244.
Tang, D., Shi, Y., Kang, R., Li, T., Xiao, W., Wang, H. & Xiao, X. (2007b). Hydrogen 
peroxide stimulates macrophages and monocytes to actively release HMGB1. 
Journal of Leukocyte Biology, 81(3), 741-747.
279
Tang, D. L., Kang, R., Xiao, W. M., Jiang, L., Liu, M. D., Shi, Y. Z., Wang, K. K., 
Wang, H. C. & Xiao, X. Z. (2007c). Nuclear heat shock protein 72 as a negative 
regulator of oxidative stress (hydrogen peroxide)-induced HMGB1 cytoplasmic 
translocation and release. Journal of Immunology, 178(11), 7376-7384.
Taniguchi, N., Kawawhara, K., Yone, K., Hashiguchi, T., Yamakuchi, M., Goto, M., 
Inoue, K., Yamada, S., Ijiri, K., Matsunaga, S., Nakajima, T., Komiya, S. & 
Maruyama, I. (2003). High mobility group box chromosomal protein 1 plays a role in 
the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis & 
Rheumatism, 48(4), 971-981.
Tavaria, M., Gabriele, T., Kola, I. & Anderson, R. L. (1996). A hitchhiker's guide to 
the human Hsp70 family. Cell Stress & Chaperones, 1(1), 23-28.
Terry, D. F., Wyszynski, D. F., Nolan, V. G., Atzmon, G., Schoenhofen, E. A., 
Pennington, J. Y., Anderson, S. L., Wilcox, M. A., Farrer, L. A., Barzilai, N., 
Baldwin, C. T. & Asea, A. (2006). Serum heat shock protein 70 level as a biomarker 
of exceptional longevity. Mechanisms of Aging and Development, 127(11), 862- 
868.
Theodorakis, N. G., Drujan, D. & De Maio, A. (1999). Thermotolerant cells show an 
attenuated expression of Hsp70 after heat shock. Journal of Biological Chemistry, 
274(17), 12081-12086.
Theriault, J. R., Adachi, H. & Calderwood, S. K. (2006). Role of scavenger 
receptors in the binding and internalization of heat shock protein 70. Journal of 
Immunology, 177(12), 8604-8611.
Thomas, J. O. (2001). HMG 1 and 2: architectural DNA-binding proteins. 
Biochemical Society Transactions, 29, 395-401.
Theriault, J. R., Mambula, S. S., Sawamura, T., Stevenson, M. A. & Calderwood, S. 
K. (2005). Extracellular HSP70 binding to surface receptors present on antigen 
presenting cells and endothelial/epithelial cells. FEBS Letters, 579, 1951-1960.
280
Tian, J., Avalos, A. M„ Mao, S. Y., Chen, B„ Senthil, K„ Wu, H„ Paaroche, P., 
Drabic, S., Glenbock, D., Sirios, C., Hua, J., An, L. L., Audoly, L., La Rosa, G., 
Bierhaus, A., Naworth, P., Marshak-Rothstein, A., Crow, M. K., Fitzgerald, K. A., 
Latz, E., Kiener, P. A. & Coyle, A. J. (2007). Toll-like receptor 9-dependent 
activation by DNA-containing immune complexes is mediated by HMGB1 and 
RAGE. Nature Immunology, 8(5), 487-496.
Tissieres, A., Mitchell, H. K. & Tracy, U. M. (1974). Protein synthesis in salivary 
glands of Drosophila melanogaster: Relation to chromosome puffs. Journal of 
Molecular Biology, 85(3), 389-398.
Todryk, S., Melcher, A. A., Hardwick, N., Linardakis, E., Bateman, A., Colombo, M.
P., Stoppacciaro, A. & Vile, R. G. (1999). Heat shock protein 70 induced during 
tumor cell killing induces Th1 cytokines and targets immature dendritic cell 
precursors to enhance antigen uptake. Journal of Immunology, 163(3), 1398-1408.
Tong, W. & Luo, W. (2000). Heat shock proteins mRNA expressions by peripheral 
blood mononuclear cells in asthma and chronic bronchitis. Chinese Medical 
Journal, 115(2), 175-177.
Triantafilou, K., Triantafilou, M., Ladha, S., Mackie, A., Dedrick, R. L., Fernandez,
N. & Cherry, R. (2001). Fluorescence recovery after photobleaching reveals that 
LPS rapidly transfers from CD14 to hsp70 and hsp90 on the cell membrane. 
Journal of Cell Science, 114, 2535-2545.
Triantafilou, K., Vakakis, E., Orthopoulos, G., Ahmed, M. A., Schumann, C., 
Lepper, P. M. & Triantafilou, M. (2005). TLR8 and TLR7 are involved in the host's 
immune response to human parechovirus 1. European Journal of Immunology, 
35(8), 2416-2423.
Triantafilou, M. & Triantafilou, K. (2002). Lipopolysaccharide recognition: CD14, 
TLRs and the LPS-activation cluster. TRENDS in Immunology, 23(6), 301-304.
Tsan, M. F. & Gao, B. (2004a). Cytokine function of heat shock proteins. American 
Journal of Physiology - Cell Physiology, 286, 739-744.
281
Tsan, M. F. & Gao, B. (2004b). Endogenous ligands of toll-like receptors. Journal of 
Leukocyte Biology, 76(3), 514-519.
Tsan, M. F. & Gao, B. (2007). Pathogen-associated molecular pattern 
contamination as putative endogenous ligands of toll-like receptors. Journal of 
Endotoxin Research, 13(1), 6-14.
Tsuchiya, D., Hong, S., Matsumori, Y., Shiina, H., Kayama, T., Swanson, R. A., 
Dillman, W. H., Liu, J. L., Panter, S. S. & Weinstein, P. R. (2003). Overexpression 
of rat heat shock protein 70 is associated with reduction of early mitochondrial 
cytochrome c release and subsequent DNA fragmentation after permanent focal 
ischemia. Journal of Cerebral Blood Flow and Metabolism, 23(6), 718-727.
Tytell, M. (2005). Release of heat shock proteins (Hsps) and the effects of 
extracellular Hsps on neural cells and tissues. International Jounal of Hyperthermia, 
21(5), 445-455.
Urbonaviciute, V., Furnrohr, B. G., Weber, C., Haslbeck, M., Wilhelm, S., 
Herrmann, M. & Voll, R. E. (2007). Factors masking HMGB1 in human serum and 
plasma. Journal of Leukocyte Biology, 81(1), 67-74.
Vabulas, R. M., Ahmad-Nejad, P., Ghose, S., Kirschning, C. J., Issels, R. D. & 
Wagner, H. (2002). HSP70 as endogenous stimulus of the Toll/lnterleukin-1 recptor 
signal pathway. The Journal of Biological Chemistry, 277(17), 15107-15112.
Valentis, B., Capobianco, A., Esposito, F., Bianchi, A., Rovere-Querini, P., 
Manfredi, A. A. & Traversari, C. (2008). Human recombinant heat shock protein 70 
affects the maturation pathways of dendritic cells in vitro and has an in vivo 
adjuvant activity. Journal of Leukocyte Biology, 84(1), 199-206.
Van Molle, W., Wielockx, B., Mahieu, T., Takada, M., Taniguchi, T., Sekikawa, K. & 
Libert, C. (2002). HSP70 protects against TNF-induced lethal inflammatory shock. 
Immunity, 16(5), 685-695.
282
Vega, V. L., Rodriguez-Silva, M., Frey, T., Gehrmann, M., Diaz, J. C., Steinem, C., 
Multhoff, G., Arispe, N. & De Maio, A. (2008). Hsp70 translocates into the plasma 
membrane after stress and is released into the extracellular environment in a 
membrane-associated form that activates macrophages. Journal of Immunology, 
180(6), 4299-4307.
Walsh, R. C„ Koukoulas, I., Garnham, A., Moseley, P. L., Hargreaves, M. & 
Febbraio, M. A. (2001). Exercise increases serum Hsp72 in humans. Cell Stress & 
Chaperones, 6(4), 386-393.
Wang, H. C., O, B., Zhang, M„ Vishnubhakat, J. M., Ombrellino, M„ Che, J., 
Frazier, A., Yang, H., Ivanova, S., Borovikova, L., Manogue, K. R., Faist, E., 
Abraham, E„ Andersson, J., Andersson, U., Molina, P. E., Abumrad, N. N„ Sama, 
A. & Tracey, K. J. (1999). HMG-1 as a late mediator of endotoxin lethality in mice. 
Science, 285(5425), 248-251.
Wang, H. H„ Yang, H., Czura, C. J., Sama, A. E. & Tracey, K. J. (2001a). HMGB1 
as a late mediator of lethal systemic inflammation. American Journal of Respiratory 
and Critical Care Medicine, 164(10), 1768-1773.
Wang, Q., Zeng, M. H„ Wang, W. & Tang, J. (2007). The HMGB1 acidic tail 
regulates HMGB1 DNA binding specificity by a unique mechanism. Biochemical 
and Biophysical Research Communications, 360(1), 14-19.
Wang, R. B., Kovalchin, J. T., Muhlenkamp, P. & Chandawarkar, R. Y. (2006a). 
Exogenous heat shock protein 70 binds macrophage lipid raft microdomain and 
stimulates phagocytosis, processing, and MHC-II presentation of antigens. Blood, 
107(4), 1636-1642.
Wang, R. B., Town, T., Gokarn, V., Flavell, R. A. & Chandawarkar, R. Y. (2006b). 
HSP70 enhances macrophage phagocytosis by interaction with lipid raft-associated 
TLR-7 and upregulating p38 MAPK and PI3K pathways. Journal of Surgical 
Research, 136(1), 58-69.
283
Wang, Y„ Whittall, T., McGowan, E., Younson, J., Kelly, C., Bergmeier, L. A., 
Singh, M. & Lehner, T. (2005). Identification of stimulating and inhibitory epitopes 
within the heat shock protein 70 molecule that modulate cytokine production and 
maturation of dendritic cells. Journal of Immunology, 174(6), 3306-3316.
Wang, Y. F„ Kelly, C. G„ Karttunen, J. T„ Whittall, T„ Lehner, P. J., Duncan, L., 
MacAry, P„ Younson, J. S., Singh, M„ Oehlmann, W„ Cheng, G. H„ Bergmeier, L. 
& Lehner, T. (2001b). CD40 is a cellular receptor mediating mycobacterial heat 
shock protein 70 stimulation of CC-chemokines. Immunity, 15(6), 971-983.
Watanabe, H., Nakanishi, I., Yamashita, K., Hayakawa, T. & Okada, Y. (1993). 
Matrix Metalloproteinase-9 (92 kDa Gelatinase type-IV collagenase) from U937 
monoblastoid cells - correlation with cellualr invasion. Journal of Cell Science, 104, 
991-999.
Weiss, Y. G., Bromberg, Z., Raj, N., Raphael, J., Goloubinoff, P., Ben-Neriah, Y. & 
Deutschman, C. S. (2007). Enhanced heat shock protein 70 expression alters 
proteasomal degradation of I kappa B kinase in experimental acute respiratory 
distress syndrome. Critical Care Medicine, 35(9), 2128-2138.
Wendling, U., Paul, L., van der Zee, R., Prakken, B., Singh, M. & van Eden, W. 
(2000). A conserved mycobacterial heat shock protein (HSP) 70 sequence prevents 
adjuvant arthritis upon nasal administration and induces IL-10-producing T cells 
that cross-react with the mammalian self-HSP70 homologue. Journal of 
Immunology, 164(5), 2711-2717.
Widlak, P„ Palyvoda, O., Kumala, S. & Garrard, W. T. (2002). Modeling apoptotic 
chromatin condensation in normal cell nuclei - Requirement for intranuclear mobility 
and actin involvement. Journal of Biological Chemistry, 277(24), 21683-21690.
Williams, J. H. H. & Ireland, H. E. (2008). Sensing danger - Hsp72 and HMGB1 as 
candidate signals. Journal of Leukocyte Biology, 83(3), 489-492.
Wright, B. H., Corton, J. M., El-Nahas, A. M., Wood, R. F. M. & Pockley, A. G. 
(2000). Elevated levels of circulating heat shock protein 70 (hsp70) in peripheral 
and renal vascular disease. Heart Vessels, 15(1), 18-22.
284
Wu, C. (1995). Heat shock transcription factors: Structure and regulation. Annual 
Review of Cell and Developmental Biology, 11,441-469.
Yamada, S., Inoue, K., Yakabe, K., Imaizumi, H. & Maruyama, I. (2003). High 
mobility group box protein 1 (HMGB1) quantified by ELISA with a monoclonal 
antibody that does not cross-react with HMGB2. Clinical Chemistry, 49(9), 1535- 
1537.
Yang, D., Chen, Q., Yang, H., Tracey, K. J., Bustin, M. & Oppenheim, J. J. (2006). 
High mobility group box-1 (HMGB1) protein induces the migration and activation of 
human dendritic cells and acts as an alarmin. Journal of Leukocyte Biology, 81(1), 
59-66.
Yang, H., Yuan, R. Q., Wang, H. C., Ochani, M. & Tracey, K. J. (2007). Role of 
HMGB1 in apoptosis-mediated sepsis lethality. Inflammation Research, 56, S88- 
S89.
Yasuda, T., Ueda, T., Shinzeki, M., Sawa, H., Nakajima, T., Takeyama, Y. & 
Kuroda, Y. (2007). Increase of high-mobility group box chromosomal protein 1 in 
blood and injured organs in experimental severe acute pancreatitis. Pancreas, 
34(4), 487-488.
Yasuda, T., Ueda, T., Takeyama, Y., Shinzeki, M., Sawa, H., Nakajima, T., Ajiki, T., 
Fujino, Y., Suzuki, Y. & Kuroda, Y. (2006). Significant increase of serum high- 
mobility group box chromosomal protein 1 levels in patients with severe acute 
pancreatitis. Pancreas, 33(4), 359-363.
Ye, Z. Y. & Gan, Y. H. (2007). Flagellin contamination of recombinant heat shock 
protein 70 is responsible for its activity on T cells. Journal of Biological Chemistry, 
282(7), 4479-4484.
Yoo, B. C., Kim, S. H., Cairns, N., Fountoulakis, M. & Lubec, G. (2001). Deranged 
expression of molecular chaperones in brains of patients with Alzheimer's disease. 
Biochemical and Biophysical Research Communications, 280(1), 249-258.
285
Yoo, C. G., Lee, S., Lee, C. T„ Kim, Y. W„ Han, S. K. & Shim, Y. S. (2000). Anti­
inflammatory effect of heat shock protein induction is related to stabilization of I 
kappa B alpha through preventing I kappa B kinase activation in respiratory 
epithelial cells. Journal of Immunology, 164(10), 5416-5423.
Yu, M., Wang, H. C., Ding, A. H., Golenbock, D. T„ Latz, E., Czura, C. J., Fenton, 
M. J., Tracey, K. J. & Yang, H. (2006). HMGB1 signals through toll-like receptor 
(TLR) 4 and TLR2. Shock, 26(2), 174-179.
Zarember, K. A. & Godowski, P. J. (2002). Tissue expression of human toll-like 
receptors and differential regulation of toll-like receptor mRNAs in leukocytes in 
response to microbes, their products, and cytokines. Journal of Immunology, 
168(2), 554-561.
Zetterstrom, C. K., Bergman, T., Ruynnel-Dagoo, B., Harris, H. E., Soder, O., 
Andersson, U. & Boman, H. G. (2002). High mobility group box chromosomal 
protein 1 (HMGB1) is an antibacterial factor produced by the human adenoid. 
Pediatric Research, 52(2), 148-154.
Zhang, G. L. & Ghosh, S. (2001). Toll-like receptor-mediated NF-kappa B 
activation: a phylogenetically conserved paradigm in innate immunity. Journal of 
Clinical Investigation, 107(1), 13-19.
Zhu, J. H., Quyyumi, A. A., Wu, H. S., Csako, G., Rott, D., Zalles-Ganley, A., 
Ogunmakinwa, J., Halcox, J. & Epstein, S. E. (2003). Increased serum levels of 
heat shock protein 70 are associated with low risk of coronary artery disease. 
Arteriosclerosis Thrombosis and Vascular Biology, 23(6), 1055-1059.
286
